WO2005037836A2 - Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors - Google Patents

Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors Download PDF

Info

Publication number
WO2005037836A2
WO2005037836A2 PCT/US2004/034219 US2004034219W WO2005037836A2 WO 2005037836 A2 WO2005037836 A2 WO 2005037836A2 US 2004034219 W US2004034219 W US 2004034219W WO 2005037836 A2 WO2005037836 A2 WO 2005037836A2
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazin
imidazo
alkyl
phenyl
substituents
Prior art date
Application number
PCT/US2004/034219
Other languages
French (fr)
Other versions
WO2005037836A3 (en
Inventor
Patricia Anne Beck
Cara Cesario
Matthew Cox
Han-Qing Dong
Kenneth Foreman
Mark Joseph Mulvihill
Anthony Innocenzo Nigro
Lydia Saroglou
Arno G. Steinig
Yingchuan Sun
Qinghua Weng
Douglas Werner
Robin Wilkes
Jonathan Williams
Original Assignee
Osi Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34465267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005037836(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to UAA200605222A priority Critical patent/UA83509C2/en
Priority to JP2006535379A priority patent/JP4916883B2/en
Priority to BRPI0415395-2A priority patent/BRPI0415395A/en
Priority to CN2004800372564A priority patent/CN1898240B/en
Priority to AU2004282219A priority patent/AU2004282219C1/en
Application filed by Osi Pharmaceuticals, Inc. filed Critical Osi Pharmaceuticals, Inc.
Priority to CA002542481A priority patent/CA2542481A1/en
Priority to AT04795392T priority patent/ATE525377T1/en
Priority to EP04795392A priority patent/EP1675860B1/en
Priority to AP2006003620A priority patent/AP2006003620A0/en
Publication of WO2005037836A2 publication Critical patent/WO2005037836A2/en
Publication of WO2005037836A3 publication Critical patent/WO2005037836A3/en
Priority to IL174948A priority patent/IL174948A0/en
Priority to NO20062136A priority patent/NO20062136L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the present invention is directed to novel imidazopyrazines, their salts, and compositions comprising them.
  • the present invention is directed to imidazopyrazines as novel tyrosine kinase inhibitors that inhibit tyrosine kinase enzymes in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
  • Phosphoryl transferases are a large family of enzymes that transfer phosphorous-containing groups from one substrate to another.
  • Kinases are a class of t enzymes that function in the catalysis of phosphoryl transfer. The phosphorylation is usually a transfer reaction of a phosphate group from ATP to the protein substrate.
  • Protein kinases Almost all kinases contain a similar 250-300 amino acid catalytic domain. Protein kinases, with at least 400 identified, constitute the largest subfamily of structurally related phosphoryl transferases and are responsible for the control of a wide variety of signal transduction processes within the cell.
  • the protein kinases may be categorized into families by the substrates they phosphorylate (e.g., protein-tyrosine, protein- serine/threonine, etc.). Protein kinase sequence motifs have been identified that generally correspond to each of these kinase families.
  • Lipid kinases e.g. PI3K constitute a separate group of kinases with structural similarity to protein kinases.
  • the "kinase domain” appears in a number of polypeptides which serve a variety of functions.
  • Su h polypeptides include, for example, transmembrane receptors, intracellular receptor associated polypeptides, cytoplasmic located polypeptides, nuclear located polypeptides and subcelmlar located polypeptides.
  • the activity of protein kinases can be regulated by a variety of mechanisms and any individual protein might be regulated by more than one mechanism. Such mechanisms include, for example, autophosphorylation, transphosphorylation by other kmases, protein-protein interactions, protein-lipid interactions, protein- polynucleotide interactions, ligand binding, and post-translational modification.
  • [4] Phosphorylation of target proteins occurs in response to a variety of extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc.), cell cycle events, environmental or nutritional stresses, etc.
  • Protein and lipid kinases regulate many different cell processes by adding phosphate groups to targets such as proteins or lipids.
  • Such cell processes include, for example, proliferation, growth, differentiation, metabolism, cell cycle events, apoptosis, motility, transcription, translation and other signaling processes.
  • Kinase catalyzed phosphorylation acts as molecular on/off switches to modulate or regulate the biological function of the target protein.
  • protein and lipid kinases can function in signaling pathways to activate or inactivate, or modulate the activity (either directly or indirectly) of the targets.
  • targets may include, for example, metabolic enzymes, regulatory proteins, receptors, cytoskeletal proteins, ion channels or pumps, or transcription factors.
  • a partial list of protein kinases includes abl, AKT, bcr-abl, Blk, Brk,
  • protein kinases represent a large family of proteins which play a central role in the regulation of a wide variety of cellular processes, maintaining control over cellular function. Uncontrolled signaling due to defective control of protein phosphorylation has been implicated in a number of diseases and disease conditions, including, for example, inflammation, cancer, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS), cardiovascular disease, dermatology, and angiogenesis.
  • CNS central nervous system
  • cardiovascular disease CAD
  • dermatology angiogenesis
  • Rous sarcoma virus RSV
  • ASV avian sarcoma virus
  • RSV Rous sarcoma virus
  • ASV avian sarcoma virus
  • deregulated protein kinase activity resulting from a variety of mechanisms, has been implicated in the pathophysiology of a number of important human disorders including, for example, cancer, CNS conditions, and immunologically related diseases.
  • the development of selective protein kinase inhibitors that can block the disease path logies and/or symptoms resulting from aberrant protein kinase activity has therefore become an important therapeutic target.
  • PTKs Protein tyrosine kinases
  • Such post- translational modification of the substrate proteins often enzymes themselves, acts as a molecular switch regulating cell proliferation, activation or differentiation (for review, see Schlessinger and Ullrich, 1992, Neuron 9:383-391).
  • Aberrant or excessive PTK activity has been observed in many disease states including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune system (e.g., autoimmune disorders), allograft rejection, and graft vs.
  • endothelial-cell specific receptor PTKs such as KDR and Tie-2 mediate the angiogenic process, and are thus involved in supporting the progression of cancers and other diseases involving inappropriate vascularization (e.g., diabetic retinopathy, choroidal neovascularization due to age-related macular degeneration, psoriasis, arthritis, retinopathy of prematurity, infantile hemangiomas).
  • endothelial-cell specific receptor PTKs such as KDR and Tie-2 mediate the angiogenic process, and are thus involved in supporting the progression of cancers and other diseases involving inappropriate vascularization (e.g., diabetic retinopathy, choroidal neovascularization due to age-related macular degeneration, psoriasis, arthritis, retinopathy of prematurity, infantile hemangiomas).
  • Tyrosine kinases can be of the receptor-type (having extracellular, transmembrane and intracellular domains
  • the Receptor Tyrosine Kinases comprise a large family of transmembrane receptors with at least nineteen distinct RTK subfamilies having diverse biological activities.
  • the RTK family includes receptors that are crucial for the growth and differentiation of a variety of cell types (Yarden and Ullrich, Ann. Rev. Biochem. 57:433-478, 1988; Ullrich and Schlessinger, Cell 61:243-254, 1990).
  • the intrinsic function of RTKs is activated upon ligand binding, which results in phosphorylation of the receptor and multiple cellular substrates, and subsequently in a variety of cellular responses (Ullrich & Schlessinger, 1990, Cell 61:203-212).
  • RTK mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), typically followed by receptor dimerization, stimulation of the intrinsic protein tyrosine kinase activity and receptor trans- phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to tr e formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response such as cell division, differentiation, metabolic effects, and changes in the extracellular microenvironment (see Schlessinger and Ullrich, 1992, Neuron 9:1-20). [9] Proteins with SH2 (src homology -2) or phosphotyrosine binding
  • PTB protein kinase domains bind activated tyrosine kinase receptors and their substrates with high affinity to propagate signals into cell. Both of "the domains recognize phosphotyrosine. (Fantl et al, 1992, Cell 69:4-13-423; Songyang et al, 1994, Mol. Cell. Biol. 14:2777-2785; Songyang et al, 1993, Cell 12:161 -11%; and Koch et al, 1991, Science 252:668-678; Shoelson, Curr Opin. Chem. Biol. (1997), 1(2), 227-234; Cowburn, Curr Opin. Struct. Biol. (1991), 7(6), 835-838).
  • substrate proteins that associate with RTKs have been identified. They may be divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates which lack such a domain but serve as adapters and associate with catalytically active molecules (Songyang et al., 1993, Cell 12:161 '-778). The specificity of the interactions between receptors or proteins and SH2 or PTB domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue.
  • FLK-1 fetal liver kinase 1
  • KDR kinase insert domain-containing receptor
  • VEGFR-2 vascular endothelial cell growth factor receptor 2
  • VEGF vascular endothelial cell growth factor receptor 2
  • NYK vascular endothelial cell growth factor receptor 2
  • Numerous studies suggest that VEGF and FLK- l/KDR/VEGFR-2 are a ligand-receptor pair that play an important role in the proliferation of vascular endothelial cells (vasculogenesis), and the formation and sprouting of blood vessels (angiogenesis).
  • VEGF plays a role in the stimulation of both normal and pathological angiogenesis (Jakeman et al, Endocrinology 133:848-859, 1993; Kolch et al, Breast Cancer Research and Treatment 36: 139-155, 1995; Ferrara et al, Endocrine Reviews 18(1); 4-25, 1997; Ferrara et al., Regulation of Angiogenesis (ed. L D. Goldberg and E.M. Rosen), 209- 232, 1997).
  • VEGF has been implicated in the control and enhancement of vascular permeability (Connolly, et al, 1. Biol. Chem. 264: 20017-20024, 1989; Brown et al, Regulation of Angiogenesis (ed. LD. Goldberg and E.M. Rosen), 233- 269, 1997).
  • Flt-1 farnesoid tyrosine kinase-I
  • VEGFR-1 vascular endothelial cell growth factor receptor 1
  • FLK-l/KDR/VEGFR-2 and Flt-l/VEGPR-1 subfamilies are expressed primarily on endothelial cells. These subclass members are specifically stimulated by members of the VEGF family of ligands (Klagsbum and D'Amore, Cytokine & Growth Factor Reviews 1: 259270,1996).
  • VEGF binds to Flt-1 with higher affinity than to FLK-1/KDR and is mitogenic toward vascular endothelial cells (Terman et al., 1992, supra; Mustonen et al. supra; DeVries et al., supra).
  • Flt-1 is believed to be essential for endothelial organization during vascular development.
  • Flt-1 expression is associated with early vascular development in mouse embryos, and with neovascularization during wound healing (Mustonen and Alitalo, supra). Expression of Flt-1 in monocytes, osteoclasts, and osteob lasts, as well as in adult tissues such as kidney glomeruli suggests an additional function for this receptor that is no related to cell growth (Mustonen and Alitalo, supra).
  • Placenta growth factor has an amino acid sequence that exhibits significant homology to the VEGF sequence (Park et al, 1. Biol. Chem. 269:25646-54,1994; Maglione et ⁇ /. Oncogene 8:925-31, 1993).
  • VEGF vascular endothelial growth factor
  • different species of P IGF arise from alternative splicing of mRNA, and the protein exists in dimeric form (Park et al, supra).
  • P1GF-1 and P1GF-2 bind to Flt-1 with high affinity, and P1GF-2 also avidly binds to neuropilin-1 (Migdal et al, 1. Biol. Chem.
  • VEGF-B is thought to play a role in the regulation of extracellular matrix degradation, cell adhesion, and migration through modulation of the expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1 (Pepper et al, Proc. Natl. Acad. Sci. U. S. A. (1998), 95(20):11709-11714).
  • VEGF-C can also bind KDR/VEGFR-2 and stimulate proliferation and migration of endothelial cells in vitro and angiogenesis in in vivo models (Lymboussaki et. al, Am. JPathol (1998), 153(2):395-403; Witzenbichler et al, Am. J. Pathol (1998), 153(2), 381-394).
  • the transgenic overexpression of VEGF-C causes proliferation and enlargement of only lymphatic vessels, while blood vessels are unaffected.
  • the expression of VEGF-C is not induced by hypoxia (Ristimaki et al, J. Biol. Chem. (1998), 273(14), 8413-8418).
  • VEGF-D Structurally similar to VEGF-C, VEGF-D is reported to bind and activate at least two VEGFRs, VEGFR-3/Flt-4 and KDR/VEGFR-2. It was originally cloned as a c-fos inducible mitogen for fibroblasts and is most prominently expressed in the mesenchymal cells of the lung and skin (Achen et al, Proc. Natl. Acad. Sci. U S. A. (1998), 95(2), 548-553 and references therein).
  • VEGF, VEGF-C and VEGF-D have been claimed to induce increases in vascular permeability in vivo in a Miles assay when injected into cutaneous tissue (PCT/US97/14696; O98/07832, Witzenbichler et al, supra).
  • PCT/US97/14696; O98/07832, Witzenbichler et al, supra The physiological role and significance of these ligands in modulating vascular hyperpermeability and endothelial responses in tissues where they are expressed remains uncertain.
  • Tie-2 is a member of a recently discovered family of endothelial cell specific RTKs involved in critical angiogenic processes such as vessel branching, sprouting, remodeling, maturation and stability. Tie-2 is the first mammalian RTK for which both agonist ligands (e.g., Angiopoietinl ("Angl”), which stimulates receptor autophosphorylation and signal transduction), and antagonist ligands (e.g., Angiopoietin2 (“Ang2”)), have been identified.
  • agonist ligands e.g., Angiopoietinl (“Angl)
  • Ang2 Angiopoietin2
  • Ang2 Angiopoietin2
  • the current model suggests that stimulation of Tie-2 kinase by the Angl ligand is directly involved in the branching, sprouting and outgrowth of new vessels, and recruitment and interaction of periendothelial support cells important in maintaining vessel integrity and inducing quiescence.
  • Tie-2 plays a role in the progression of rheumatoid arthritis.
  • Point mutations producing constitutively activated forms of Tie-2 have been identified in association with human venous malfonnation disorders. Tie-2 inhibitors are, thereful, useful in treating such disorders, and in other situations of inappropriate neovascularization.
  • Non-receptor tyrosine kinases represent a collection of cellular enzymes which lack extracellular and transmembrane sequences (see, Bohlen, 1993, Oncogene 8:2025-2031). Over twenty- four individual non-receptor tyrosine kinases, comprising eleven (11) subfamilies (Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps, Fak, Jak, Ack and LTMK) have been identified.
  • the Src subfamily of non-receptor tyrosine kinases is comprised of the largest number of PTKs and include Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk.
  • the Src subfamily of enzymes has been linked to oncogenesis and immune responses.
  • Plk- 1 is a serine/threonine kinase which is an important regulator of cell cycle progression. It plays critical roles in the assembly and the dynamic function of the mitotic spindle apparatus. Plk -1 and related kinases have also been shown to be closely involved in the activation and inactivation of other cell cycle regulators, such as cyclin-dependent kinases. High levels of Plk-1 expression are associated with cell proliferation activities. It is often found in malignant tumors of various origins. Inhibitors of Plk-1 are expected to block cancer cell proliferation by disrupting processes involving mitotic spindles and inappropriately activated cyclin-dependent kinases.
  • Cdc2 (cdkl)/cyclin B is another serine/threonine kinase enzyme which belongs to the cyclin-dependent kinase (cdks) family. These enzymes are involved in the critical transition between various phases of cell cycle progression. It is believed that uncontrolled cell proliferation, the hallmark of cancer, is dependent upon elevated cdk activities in these cells. The loss of control of cdk regulation is a frequent event in hyperproliferative diseases and cancer (Pines, Current Opinion in Cell Biology, 4:144-148 (1992); Lees, Current Opinion in Cell Biology, 7:773-780 (1995); Hunter and Pines, Cell, 79:573-582 (1994)). The inhibition of elevated cdk activities in cancer cells by cdc2/cyclin B kinase inhibitors could suppress proliferation and may restore the normal control of cell cycle progression.
  • cdks cyclin-dependent kinase
  • Malignant cells are associated with the loss of control over one or more cell cycle elements. These elements range from cell surface receptors to the regulators of transcription and translation, including the insulin-like growth factors, insulin growth factor-I (IGF-1) and insulin growth factor-2 (IGF-2). [M.J. Ellis, "The Insulin-Like Growth Factor Network and Breast Cancer", Breast Cancer, Molecular Genetics, Patho genesis and Therapeutics, Humana Press 1999].
  • the insulin growth factor system consists of families of ligands, insulin growth factor binding proteins, and receptors.
  • IGF-1 A major physiological role of the IGF-1 system is the promotion of normal growth and regeneration, and overexpressed IGF-IR can initiate mitogenesis and promote ligand-dependent neoplastic transformation. Furthermore, IGF-IR plays an important role in the establishment and maintenance of the malignant phenotype..
  • IGF-IR exists as a heterodimer, with several disulfide bridges. The tyrosine kinase catalytic site and the ATP binding site are located on the cytoplasmic portion of the beta subunit. Unlike the epidermal growth factor (EGF) receptor, no mutant oncogenic forms of the IGF-IR have been identified. However, several oncogenes have been demonstrated to affect IGF-1 and IGF-IR expression.
  • EGF epidermal growth factor
  • Apoptosis is a ubiquitous physiological process used to eliminate damaged or unwanted cells in multicellular organisms. Disregulation of apoptosis is believed to be involved in the pathogenesis of many human diseases. The failure of apoptotic cell death has been implicated in various cancers, as well as autoimmune disorders. Conversely, increased apoptosis is associated with a variety of diseases involving cell loss such as neurodegenerative disorders and AIDS. As such, regulators of apoptosis have become an important therapeutic target.
  • IGF-IR abrogates progression into apoptosis, both in vivo and in vitro. It has also been shown that a decrease in the level of IGF-IR below wild-type levels causes apoptosis of tumor cells in vivo. The ability of IGF-IR disruption to cause apoptosis appears to be diminished in normal, non-tumorigenic cells.
  • the type 1 insulin-like growth factor receptor (IGF-IR) is a transmembrane RTK that binds primarily to IGF-1 but also to 1GF-II and insulin with lower affinity. Binding of IGF-1 to its receptor results in receptor oligomerization, activation of tyrosine kinase, intermolecular receptor autophosphorylation and phosphorylation of cellular substrates (major substrates are TRS1 and She). The ligand-activated IGF-IR induces mitogenic activity in normal cells and plays an important role in abnormal growth.
  • IGF-IR insulin-like growth factor receptor
  • IGF-1 pathway important role of the IGF-1 pathway in human tumor development: 1) IGF-IR overexpression is frequently found in various tumors (breast, colon, lung, sarcoma.) and is often associated with an aggressive phenotype. 2) High circulating IGF1 concentrations are strongly correlated with prostate, lung and breast cancer risk. Furthermore, IGF-IR is required for establishment and maintenance of the transformed phenotype in vitro and in vivo (Baserga R. Exp. Cell. Res., 1999, 253, 1-6).
  • IGF-IR The kinase activity of IGF-IR is essential for the transforming activity of several oncogenes: EGFR, PDGFR, SV40 T antigen, activated Ras, Raf, and v-Src.
  • the expression of IGF-IR in normal fibroblasts induces neoplastic phenotypes, which can then form tumors in vivo.
  • IGF- IR expression plays an important role in anchorage-independent growth. IGF-IR has also been shown to protect cells from chemotherapy-, radiation-, and cytokine- induced apoptosis.
  • Examples of such kinase research include, for example: (1) inhibition of c-Src (Brickell, Critical Reviews in Onc ⁇ genesis, 3:401-406 (1992); Courtneidge, Seminars in Cancer Biology, 5:236-246 (1994), raf (Powis, Pharmacology & Therapeutics, 62:57-95 (1994)) and the cyclin-dependent kinases (CDKs) 1, 2 and 4 in cancer (Pines, Current Opinion in Cell Biology, 4:144-148 (1992); Lees, Current Opinion in Cell Biology, 1:113-780 (1995); Hunter and Pines, Cell, 79:573-582 (1994)), (2) inhibition of CDK2 or PDGF-R kinase in restenosis (Buchdunger et al, Proceedings of the National Academy of Science USA, 92:2258- 2262 (1995)), (3) inhibition of CDK5 and GSK3 kinases in Alzheimers (Hosoi et al, Journal of Biochemistry (Tokyo),
  • Inhibitors of certain kinases may be useful in the treatment of diseases when the kinase is not misregulated, but it nonetheless essential for maintenance of the disease state. In this case, inhibition of the kinase activity would act either as a cure or palliative for these diseases.
  • viruses such as human papilloma virus
  • a virus disrupts the cell cycle and drive cells into the S-phase of the cell cycle
  • Preventing cells from entering DNA synthesis after viral infection by inhibition of essential S-phase initiating activities such as CDK2 may disrupt the virus life cycle by preventing virus replication.
  • This same principle may be used to protect normal cells of the body from toxicity of cycle- specific chemotherapeutic agents (Stone et al, Cancer Research, 56:3199-3202 (1996); Kohn et al, Journal of Cellular Biochemistry, 54:44-452 (1994).
  • Inhibition of CDK 2 or 4 will prevent progression into the cycle in normal cells and limit the toxicity of cytotoxics which act in S-phase, G2 or mitosis.
  • CDK2/cyclin E activity has also been shown to regulate
  • NF-kB Inhibition of CDK2 activity stimulates NF-kB-dependent gene expression, an event mediated through interactions with the p300 co-activator (Perkins et al, Science, 275:523-527 (1997)).
  • inhibition of CDK2 may suppress apoptosis induced by cytotoxic drugs via a mechanism which involves NF- kB and be useful where regulation of NF-kB plays a role in etiology of disease.
  • cytotoxic drugs via a mechanism which involves NF- kB and be useful where regulation of NF-kB plays a role in etiology of disease.
  • fungal infections Aspergillosis is a common infection in immune-compromised patients (Armstrong, Clinical Infectious Diseases, 16: 1- 7 (1993)).
  • WO 94/03427 tricyclic polyhydroxylic compounds (International Patent Publication No. WO 92/21660) and benzylphosphonic acid compounds (International Patent Publication No. WO 91/15495) have been described as compounds for use as tyrosine kinase inhibitors for use in the treatment of cancer.
  • Anil ocinnolines (PCT WO97/34876) and quinazoline derivative compounds (International Patent Publication No. WO 97/22596; International Patent Publication No. WO97/42187) have been described as inhibitors of angiogenesis and vascular permeability.
  • IGF-IR performs important roles in cell division, development, and metabolism, and in its activated state, plays a role in oncogenesis and suppression of apoptosis. IGF-IR is known to be overexpressed in a number of cancer cell lines (IGF-IR overexpression is linked to acromegaly and to cancer of the prostate). By contrast, down-regulation of IGF-IR expression has been shown to result in the inhibition of tumorigenesis and an increased apoptosis of tumor cells. [35] International Patent Publication Nos. WO 03/018021 and WO
  • Patent Publication Nos. WO 02/102804 and WO 02/102805 describe cyclolignans and cyclolignans as IGF-IR inhibitors
  • International Patent Publication No. WO 02/092599 describes pyrrolopyrimidines for the treatment of a disease which responds to an inhibition of the IGF-IR tyrosine kinase
  • International Patent Publication No. WO 01/72751 describes pyrrolopyrimidines as tyrosine kinase inhibitors.
  • International Patent Publication No. WO 00/71129 describes pyrrolotriazine inhibitors of ldnases.
  • International Patent Publication No. WO 97/28161 describes pyrrolo [2,3- djpyrimidines and their use as tyrosine ldnase inhibitors.
  • WO 00/17203 describes pyrrolopyrimidines as protein kinase inhibitors.
  • Japanese Patent Publication No. JP 07/133280 describes a cephem compound, its production and antimicrobial composition.
  • A. Albert et al., Journal of the Chemical Society, !_1: 1540-1547 (1970) describes pteridine studies and pteridines unsubstituted in the 4-position, a synthesis from pyrazines via 3,4-dhydropteridines.
  • Formula I inhibit the IGF-IR enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of IGF-IR.
  • the compounds of this invention are useful as inhibitors of serine/threonine and tyrosine kinases.
  • compounds of this invention are useful as inhibitors of tyrosine kinases that are important in hyperproliferative diseases, especially cancer.
  • the present invention relates to a compound of Formula I:
  • Q 1 is aryl 1 , heteroaryl 1 , cycloalkyl, heterocyclyl, cycloalkenyl, or heterocyclo alkenyl, any of which is optionally substituted by one to five independent G 1 substituents;
  • R 1 is alkyl, cycloalkyl, bicycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, or heterobicycloalkyl, any of which is optionally substituted by one or more independent G 11 substituents;
  • G 1 and G 41 are each independently halo, oxo, -CF 3 , -OCF 3 , -OR 2 ,
  • G 11 is halo, oxo, -CF 3 , -OCF 3 , -OR 21 , -NR 21 R 31 (R 3al ) j4 , -C(0)R 21 ,
  • oalkylthioC 2-1 oalkenyl, C 1- ⁇ oalkylthioC 2-10 alkynyl, cycloC 3-8 alkyl, cycloC 3 _salkenyl, cycloC 3-8 alkylC 1-10 alkyl, cycloC 3-8 alkenylC 1-10 alkyl, cycloC 3-8 alkylC 2-10 alkenyl, cycloC 3-8 alkenylC 2-10 alkenyl, cycloC 3-8 alkenylC 2-10 alkenyl, cycloC 3-8 alkylC 2-10 alkynyl, cycloC 3-8 alkenylC 2 -
  • R 222al , R 3331 , and R 333 l are each independently equal to C 0- ⁇ 0 alkyl, C 2-10 alkenyl, C 2- ioalkynyl, C oalkoxyC oalkyl, C 1-1 oalkoxyC 2-1 oalkenyl, C 1-10 alkoxyC 2-1 oalkyn;yl, C ⁇ _ C 1 - 10 alkylthioC 2-1 oalkenyl, C 1-10 alkylthioC 2- ⁇ 0 alkynyl, cycloC 3- 8 alkyl, cycloC -8 alkenyl, cycloC 3-8 alkylC 1-10 alkyl, cycloCs-salkenylCi-ioalkyl, cycloC 3- 8 alkylC 2-10 alkenyl, cycloC 3-8 alkenylC 2-10 alkenyl, cycloC 3-8 alkenylC 2-10 alkenyl,
  • R 10 taken together with the phosphinamide or phosphonamide, is a 5-,
  • R 5 , R 6 , and G 111 are each independently a Co -10 alkyl, C 2-10 alkenyl, C 2 .
  • R 4 is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more G 41 substituents;
  • R 69 is halo, -OR 78 , -SH, -NR 78 R 88 , -CO 2 R 78 , -CONR 78 R 88 , -NO 2 ,
  • n, m, jl, jla, j2a, j3a, j4, j4a, j5a, j6a, j7, and j8 are each independently equal to 0, l, or 2.
  • Formula I or a pharmaceutically acceptable salt thereof, wherein R 1 is cycloalkyl, aryl, heteroaryl, aralkyl, or heterocyclyl, any of which is optionally substituted by one or more G 11 substituents and the other variables are described as above for Formula I.
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is cycloalkyl, optionally substituted by one or more G 11 substituents and the other variables are described as above for Formula I.
  • R 1 is cycloalkyl, optionally substituted by one or more G ⁇ substituents;
  • Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents;
  • G 1 is halo, -OR 2 , -NR 2 R 3 , -C(O)R 2 , -CO 2 R 2 , -CONR 2 R 3 ,
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is cycloalkyl, optionally substituted by one or more G 11 substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents; [61] G 1 is halo, -OR 2 , -NR 2 R 3 , -C(O)R 2 , -CO 2 R 2 , -CONR 2 R 3 ,
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is cycloalkyl, optionally substituted by one or more G 11 substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents; [64] at least one of said G 1 substituents is -(X ⁇ n - ⁇ m -R 4 ; [65] X 1 and Y 1 are each independently equal to -O-, -NR 7 -, -CR 5 R 6 -,
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R is cycloalkyl, optionally substituted by one or more G 11 substituents; wherein Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents;
  • At least one of said G 1 substituents is -(X ⁇ n -O ⁇ m -R 4 ;
  • X 1 and Y 1 are each independently equal to -O- or -CR 5 R 6 -;
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is cycloalkyl, optionally substituted by one or more G substituents; Q is aryl or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents;
  • At least one of said G 1 substituents is -(X ⁇ n - ⁇ -R 4 ;
  • X 1 and Y 1 are each independently equal to -O- or -CH 2 -;
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is cycloalkyl, optionally substituted by one or more G 11 substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents;
  • At least one of said G 1 substituents is -(X ⁇ n -fY ⁇ m -R 4 ;
  • R 4 is H, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G 41 substituents;
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is cycloalkyl, optionally substituted by one or more G u substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents;
  • At least one of said G 1 substituents is -(X 1 ) n -(Y 1 ) m -R 4 ;
  • R 4 is aryl or heteroaryl, optionally substituted by one or more independent G 41 substituents; [82] and the other variables are described as above for Formula I.
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R is cycloalkyl, optionally substituted by one or more G u substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents; [84] at least one of said G 1 substituents is -(X 1 ) n -(Y 1 ) m -R 4 ;
  • R 4 is aryl or heteroaryl, optionally substituted by one or more G 11 substituents;
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R is cycloalkyl substituted by one or more independent G 11 substituents;
  • G 11 is -OR 21 , -NR 21 R 31 , -CO 2 R 21 , -C(O)R 21 , -CONR 21 R 31 ,
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is cis- or trans- cyclobutyl substituted at the 3 -position by G ,
  • G 11 is -OH, -NH 2 , -N(CH 3 ) 2 , -NHAc, -NH(CO)NHCH 3 ,
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R is cis- or trans- cyclohexyl substituted at the 4-position by G 1 ; [97] G 1 r is -OH, -NH 2 , -N(CH 3 ) 2 , -NHAc, -NH(CO)NHCH 3 ,
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein [100] Q 1 is aryl 1 substituted by one to five independent G 1 ; at least one of said G 1 substituents is -(X 1 ) n -(Y 1 ) m -R 4 ; n and m are both equal to 1; [101] x s -O-;
  • R 4 is aryl, optionally substituted by one or more G 41 substituents; 1
  • R is cis- or trans- cyclohexyl substituted at the 4-position by G ;
  • G u is -OH, -NH 2 , -N(CH 3 ) 2 , -NHAc, -NH(CO)NHCH 3 ,
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein [108] Q 1 is aryl 1 substituted by one to five independent G 1 ; at least one of said G 1 substituents is -(X l ) n -(Y l ) m -R 4 ; n and m are both equal to 1; [109] X 1 is -O-;
  • R 4 is aryl, optionally substituted by one or more G 41 substituents
  • R 1 is cis- or trans- cyclobutyl substituted at the 3 -position by G 1 J ;
  • G 11 is -OH, -NH 2 , -N(CH 3 ) 2 , -NHAc, -NH(CO)NHCH 3 ,
  • R 1 is aryl, optionally substituted by one or more G 11 substituents
  • Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents
  • G 1 is halo, -OR 2 , -NR 2 R 3 , -C(O)R 2 , -CO 2 R 2 , -CONR 2 R 3 ,
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R is aryl, optionally substituted by one or more G 11 substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents;
  • G 1 is halo, -OR 2 , -NR 2 R 3 , -C(O)R 2 , -CO 2 R 2 , -CONR 2 R 3 ,
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is aryl, optionally substituted by one or more G 11 substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents;
  • At least one of said G 1 substituents is -(X ⁇ n - ⁇ m -R 4 ;
  • X 1 and Y 1 are each independently equal to -O-, -NR 7 -, -CR 5 R 6 -
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is aryl, optionally substituted by one or more G 11 substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents;
  • At least one of said G 1 substituents is -(X 1 ) n -(Y 1 ) m -R 4 ;
  • X 1 and Y 1 are each independently equal to -O- or -CR 5 R 6 -;
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is aryl, optionally substituted by one or more G 11 substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents;
  • At least one of said G 1 substituents is -(X 1 ) n -(Y ) m -R ;
  • X 1 and Y 1 are each independently equal to -O- or -CH 2 -;
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is aryl, optionally substituted by one or more G 11 substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents;
  • At least one of said G 1 substituents is -(X 1 ) n -(Y 1 ) m -R 4 ;
  • R 4 is H, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G 41 substituents;
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is aryl, optionally substituted by one or more G 11 substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents;
  • At least one of said G 1 substituents is -(X 1 ) n -(Y 1 ) m -R 4 ;
  • R 4 is aryl or heteroaryl, optionally substituted by one or more independent G 41 substituents;
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is aryl, optionally substituted by one or more G 11 substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is_substituted by one to five independent G 1 substituents;
  • At least one of said G 1 substituents is -(X 1 ) n -(Y 1 ) m -R 4 ;
  • R 4 is aryl or heteroaryl, optionally substituted by one or more G 41 substituents;
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein [147] R 1 is cycloalkyl substituted by one or more independent G substituents,
  • G u is -OR 21 , -NR 1 R 31 (R 31a ) j4 , -C(O)R 21 , -CO 2 R 21 , -CONR 21 R 31 ,
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein [151] R 1 is cycloalkyl substituted by one or more independent G substituents;
  • G u is -OR 21 , -NR 21 R 31 , -CO 2 R 21 , -C(O)R 21 , -CONR 21 R 31 ,
  • a compound is represented by Formula I, or a phannaceutically acceptable salt thereof, wherein 1 1 1
  • R is phenyl optionally substituted by one or more independent G substituents
  • a compound is represented by Formula I, or a phannaceutically acceptable salt thereof, wherein
  • Q 1 is aryl 1 substituted by one to five G 1 substituents; at least one of said G 1 substituents is -(X 1 ) n -(Y 1 ) m -R 4 ;
  • Y 1 is -CH 2 -;
  • R 4 is aryl, optionally substituted by one or more G 41 substituents
  • R 1 is phenyl substituted by one or more independent G 11 substituents
  • a compound is represented by Formula I, or a salt thereof, wherein R 1 is heterocyclyl, optionally substituted by one or more G n substituents and the other variables are described as above for Formula I.
  • R 1 is heterocyclyl, optionally substituted by one or more G 11 substituents
  • Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G substituents
  • G 1 is halo, -OR 2 , -NR 2 R 3 , -C(O)R 2 , -CO 2 R 2 , -CONR 2 R 3 ,
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is heterocyclyl, optionally substituted by one or more G 11 substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to fivejndependent G 1 substituents; [ 169] G 1 is halo, -OR 2 , -NR 2 R 3 , -C(O)R 2 , -CO 2 R 2 , -CONR 2 R 3 ,
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is heterocyclyl, optionally substituted by one or more G 11 substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents; [172] wherein at least one of said G 1 substituents is -(X 1 ) n -(Y 1 ) m -R 4 ;
  • X 1 and Y 1 are each independently equal to -O-, -NR 7 -, -CR 5 R 6 -
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is heterocyclyl, optionally substituted by one or more G 11 substituents; Q 1 is aryl 1 or 1 1 heteroaryl , any of which is substituted by one to five independent G substituents; [176] at least one of said G 1 substituents is -(X 1 ) n -(Y 1 ) m -R 4 ;
  • X 1 and Y 1 are each independently equal to -O- or -CR 5 R 6 -;
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is heterocyclyl, optionally substituted by one or more G ⁇ substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents; [180] wherein at least one of said G 1 substituents is -(X 1 ) n -(Y 1 ) m -R 4 ;
  • X 1 and Y 1 are each independently equal to -O- or -CH 2 -;
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 is heterocyclyl, optionally substituted by one or more G 11 substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents; [184] wherein at least one of said G 1 substituents is -(X 1 ) n -(Y 1 ) m -R 4 ; [185] R 4 is H, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G 41 substituents; [186] and the other variables are described as above for Formula I.
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R is heterocyclyl, optionally substituted by one or more G 11 substituents; Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents;
  • R 4 is aryl or heteroaryl, optionally substituted by one or more independent G 41 substituents;
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein Q 1 is aryl 1 or heteroaryl 1 , any of which is substituted by one to five independent G 1 substituents;
  • R 4 is aryl or heteroaryl, optionally substituted by one or more G 41 substituents;
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R 1 is heterocyclyl represented by the structural formula:
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein [ 199] R is heterocyclyl represented by the structural formula:
  • G 1 ! is equal to -C(O)R 2 , -CO 2 R 2 , -CONR 2 R 3 , -SO 2 NR 2 R 3 ,
  • a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein [203] R 1 is heterocyclyl represented by the structural formula:
  • G 11 is equal to -C(O)R 2 , -CO 2 R 2 , -CONR 2 R 3 , -SO 2 NR 2 R 3 ,
  • a compound is represented by Formula I, or a phannaceutically acceptable salt thereof, wherein [207] R 1 is heterocyclyl represented by the structural formula:
  • G 11 is equal to -C(O)R 2 , -CO 2 R 2 , -CONR 2 R 3 , -SO 2 NR 2 R 3 ,
  • G 11 is equal to -C(O)R 2 , -CO 2 R 2 , -CONR 2 R 3 , -SO 2 NR 2 R 3 ,
  • the compounds of the present invention include compounds represented by Formula I, or a pharmaceutically salt thereof,
  • Q 1 is aryl 1 or heteroaryl 1 , any of which is optionally substituted by one or more independent G 1 substituents;
  • Q 1 is heteroaryl 1 , any of which is optionally substituted by one or more independent G 1 substituents; or
  • G 1 is halo, -CF 3 , -OCF 3 , -OR 2 , -NR 2 R 3 , -C(O)R 2 , -CO 2 R 2 ,
  • G 1 is halo, -OR 2 , -NR 2 R 3 , -C(O)R 2 , -CO 2 R 2 , -CONR 2 R 3 ,
  • X 1 and Y 1 are each independently -O-, -NR 7 -, -S(O) j7 -
  • G 1 substituents wherein at least one of said G 1 substituents is -(X 1 ) n -(Y 1 ) m -R 4 J and wherein X 1 and Y 1 are each independently equal to -O-, -NR 7 -, -CR 5 R -, -S(O)j 7 -, or -C(O)-, and wherein n and m are both equal to 1 and j ' 7 is equal to 1 or 2; or
  • Q 1 is substituted by said one to five independent G 1 substituents wherein at least one of said G 1 substituents is -(X 1 ) n -(Y 1 ) m -R 4 , and wherein X 1 and Y 1 are each independently -O- or -CR 5 R 6 -, and wherein n and m are equal to 1; or
  • R 1 is cycloalkyl, bicycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, or heterobicycloalkyl, any of which is optionally substituted by one or more independent G 11 substituents; or
  • R 1 is cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, or heterocyclyl, any of which is optionally substituted by one or more independent G 11 substituents; or
  • R 1 is cycloalkyl or heterocyclyl, any of which is optionally substituted by one or more independent G 11 substituents;
  • R 1 is cycloalkyl optionally substituted by one or more independent G 11 substituents
  • R 1 is heterocyclyl optionally substituted by one or more independent G 11 substituents
  • R 1 is aryl, heteroaryl, aralkyl, or heteroaralkyl, any of which is optionally substituted by one or more independent G 11 substituents;
  • R 1 is aryl or heteroaryl, any of which is optionally substituted by one or more independent G 11 substituents;
  • G 11 is -OR 21 , -NR 21 R 31 (R 31a ) j4 , -C(O)R 21 , -CO 2 R 21 ,
  • G 11 is -OR 21 , -NR 21 R 31 , -CO 2 R 21 , -C(O)R 21 , -CONR 21 R 31 ,
  • R 4 is alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G 41 substituents; or wherein Q 1 is phenyl substituted by said one to five independent G 1 substituents wherein at least one of said G 1 substituents is
  • R 1 is aryl, heteroaryl, cycloalkyl or heterocyclyl, optionally substituted by one or more independent G 11 substituents;
  • R 1 is cycloalkyl or heterocyclyl, optionally substituted by one or more independent G 11 substituents;
  • R 1 is cycloalkyl, optionally substituted by one or more independent G 11 substituents;
  • R 1 is cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted by one or more independent G 11 substituents;
  • G 11 is -OR 21 , -NR 21 R 31 , -CO 2 R 21 , -C(O)R 21 , -CONR 21 R 31 ,
  • R 1 is cycloalkyl or heterocyclyl, optionally substituted by one or more independent G 11 substituents;
  • R 1 is cycloalkyl, optionally substituted by one or more independent G 11 substituents;
  • R 1 is cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted by one or more independent G 11 substituents;
  • G 11 is -OR 21 , -NR 21 R 31 , -CO 2 R 21 , -C(O)R 21 , -CONR 21 R 31 ,
  • R 1 is aryl, heteroaryl, cycloalkyl or heterocyclyl, optionally substituted by one or more independent G 11 substituents;
  • R 1 is cycloalkyl or heterocyclyl, optionally substituted by one or more independent G 11 substituents;
  • R 1 is cycloalkyl, optionally substituted by one or more independent G 11 substituents;
  • R 1 is cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted by one or more independent G 11 substituents; or [252] wherein G 11 is -OR 21 , -NR 21 R 31 , -CO 2 R 21 , -C(O)R 21 , -CONR 21 R 31 ,
  • R 4 is (C 0 -C 6 )alkyl
  • R 4 is H or methyl
  • R 4 is H or methyl
  • R 1 is aryl, heteroaryl, cycloalkyl or heterocyclyl, optionally substituted by one or more independent G 11 substituents;
  • R 1 is cycloalkyl or heterocyclyl, optionally substituted by one or more independent G 11 substituents;
  • R 1 is cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted by one or more independent G 11 substituents;
  • G 11 is -OR 21 , -NR 21 R 31 , -CO 2 R 21 , -C(O)R 21 , -CONR 21 R 31 ,
  • R 4 is phenyl optionally substituted with G 41 ;
  • R 1 is aryl, heteroaryl, cycloalkyl or heterocyclyl, optionally substituted by one or more independent G 11 substituents;
  • R 1 is cycloalkyl or heterocyclyl, optionally substituted by one or more independent G 11 substituents;
  • R 1 is cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted by one or more independent G 11 substituents;
  • G ⁇ is -OR 21 , -NR 21 R 31 , -CO 2 R 21 , -C(O)R 21 , -CONR 21 R 31 ,
  • R 1 is cis- or trans- cyclobutyl substituted at the 3 -position by
  • G 11 wherein G 11 is -OH, -NH 2 , -N(CH 3 ) 2 , -NHAc, -NH(CO)NHCH 3 ,
  • R 1 is cis- or trans- cyclohexyl substituted at the 4-position by
  • G 11 wherein G 11 is -OH, -NH 2 , -N(CH 3 ) 2 , -NHAc, -NH(CO)NHCH 3 , -NH(CO)OCH 3 , -CH 2 OH, -CH 2 NH 2 , -CH 2 NHAc, CO 2 H, CONH 2 , -CH 2 N(CH 3 ) 2 , -CH 2 NH(CO)NHMe, -CH 2 NH(CO)OCH 3 , CO 2 CH 3 , CONHCH 3 ,
  • the present invention includes a method of inhibiting protein kinase activity comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of inhibiting IGF-IR activity comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of inhibiting protein kinase activity wherein the activity of said protein kinase affects hyperproliferative disorders comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of inhibiting protein kinase activity wherein the activity of said protein kinase influences angiogenesis, vascular permeability, immune response, cellular apoptosis, tumor growth, or inflammation comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity, said method comprising administering to the patient a therapeutically effective amount of a compound of
  • the present invention includes a method of treating a patient having a condition which is mediated by IGF-IR activity, said method comprising administering to the patient a therapeutically effective amount of a compound of
  • the present invention includes a method of treating a patient having a hyperproliferative disorder, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the activity of said protein kinase influences angiogenesis, vascular permeability, immune response, cellular apoptosis, tumor growth, or inflammation, said method comprising administering to the patient a therapeutically effective amount of a compound of
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the protein kinase is a protein serine/threonine kinase or a protein tyrosine kinase, said method comprising administering to the patient a therapeutically effective amount of a compound of
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is one or more ulcers, said method comprising administering to the patient a therapeutically effective amount of a compound of
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is one or more ulcers wherein the ulcer or ulcers are caused by a bacterial or fungal infection; or the ulcer or ulcers are Mooren ulcers; or the ulcer or ulcers are a symptom of ulcerative colitis, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is Lyme disease, sepsis or infection by Herpes simplex, Herpes Zoster, human immunodeficiency virus, parapoxvirus, protozoa, or toxoplasmosis, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is Lyme disease, sepsis or infection by Herpes simplex, Herpes Zoster, human immunodeficiency virus, parapoxvirus, protozoa, or toxoplasmosis, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is von Hippel Lindau disease, pemphigoid, psoriasis, Paget's disease, or polycystic kidney disease, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is fibrosis, sarcoidosis, cirrhosis, thyroiditis, hyperviscosity syndrome, Osier- Weber-Rendu disease, chronic occlusive pulmonary disease, asthma, exudtaes, ascites, pleural effusions, pulmonary edema, cerebral edema or edema following burns, trauma, radiation, stroke, hypoxia, or ischemia, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition wliich is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is ovarian hyperstimulation syndrome, preeclainpsia, menometrorrhagia, or endometriosis, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase-activity is chronic inflammation, systemic lupus, glomerulonephritis, synovitis, inflammatory bowel disease, Crohn's disease, glomerulonephritis, rheumatoid arthritis and osteoarthritis, multiple sclerosis, or graft rejection, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is sickle cell anaemia, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is an ocular condition, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is an ocular condition wherein the ocular condition is ocular or macular edema, ocular neovascular disease, seleritis, radial keratotomy, uveitis, vitritis, myopia, optic pits, chronic retinal detachment, post-laser treatment complications, conjunctivitis, Stargardt's disease, Eales disease, retinopathy, or macular degeneration, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is a cardiovascular condition, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is atherosclerosis, restenosis, ischemia/reperfusion injury, vascular occlusion, venous malformation, or carotid obstructive disease, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is cancer, said method comprising admimstering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is cancer wherein the cancer is a solid tumor, a sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, a rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, an hematopoietic malignancy, or malignant ascites, said method comprising administering to the patient a therapeutically effective amount of a compound of Fonnula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is cancer wherein the cancer is Kaposi's sarcoma, Hodgkin's disease, lymphoma, myeloma, or leukemia, said method comprising administering to the patient a therapeutically effective amount of a compound of Fonnula I or a pharmaceutically acceptable salt thereof.
  • the present invention includes a method of treating a patient having a condition wliich is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is Crow-Fukase (POEMS) syndrome or a diabetic condition, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • POEMS Crow-Fukase
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is Crow-Fukase (POEMS) syndrome or a diabetic condition wherein the diabetic condition is insulin-dependent diabetes mellitus glaucoma, diabetic retinopathy, or microangiopathy, said method comprising admimstering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • POEMS Crow-Fukase
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the protein kinase activity is involved in T cell activation, B cell activation, mast cell degranulation, monocyte activation, signal transduction, apoptosis, the potentiation of an inflammatory response or a combination thereof, said method comprising administering to the patient a therapeutically effective amount of a compound of
  • the present invention includes a composition comprising a compound according to Formula I, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
  • the present invention includes a composition comprising a compound according to Formula I, or a pharmaceutically acceptable salt thereof; and an anti- neoplastic, anti-tumor, anti-angiogenic, or chemotherapeutic agent.
  • the present invention includes a composition comprising a compound according to Formula I, or a pharmaceutically acceptable salt thereof; and a cytotoxic cancer therapeutic agent.
  • the present invention includes a composition comprising a compound according to Formula I, or a pharmaceutically acceptable salt thereof; and an angiogenesis inhibiting cancer therapeutic agent.
  • the present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity, said method comprising admimstering to the patient a therapeutically effective amount of a pharmaceutical composition comprising a compound according to Formula I, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
  • connection of compound name moieties are at the rightmost recited moiety. That is, the substituent name starts with a terminal moiety, continues with any bridging moieties, and ends with the connecting moiety.
  • substituent name starts with a terminal moiety, continues with any bridging moieties, and ends with the connecting moiety.
  • hetarylthioC 1- alkyl has a heteroaryl group connected through a thio sulfur to a C 1-4 alkyl that connects to the chemical species bearing the substituent.
  • Co -4 alkyl is used to mean an alkyl having 0-4 carbons - that is, 0, 1, 2, 3, or 4 carbons in a straight or branched configuration.
  • An alkyl having no carbon is hydrogen when the alkyl is a terminal group.
  • An alkyl having no carbon is a direct bond when the alkyl is a bridging
  • alkyl includes both branched and straight chain alkyl groups. Typical alkyl groups are methyl, ethyl, n- propyl, isopropyl, ra-butyl, see-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, isooctyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, hexadecyl, octadecyl, eicosyl and the like.
  • halo refers to fluoro, chloro, bromo or iodo.
  • haloalkyl refers to an alkyl group substituted with one or more halo groups, for example chloromethyl, 2-bromoethyl, 3-iodopropyl, trifluoromethyl, perfluoropropyl, 8-chlorononyl and the like.
  • cycloalkyl refers to a cyclic aliphatic ring structure, optionally substituted with alkyl, hydroxy and halo, such as cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl, 2-hydroxycyclopentyl, cyclohexyl, 4- chlorocyclohexyl, cycloheptyl, cyclooctyl and the like.
  • alkylcarbonyloxyalkyl refers to an ester moiety, for example acetoxymethyl, «-butyryloxyethyl and the like.
  • alkynylcarbonyl refers to an alkynylketo functionality, for example propynoyl and the like.
  • hydroxyalkyl refers to an alkyl group substituted with one or more hydroxy groups, for example hydroxymethyl, 2,3-dihydroxybutyl and the like.
  • alkylsulfonylalkyl refers to an alkyl group substituted with an alkylsulfonyl moiety, for example mesylmethyl, isopropylsulfonylethyl and the like.
  • alkylsulfonyl refers to a sulfonyl moiety substituted with an alkyl group, for example mesyl, H-propylsulfonyl and the like.
  • acetylaminoalkyl refers to an alkyl group substituted with an amide moiety, for example acetylaminomethyl and the like.
  • acetylaminoalkenyl refers to an alkenyl group substituted with an amide moiety, for example 2-(acetylamino)vinyl and the like.
  • alkenyl refers to an ethylenically unsaturated hydrocarbon group, straight or branched chain, having 1 or 2 ethylenic bonds, for example vinyl, allyl, 1-butenyl, 2-butenyl, isopropenyl, 2- ⁇ entenyl and the like.
  • haloalkenyl refers to an alkenyl group substituted with one or more halo groups.
  • cycloalkenyl refers to a cyclic aliphatic ring structure, optionally substituted with alkyl, hydroxy and halo, having 1 or 2 ethylenic bonds such as methylcyclopropenyl, trifluoromethylcyclopropenyl, cyclopentenyl, cyclohexenyl, 1,4-cyclohexadienyl and the like.
  • alkynyl refers to an unsaturated hydrocarbon group, straight or branched, having 1 or 2 acetylenic bonds, for example ethynyl, propargyl and the like.
  • haloalkynyl refers to an alkynyl group substituted with one or more halo groups.
  • alkylcarbonyl refers to an alkylketo functionality, for example acetyl, n-butyryl and the like.
  • alkenylcarbonyl refers to an alkenylketo functionality, for example, propenoyl and the like.
  • aryl refers to phenyl or naphthyl which may be optionally substituted.
  • Typical aryl substituents include, but are not limited to, phenyl, 4- chlorophenyl, 4-fluorophenyl, 4-bromophenyl, 3-nitrophenyl, 2-methoxyphenyl, 2- methylphenyl, 3-methyphenyl, 4-methylphenyl, 4-ethylphenyl, 2-methyl-3- methoxyphenyl, 2,4-dibromophenyl, 3,5-difluorophenyl, 3,5-dimethylphenyl, 2,4,6- trichlorophenyl, 4-methoxyphenyl, naphthyl, 2-chloronaphthyl, 2,4-dimethoxyphenyl, 4-(trifluoromethyl)phenyl and 2-iodo-4-methylphenyl.
  • aryl ⁇ ' refers to phenyl which may be optionally substituted.
  • Typical aryl 1 substituents include, but are not limited to, phenyl, 4-chlorophenyl, 4- fluorophenyl, 4-bromophenyl, 3-nitrophenyl, 2-methoxyphenyl, 2-methylphenyl, 3- methyphenyl, 4-methylphenyl, 4-ethylphenyl, 2-methyl-3-methoxyphenyl, 2,4- dibromophenyl, 3,5-difluorophenyl, 3,5-dimethylphenyl, 2,4,6-trichlorophenyl, 4- methoxyphenyl, 2,4-dimethoxyphenyl, 4-(trifluoromethyl)phenyl and 2-iodo-4- methylphenyl.
  • heteroaryl or “hetaryl” refer to a substituted or unsubstituted 5- or 6-membered unsaturated ring containing one, two, three or four heteroatoms, preferably one or two heteroatoms independently selected from oxygen, nitrogen and sulfur or to a bicyclic unsaturated ring system containing up to 10 atoms including one heteroatom selected from oxygen, nitrogen and sulfur.
  • hetaryls include, but are not limited to, 2-, 3- or 4-pyridinyl, pyrazinyl, 2-, 4-, or 5- pyrimidinyl, pyridazinyl, triazolyl, tetrazolyl, imidazolyl, 2- or 3-thienyl, 2- or 3- furyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzimidazolyl, benzotriazolyl, benzofuranyl, and benzothienyl.
  • heterocyclic ring may be optionally substituted with up to two substituents.
  • heteroaryl 1 or “hetaryl 1” refer to a substituted or unsubstituted 5- or 6-membered unsaturated ring containing one, two, three or four heteroatoms, preferably one or two heteroatoms independently selected from oxygen, nitrogen and sulfur.
  • hetaryls include, but are not limited to, 2-, 3- or 4- pyridinyl, pyrazinyl, 2-, 4-, or 5-pyrimidinyl, pyridazinyl, triazolyl, tetrazolyl, imidazolyl, 2- or 3-thienyl, 2- or 3-furyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl.
  • the heterocyclic ring may be optionally substituted with up to two substituents.
  • aryl-alkyl or "arylalkyl” are used to describe a group wherein the alkyl chain can be branched or straight chain with the aryl portion, as defined hereinbefore, forming a bridging portion of the aryl-alkyl moiety.
  • aryl-alkyl groups include, but are not limited to, optionally substituted benzyl, phenethyl, phenpropyl and phenbutyl such as 4-chlorobenzyl, 2,4-dibromobenzyl, 2- methylbenzyl, 2-(3-fluorophenyl)ethyl, 2-(4-methylphenyl)ethyl, 2-(4-
  • aryl-cycloalkyl or "arylcycloalkyl” are used to describe a group wherein the aryl group is attached to a cycloalkyl group, for example phenylcyclopentyl and the like.
  • aryl-alkenyl or "arylalkenyl” are used to describe a group wherein the alkenyl chain can be branched or straight chain with the aryl portion, as defined hereinbefore, forming a bridging portion of the aralkenyl moiety, for example styryl (2-phenylvinyl), phenpropenyl and the like.
  • aryl-alkynyl or "arylalkynyl” are used to describe a group wherein the alkynyl chain can be branched or straight chain with the aryl portion, as defined hereinbefore, forming a bridging portion of the aryl-alkynyl moiety, for example 3 -phenyl- 1-propynyl and the like.
  • aryl-oxy or "aryloxy” are used to describe a terminal aryl group attached to a bridging oxygen atom.
  • Typical aryl-oxy groups include phenoxy,
  • aryl-oxyalkyl or "aryloxyalkyl” are used to describe a group wherein an alkyl group is substituted with an aryl-oxy group, for example pentafluorophenoxymethyl and the like.
  • heteroaryloxy are used to describe a terminal hetaryl group attached to a bridging oxygen atom.
  • Typical hetaryl-oxy groups include 4,6-dimethoxypyrimidin-2-yloxy and the like.
  • heteroarylalkyl or “heteroarylalkyl” or “hetaryl-alkyl” or
  • heteroaryl-alkyl are used to describe a group wherein the alkyl chain can be branched or straight chain with the heteroaryl portion, as defined hereinbefore, forming a bridging portion of the heteroaralkyl moiety, for example 3-furylmethyl, thenyl, furfuryl and the like.
  • heteroarylalkenyl or “heteroarylalkenyl” or “hetaryl-alkenyl” or “heteroaryl-alkenyl” are used to describe a group wherein the alkenyl chain can be branched or straight chain with the heteroaryl portion, as defined hereinbefore, forming a bridging portion of the heteroaralkenyl moiety, for example 3-(4-pyridyl)- 1-propenyl.
  • heteroaryl-alkynyl or “heteroaryl-alkynyl” are used to describe a group wherein the alkynyl chain can be branched or straight chain with the heteroaryl portion, as defined hereinbefore, forming a bridging portion of the heteroaralkynyl moiety, for example 4-(2-thienyl)- 1 -butynyl.
  • heterocyclyl refers to a substituted or unsubstituted 5 or 6 membered saturated ring containing one, two or three heteroatoms, preferably one or two heteroatoms independently selected from oxygen, nitrogen and sulfur or to a bicyclic ring system containing up to 10 atoms including one heteroatom selected from oxygen, nitrogen and sulfur wherein the ring containing the heteroatom is saturated.
  • heterocyclyls include, but are not limited to, tetrahydrofuranyl, tetrahydrofuryl, pyrrolidinyl, piperidinyl, 4-pyranyl, tetrahydropyranyl, thiolanyl, morpholinyl, piperazinyl, dioxolanyl, dioxanyl, indolinyl, 5-methyl-6-chromanyl and
  • heterocyclylalkyl or “heterocyclyl-alkyl” are used to describe a group wherein the alkyl chain can be branched or straight chain with the heterocyclyl portion, as defined hereinabove, forming a bridging portion of the heterocyclylalkyl moiety, for example 3-piperidinyhnethyl and the like.
  • heterocyclylalkenyl or “heterocyclyl-alkenyl” are used to describe a group wherein the alkenyl chain can be branched or straight chain with the heterocyclyl portion, as defined hereinbefore, forming a bridging portion of the heterocyclylalkenyl moiety, for example 2-morpholinyl-l-propenyl.
  • heterocyclylalkynyl or “heterocyclyl-alkynyl” are used to describe a group wherein the alkynyl chain can be branched or straight chain with the heterocyclyl portion, as defined hereinbefore, forming a bridging portion of the heterocyclylalkynyl moiety, for example 2-pyrrolidinyl-l-butynyl.
  • carboxylalkyl includes both branched and straight chain alkyl groups as defined hereinbefore attached to a carboxyl (-COOH) group.
  • carboxylalkenyl includes both branched and straight chain alkenyl groups as defined hereinbefore attached to a carboxyl (-COOH) group.
  • carboxylalkynyl includes both branched and straight chain alkynyl groups as defined hereinbefore attached to a carboxyl (-COOH) group.
  • carboxylcycloalkyl refers to a carboxyl (-COOH) group attached to a cyclic aliphatic ring structure as defined hereinbefore.
  • carboxylcycloalkenyl refers to a carboxyl (-COOH) group attached to a cyclic aliphatic ring structure having 1 or 2 ethylenic bonds as defined hereinbefore.
  • cycloalkylalkyl or "cycloalkyl-alkyl” refer to a cycloalkyl group as defined hereinbefore attached to an alkyl group, for example cyclopropylmethyl, cyclohexylethyl and the like.
  • cycloalkylalkenyl or "cycloalkyl-alkenyl” refer to a cycloalkyl group as defined hereinbefore attached to an alkenyl group, for example cyclohexylvinyl, cycloheptylallyl and the like.
  • cycloalkylalkynyl or "cycloalkyl-alkynyl” refer to a cycloalkyl group as defined hereinbefore attached to an alkynyl group, for example cyclopropylpropargyl, 4-cyclopentyl-2-butynyl and the like.
  • cycloalkenylalkyl or “cycloalkenyl-alkyl” refer to a cycloalkenyl group as defined hereinbefore attached to an alkyl group, for example 2-
  • cycloalkenylalkenyl or “cycloalkenyl-alkenyl” refer to a cycloalkenyl group as defined hereinbefore attached to an alkenyl group, for example l-(cyclohexen-3-yl)allyl and the like.
  • cycloalkenylalkynyl or “cycloalkenyl-alkynyl” refer to a cycloalkenyl group as defined hereinbefore attached to an alkynyl group, for example l-(cyclohexen-3-yl)propargyl and the like.
  • carboxylcycloalkylalkyl refers to a carboxyl (-COOH) group attached to the cycloalkyl ring portion of a cycloalkylalkyl group as defined hereinbefore.
  • carboxyl (-COOH) group attached to the cycloalkyl ring portion of a cycloalkylalkenyl group as defined hereinbefore.
  • carboxylcycloalkylalkynyl refers to a carboxyl (-COOH) group attached to the cycloalkyl ring portion of a cycloalkylalkynyl group as defined hereinbefore.
  • carboxylcycloalkenylalkyl refers to a carboxyl (-COOH) group attached to the cycloalkenyl ring portion of a cycloalkenylalkyl group as defined hereinbefore.
  • carboxylcycloalkenylalkenyl refers to a carboxyl (-COOH) group attached to the cycloalkenyl ring portion of a cycloalkenylalkenyl group as defined hereinbefore.
  • carboxylcycloalkenylalkynyl refers to a carboxyl (-COOH) group attached to the cycloalkenyl ring portion of a cycloalkenylalkynyl group as defined hereinbefore.
  • alkoxy includes both branched and straight chain terminal alkyl groups attached to a bridging oxygen atom. Typical alkoxy groups include methoxy, ethoxy, ⁇ -propoxy, isopropoxy, tert-butoxy and the like.
  • haloalkoxy refers to an alkoxy group substituted with one or more halo groups, for example chloromethoxy, trifluoromethoxy, difluoromethoxy, perfluoroisobutoxy and the like.
  • alkoxyalkoxyalkyl refers to an alkyl group substituted with an alkoxy moiety which is in turn substituted with a second alkoxy moiety, for example methoxymethoxymethyl, isopropoxymethoxyethyl and the like.
  • alkylthio includes both branched and straight chain alkyl groups attached to a bridging sulfur atom, for example methylthio.
  • haloalkylthio refers to an alkylthio group substituted with one or more halo groups, for example trifluoromethylthio.
  • alkoxyalkyl refers to an alkyl group substituted with an alkoxy group, for example isopropoxymethyl.
  • alkoxyalkenyl refers to an alkenyl group substituted with an alkoxy group, for example 3-methoxyallyl.
  • alkoxyalkynyl refers to an alkynyl group substituted with an alkoxy group, for example 3-methoxypropargyl.
  • alkoxycarbonylalkyl refers to a straight chain or branched alkyl substituted with an alkoxycarbonyl, for example ethoxycarbonylmethyl, 2-
  • alkoxycarbonylalkenyl refers to a straight chain or branched alkenyl as defined hereinbefore substituted with an alkoxycarbonyl, for example 4-(ethoxycarbonyl)-2-butenyl and the like.
  • alkoxycarbonylalkynyl refers to a straight chain or branched alkynyl as defined hereinbefore substituted with an alkoxycarbonyl, for example 4-(ethoxycarbonyl)-2-butynyl and the like.
  • haloalkoxyalkyl refers to a straight chain or branched alkyl as defined hereinbefore substituted with a haloalkoxy, for example 2- chloroethoxyniethyl, trifluoromethoxymethyl and the like.
  • haloalkoxyalkenyl refers to a straight chain or branched alkenyl as defined hereinbefore substituted with a haloalkoxy, for example 4-
  • haloalkoxyalkynyl refers to a straight chain or branched alkynyl as defined hereinbefore substituted with a haloalkoxy, for example 4-(2- fluoroethoxy)-2-butynyl and the like.
  • alkylthioalkyl refers to a straight chain or branched alkyl as defined hereinbefore substituted with an alkylthio group, for example methylthiomethyl, 3-(isobutylthio)heptyl and the like.
  • alkylthioalkenyl refers to a straight chain or branched allcenyl as defined hereinbefore substituted with an allcylthio group, for example 4-
  • alkylthioalkynyl refers to a straight chain or branched alkynyl as defined hereinbefore substituted with an alkylthio group, for example 4-
  • haloalkylthioalkyl refers to a straight chain or branched alkyl as defined hereinbefore substituted with an haloalkylthio group, for example 2- chloroethylthiomethyl, trifluoromethylthiomethyl and the like.
  • haloalkylthioalkenyl refers to a straight chain or branched alkenyl as defined hereinbefore substituted with an haloalkylthio group, for example
  • haloalkylthioalkynyl refers to a straight chain or branched alkynyl as defined hereinbefore substituted with a haloalkylthio group, for example 4-
  • dialkoxyphosphorylalkyl refers to two straight chain or branched alkoxy groups as defined hereinbefore attached to a pentavalent phosphorous atom, containing an oxo substituent, which is in turn attached to an alkyl, for example diethoxyphosphorylmethyl.
  • oligomer refers to a low-molecular weight polymer, whose number average molecular weight is typically less than about 5000 g/mol, and whose degree of polymerization (average number of monomer units per chain) is greater than one and typically equal to or less than about 50.
  • the invention also encompasses a pharmaceutical composition that is comprised of a compound of Formula I in combination with a pharmaceutically acceptable carrier.
  • the composition is comprised of a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of a compound of Formula I as described above (or a pharmaceutically acceptable salt thereof).
  • the invention encompasses a pharmaceutical composition for the treatment of disease by inhibiting kinases, comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula I as described above (or a pharmaceutically acceptable salt thereof).
  • salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
  • the compound of the present invention is acidic, its corcesponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Particularly prefened are the ammonium, calcium, magnesium, potassium and sodium slats.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines.
  • Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N',N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmo holine, N- ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylameine, tri
  • the compound of the present invention is basic, its conesponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, formic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methaiiesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
  • compositions of the present invention comprise a compound represented by Formula I (or a pharmaceutically acceptable salt thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.
  • the compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
  • the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • the compounds represented by Formula I, or a prodrug, or a metabolite, or a pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
  • the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
  • compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in- water emulsion, or as a water-in-oil liquid emulsion, addition to the common dosage forms set out above, the compound represented by Formula I, or a pharmaceutically acceptable salt thereof, may also be administered by controlled release means and/or delivery devices.
  • the compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both.
  • the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound, or a pharmaceutically acceptable salt, of Formula I.
  • the compounds of Formula I, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
  • the pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
  • solid carriers include lactose, tena alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
  • liquid carriers are sugar syrup, peanut oil, olive oil, and water.
  • gaseous carriers include carbon dioxide and nitrogen.
  • any convenient pharmaceutical media may be employed.
  • water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the prefened oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques.
  • a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient.
  • a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
  • Unit dosage fonns will generally contain between from about lmg to about 2g of the active ingredient, typically 25mg, 50mg, lOOmg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or lOOOmg.
  • Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
  • a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
  • Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions, i all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability.
  • the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
  • Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention, or a pharmaceutically acceptable salt thereof, via conventional processing methods.
  • a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt% to about 10wt% of the compound, to produce a cream or ointment having a desired consistency.
  • compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds. [398] In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound described by Formula I, or pharmaceutically acceptable salts thereof, may also be prepared in powder or liquid concentrate form.
  • dosage levels on the order of from about O.Olmg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above- indicated conditions, or alternatively about 0.5mg to about 7g per patient per day.
  • inflammation, cancer, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS), cardiovascular disease, dermatology, and angiogenesis may be effectively treated by the administration of from about 0.01 to 50mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 3.5g per patient per day.
  • the invention also encompasses a pharmaceutical composition that is comprised of a compound of Formula I in combination with a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier Preferably the composition is comprised of a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of a compound of Formula I as described above, or a pharmaceutically acceptable salt thereof.
  • the invention encompasses a pharmaceutical composition for the treatment of disease by inhibiting tyrosine kinase enzymes, resulting in cell proliferation, growth, differentiation, metabolism, cell cycle events, apoptosis, motility, transcription, phosphorylation, translation and other signaling processes, comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of formula I as described above (or a pharmaceutically acceptable salt thereof).
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
  • salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, fenous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Particularly prefened are the ammonium, calcium, magnesium, potassium and sodium slats.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines.
  • organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N'.N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylameine, trimethylamine, tripropylamine, trometrxamine and the like.
  • ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N'.N'-dibenzylethylenediamine, diethylamine
  • the compound of the present invention is basic, its conesponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric-, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
  • compositions of the present invention comprise a compound represented by formula I, or a pharmaceutically acceptable salt thereof, as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.
  • the compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being admimstered.
  • the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • the compounds represented by Formula I, or phannaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration. E.g., oral or parenteral (including intravenous).
  • the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
  • compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in- ater emulsion, or as a water-in-oil liquid emulsion.
  • the compound represented by Formula I, or a pharmaceutically acceptable salt thereof may also be administered by controlled release means and/or delivery devices.
  • the compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
  • compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt of Formula I.
  • the compounds of Formula I, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
  • the pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
  • solid carriers include lactose, tena alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
  • liquid carriers are sugar syrup, peanut oil, olive oil, and water.
  • gaseous carriers include carbon dioxide and nitrogen.
  • any convenient pharmaceutical media may be employed.
  • water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the prefened oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques.
  • a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient.
  • a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
  • Unit dosage forms will generally contain between from about lmg to about 2g of the active ingredient, typically 25mg, 50mg, lOOmg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or lOOOmg.
  • Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
  • a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
  • Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthennore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions, hi all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability.
  • the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
  • Pharmaceutical compositions of the present invention can be in a form suitable for topical sue such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention, or a pharmaceutically acceptable salt thereof, via conventional processing methods.
  • a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt% to about 10wt% of the compound, to produce a cream or ointment having a desired consistency.
  • compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. He suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds.
  • the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like.
  • other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient
  • dosage levels on the order of from about O.Olmg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above- indicated conditions, or alternatively about 0.5mg to about 7g per patient per day.
  • inflammation, cancer, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS), cardiovascular disease, dermatology, and angiogenesis may be effectively treated by the administration of from about 0.01 to 50mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 3.5g per patient per day.
  • IGF-IR insulin-like growth factor- 1 receptor
  • the IGF-IR inhibitory of a compound of formula I can be shown in a tyrosine kinase assay using purified GST fusion protein containing the cytoplasmic kinase domain of human IGF-IR expressed in Sf9 cells. This assay is carried out in a final volume of 90 ⁇ L containing 1-lOOnM (depending on the specific activity) in an Immulon-4 96-well plate (Thermo Labsystems) pre-coated with l ⁇ g/well of substrate poly-glu-tyr (4: 1 ratio) in kinase buffer (50mM Hepes, pH 7.4, 125mM NaCl, 24mM
  • HRP horse radish peroxidase
  • PBS phosphate buffered saline
  • BSA bovine serum albumin
  • Tween-20 200 ⁇ M Na 3 VO 4 for 2 hours at room temperature.
  • the bound anti-phosphotyrosine antibody was detected by incubation with lOO ⁇ l/well ABTS (Kirkegaard & Peny Labs, Inc.) for 30 minutes at room temperature. The reaction was stopped by the addition of lOO ⁇ l /well 1% SDS, and the phosphotyrosine dependent signal was measured by a plate reader at 405/490 nm.
  • Examples 1-21 showed inhibition of IGF-IR.
  • Examples 1-21 showed efficacy and activity by inhibiting IGF-IR in the biochemical assay with IC 50 values less than 15 ⁇ M.
  • the IC5 0 value is less than 5 ⁇ M. More advantageously, the IC 50 value is less than l ⁇ M. Even more advantageously, the IC 50 value is less than 200nM.
  • the most prefened Examples are selective towards IGF-IR.
  • NH 3T3 cells stably expressing full-length human IGF-IR were seeded at lxlO 4 cells/well in 0.1 ml Dulbecco's minimal essential medium (DMEM) supplemented with 10% fetal calf serum (FCS) per well in 96-well plates.
  • DMEM Dulbecco's minimal essential medium
  • FCS fetal calf serum
  • the medium is replaced with starvation medium (DMEM containing 0.5% FCS) for 2 hours and a compound was diluted in 100% dimethyl sulfoxide (DMSO), added to the cells at six final concentrations in duplicates (20, 6.6, 2.2, 0.74, 0.25 and 0.082 ⁇ M), and incubated at 37°C for additional 2 hours.
  • DMSO dimethyl sulfoxide
  • IGF-IR in the above assay with IC 50 values between lOO ⁇ M - about 8nM, with selectivity over insulin receptor expected to be in a range from 1-15 fold.
  • the selectivity is preferably 5 fold, even more preferably the selectivity is 10 fold.
  • the IC 5 o value is less than 5 ⁇ M. More advantageously, the IC 5 o value is less than l ⁇ M. Even more advantageously, the IC 50 value is less than 200nM.
  • Insulin receptor autophosphotyrosme assays are performed essentially as described above for IGF-IR cell-based assays, but use insulin (10 nM) as activating ligand and an insulin receptor antibody as capture antibody with HepG2 cells expressing endogenous human insulin receptor.
  • Suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; dimethylformamide (DMF); dimethyl sulfoxide (DMSO); acetonitrile; alcoholics such as methanol, ethanol, isopropanol, trifluoroethanol, and the like; and chlorinated solvents such as methylene chloride (CH 2 C1 2 ) or chloroform (CHC1 3 ). If desired, mixtures of these solvents were used, however, the prefened solvent was isopropanol.
  • ethers such as tetrahydrofuran (THF), glyme, and the like
  • DMF dimethylformamide
  • DMSO dimethyl sulfoxide
  • acetonitrile alcoholics such as methanol, ethanol, isopropanol, trifluoroethanol, and the like
  • chlorinated solvents such as methylene chlor
  • the above process was carried out at temperatures between about -78 °C and about 120 °C. Preferably, the reaction was carried out between 80 °C and about 100 °C.
  • the above process to produce compounds of the present invention was preferably carried out at about atmospheric pressure although higher or lower pressures were used if desired. Substantially, equimolar amounts of reactants were preferably used although higher or lower amounts were used if desired. [432]
  • the compounds of Formula II of Scheme 1 were prepared as shown below in Scheme 2.
  • an intermediate of Formula III was treated ⁇ vith POCl 3 in a suitable solvent at a suitable reaction temperature.
  • suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; and chlorinated solvents such as methylene chloride (CH 2 C1 2 ) or chloroform (CHC1 3 ). If desired, mixtures of these solvents were used.
  • the prefened solvent was methylene chloride.
  • the above process was carried out at temperatures between about -78 °C and about 120 °C.
  • the reaction was carried out between 40 °C and about 70 °C.
  • the above process to produce compounds of the present invention was preferably carried out at about atmospheric pressure although higher or lower pressures were used if desired. Substantially, equimolar amounts of reactants were preferably used although higher or lower amounts were used if desired.
  • Formula IV and compound of Formula V were reacted under suitable amide coupling conditions.
  • Suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; dimethylformamide (DMF); dimethyl sulfoxide (DMSO); acetonitrile; halogenated solvents such as chloroform or methylene chloride. If desired, mixtures of these solvents were used, however the prefened solvent was methylene chloride.
  • Formula VI is reacted under suitable reaction conditions in a suitable solvent.
  • suitable conditions include treatment of compound of Fonnula VI with hydrazine in a suitable solvent.
  • suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; dimethylformamide (DMF); dimethyl sulfoxide (DMSO); acetonitrile; halogenated solvents such as chloroform or methylene chloride; alcoholic solvents such as methanol and ethanol. If desired, mixtures of these solvents may be used, however the prefened solvent was ethanol.
  • suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like.
  • THF tetrahydrofuran
  • the prefened solvent was THF.
  • the above process was carried out at temperatures between about -78 °C and about 20 °C. The prefened temperature was about 0 °C.
  • Lithiated 2-chloropyrazine may be obtained by treating 2- chloropyrazine with a base such as lithium tetramethylpiperidide (Li-TMP).
  • Lithium tetramethylpiperidide may be prepared by reacting tetramethylpiperidine with n- butyllithium at -78 °C and warming up to 0 °C.
  • Suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like.
  • Polar solvents such as hexamethylphosphoramide (HMPA), 1,3- dimethyl-3,4,5,6-tetrahydro-2(lH)-pyrimidinone (DMPU), and the like may be added if necessary. If desired, mixtures of these solvents were used, however, the prefened solvent was THF.
  • the above process may be canied out at temperatures between about -80 °C and about 20 °C. Preferably, the reaction was carried out at -78 °C to 0 °C.
  • the above process to produce compounds of the present invention was preferably carried out at about atmospheric pressure although higher or lower pressures were used if desired. Substantially, equimolar amounts of reactants were preferably used although higher or lower amounts were used if desired.
  • a compound of Formula VII was reacted with a phthalimide under typical Mitsunobu conditions in a suitable solvent in the presence of suitable reactants.
  • suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; dimethylformamide (DMF); dimethyl sulfoxide (DMSO); acetonitrile (CH 3 CN); chlorinated solvents such as methylene chloride (CH 2 C1 2 ) or chloroform (CHC1 3 ).
  • Suitable reactants for use in the above process included, but were not limited to, triphenylphosphine and the like and an azodicarboxylate (DIAD, DEAD, DBAD).
  • the desired reactants were triphenylphosphine and DIAD.
  • the above process may be carried out at temperatures between about -78 °C and about 100 °C. Preferably, the reaction was carried out at 22 °C.
  • the above process to produce compounds of the present invention was preferably carried out at about atmospheric pressure although higher or lower pressures were used if desired. Substantially, equimolar amounts of reactants were preferably used although higher or lower amounts were used if desired.
  • triphenylphospine DIAD and phthalimide was used per equivalent of compound of Formula VII.
  • the compounds of Formula VII were prepared according to known procedures (Pie, N.; et. al. Tetrahedron, 1998, 54, 9701- 9710) from aldehydes Q 1 — CHO.
  • compound of Formula VII can be reacted with Ts 2 O, Ms O, Tf 2 O, TsCl, MsCl, or SOCl 2 in which the hydroxy group is converted to a leaving group such as its respective tosylate, mesylate triflate or halogen such as chloro and subsequently reacted with an amine equivalent such as NH(Boc) 2 , phthalimide, or azide.
  • Conversion of the amine equivalents by known methods such as by treating under acidic conditions (NH(Boc) 2 ), with hydrazine (phthalimide) as shown in Scheme 4, or with triphenylphosphine/water (azide) will afford the desired amine as shown in Scheme 4.
  • Formula I and A 3 hydrogen or alkyl such as methyl or ethyl.
  • R 1 Z— CONR 2 R 3
  • suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; dimethylformamide (DMF); dimethyl sulfoxide (DMSO); acetonitrile; alcoholics such as methanol, ethanol, isopropanol, trifluoroethanol, and the like; and chlorinated solvents such as methylene chloride (CH C1 2 ) or chloroform (CHC1 3 ).
  • ethers such as tetrahydrofuran (THF), glyme, and the like
  • DMF dimethylformamide
  • DMSO dimethyl sulfoxide
  • alcoholics such as methanol, ethanol, isopropanol
  • the prefened solvent was isopropanol.
  • the above process was carried out at temperatures between about -78 °C and about 120 °C.
  • the reaction was carried out between 80 °C and about
  • R 1 Z — CONR 2 R 3
  • HNR 2 R 3 ammonia
  • Suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; dimethylformamide (DMF); dimethyl sulfoxide (DMSO); acetonitrile; alcoholics such as methanol, ethanol, isopropanol, trifluoroethanol, and the like; and chlorinated solvents such as methylene chloride (CH 2 C1 2 ) or chloroform (CHC1 3 ). If desired, mixtures of these solvents were used.
  • the prefened solvent was isopropanol.
  • the above process was carried out at temperatures between about -78 °C and about 120 °C.
  • the reaction was carried out between 80 °C and about 100 °C.
  • the above process to produce compounds of the present invention was preferably carried out at about atmospheric pressure although higher or lower pressures were used if desired. Substantially, equimolar amounts of reactants were preferably used although higher or lower amounts were used if desired.
  • the compounds of Fonnula II-B (compounds of Formula II where R 1
  • suitable leaving group such as OTs, OMs, OTf, or halo such as chloro, bromo, or iodo
  • d 0 or 1
  • a 5 N, O or S.
  • a compound of Formula I-C is treated with a suitable acylating agent in the presence of a suitable base in a suitable solvent.
  • suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; and chlorinated solvents such as methylene chloride (CH 2 C1 2 ) or chloroform (CHC1 3 ). If desired, mixtures of these solvents were used, however, the prefened solvent was chloroform.
  • Suitable bases for use in the above process included, but were not limited to, trialkylamines such as diisopropylethylamine, triethylamine, or resion bound trialkylamines such as PS-DEEA.
  • the prefened base was PS-DIEA.
  • the suitable acylating agent was acetic anhydride
  • the above process was carried out at temperatures between about -78 °C and about 120 °C.
  • the reaction was carried out between 0 °C and about 20 °C.
  • Compound of Formula I-D (compounds of Formula I where 1 7
  • R Z — H and Z is a heterocyclyl ring containing a nitrogen atom connected to H) can be subjected to various conditions including but not limited to reductive aminations, alkylations and ar(hetar)ylations, and acylations to afford amides, ureas, guanidines, carbamates, thiocarbamates, and variously substituted nitrogen adducts to afford the net conversion of NH to NR 2 .
  • EXAMPLE 11 tr ⁇ «.s- ⁇ 4-[8-Amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexyl ⁇ -methanol (compound of Formula I-B where
  • reaction mixture was concentrated in vacuo to a yellow solid, dissolved in cold EtOAc and neutralized with cold sat. NaHCO 3 .
  • the aqueous layer was extracted with EtOAc (3x) and the combined organic layers were dried over Na 2 SO 4 , filtered and concentrated in vacuo.
  • 3-[l-(3-Benzyloxy- phenyl)-8-chloro-imidazo[l,5-a]pyrazin-3-yl]-cyclobutanone can be prepared from 1- (3-benzyloxyphenyl)-8-chloro-3-(3-methylenecyclobutyl)-imidazo[l,5- ⁇ ]pyrazine (Example 44b) as follows: To a solution of l-(3-benzyloxyphenyl)-8-chloro-3-(3- methylenecyclobutyl)-imidazo[l,5- ]pyrazine (100 mg, 0.25 mmol) in THF (3 mL) and water (1 mL) were added NMO (0.1 mL, 0.5 mmol, 50% aq.
  • EXAMPLE 15 cw- ⁇ 4-[8-Amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexyl ⁇ -methanol (compound of Formula I-B where
  • Ph-(3-OBn) was prepared as described for the synthesis of trans- ⁇ 4-[l-(3- benzyloxy-phenyl)-8-chloro-imidazo[ 1 ,5-a]pyrazin-3-yl]-cyclohexyl ⁇ -methanol
  • EXAMPLE 16 c/s-2- ⁇ 4-[8-Amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexylmethyl ⁇ -isoindole-l,3-dione (compound of
  • EXAMPLE 20 cts-N- ⁇ 4-[8-Amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexylmethyl ⁇ -acetamide (compound of Formula I-
  • EXAMPLE 23 l-(3-Bromo-phenyl)-3-cyclobutylimidazo[l,5- ⁇ ]pyrazin-8-ylamine: Prepared according to the procedures for l-(3-Benzyloxy- phenyl)-3-cyclobutyl-imidazo[l,5-a]pyrazin-8-ylamine, Light pink solid, 1H NMR
  • reaction mixture was heated to 90 °C overnight with stirring, cooled, diluted with CH 2 C1 2 , filtered through Celite, and the resin washed with additional CH 2 C1 2 .
  • the filtrate was concentrated in vacuo, redissolved in DCM, and purified by chromatography (Jones Flashmaster Personal, 50:50 Hexane:EtOAc to 100 % EtOAc) to afford desired imidazopyrazines Examples 24-26.
  • EXAMPLE 25 3-Cyclobutyl-l-(4'-methylbiphenyl-3-yl)-imidazo[l,5- ⁇ ]pyrazin-8-ylamine: Off-white solid, MS (ES) 355.37 (M+l).
  • EXAMPLE 27 l-(3-Benzyloxyphenyl)-3- cyclopentylmethylimidazo[l,5-a]pyrazin-8-ylamine: Prepared according to the procedures for 1 -(3-Benzyloxy-phenyl)-3-cyclobutyl-imidazo[l,5-a]pyrazin-8- ylamine, Clear oil, MS (ES) 399.20 (M+l).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)

Abstract

Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.

Description

IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS
BACKGROUND OF THE INVENTION [1] The present invention is directed to novel imidazopyrazines, their salts, and compositions comprising them. In particular, the present invention is directed to imidazopyrazines as novel tyrosine kinase inhibitors that inhibit tyrosine kinase enzymes in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer. [2] Phosphoryl transferases are a large family of enzymes that transfer phosphorous-containing groups from one substrate to another. Kinases are a class of t enzymes that function in the catalysis of phosphoryl transfer. The phosphorylation is usually a transfer reaction of a phosphate group from ATP to the protein substrate. Almost all kinases contain a similar 250-300 amino acid catalytic domain. Protein kinases, with at least 400 identified, constitute the largest subfamily of structurally related phosphoryl transferases and are responsible for the control of a wide variety of signal transduction processes within the cell. The protein kinases may be categorized into families by the substrates they phosphorylate (e.g., protein-tyrosine, protein- serine/threonine, etc.). Protein kinase sequence motifs have been identified that generally correspond to each of these kinase families. Lipid kinases (e.g. PI3K) constitute a separate group of kinases with structural similarity to protein kinases. [3] The "kinase domain" appears in a number of polypeptides which serve a variety of functions. Su h polypeptides include, for example, transmembrane receptors, intracellular receptor associated polypeptides, cytoplasmic located polypeptides, nuclear located polypeptides and subcelmlar located polypeptides. The activity of protein kinases can be regulated by a variety of mechanisms and any individual protein might be regulated by more than one mechanism. Such mechanisms include, for example, autophosphorylation, transphosphorylation by other kmases, protein-protein interactions, protein-lipid interactions, protein- polynucleotide interactions, ligand binding, and post-translational modification. [4] Phosphorylation of target proteins occurs in response to a variety of extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc.), cell cycle events, environmental or nutritional stresses, etc. Protein and lipid kinases regulate many different cell processes by adding phosphate groups to targets such as proteins or lipids. Such cell processes include, for example, proliferation, growth, differentiation, metabolism, cell cycle events, apoptosis, motility, transcription, translation and other signaling processes. Kinase catalyzed phosphorylation acts as molecular on/off switches to modulate or regulate the biological function of the target protein. Thus, protein and lipid kinases can function in signaling pathways to activate or inactivate, or modulate the activity (either directly or indirectly) of the targets. These targets may include, for example, metabolic enzymes, regulatory proteins, receptors, cytoskeletal proteins, ion channels or pumps, or transcription factors.
[5] A partial list of protein kinases includes abl, AKT, bcr-abl, Blk, Brk,
Btk, c-kit, c-met, c-src, CDK1, CDK2, CDK3, CDK4, CDKS, CDK6, CDK7, CDK8, CDK9, CDK10, cRafl, CSFir, CSK, EGrFR, ErbB2, ErbB3, ErbB4, Erk, Fak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, flt-1, Fps, Frk, Fyn, Hck, IGF-IR, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDGFR, PIK, PKC, PYK2, ron, tie, tie2, TRK, Yes, and Zap70. Thus, protein kinases represent a large family of proteins which play a central role in the regulation of a wide variety of cellular processes, maintaining control over cellular function. Uncontrolled signaling due to defective control of protein phosphorylation has been implicated in a number of diseases and disease conditions, including, for example, inflammation, cancer, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS), cardiovascular disease, dermatology, and angiogenesis. [6] Initial interest in protein kinases as pharmacological targets was stimulated by findings that many viral oncogenes encode structurally modified cellular protein kinases with constitutive enzyme activity. One early example was the Rous sarcoma virus (RSV) or avian sarcoma virus (ASV), which caused highly malignant tumors of the same type or sarcomas within infected chickens. Subsequently, deregulated protein kinase activity, resulting from a variety of mechanisms, has been implicated in the pathophysiology of a number of important human disorders including, for example, cancer, CNS conditions, and immunologically related diseases. The development of selective protein kinase inhibitors that can block the disease path logies and/or symptoms resulting from aberrant protein kinase activity has therefore become an important therapeutic target. [7] Protein tyrosine kinases (PTKs) are enzymes that catalyse the phosphorylation of specific tyrosine residues in cellular proteins. Such post- translational modification of the substrate proteins, often enzymes themselves, acts as a molecular switch regulating cell proliferation, activation or differentiation (for review, see Schlessinger and Ullrich, 1992, Neuron 9:383-391). Aberrant or excessive PTK activity has been observed in many disease states including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune system (e.g., autoimmune disorders), allograft rejection, and graft vs. host disease, hi addition, endothelial-cell specific receptor PTKs such as KDR and Tie-2 mediate the angiogenic process, and are thus involved in supporting the progression of cancers and other diseases involving inappropriate vascularization (e.g., diabetic retinopathy, choroidal neovascularization due to age-related macular degeneration, psoriasis, arthritis, retinopathy of prematurity, infantile hemangiomas). [8] Tyrosine kinases can be of the receptor-type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular). The Receptor Tyrosine Kinases (RTKs) comprise a large family of transmembrane receptors with at least nineteen distinct RTK subfamilies having diverse biological activities. The RTK family includes receptors that are crucial for the growth and differentiation of a variety of cell types (Yarden and Ullrich, Ann. Rev. Biochem. 57:433-478, 1988; Ullrich and Schlessinger, Cell 61:243-254, 1990). The intrinsic function of RTKs is activated upon ligand binding, which results in phosphorylation of the receptor and multiple cellular substrates, and subsequently in a variety of cellular responses (Ullrich & Schlessinger, 1990, Cell 61:203-212). Thus, RTK mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), typically followed by receptor dimerization, stimulation of the intrinsic protein tyrosine kinase activity and receptor trans- phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to tr e formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response such as cell division, differentiation, metabolic effects, and changes in the extracellular microenvironment (see Schlessinger and Ullrich, 1992, Neuron 9:1-20). [9] Proteins with SH2 (src homology -2) or phosphotyrosine binding
(PTB) domains bind activated tyrosine kinase receptors and their substrates with high affinity to propagate signals into cell. Both of" the domains recognize phosphotyrosine. (Fantl et al, 1992, Cell 69:4-13-423; Songyang et al, 1994, Mol. Cell. Biol. 14:2777-2785; Songyang et al, 1993, Cell 12:161 -11%; and Koch et al, 1991, Science 252:668-678; Shoelson, Curr Opin. Chem. Biol. (1997), 1(2), 227-234; Cowburn, Curr Opin. Struct. Biol. (1991), 7(6), 835-838). Several intracellular substrate proteins that associate with RTKs have been identified. They may be divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates which lack such a domain but serve as adapters and associate with catalytically active molecules (Songyang et al., 1993, Cell 12:161 '-778). The specificity of the interactions between receptors or proteins and SH2 or PTB domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. For example, differences in the binding affinities between SID domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors correlate with the observed differences in their substrate phosphorylation profiles (Songyang et al, 1993, Cell 12:161 '-778). Observations suggest that the function of each receptor tyrosine kinase is determined not only by its pattern of expression and ligand availability but also by the array of downstream signal transduction pathways that are activated by a particular receptor as well as the timing and duration of those stimuli. Thus, phosphorylation provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.
[10] Several receptor tyrosine kinases such as FGFR-1, PDGFR, Tie-2 and c-Met, and growth factors that bind thereto, have been suggested to play a role in angiogenesis, although some may promote angiogenesis indirectly (Mustonen and Alitalo, J. Cell Biol. 129:895-898, 1995). One such receptor tyrosine kinase, known as "fetal liver kinase 1" (FLK-1), is a member of the type III subclass of RTKs. Human FLK-1 is also known as "kinase insert domain-containing receptor" (KDR) (Terman et al, Oncogene 6:1677-83, 1991). It is also called "vascular endothelial cell growth factor receptor 2" (VEGFR-2) since it binds vascular endothelial cell growth factor (VEGF) with high affinity. The murine version of FLK-1 /VEGFR-2 has also been called NYK. (Oelrichs et al, Oncogene 8(1):11-15, 1993). Numerous studies (such as those reported in Millauer et al., supra), suggest that VEGF and FLK- l/KDR/VEGFR-2 are a ligand-receptor pair that play an important role in the proliferation of vascular endothelial cells (vasculogenesis), and the formation and sprouting of blood vessels (angiogenesis). Accordingly, VEGF plays a role in the stimulation of both normal and pathological angiogenesis (Jakeman et al, Endocrinology 133:848-859, 1993; Kolch et al, Breast Cancer Research and Treatment 36: 139-155, 1995; Ferrara et al, Endocrine Reviews 18(1); 4-25, 1997; Ferrara et al., Regulation of Angiogenesis (ed. L D. Goldberg and E.M. Rosen), 209- 232, 1997). In addition, VEGF has been implicated in the control and enhancement of vascular permeability (Connolly, et al, 1. Biol. Chem. 264: 20017-20024, 1989; Brown et al, Regulation of Angiogenesis (ed. LD. Goldberg and E.M. Rosen), 233- 269, 1997). l
[11] Another type III subclass RTI related to FLK-1/KDR (DeVries et al.
Science 255:989-991, 1992; Shibuya et al., Oncogene 5:519-524, 1990) is "fms-like tyrosine kinase-I" (Flt-1), also called "vascular endothelial cell growth factor receptor 1" (VEGFR-1). Members of the FLK-l/KDR/VEGFR-2 and Flt-l/VEGPR-1 subfamilies are expressed primarily on endothelial cells. These subclass members are specifically stimulated by members of the VEGF family of ligands (Klagsbum and D'Amore, Cytokine & Growth Factor Reviews 1: 259270,1996). VEGF binds to Flt-1 with higher affinity than to FLK-1/KDR and is mitogenic toward vascular endothelial cells (Terman et al., 1992, supra; Mustonen et al. supra; DeVries et al., supra). Flt-1 is believed to be essential for endothelial organization during vascular development. Flt-1 expression is associated with early vascular development in mouse embryos, and with neovascularization during wound healing (Mustonen and Alitalo, supra). Expression of Flt-1 in monocytes, osteoclasts, and osteob lasts, as well as in adult tissues such as kidney glomeruli suggests an additional function for this receptor that is no related to cell growth (Mustonen and Alitalo, supra). [12] Placenta growth factor (P1GF) has an amino acid sequence that exhibits significant homology to the VEGF sequence (Park et al, 1. Biol. Chem. 269:25646-54,1994; Maglione et α/. Oncogene 8:925-31, 1993). As with VEGF, different species of P IGF arise from alternative splicing of mRNA, and the protein exists in dimeric form (Park et al, supra). P1GF-1 and P1GF-2 bind to Flt-1 with high affinity, and P1GF-2 also avidly binds to neuropilin-1 (Migdal et al, 1. Biol. Chem. 273 (35): 22272-22278), but neither binds to FLK-1/KDR (Park et al, supra). P1GF has been reported to potentiate both the vascular permeability and mitogenic effect of VEGF on endothelial cells when VEGF is present at low concentrations (purportedly due to heterodimer formation) (Park et al, supra). [13] VEGF-B is thought to play a role in the regulation of extracellular matrix degradation, cell adhesion, and migration through modulation of the expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1 (Pepper et al, Proc. Natl. Acad. Sci. U. S. A. (1998), 95(20):11709-11714).
[ 14] VEGF-C can also bind KDR/VEGFR-2 and stimulate proliferation and migration of endothelial cells in vitro and angiogenesis in in vivo models (Lymboussaki et. al, Am. JPathol (1998), 153(2):395-403; Witzenbichler et al, Am. J. Pathol (1998), 153(2), 381-394). The transgenic overexpression of VEGF-C causes proliferation and enlargement of only lymphatic vessels, while blood vessels are unaffected. Unlike VEGF, the expression of VEGF-C is not induced by hypoxia (Ristimaki et al, J. Biol. Chem. (1998), 273(14), 8413-8418). [15] Structurally similar to VEGF-C, VEGF-D is reported to bind and activate at least two VEGFRs, VEGFR-3/Flt-4 and KDR/VEGFR-2. It was originally cloned as a c-fos inducible mitogen for fibroblasts and is most prominently expressed in the mesenchymal cells of the lung and skin (Achen et al, Proc. Natl. Acad. Sci. U S. A. (1998), 95(2), 548-553 and references therein). VEGF, VEGF-C and VEGF-D have been claimed to induce increases in vascular permeability in vivo in a Miles assay when injected into cutaneous tissue (PCT/US97/14696; O98/07832, Witzenbichler et al, supra). The physiological role and significance of these ligands in modulating vascular hyperpermeability and endothelial responses in tissues where they are expressed remains uncertain.
[16] Tie-2 (TEK) is a member of a recently discovered family of endothelial cell specific RTKs involved in critical angiogenic processes such as vessel branching, sprouting, remodeling, maturation and stability. Tie-2 is the first mammalian RTK for which both agonist ligands (e.g., Angiopoietinl ("Angl"), which stimulates receptor autophosphorylation and signal transduction), and antagonist ligands (e.g., Angiopoietin2 ("Ang2")), have been identified. The current model suggests that stimulation of Tie-2 kinase by the Angl ligand is directly involved in the branching, sprouting and outgrowth of new vessels, and recruitment and interaction of periendothelial support cells important in maintaining vessel integrity and inducing quiescence. The absence of Angl stimulation of Tie-2 or the inhibition of Tie-2 autophosphorylation by Ang2, which is produced at high levels at sites of vascular regression, may cause a loss in vascular structure and matrix contacts resulting in endothelial cell death, especially in the absence of growth/survival stimuli. Recently, significant upregulation of Tie-2 expression has been found within the vascular synovial pannus of arthritic joints of humans, consistent with a role in the inappropriate neovascularization, suggesting that Tie-2 plays a role in the progression of rheumatoid arthritis. Point mutations producing constitutively activated forms of Tie-2 have been identified in association with human venous malfonnation disorders. Tie-2 inhibitors are, thereful, useful in treating such disorders, and in other situations of inappropriate neovascularization.
[17] Non-receptor tyrosine kinases represent a collection of cellular enzymes which lack extracellular and transmembrane sequences (see, Bohlen, 1993, Oncogene 8:2025-2031). Over twenty- four individual non-receptor tyrosine kinases, comprising eleven (11) subfamilies (Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps, Fak, Jak, Ack and LTMK) have been identified. The Src subfamily of non-receptor tyrosine kinases is comprised of the largest number of PTKs and include Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. The Src subfamily of enzymes has been linked to oncogenesis and immune responses.
[18] Plk- 1 is a serine/threonine kinase which is an important regulator of cell cycle progression. It plays critical roles in the assembly and the dynamic function of the mitotic spindle apparatus. Plk -1 and related kinases have also been shown to be closely involved in the activation and inactivation of other cell cycle regulators, such as cyclin-dependent kinases. High levels of Plk-1 expression are associated with cell proliferation activities. It is often found in malignant tumors of various origins. Inhibitors of Plk-1 are expected to block cancer cell proliferation by disrupting processes involving mitotic spindles and inappropriately activated cyclin-dependent kinases.
[19] Cdc2 (cdkl)/cyclin B is another serine/threonine kinase enzyme which belongs to the cyclin-dependent kinase (cdks) family. These enzymes are involved in the critical transition between various phases of cell cycle progression. It is believed that uncontrolled cell proliferation, the hallmark of cancer, is dependent upon elevated cdk activities in these cells. The loss of control of cdk regulation is a frequent event in hyperproliferative diseases and cancer (Pines, Current Opinion in Cell Biology, 4:144-148 (1992); Lees, Current Opinion in Cell Biology, 7:773-780 (1995); Hunter and Pines, Cell, 79:573-582 (1994)). The inhibition of elevated cdk activities in cancer cells by cdc2/cyclin B kinase inhibitors could suppress proliferation and may restore the normal control of cell cycle progression.
[20] Malignant cells are associated with the loss of control over one or more cell cycle elements. These elements range from cell surface receptors to the regulators of transcription and translation, including the insulin-like growth factors, insulin growth factor-I (IGF-1) and insulin growth factor-2 (IGF-2). [M.J. Ellis, "The Insulin-Like Growth Factor Network and Breast Cancer", Breast Cancer, Molecular Genetics, Patho genesis and Therapeutics, Humana Press 1999]. The insulin growth factor system consists of families of ligands, insulin growth factor binding proteins, and receptors.
[21] A major physiological role of the IGF-1 system is the promotion of normal growth and regeneration, and overexpressed IGF-IR can initiate mitogenesis and promote ligand-dependent neoplastic transformation. Furthermore, IGF-IR plays an important role in the establishment and maintenance of the malignant phenotype.. [22] IGF-IR exists as a heterodimer, with several disulfide bridges. The tyrosine kinase catalytic site and the ATP binding site are located on the cytoplasmic portion of the beta subunit. Unlike the epidermal growth factor (EGF) receptor, no mutant oncogenic forms of the IGF-IR have been identified. However, several oncogenes have been demonstrated to affect IGF-1 and IGF-IR expression. The correlation between a reduction of IGF-IR expression and resistance to transformation has been seen. Exposure of cells to the mRNA antisense to IGF-IR RNA prevents soft agar growth of several human tumor cell lines. [23] Apoptosis is a ubiquitous physiological process used to eliminate damaged or unwanted cells in multicellular organisms. Disregulation of apoptosis is believed to be involved in the pathogenesis of many human diseases. The failure of apoptotic cell death has been implicated in various cancers, as well as autoimmune disorders. Conversely, increased apoptosis is associated with a variety of diseases involving cell loss such as neurodegenerative disorders and AIDS. As such, regulators of apoptosis have become an important therapeutic target. It is now established that a major mode of tumor survival is escape from apoptosis. IGF-IR abrogates progression into apoptosis, both in vivo and in vitro. It has also been shown that a decrease in the level of IGF-IR below wild-type levels causes apoptosis of tumor cells in vivo. The ability of IGF-IR disruption to cause apoptosis appears to be diminished in normal, non-tumorigenic cells.
[24] Inappropriately high protein kinase activity has been implicated in many diseases resulting from abnormal cellular function. This might arise either directly or indirectly, by failure of the proper control mechanisms for the kinase, related to mutation, over-expression or inappropriate activation of the enzyme; or by over- or underproduction of cytokines or growth factors also participating in the transduction of signals upstream or downstream of the kinase. In all of these instances, selective inhibition of the action of the kinase might be expected to have a beneficial effect.
[25] The type 1 insulin-like growth factor receptor (IGF-IR) is a transmembrane RTK that binds primarily to IGF-1 but also to 1GF-II and insulin with lower affinity. Binding of IGF-1 to its receptor results in receptor oligomerization, activation of tyrosine kinase, intermolecular receptor autophosphorylation and phosphorylation of cellular substrates (major substrates are TRS1 and She). The ligand-activated IGF-IR induces mitogenic activity in normal cells and plays an important role in abnormal growth.
[26] Several clinical reports underline the important role of the IGF-1 pathway in human tumor development: 1) IGF-IR overexpression is frequently found in various tumors (breast, colon, lung, sarcoma.) and is often associated with an aggressive phenotype. 2) High circulating IGF1 concentrations are strongly correlated with prostate, lung and breast cancer risk. Furthermore, IGF-IR is required for establishment and maintenance of the transformed phenotype in vitro and in vivo (Baserga R. Exp. Cell. Res., 1999, 253, 1-6). The kinase activity of IGF-IR is essential for the transforming activity of several oncogenes: EGFR, PDGFR, SV40 T antigen, activated Ras, Raf, and v-Src. The expression of IGF-IR in normal fibroblasts induces neoplastic phenotypes, which can then form tumors in vivo. IGF- IR expression plays an important role in anchorage-independent growth. IGF-IR has also been shown to protect cells from chemotherapy-, radiation-, and cytokine- induced apoptosis. Conversely, inhibition of endogenous IGF-IR by dominant negative IGF-IR, triple helix formation or antisense expression vector has been shown to repress transfonning activity in vitro and tumor growth in animal models. [27] Many of the tyrosine kinases, whether an RTK or non-receptor tyrosine kinase, have been found to be involved in cellular signaling pathways involved in numerous pathogenic conditions, including cancer, psoriasis, and other hyperproHferative disorders or hyper-immune responses. Therefore, much research is ongoing for inhibitors of kinases involved in mediating or maintaining disease states to treat such diseases. Examples of such kinase research include, for example: (1) inhibition of c-Src (Brickell, Critical Reviews in Oncσgenesis, 3:401-406 (1992); Courtneidge, Seminars in Cancer Biology, 5:236-246 (1994), raf (Powis, Pharmacology & Therapeutics, 62:57-95 (1994)) and the cyclin-dependent kinases (CDKs) 1, 2 and 4 in cancer (Pines, Current Opinion in Cell Biology, 4:144-148 (1992); Lees, Current Opinion in Cell Biology, 1:113-780 (1995); Hunter and Pines, Cell, 79:573-582 (1994)), (2) inhibition of CDK2 or PDGF-R kinase in restenosis (Buchdunger et al, Proceedings of the National Academy of Science USA, 92:2258- 2262 (1995)), (3) inhibition of CDK5 and GSK3 kinases in Alzheimers (Hosoi et al, Journal of Biochemistry (Tokyo), 117:741-749 (1995); Aplin et α/., Journal of Neurochemistry, 67:699-707 (1996), (4) inhibition of c-Src kinase in osteoporosis (Tanaka et al, Nature, 383:528-531 (1996), (5) inhibition of GSK-3 kinase in type-2 diabetes (Borthwick et al, Biochemical & Biophysical Research Communications, 210:738-745 (1995), (6) inhibition of the p38 kinase in inflammation (Badger et al, The Journal of Pharmacology and Experimental Therapeutics, 279:1453-1461 (1996)), (7) inhibition of VEGF-R 1-3 and TIE-1 and 2 kinases in diseases which involve angiogenesis (Shawver et al, Drug Discovery Today, 2:50-63 (1997)), (8) inhibition of UL97 kinase in viral infections (He et al, Journal of Virology, 71 :405- 411 (1997)), (9) inhibition of CSF-1R kinase in bone and hematopoetic diseases (Myers et. al, Bioorganic & Medicinal Chemistry Letters, 7:421-424 (1997), and (10) inhibition of Lck kinase in autoimmune diseases and transplant rejection (Myers et. al, Bioorganic & Medicinal Chemistry Letters, 7:417-420 (1997)). [28] Inhibitors of certain kinases may be useful in the treatment of diseases when the kinase is not misregulated, but it nonetheless essential for maintenance of the disease state. In this case, inhibition of the kinase activity would act either as a cure or palliative for these diseases. For example, many viruses, such as human papilloma virus, disrupt the cell cycle and drive cells into the S-phase of the cell cycle (Vousden, FASEB Journal, 7:8720879 (1993)). Preventing cells from entering DNA synthesis after viral infection by inhibition of essential S-phase initiating activities such as CDK2, may disrupt the virus life cycle by preventing virus replication. This same principle may be used to protect normal cells of the body from toxicity of cycle- specific chemotherapeutic agents (Stone et al, Cancer Research, 56:3199-3202 (1996); Kohn et al, Journal of Cellular Biochemistry, 54:44-452 (1994). Inhibition of CDK 2 or 4 will prevent progression into the cycle in normal cells and limit the toxicity of cytotoxics which act in S-phase, G2 or mitosis.
[29] Furthermore, CDK2/cyclin E activity has also been shown to regulate
NF-kB. Inhibition of CDK2 activity stimulates NF-kB-dependent gene expression, an event mediated through interactions with the p300 co-activator (Perkins et al, Science, 275:523-527 (1997)). NF-kB regulates genes involved in inflammatory responses (such as hematopoetic growth factors, chemokines and leukocyte adhesion molecules) (Baeuerle and Henkel, Annual Review of Immunology, 12:141-179 (1994)) and maybe involved in the suppression of apoptotic signals within the cell (Beg and Baltimore, Science, 274:782-784 (1996); Wang et al, Science, 274:784-787 (1996); Van Antwerp et al, Science, 274:787-789 (1996). Thus, inhibition of CDK2 may suppress apoptosis induced by cytotoxic drugs via a mechanism which involves NF- kB and be useful where regulation of NF-kB plays a role in etiology of disease. [30] A further example of the usefulness of kinase inhibition is fungal infections: Aspergillosis is a common infection in immune-compromised patients (Armstrong, Clinical Infectious Diseases, 16: 1- 7 (1993)). Inhibition of the Aspergillus kinases Cdc2/CDC28 or Nim A (Osmani et al, EMBO Journal, 10:2669- 2679 (1991); Osmani et al, Cell, 67:283-291 (1991)) may cause arrest or death in the fungi, effectively treating these infections.
[31] The identification of effective small comp ounds which specifically inhibit signal transduction and cellular proliferation by modulating the activity of receptor and non-receptor tyrosine and serine/threonine kinases to regulate and modulate abnormal or inappropriate cell proliferation, differentiation, or metabolism is therefore desirable. In particular, the identification of methods and compounds that specifically inhibit the function of a tyrosine kinase which is essential for angiogenic processes or the formation of vascular hyperpermeability leading to edema, ascites, effusions, exudates, and macromolecular extravasation and matrix deposition as well as associated disorders would be beneficial.
[32] hi view of the importance of PTKs to the control, regulation, and modulation of cell proliferation and the diseases and disorders associated with abnormal cell proliferation, many attempts have been made to identify receptor and non-receptor tyrosine kinase inhibitors using a variety of approaches, including the use of mutant ligands (U.S. Patent No. 4,966,849), soluble receptors and antibodies (International Patent Publication No. WO 94/10202; Kendall & Thomas, 1994, Proc. Natl. Acad. Sci 90:10705-09; Kim et al, 1993, Nature 362:841-844), RNA ligands (Jellinek, et al, Biochemistry 33:1045056; Takano, et al, 1993, Mol. Bio. Cell 4:358A; Kinsella, et al. 1992, Exp. Cell Res. 199:56-62; Wright, et αl, 1992,1. Cellular Phys. 152:448-57) and tyrosine kinase inhibitors (International Patent Publication Nos. WO 94/03427; WO 92/21660; WO 91/15495; "WO 94/14808; U.S. Patent No. 5,330,992; Mariani, et al, 1994, Froc. Am. Assoc. Cancer Res. 35:2268). [33] More recently, attempts have been made to identify small molecules which act as tyrosine kinase inhibitors. Bis-, mono-cyclic, bicyclic or heterocyclic aryl compounds (International Patent Publication No. WO 92/20642) and vinylene- azaindole derivatives (International Patent Publication No. WO 94/14808) have been described generally as tyrosine kinase inhibitors. Styryl compounds (U.S. Patent No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Patent No. 5,302,606), certain quinazoline derivatives (EP Application No. 0566266 Al; Expert Opin. Ther. Pat. (1998), 8(4): 475-478), selenoindoles and selenides (International Patent Publication No. WO 94/03427), tricyclic polyhydroxylic compounds (International Patent Publication No. WO 92/21660) and benzylphosphonic acid compounds (International Patent Publication No. WO 91/15495) have been described as compounds for use as tyrosine kinase inhibitors for use in the treatment of cancer. Anil ocinnolines (PCT WO97/34876) and quinazoline derivative compounds (International Patent Publication No. WO 97/22596; International Patent Publication No. WO97/42187) have been described as inhibitors of angiogenesis and vascular permeability. Bis(indolyhnaleimide) compounds have been described as inhibiting particular PKC serine/threonine kinase isoforms whose signal transducing function is associated with altered vascular permeability in VEGF-related diseases (International Patent Publication Nos. WO 97/40830 and WO 97/40831). [34] IGF-IR performs important roles in cell division, development, and metabolism, and in its activated state, plays a role in oncogenesis and suppression of apoptosis. IGF-IR is known to be overexpressed in a number of cancer cell lines (IGF-IR overexpression is linked to acromegaly and to cancer of the prostate). By contrast, down-regulation of IGF-IR expression has been shown to result in the inhibition of tumorigenesis and an increased apoptosis of tumor cells. [35] International Patent Publication Nos. WO 03/018021 and WO
03/018022 describe pyrimidines for treating IGF-IR related disorders, International Patent Publication Nos. WO 02/102804 and WO 02/102805 describe cyclolignans and cyclolignans as IGF-IR inhibitors, International Patent Publication No. WO 02/092599 describes pyrrolopyrimidines for the treatment of a disease which responds to an inhibition of the IGF-IR tyrosine kinase, International Patent Publication No. WO 01/72751 describes pyrrolopyrimidines as tyrosine kinase inhibitors. International Patent Publication No. WO 00/71129 describes pyrrolotriazine inhibitors of ldnases. International Patent Publication No. WO 97/28161 describes pyrrolo [2,3- djpyrimidines and their use as tyrosine ldnase inhibitors.
[36] Parrizas, et al. describes tyrphostins with in vitro and in vivo IGF-IR inhibitory activity (Endocrinology, 138:1427-1433 (1997)), and International Patent Publication No. WO 00/35455 describes heteroaryl-aryl ureas as IGF-IR inhibitors. International Patent Publication No. WO 03/048133 describes pyrimidine derivatives as modulators of IGF-IR. International Patent Publication No. WO 03/024967 describes chemical compounds with inhibitory effects towards kinase proteins. International Patent Publication No. WO 03/068265 describes methods and compositions for treating hyperproliferative conditions. International Patent Publication No. WO 00/17203 describes pyrrolopyrimidines as protein kinase inhibitors. Japanese Patent Publication No. JP 07/133280 describes a cephem compound, its production and antimicrobial composition. A. Albert et al., Journal of the Chemical Society, !_1: 1540-1547 (1970) describes pteridine studies and pteridines unsubstituted in the 4-position, a synthesis from pyrazines via 3,4-dhydropteridines. A. Albert et al., Chem. Biol. Pteridines Proc. Int. Symp., 4th, 4: 1-5 (1969) describes a synthesis of pteridines (unsubstituted in the 4-position) from pyrazines, via 3-4- dihydropteridines . SUMMARY OF THE INVENTION
[37] The present invention relates to compounds of Formula I:
Figure imgf000016_0001
[38] or a pharmaceutically acceptable salt thereof. The compounds of
Formula I inhibit the IGF-IR enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of IGF-IR. The compounds of this invention are useful as inhibitors of serine/threonine and tyrosine kinases. In particular, compounds of this invention are useful as inhibitors of tyrosine kinases that are important in hyperproliferative diseases, especially cancer.
DETAILED DESCRIPTION OF THE INVENTION
[39] The present invention relates to a compound of Formula I:
Figure imgf000016_0002
[40] or a pharmaceutically acceptable salt thereof, wherein: [41] Q1 is aryl1, heteroaryl1, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocyclo alkenyl, any of which is optionally substituted by one to five independent G1 substituents;
[42] R1 is alkyl, cycloalkyl, bicycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, or heterobicycloalkyl, any of which is optionally substituted by one or more independent G11 substituents;
[43] G1 and G41 are each independently halo, oxo, -CF3, -OCF3, -OR2,
-NR2R3(R3a)jb -C(O)R2, -CO2R2, -CONR2R3, -NO2, -CN, -S(O j!R2, -SO2NR2R3, NR2(C=O)R3, NR2(C=O)OR3, NR2(C=O)NR2R3, NR2S(O)jlR3, -(OS)OR2, -(C=O)SR2, -NR2(C=NR3)NR2aR3a, -NR2(C=NR3)OR2a, -NR2(C=NR3)SR3a, -O(C=O)OR2, -O(C=O)NR2R3, -O(C=O)SR2, -S(C=O)OR2, -S(OO)NR2R3, C0- 10alkyl, C2-10alkenyl, C2,ioalkynyl,
Figure imgf000017_0002
Cι-10alkoxyC2-1oalkenyl,
Figure imgf000017_0001
1oalkoxyC2.1oalkynyl, CnQalkylthioCi-ioalkyl, C1-1oalkylthioC2-1oalkenyl, Ci. ιoalkylthioC2-1oalkynyl, cycloC3-8alkyl, cycloC3-8alkenyl, cycloC3-8alkylCι-ioalkyl, cycloCs-salkenylCu^alkyl, cycloC3-8alkylC2-10alkenyl, cycloC3-8alkenylC2-1oalkenyl, cycloC3-8alkylC2-1oalkynyl, cycloC3-8alkenylC2-ιoalkynyl, heterocyclyl-Co-^alkyl, heterocyclyl-C2-1oalkenyl, or heterocyclyl-C2-ι0alkynyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, —OR222, -NR 22R333(R333a)jla, -C(O)R222, -CO2R222, ~CONR222R333, -N02, -CN, -S(O)jlaR222, -SO2NR222R333, NR2 2(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)jlaR333, -(C=S)OR222, -(C=O)SR222, -NR222(C=NR333)NR222aR333a, -NR222(C=NR333)OR222a, -NR222(C= R333)SR333a, -O(C=O)OR222, -O(C=O)NR222R333, -O(C=O)SR222, -S(C=O)OR222, or -S(C=O)NR222R333 substituents; or -(X1)n-(Y1)m-R4; or aryl-C0-ιOalkyl, aryl-C2- 10alkenyl, or aryl-C -1oalkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333(R333a)j2a, -C(O)R222, -CO2R222, -CONR222R333, -NO2, -CN, -S(O)j2aR222, -SO2NR2 R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(0)j2aR333, -(C=S)OR222, ~(C=O)SR222, ~NR2 2(C=NR333)NR 22aR333a, -NR222(C=NR333)OR222a, -NR222(C=NR333)SR333a, -O(C=O)OR222, -O(C=O)NR222R333, -0(C=O)SR222, -S(C=O)OR222, or -S(C=O)NR222R333 substituents; or hetaryl-C0-10alkyl, hetaryl-C2- 10allcenyl, or hetaryl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333(R333a)j3a, -C(O)R222,
-CO2R222, -CONR222R333, -NO2, -CN, -S(O)j3aR222, -SO2NR222R333,
NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j3aR333,
-(C=S)OR222, -(C=O)SR222, -NR222(C=NR333)NR222aR333a, -NR222(C=NR333)OR222a,
-NR222(C=NR333)SR333a, -O(C=O)OR222, -O(C=O)NR222R333, -O(C=O)SR222,
-S(C=O)OR222, or -S(C=O)NR222R333 substituents;
[44] G11 is halo, oxo, -CF3, -OCF3, -OR21, -NR21R31(R3al)j4, -C(0)R21,
-CO2R21, -CONR21R31, -NO2, -CN, -S(O)j4R21, -SO2NR21R31, NR21(C=0)R31,
NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31, -(C=S)OR21, -(C=0)SR21,
-NR21(C=NR31)NR2alR3al, -NR21(C=NR31)OR2al, -NR21(C=NR31)SR3al,
-O(C=O)OR21, -O(C=O)NR21R31, -O(C=O)SR21, -S(C=O)OR21, -S(C=0)NR21R31,
-P(O)OR21OR31, C0-10alkyl, C2-10alkenyl, C2.10alkynyl, C1-10alkoxyC1-10aU yl, Ci-
1oalkoxyC2-10alkenyl, Cι-1oalkoxyC2-10alkynyl, C oalkylthioCi-iQalkyl, Cj.
1oalkylthioC2-1oalkenyl, C1-ιoalkylthioC2-10alkynyl, cycloC3-8alkyl, cycloC3_salkenyl, cycloC3-8alkylC1-10alkyl, cycloC3-8alkenylC1-10alkyl, cycloC3-8alkylC2-10alkenyl, cycloC3-8alkenylC2-10alkenyl, cycloC3-8alkylC2-10alkynyl, cycloC3-8alkenylC2-
10alkynyl, heterocyclyl-C0-1oalkyl, heterocyclyl-C2-ι0alkenyl, or heterocyclyl— C2-
10alkynyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j4a, -C(O)R2221, -CO2R2221,
-CONR2221R3331, -NO2, -CN, -S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=0)R3331,
NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C=S) R2221,
-(CO)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al ,
-NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -0(C= )SR2221,
-S(C=O)OR2221, -P(O)OR2221OR3331, or -S(0=0)NR2221R3331 substituents; or a yl-Co-ioalkyl, aryl-C2-10alkenyl, or aryl-C2-10alkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR2221,
-NR2221R3331(R333al)j5a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN,
-S(O)j5aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331,
NR2221(C=O)NR2221R3331, NR2221S(O)j5aR3331, -(C=S)OR2221, -(C=O)SR2221,
-NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al,
-NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -0(C=O)SR2221,
-S(C=O)OR2221, -P(O)OR2221OR3331, or -S(C=O)NR2221R3331 substituents; or hetaryl-Co-ioalkyl, hetaryl-C2-10alkenyl, or hetaryl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR , -NR2221R3331(R333al)j6a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j6aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2 1(C=O)OR3331, NR2221(C^O)NR2221R3331, NR 221S(O)j6aR3331, -(C=S)OR2221, -(CO)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al, -NR2 21(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, -P(O)OR2221OR3331, or -S(C=O)NR2221R3331 substituents; or G11 is taken together with the carbon to which it is attached to form a double bond which is substituted with R5 and G111;
[45] R2, R2a, R3, R3a, R222, R222a, R333, R333a, R21, R2al, R31, R3al, R2221 ,
R222al, R3331, and R333 l are each independently equal to C0-ι0alkyl, C2-10alkenyl, C2- ioalkynyl, C oalkoxyC oalkyl, C1-1oalkoxyC2-1oalkenyl, C1-10alkoxyC2-1oalkyn;yl, Cι_
Figure imgf000019_0001
C1-10alkylthioC2-1oalkenyl, C1-10alkylthioC2-ι0alkynyl, cycloC3- 8alkyl, cycloC -8alkenyl, cycloC3-8alkylC1-10alkyl, cycloCs-salkenylCi-ioalkyl, cycloC3- 8alkylC2-10alkenyl, cycloC3-8alkenylC2-10alkenyl, cycloC3-8alkylC -10alkynyl, cyoloC3- 8alkenylC2-1oalkynyl, heterocyclyl-Co-ioalkyl, heterocyclyl-C2-1oalkenyl, or heterocyclyl-C2-1oalkynyl, any of which is optionally substituted by one or more G111 substituents; or aryl-Co-ioalkyl, aryl-C -1oalkenyl, or aryl-C2-10alkynyl, hetaryl-Co-^alkyl, hetaryl-C2.1oalkenyl, or hetaryl-C2-1oalkynyl, any of which is optionally substituted by one or more G111 substituents; or in the case of -NR2R3(R3a)jl or -NR222R333(R333a)jla or -NR222R333(R333a)j2a or -NR2221R3331(R333al)j3a or -NR2221R3331(R333al)j4a or -NR2221R3331(R333al)j5a or -NR2221R3331(R333al)j6a, R2 and R3 or R222 and R333 or R2221 and R3331 taken together with the nitrogen atom to which they are attached form a 3-10 membered saturated ring, unsaturated ring, heterocyclic saturated ring, or heterocyclic unsaturated ring, wherein said ring is optionally substituted by one or more G111 substituents; [46] X1 and Y1 are each independently -O-, -NR7-, -S(O)j7- -CR5R6-,
-N(C(O)OR7)-, -N(C(O)R7)-, -N(SO2R7)-, -CH2O- -CH2S- -CH2N(R7)- -CH(NR7)-, -CH2N(C(O)R7)-, -CH2N(C(O)OR7)-, -CH2N(SO2R7)-, -CH(NHR7)-, -CH(NHC(O)R7)-, -CH(NHSO2R7)-, -CH(NHC(O)OR7)-, -CH(OC(O)R7)-, -CH(OC(O)NHR7)-, -CH-CH-, -C - -, -C(=NOR7)-, -C(O)-, -CH(OR7)-, -C(O)N(R7)-, -N(R7)C(O)-, -N(R7)S(O)-, -N(R7)S(O)2- -OC(O)N(R7)-, -N(R7)C(O)N(R7)-, -NR7C(O)O- -S(O)N(R7)-, -S(O)2N(R7)-, -N(C(O)R7)S(O)-, -N(C(O)R7)S(O)2-, -N(R7)S(O)N(R7)-, -N(R7)S(O)2N; (R7)-, -C(O)N(R7)C(O)-, -S(O)N(R7)C(O)-, -S(O)2N(R7)C(O)-, -OS(O)N(R7)-, -OS(O)2N(R7)-, -N(R7)S(O)O-, -N(R7)S(O)2O-, -N(R7)S(O)C(O)- -N(R7)S(O)2C(O)-, -SON(C(O)R7)-, -SO2N(C(O)R7)-, -N(R7)SON(R7)-, -N(R7)SO2N(R7)-, -C(O)O- -N(R7)P(OR8)O-, -N(R7)P(OR8)-, -N(R7)P(O)(OR8)O- -N(R7)P(O)(OR8)-, -N(C(O)R7)P(OR8)O- -N(C(O)R7)P(OR8)-, -N(C(O)R7)P(O)(OR8)O-, -N(C(O)R7)P(OR8)-, -CH(R7)S(O)-, -CH(R7)S(O)2- -CH(R7)N(C(O)OR7)- -CH(R7)N(C(O)R7)-, -CH(R7)N(SO2R7)-, -CH(R7)O- -CH(R7)S- -CH(R7)N(R7)-, -CH(R7)N(C(O)R7)-, -CH(R7)N(C(O)OR7)-, -CH(R7)N(SO2R7)-, -CH(R7)C(=NOR7)-, -CH(R7)C(O)-, -CH(R7)CH(OR7)-, -CH(R7)C(O)N(R7)-, -CH(R7)N(R7)C(O)-, -CH(R7)N(R7)S(O)-, -CH(R7)N(R7)S(O)2-, -CH(R7)OC(O)N(R7)-, -CH(R7)N(R7)C(O)N(R7)-, -CH(R7)NR7C(O)O-, -CH(R7)S(O)N(R7)-, -CH(R7)S(O)2N(R7)-, -CH(R7)N(C(O)R7)S(O)-, -CH(R7)N(C(O)R7)S(O)-, -CH(R7)N(R7)S(O)N(R7)-, -CH(R7)N(R7)S(O)2N(R7)-, -CH(R7)C(O)N(R7)C(O)-, -CH(R7)S(O)N(R7)C(O)-, -CH(R7)S(O)2N(R7)C(O)- -CH(R7)OS(O)N(R7)-, -CH(R7)OS(O)2N(R7)-, -CH(R7)N(R7)S(O)O-, -CH(R7)N(R7)S(O)2O-, -CH(R7)N(R7)S(O)C(O)-, -CH(R7)N(R7)S(O)2C(O)-, -CH(R7)SON(C(O)R7)-, -CH(R7)SO2N(C(O)R7)-, -CH(R7)N(R7)SON(R7)-, -CH(R7)N(R7)SO2N(R7)-, -CH(R7)C(O)O-, -CH(R7)N(R7)P(OR8)O- -CH(R7)N(R7)P(OR8)-, -CH(R7)N(R7)P(O)(OR8)O-, -CH(R7)N(R7)P(O)(OR8)-, -CH(R7)N(C(O)R7)P(OR8)O-, -CH(R7)N(C(O)R7)P(OR8)- -CH(R7)N(C(O)R7)P(O)(OR8)O-, or -CH(R7)N(C(O)R7)P(OR8)-; [47] or X1 and Y1 are each independently represented by one of the following structural formulas:
Figure imgf000021_0001
[48] R10, taken together with the phosphinamide or phosphonamide, is a 5-,
6-, or 7-membered aryl, heteroaryl or heterocyclyl ring system; [49] R5, R6, and G111 are each independently a Co-10alkyl, C2-10alkenyl, C2.
10alkynyl, CMoalkoxyCMoalkyl, C1-1oalkoxyC2-ιoalkenyl, C1-1oalkoxyC2-10allcynyl, C1-10alkylthioC1-10alkyl, C1-1oalkylthioC -10alkenyl,
Figure imgf000021_0002
cycloC3-8alkyl, cycloC3-8alkenyl,
Figure imgf000021_0003
cycloCs-salkenyl .ioalkyl, cycloC3-8alkylC2-ιoalkenyl, cycloC3-8alkenylC -1oalkenyl, cycloC3-8alkylC2-1oalkynyl, cycloC3-8alkenylC2-1oalkynyl, heterocyclyl-Co-ioalkyl, heterocyclyl-C2-ιoalkenyl, or heterocyclyl~C2-10alkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR77, -NR77R87, -C(O)R77, -CO2R77, -CONR77R87, -NO2, -CN, -S(O)j5aR77, -SO2NR77R87, NR77(C=O)R87, NR77(C=O)OR87, NR77(C=0)NR78R87, NR77S(O)j5aR87, -(C=S)OR77, -(C=0)SR77, -NR77(C=NR87)NR78R88, -NR77(C=NR87)OR78, -NR77(C=NR87)SR78, -O(C=O)OR77, -O(C=O)NR77R87, -O(C=O)SR77, -S(C=O)OR77, -P(O)OR77OR87, or -S(C=O)NR77R87 substituents; or aryl-C0-1oalkyl, aryl-C2-ιoalkenyl, or aryl-C2- ^alkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR77, -NR77R87, -C(O)R77, -CO2R77, -CONR77R87, -NO2, -CN, -S(O)j5aR77, -SO2NR77R87, NR77(C=O)R87, NR77(C=O)OR87, NR77(C=O)NR78R87, NR77S(O)j5aR87, -(C=S)OR77, -(C=O)SR77, -NR77(C=NR87)NR78R88, -NR77(C=NR87)OR78, -NR77(C=NR87)SR78, -O(C=O)OR77, -O(C=O)NR77R87, -O(C=O)SR77, -S(C=O)OR77, -P(O)OR77OR87, or -S(C=O)NR77R87 substituents; or hetaryl-C0-1oallcyl, hetaryl-C2-10alkenyl, or hetaryl-C2.1oalkynyl, any of which is 11 optionally substituted with one or more independent halo, -CF , -OCF3, -OR , -NR77R87, -C(O)R77, -CO2R77, -CONR77R87, -NO2, -CN, -S(O)j5aR77, -SO2NR77R87, NR77(C=O)R87, NR77(C=O)OR87, NR77(C=O)NR78R87, NR77S(O)j5aR87, ~(C=S)OR77, ~(C=O)SR77, -NR77(C=NR87)NR78R88, -NR77(C=NR87)OR78, -NR77(C=NR87)SR78, -O(C=O)OR77, -O(C=O)NR77R87, -O(C=O)SR77, -S(C=O)OR77, -P(O)OR77OR87, or -S(C=O)NR77R87 substituents; or R5 with R6 taken together with the respective carbon atom to which they are attached, form a 3-10 membered saturated or unsaturated ring, wherein said ring is optionally substituted with R69; or R5 with R6 taken together with the respective carbon atom to which they are attached, form a 3-10 membered saturated or unsaturated heterocyclic ring, wherein said ring is optionally substituted with R69; [50] R7 and R8 are each independently H, acyl, alkyl, alkenyl, aryl, heteroaryl, heterocyclyl or cycloalkyl, any of which is optionally substituted by one or more G111 substituents;
[51] R4 is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more G41 substituents;
[52] R69 is halo, -OR78, -SH, -NR78R88, -CO2R78, -CONR78R88, -NO2,
-CN, -S(O)j8R78, -SO2NR78R88, C0-10alkyl, C2-10alkenyl, C2-10alkynyl, CMoalkox d, 10alkyl, C1-1oalkoxyC2-ιoalkenyl, C1-10alkoxyC2-1oalkynyl,
Figure imgf000022_0001
Ci- 1QalkylthioC2-1oalkenyl, C1-1oalkylthioC2-10alkynyl, cycloC3-8alkyl, cycloC3-8alkenyl,
Figure imgf000022_0002
cycloC3-8alkenylCMoalkyl, cycloC3-8alkylC2-1oalkenyl, cycloC3-8alkenylC2-1oalkenyl, cycloC3-8alkylC -ιoalkynyl, cycloC -8alkenylC2. loalkynyl, heterocyclyl-Co-10alkyl, heterocyclyl-C2-ιoalkenyl, or heterocyclyl-C - ^alkynyl, any of which is optionally substituted with one or more independent halo, cyano, nitro, -OR778, -SO2NR778R888, or -NR778R888 substituents; or aryl-C0-ι0alkyl, aryl-C2-1oalkenyl, or aryl-C2-10alkynyl, any of which is optionally substituted with one or more independent halo, cyano, nitro, -OR778, .ioalkyl, C2-1oalkenyl, C2- 10alkynyl, haloCι-10alkyl, haloC2-ιoalkenyl, haloC2.1oalkynyl, -COOH, Ci- 4alkoxycarbonyl, -CONR778R888, -SO2NR778R888, or -NR778R888 substituents; or hetaryl-Co-ioalkyl, hetaryl-C2-1oalkenyl, or hetaryl-C2,10all ynyl, any of which is optionally substituted with one or more independent halo, cyano, nitro, -OR778, . 10alkyl, C2-10alkenyl, C2-1oalkynyl, haloC1-10alkyl, haloC2-10alkenyl, haloC2-10alkynyl, -COOH, C1-4alkoxycarbonyl, -CONR778R888, -SO2NR778R888, or -NR778R888 substituents; or mono(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)aminoC1-6alkyl, mono(aryl)aminoC1-6alkyl, di(aryl)aminoC1-6alkyl, or -N(C1-6alkyl)-C1-6alkyl-aryl, any of which is optionally substituted with one or more independent halo, cyano, nitro, -OR778, C^oalkyl, C2-1oalkenyl, C2-10alkynyl, haloC1-10alkyl, haloC -10alkenyl, haloC2-10allcynyl, -COOH, C1-4alkoxycarbonyl, -CONR778R888, -SO2NR778R888, or -NR778R888 substituents; or in the case of -NR78R88, R78 and R88 taken together with the nitrogen atom to which they are attached form a 3-10 membered saturated ring, unsaturated ring, heterocyclic saturated ring, or heterocyclic unsaturated ring, wherein said ring is optionally substituted with one or more independent halo, cyano, hydroxy, nitro, C1-10alkoxy, -SO2NR778R888, or -NR778R888 substituents; [53] R77, R78, R87, R88, R778, and R888 are each independently C0-10alkyl,
C -1oalkenyl, C2-ιoalkynyl, C1.10alkoxyC1-10alkyl, C1-10alkoxyC2-1oalkenyl, C1-1oalkoxyC2-10alkynyl,
Figure imgf000023_0001
C1-10alkylthioC2-1oalkenyl, C1-ιoalkylthioC2-1oalkynyl, cycloC3-8alkyl, cycloC3-8alkenyl, cycloCs-sal ylCuio l yl, cycloCs-salkenyld-ioalkyl, cycloC3-8alkylC2-1oalkenyl, cycloC3-8alkenylC2-1oalkenyl, cycloC3-8alkylC2-ιoalkynyl, cycloC3-8alkenylC2-10alkynyl, heterocyclyl-C0-10alkyl, heterocyclyl-C2-1oalkenyl, heterocyclyl-C2-10alkynyl, CMoalkylcarbonyl, C2-ιoalkenylcarbonyl, C2-10alkynylcarbonyl, C1-10alkoxycarbonyl, d-ioalkoxycarbonylCϊ.ioalkyl, monoCι-6alkylaminocarbonyl, di -ealkylaminocarbonyl, mono(aryl)aminocarbonyl, di(aryl)aminocarbonyl, or C oalky^ary aminocarbonyl, any of which is optionally substituted with one or more independent halo, cyano, hydroxy, nitro, .ioalkoxy, -SO2N(Co- alkyl)(Co-4alkyl), or -N(Co- alkyl)(C0- alkyl) substituents; or aryl-Co-ioalkyl, aryl-C -10alkenyl, or aryl-C2-10alkynyl, any of which is optionally substituted with one or more independent halo, cyano, nitro, -O(Co-4alkyl), C^oa-kyl, C -ιoalkenyl, C2-10alkynyl, halod-ioalkyl, haloC2-10alkenyl, haloC2-1oalkynyl, -COOH, C1-4alkoxycarbonyl, -CON(Co- alkyl)(C0-ιoalkyl),
Figure imgf000023_0002
or -N(Co- alkyl)(C0- alkyl) substituents; or hetaryl-Co-10alkyl, hetaryl-C2-10alkenyl, or hetaryl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, cyano, nitro, -O(C0-4alkyl), Ci-ioalkyl, C2-10alkenyl, C2-10alkynyl, haloC1-10alkyl, haloC2-ιoalkenyl, haloC2- 10alkynyl, -COOH, C1-4alkoxycarbonyl, -CON(Co-4alkyl)(C0-4alkyl), -SO2N(C0-4alkyl)(C0- alkyl), or -N(Co-4allcyl)(C0- alkyl) substituents; or
Figure imgf000024_0001
di(d-6alkyl)aminoC1-6alkyl, mono(aryl)aminoC1-6alkyl, di(aryl)aminoC1-6alkyl, or
Figure imgf000024_0002
any of which is optionally substituted with one or more independent halo, cyano, nitro, -O(C0- alkyl), Cι-10alkyl, C2-1oalkenyl, C2,ι0alkynyl, halod-ioalkyl, haloC2-1oalkenyl, haloC2-ιoalkynyl, -COOH, C1- alkoxycarbonyl, -CON(C0-4alkyl)(C0-4alkyl), -SO2N(C0-4alkyl)(C0- alkyl), or -N(C0- alkyl)(C0-4alkyl) substituents; and
[54] n, m, jl, jla, j2a, j3a, j4, j4a, j5a, j6a, j7, and j8 are each independently equal to 0, l, or 2.
[55] hi an aspect of the present invention, a compound is represented by
Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is cycloalkyl, aryl, heteroaryl, aralkyl, or heterocyclyl, any of which is optionally substituted by one or more G11 substituents and the other variables are described as above for Formula I.
[56] In a second aspect of the present invention, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is cycloalkyl, optionally substituted by one or more G11 substituents and the other variables are described as above for Formula I.
[57] In an embodiment of this second aspect, a compound is represented by
Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is cycloalkyl, optionally substituted by one or more Gπ substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents; [58] G1 is halo, -OR2, -NR2R3, -C(O)R2, -CO2R2, -CONR2R3,
-SO2NR2R3, NR2(C=O)R3, NR2(C=O)OR3, NR2(C=O)NR2R3, NR2S(O)jlR3, -O(C=O)OR2, -O(CO)NR2R3, C0-10alkyl, C2-10alkenyl, CwoalkoxyCwoalkyl, Ci. ioalkyl od-ioalkyl, cycloC3-8alkyl, cycloC3-8alkenyl, or heterocyclyl-C0-ι0alkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, ~OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR22 R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333,
Figure imgf000025_0001
-O(C=O)NR222R333 substituents; or -(X1)n-(Y1)m-R4; or aryl-C0-10alkyl, optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j2aR333, -NR222(C-NR333)NR 22aR333a, or -O(C=O)NR222R333 substituents; or hetaryl-C0- 10alkyl, optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR 22(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j3aR333, -NR222(C-NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; [59] and the other variables are described as above for Fonnula I.
[60] In another embodiment of this second aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is cycloalkyl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents; [61] G1 is halo, -OR2, -NR2R3, -C(O)R2, -CO2R2, -CONR2R3,
-SO2NR2R3, NR2(C=O)R3, NR2(C=O)OR3, NR2(C=O)NR2R3, NR2S(O)jiR3, -O(C=O)OR2, -O(C=O)NR2R3, C0-ιoalkyl, C2-10alkenyl, d.joallcoxyd.joalkyl, d- ioalkylthioCi.ioallcyl, cycloC3-8alkyl, cycloC3-salkenyl, or heterocyclyl-C0-ιoalkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)jlaR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR2 2R333 substituents; or -(X1)n-(Y1)m-R4; [62] and the other variables are described as above for Formula I.
[63] In another embodiment of this second aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is cycloalkyl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents; [64] at least one of said G1 substituents is -(X^n- ^m-R4; [65] X1 and Y1 are each independently equal to -O-, -NR7-, -CR5R6-,
-S(O)j7-, or -C(O)-;
[66] and the other variables are described as above for Formula I.
[67] In another embodiment of this second aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R is cycloalkyl, optionally substituted by one or more G11 substituents; wherein Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents;
[68] at least one of said G1 substituents is -(X^n-O^m-R4;
[69] X1 and Y1 are each independently equal to -O- or -CR5R6-;
[70] and the other variables are described as above for Formula I.
[71] In another embodiment of this second aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is cycloalkyl, optionally substituted by one or more G substituents; Q is aryl or heteroaryl1, any of which is substituted by one to five independent G1 substituents;
[72] at least one of said G1 substituents is -(X^n-^^-R4;
[73] X1 and Y1 are each independently equal to -O- or -CH2-;
[74] and the other variables are described as above for Formula I.
[75] In another embodiment of this second aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is cycloalkyl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents;
[76] at least one of said G1 substituents is -(X^n-fY^m-R4;
[77] R4 is H, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G41 substituents;
[78] and the other variables are described as above for Formula I.
[79] In another embodiment of this second aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is cycloalkyl, optionally substituted by one or more Gu substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents;
[80] at least one of said G1 substituents is -(X1)n-(Y1)m-R4;
[81] R4 is aryl or heteroaryl, optionally substituted by one or more independent G41 substituents; [82] and the other variables are described as above for Formula I.
[83] In another embodiment of this second aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R is cycloalkyl, optionally substituted by one or more Gu substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents; [84] at least one of said G1 substituents is -(X1)n-(Y1)m-R4;
[85] R4 is aryl or heteroaryl, optionally substituted by one or more G11 substituents;
[86] and the other variables are described as above for Formula I.
[87] In another embodiment of this second aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R is cycloalkyl substituted by one or more independent Gu substituents; [88] Gπ is -OR21, -NR21R31(R31a)j4, -C(O)R21, -CO2R21, -CONR21R31,
Figure imgf000027_0001
-O(C=O)OR21, -O(C=O)NR21R31, C0-l0alkyl, cycloC3-8alkyl, cycloC3-8alkenyl, heterocyclyl-Co-ioalkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333a)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j4aR2221, -SO2NR2221R3331, NR22 1(C=O)R3331, NR2221(C=O)OR3331, NR 221(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR33 al, -NR 221(C=NR3331)OR222al, -NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents; or aryl-C0-ιOalkyl, aryl-C2- 10alkenyl, or aryl-C2-ioalkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j5a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j5aR2221, -SO2NR2221R3331, NR22 1(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j5aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al, -NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents; or hetaryl-Co-ioalkyl, hetaryl-C2-1oalkenyl, or hetaryl-C2.1oalkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR2221, -NR 221R3331(R333al)j6a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2,
-CN, -S(O)j6aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(O=0)0R3331,
NR2221(C=O)NR2221R3331, NR2221S(O)j6aR3331, -(C=S)OR2221, -(C=O)SR2221,
-NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al,
-NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(CO)NR22 1R3331, -O(C=O)SR2221,
-S(C=O)OR2221, or -S(C=0)NR2221R3331 substituents;
[89] and the other variables are described as above for Formula I.
[90] In another embodiment of this second aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R is cycloalkyl substituted by one or more independent G11 substituents;
[91] G11 is -OR21, -NR21R31, -CO2R21, -C(O)R21, -CONR21R31,
NR21(C=O)R31, NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31,
-O(C=O)OR21, -O(C=O)NR21R31, C0-ι0alkyl, cycloC3-8alkyl, cycloC3-8alkenyl, heterocyclyl-C0-1oalkyl, or heterocyclyl-C2-10alkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221,
-NR2221R3331(R333al)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN,
-S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=0)R3331, NR 221(CO)OR3331,
NR22 1(C=O)NR 221R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221,
-NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al,
-NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR 221R3331, -O(C=O)SR2221,
-S(C=O)OR2221, or -S(CO)NR2221R3331 substituents;
[92] and the other variables are described as above for Formula I.
[93] In another embodiment of this second aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is cis- or trans- cyclobutyl substituted at the 3 -position by G ,
[94] G11 is -OH, -NH2, -N(CH3)2, -NHAc, -NH(CO)NHCH3,
-NH(CO)OCH3, -CH2OH, -CH2NH2, -CH2NHAc, CO2H, CONH2, -CH2N(CH3)2,
-CH2NH(CO)NHMe, -CH2NH(CO)OCH3, CO2CH3, CONHCH3,
Figure imgf000028_0001
[95] and the other variables are described as above for Formula I. [96] In another embodiment of this second aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R is cis- or trans- cyclohexyl substituted at the 4-position by G1 ; [97] G1 r is -OH, -NH2, -N(CH3)2, -NHAc, -NH(CO)NHCH3,
-NH(CO)OCH3, -CH2OH, -CH2NH2, -CH2NHAc, CO2H, CONH2, -CH2N(CH3)2, -CH2NH(CO)NHMe, -CH2NH(CO)OCH3, CO2CH3, CONHCH3,
Figure imgf000029_0001
[98] and the other variables are described as above for Formula I.
[99] In another embodiment of this second aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein [100] Q1 is aryl1 substituted by one to five independent G1; at least one of said G1 substituents is -(X1)n-(Y1)m-R4; n and m are both equal to 1; [101] x s -O-;
[102] Y! is -CH2-;
[103] R4 is aryl, optionally substituted by one or more G41 substituents; 1
[104] R is cis- or trans- cyclohexyl substituted at the 4-position by G ;
[105] Gu is -OH, -NH2, -N(CH3)2, -NHAc, -NH(CO)NHCH3,
-NH(CO)OCH3, -CH2OH, -CH2NH2, -CH2NHAc, CO2H, CONH2, -CH2N(CH3)2, -CH2NH(CO)NHMe, -CH2NH(CO)OCH3, CO2CH3, CONHCH3,
Figure imgf000029_0002
[106] and the other variables are described as above for Formula I.
[107] In still another embodiment of this second aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein [108] Q1 is aryl1 substituted by one to five independent G1; at least one of said G1 substituents is -(Xl)n-(Yl)m-R4; n and m are both equal to 1; [109] X1 is -O-;
[110] Y s -CHz-;
[111] R4 is aryl, optionally substituted by one or more G41 substituents;
[112] R1 is cis- or trans- cyclobutyl substituted at the 3 -position by G1 J ; [113] G11 is -OH, -NH2, -N(CH3)2, -NHAc, -NH(CO)NHCH3,
-NH(CO)OCH3, -CH2OH, -CH2NH2, -CH2NHAc, CO2H, CONH2, -CH2N(CH3)2, -CH2NH(CO)NHMe, -CH2NH(CO)OCH3, CO2CH3, CONHCH3,
Figure imgf000030_0001
[114] and the other variables are described as above for Formula I.
[115] hi a third aspect of the present invention, a compound is represented by
Formula I, or a salt thereof, wherein R1 is aryl, optionally substituted by one or more G11 substituents, and the other variables are described as above for Formula I. [116] hi an embodiment of this third aspect, a compound is represented by
Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is aryl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents; [117] G1 is halo, -OR2, -NR2R3, -C(O)R2, -CO2R2, -CONR2R3,
-SO2NR2R3, NR2(C=O)R3, NR (C=O)OR3, NR2(C=O)NR2R3, NR2S(O)jlR3, -O(C=O)OR2, -O(C=O)NR2R3, C0-ι0alkyl, C2-10alkenyl, CMoalko yC oal yl, d. 10alkylthiod-ιoalkyl, cycloC3-8alkyl, cycloC3-8alkenyl, or heterocyclyl-Co-10alkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)jlaR333, -NR222(C=NR333)NR222aR333a, or -O(C-O)NR222R333 substituents; or -(X1)n-(Y1)m-R4; or aryl-C0-10alkyl, optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR22 R333, -SO2NR222R333, NR2 2(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j2aR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or hetaryl-C0- loalkyl, optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j3aR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; [118] and the other variables are described as above for Formula I. [119] hi another embodiment of this third aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R is aryl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents;
[120] G1 is halo, -OR2, -NR2R3, -C(O)R2, -CO2R2, -CONR2R3,
-SO2NR2R3, NR2(C=O)R3, NR2(C=O)OR3, NR2(O=0)NR2R3, NR2S(O)jlR3,
-O(C=O)OR2, -O(C=O)NR2R3, C0.10alkyl, C2-10alkenyl,
Figure imgf000031_0001
d-
Figure imgf000031_0002
cycloC3-8alkyl, cycloC3,8alkenyl, or heterocyclyl-Co-ι0alkyl, or heterocyclyl-C -10alkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222,
-CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333,
NR2 2(C=O)NR222R333, NR222S(O)jlaR333, -NR222(C=NR333)NR222aR333a, or
-O(C=O)NR222R333 substituents; or
Figure imgf000031_0003
[121] and the other variables are described as above for Formula I.
[122] hi another embodiment of this third aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is aryl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents;
[123] at least one of said G1 substituents is -(X^n- ^^m-R4;
[124] X1 and Y1 are each independently equal to -O-, -NR7-, -CR5R6-
-S(O)j7- or -C(O)-;
[125] and the other variables are described as above for Formula I.
[126] In another embodiment of this third aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is aryl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents;
[127] at least one of said G1 substituents is -(X1)n-(Y1)m-R4;
[128] X1 and Y1 are each independently equal to -O- or -CR5R6-;
[129] and the other variables are described as above for Formula I.
[130] In another embodiment of this third aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is aryl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents;
[131] at least one of said G1 substituents is -(X1)n-(Y )m-R ;
[132] X1 and Y1 are each independently equal to -O- or -CH2-;
[133] and the other variables are described as above for Formula I.
[134] In another embodiment of this third aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is aryl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents;
[135] at least one of said G1 substituents is -(X1)n-(Y1)m-R4;
[136] R4 is H, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G41 substituents;
[137] and the other variables are described as above for Formula I.
[138] In another embodiment of this third aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is aryl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents;
[139] at least one of said G1 substituents is -(X1)n-(Y1)m-R4;
[140] R4 is aryl or heteroaryl, optionally substituted by one or more independent G41 substituents;
[141] and the other variables are described as above for Formula I.
[142] In another embodiment of this third aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is aryl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is_substituted by one to five independent G1 substituents;
[143] at least one of said G1 substituents is -(X1)n-(Y1)m-R4;
[144] R4 is aryl or heteroaryl, optionally substituted by one or more G41 substituents;
[145] and the other variables are described as above for Formula I.
[146] i another embodiment of this third aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein [147] R1 is cycloalkyl substituted by one or more independent G substituents,
[148] Gu is -OR21, -NR 1R31(R31a)j4, -C(O)R21, -CO2R21, -CONR21R31,
NR21(C=O)R31, NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31, -O(C=O)OR21, -O(C=O)NR21R31, C0-10alkyl, cycloC3-8alkyl, cycloC3-8alkenyl, heterocyclyl-Co-ioalkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR , -NR2221R3331(R333a)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR22 1R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2 1(C=NR3331)NR22 alR333al, -NR2221(C=NR3331)OR222al,
Figure imgf000033_0001
-O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents; or aryl-C0-10alkyl, aryl-C2- 10alkenyl, or aryl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j5a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j5aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j5aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al, -NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents; or hetaryl-C0-10alkyl, hetaryl-C2-1oalkenyl, or hetaryl-C2-10alkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j6a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j6aR2221, -SO2NR 221R3331, NR2221(C=O)R3331, NR22 1(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j6aR3331, -(G=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al, -NR22 1(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents; [149] and the other variables are described as above for Formula I.
[150] i another embodiment of this third aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein [151] R1 is cycloalkyl substituted by one or more independent G substituents;
[152] Gu is -OR21, -NR21R31, -CO2R21, -C(O)R21, -CONR21R31,
NR21(C=O)R31, NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31,
-O(C=O)OR21, -O(C=O)NR21R31, C0-ιoalkyl, cycloC3-8alkyl, cycloC3-8alkenyl, heterocyclyl-Co-ioalkyl, or heterocyclyl-C2_10alkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221,
-NR2221R3331(R333al)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN,
-S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331,
Figure imgf000034_0001
NR22 1S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221,
-NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al, !
-NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221,
-S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents;
[153] and the other variables are described as above for Fonnula I.
[154] In another embodiment of this third aspect, a compound is represented by Formula I, or a phannaceutically acceptable salt thereof, wherein 1 1 1
[155] R is phenyl optionally substituted by one or more independent G substituents;
[156] and the other variables are described as above for Formula I.
[157] In still another embodiment of this third aspect, a compound is represented by Formula I, or a phannaceutically acceptable salt thereof, wherein
[158] Q1 is aryl1 substituted by one to five G1 substituents; at least one of said G1 substituents is -(X1)n-(Y1)m-R4;
[159] X s -O-;
[160] Y1 is -CH2-;
[161] R4 is aryl, optionally substituted by one or more G41 substituents;
[162] R1 is phenyl substituted by one or more independent G11 substituents;
[163] and the other variables are described as above for Formula I.
[164] In a fourth aspect of the present invention, a compound is represented by Formula I, or a salt thereof, wherein R1 is heterocyclyl, optionally substituted by one or more Gn substituents and the other variables are described as above for Formula I.
[165] In an embodiment of this fourth aspect, a compound is represented by
Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is heterocyclyl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G substituents; [166] G1 is halo, -OR2, -NR2R3, -C(O)R2, -CO2R2, -CONR2R3,
-SO2NR2R3, NR2(QO)R3, NR2(C=O)OR3, NR2(C=O)NR2R3, NR2S(O)jiR3, -O(C=O)OR2, -O(C=O)NR2R3, C0-ι0alkyl, C2-10alkenyl, Cι-10alkoxyC1-10allcyl, Ci- ioalkylthioCi-walkyl, cycloC3-8alkyl, cycloC3-8alkenyl, or heterocyclyl-C0-10alkyl, or heterocyclyl-C -1oalkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)jlaR333, -NR222(C=NR333)NR 22aR333a, or -O(C=O)NR222R333 substituents; or -(X1)n-(Y1)m-R4; or aryl-C0-ι0alkyl, optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR 22R333, NR222S(O)j2aR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or hetaryl-C0- loalkyl, optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR 2 (C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j3aR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; [167] and the other variables are described as above for Formula I.
[168] In another embodiment of this fourth aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is heterocyclyl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to fivejndependent G1 substituents; [ 169] G1 is halo, -OR2, -NR2R3, -C(O)R2, -CO2R2, -CONR2R3,
-SO2NR2R3, NR2(C=O)R3, NR2(C=O)OR3, NR2(C=O)NR2R3, NR2S(O)jlR3, -O(C=O)OR2, -O(C=O)NR2R3, C0.10alkyl, C2-10alkenyl,
Figure imgf000035_0001
Ci.
Figure imgf000035_0002
cycloC3-8alkyl, cycloC3-8alkenyl, or heterocyclyl-Co-ioalkyl, or heterocyclyl-C2-10alkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)jlaR333, -NR2 2(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or -(X^-t ^-R4; [170] and the other variables are described as above for Formula I.
[171] In another embodiment of this fourth aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is heterocyclyl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents; [172] wherein at least one of said G1 substituents is -(X1)n-(Y1)m-R4;
[173] X1 and Y1 are each independently equal to -O-, -NR7-, -CR5R6-
-S(O)j7-, or -C(O)-;
[174] and the other variables are described as above for Formula I.
[175] In another embodiment of this fourth aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is heterocyclyl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or 1 1 heteroaryl , any of which is substituted by one to five independent G substituents; [176] at least one of said G1 substituents is -(X1)n-(Y1)m-R4;
[ 177] X1 and Y1 are each independently equal to -O- or -CR5R6-;
[178] and the other variables are described as above for Formula I.
[179] In another embodiment of this fourth aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is heterocyclyl, optionally substituted by one or more Gπ substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents; [180] wherein at least one of said G1 substituents is -(X1)n-(Y1)m-R4;
[181] X1 and Y1 are each independently equal to -O- or -CH2-;
[ 182] and the other variables are described as above for Formula I.
[183] In another embodiment of this fourth aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is heterocyclyl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents; [184] wherein at least one of said G1 substituents is -(X1)n-(Y1)m-R4; [185] R4 is H, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G41 substituents; [186] and the other variables are described as above for Formula I.
[187] i another embodiment of this fourth aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R is heterocyclyl, optionally substituted by one or more G11 substituents; Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents;
[188] wherein at least one of said G1 substituents is -(X^n-^^m-R4;
[189] R4 is aryl or heteroaryl, optionally substituted by one or more independent G41 substituents;
[190] and the other variables are described as above for Formula I.
[191] In another embodiment of this fourth aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein Q1 is aryl1 or heteroaryl1, any of which is substituted by one to five independent G1 substituents;
[192] wherein at least one of said G1 substituents is -(X1)n-(Y1)m-R4;
[193] R4 is aryl or heteroaryl, optionally substituted by one or more G41 substituents;
[ 194] and the other variables are described as above for Formula I.
[195] In another embodiment of this fourth aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein
[196] R1 is heterocyclyl represented by the structural formula:
( 2? ) V..-N
[197] and the other variables are described as above for Formula I.
[198] In another embodiment of this fourth aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein [ 199] R is heterocyclyl represented by the structural formula:
Figure imgf000038_0001
[200] wherein G1 ! is equal to -C(O)R2, -CO2R2, -CONR2R3, -SO2NR2R3,
-S^jtR3, Co-ioalkyl, C2-10alkenyl, d.ioalkoxyCi-ioalkyl, d.iQal ylthioCMoalkyl, cycloC3-8alkyl, cycloC3-8alkenyl, or heterocyclyl-C0-1oalkyl, or heterocyclyl-C - 10alkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR 22(C=O)NR222R333, NR222S(O)jlaR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or -(X1)n-(Y1)m-R4; or aryl-C0-1oalkyl, optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j2aR333, -NR222(C=NR333)NR222aR333a, or
-O(C=O)NR R substituents; or hetaryl-C0-1oalkyl, optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR 22S(O)j3aR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents;
[201] and the other variables are described as above for Formula I.
[202] In another embodiment of this fourth aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein [203] R1 is heterocyclyl represented by the structural formula:
Figure imgf000038_0002
[204] wherein G11 is equal to -C(O)R2, -CO2R2, -CONR2R3, -SO2NR2R3,
-S(O)j!R3, C0-1oalkyl, C2-10alkenyl, C oalkoxyd.ϊoalkyI, C1-10alkylthioC1-10alkyl, cycloC -8alkyl, cycloC3-8alkenyl, or heterocyclyl-Co-ioalkyl, or heterocyclyl-C2- 10alkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR 22R333, -SO2NR2 2R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)jlaR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or -(X1)n-(Y1)ra-R4;
[205] and the other variables are described as above for Formula I.
[206] In another embodiment of this fourth aspect, a compound is represented by Formula I, or a phannaceutically acceptable salt thereof, wherein [207] R1 is heterocyclyl represented by the structural formula:
Figure imgf000039_0001
[208] wherein G11 is equal to -C(O)R2, -CO2R2, -CONR2R3, -SO2NR2R3,
-S(O)j!R3, C0-10alkyl, C2.ι0alkenyl, d-ioalkoxyd-ioalkyl, d-ioalkylthiod-ioalkyl, cycloC3-8alkyl, cycloC3-8alkenyl, or heterocyclyl-Co-ioalkyl, or heterocyclyl-C2- 10alkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR22 R333, NR2 2(C=O)R333, NR222(C=O)OR333, NR222(CO)NR222R333, NR222S(O)jlaR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or -(X1)n-(Y1)m-R4; or aryl-Co-10alkyl, optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j2aR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR R substituents; or hetaryl-Co-ioalkyl, optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR 22(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j3aR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; [209] and the other variables are described as above for Formula I. [210] In still another embodiment of this fourth aspect, a compound is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein R is heterocyclyl represented by the structural formula:
N I G
[211] wherein G11 is equal to -C(O)R2, -CO2R2, -CONR2R3, -SO2NR2R3,
-S^^R3, C0-10alkyl, C2-1oalkenyl, CMoalkoxyd-ioalkyl, d-ioalkylthiod-ioalkyl, cycloC -8alkyl, cycloC3-8alkenyl, or heterocyclyl-Co-ioalkyl, or heterocyclyl-C - ^alkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)jlaR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or -(X1)n-(Y1)m-R4; [212] and the other variables are described as above for Formula I.
[213] The compounds of the present invention include compounds represented by Formula I, or a pharmaceutically salt thereof,
[214] wherein Q1 is aryl1 or heteroaryl1, any of which is optionally substituted by one or more independent G1 substituents; or
[215] wherein Q1 is heteroaryl1, any of which is optionally substituted by one or more independent G1 substituents; or
[216] wherein Q1 is aryl1, any of which is optionally substituted by one or more independent G1 substituents; or
[217] wherein G1 is halo, -CF3, -OCF3, -OR2, -NR2R3, -C(O)R2, -CO2R2,
-CONR2R3, -S(O)j!R2, -SO2NR2R3, NR2(C=O)R3, NR2(C=O)OR3,
NR2(C=O)NR R3, NR2S(O)αR3, -O(C=O)OR2, -O(C=O)NR2R3, C0-10alkyl, C2-
10alkenyl, C2-1oalkynyl, Cι-10alkoxyd-ιoalkyl, C1-10alkoxyC2-1oalkenyl, C1-10alkoxyC2-
10alkynyl, d-iQalkylthiod.ioalkyl, C1-1oalkylthioC2-ιoalkenyl, C1-1oalkylthioC -
10alkynyl, cycloC3-8alkyl, cycloC -8alkenyl, cycloC3-salkylC]-10alkyl, cycloC3-
8alkenylC1-10alkyl, cycloC3-8alkylC2-1oalkenyl, cycloC3-8alkenylC2.ι0alkenyl, cycloC3- salkylC2.1oalkynyl, cycloC3-8alkenylC2-1oalkynyl, heterocyclyl-Co-ioalkyl, heterocyclyl-C2-10alkenyl, or heterocyclyl-C2-10alkynyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR , -NR222R333(R333a)jla, -C(O)R222, -CO2R222, -CONR222R333, -NO2, -CN, -S(O)jlaR222, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)jiaR333, -(C=S)OR222, -(C=O)SR222, -NR222(C=NR333)NR222aR333a, -NR222(C=NR333)OR222a, -NR22 (C=NR333)SR333a, -O(C=O)OR222, -O(C=O)NR222R333, -O(C=O)SR222, -S(C=O)OR222, or -S(C=O)NR222R333 substituents; or -(X1)n-(Y1)m-R4; or aryl-C0-ιoalkyl, aryl-C2- ioalkenyl, or aryl-C2-1oalkynyl, any of which is optionally substituted with one or t more independent halo, -CF3, -OCF3, -OR222, -NR222R333(R333a)j2a, -C(O)R222, -CO2R222, -CONR222R333, -NO2, -CN, -S(O)j2aR222, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j2aR333, -(C=S)OR222, -(C=O)SR222, -NR222(C=NR333)NR222aR333a, -NR222(C=NR333)OR222a, -NR222(C=NR333)SR333a, -O(C=O)OR222, -O(C=O)NR222R333, -O(C=O)SR222, -S(C=O)OR222, or -S(C=O)NR222R333 substituents; or hetaryl-C0-i0alkyl, hetaryl-C2- 10alkenyl, or hetaryl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333(R333a)j3a, -C(O)R222, -CO2R222, -CONR222R333, -NO2, -CN, -S(O)j3aR222, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j3aR333, -(C=S)OR222, -(C=O)SR222, -NR222(C=NR333)NR222aR333a, -NR222(C=NR333)OR222a, -NR222(C=NR333)SR333a, -O(C=O)OR222, -O(C=O)NR222R333, -O(C=O)SR222, -S(C=O)OR222, or -S(C=O)NR222R333 substituents; or
[218] wherein G1 is halo, -OR2, -NR2R3, -C(O)R2, -CO2R2, -CONR2R3,
-SO2NR2R3, NR2(C=O)R3, NR2(C=O)OR3, NR2(C=O)NR2R3, NR2S(O)jlR3, -O(C=O)OR2, -O(C=O)NR2R3, C0-10alkyl, C2-10alkenyl, C1-10alkoxyC1-10allcyl, C.. 10alkoxyC2.10alkenyl, d-KjalkylthioCi-ioalkyl, C1-10alkylthioC2-10alkenyl, cycloC3- 8alkyl, cycloC3-8alkenyl, cycloC -8alkylC1-10alkyl, cycloC3-8alkenylC1-10alkyl, cycloC3, 8alkylC2-1oalkenyl, cycloC3-8allcenylC2-1oalkenyl, or heterocyclyl-Co-ioalkyl, or heterocyclyl-C2-ιoalkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR 22R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR22 S(O)jlaR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or -(X1)n-(Y1)m-R4; or aryl-C0-10alkyl optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR22 (C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR 22S(O)j2aR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or hetaryl-C0- loalkyl, optionally substituted with one or more independent halo, -CF , -OCF , -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j3aR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or [219] wherein G1 is halo, -OR2, -NR2R3, -C(O)R2, -CO2R2, -CONR2R3,
-SO2NR2R3, NR (C=O)R3, NR2(C=O)OR3, NR2(C=O)NR2R3, NR2S(O)jlR3, -O(C=O)OR2, -O(C=O)NR2R3, C0-10alkyl, C2-10alkenyl, d-ioalkoxyC oalkyl, C_. KjalkylthioCMQalkyl, cycloC3-8alkyl, cycloC3-8alkenyl, or heterocyclyl-Co-ι0alkyl, or heterocyclyl-C2-10alkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR 22S(O)jlaR333, -NR 22(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or -(X1)n-(Y1)m-R4; or aryl-C0-ι0alkyl, optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j2aR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or hetaryl-C0- 10alkyl, optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j3aR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or [220] wherein G1 is halo, -OR2, -NR2R3, -C(O)R2, -CO2R2, -CONR2R3,
-SO2NR2R3, NR2(C=O)R3, NR2(C=O)OR3, NR2(C=O)NR2R3, NR2S(O)jlR3, -O(C=O)OR2, -O(C=O)NR2R3, C0-ιoalkyl, C2.10alkenyl, CMoalkoxyd-ioalkyl, C.. ^alkylthioCMoalkyl, cycloC3-8alkyl, cycloC3-8allcenyl, or heterocyclyl-Co-10alkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333,
Figure imgf000043_0001
-O(C=O)NR222R333 substituents; or
Figure imgf000043_0002
or [221] wherein X1 and Y1 are each independently -O-, -NR7-, -S(O)j7-
-CR5R6-, -N(C(O)OR7)-, -N(C(O)R7)-, -N(SO2R7)-, -CH2O-, -CH2S- -CH2N(R7)-, -CH(NR7)-, -CH2N(C(O)R7)-, -CH2N(C(O)OR7)-, -CH2N(SO2R7)-, -CH(NHR7)-, -CH(NHC(O)R7)-, -CH(NHSO2R7)-, -CH(NHC(O)OR7)-, -CH(OC(O)R7)-, -CH(OC(O)NHR7)-, -C(O)-, -CH(OR7)-, -C(O)N(R7)-, -N(R7)C(O)-, -N(R7)S(O)-, -N(R7)S(O)2- -OC(O)N(R7)-, -N(R7)C(O)N(R7)- -NR7C(O)O- -S(O)N(R7)-, -S(O)2N(R7)-, -N(C(O)R7)S(O)-, -N(C(O)R7)S(O)2-, -N(R7)S(O)N(R7)-, -N(R7)S(O)2N(R7)-, -C(O)N(R7)C(O)-, -S(O)N(R7)C(O)-, -S(O)2N(R7)C(O)-, -OS(O)N(R7)-, -OS(O)2N(R7)-, -N(R7)S(O)O-, -N(R7)S(O)2O-, -N(R7)S(O)C(O)-, -N(R7)S(O)2C(O)-, -SON(C(O)R7)-, -SO2N(C(O)R7)-, -N(R7)SON(R7)-, -N(R7)SO2N(R7)-, -C(O)O- -CH(R7)S(O)-, -CH(R7)S(O)2-, -CH(R7)N(C(O)OR7)-, -CH(R7)N(C(O)R7)-, -CH(R7)N(SO2R7)-, -CH(R7)O-, -CH(R7)S- -CH(R7)N(R7)-, -CH(R7)N(C(O)R7)-, -CH(R7)N(C(O)OR7)-, -CH(R7)N(SO2R7)-, -CH(R7)C(=NOR7)-, -CH(R7)C(O)-, -CH(R7)CH(OR7)-, -CH(R7)C(O)N(R7)-, -CH(R7)N(R7)C(O)-, -CH(R7)N(R7)S(O)-, -CH(R7)N(R7)S(O)2-, -CH(R7)OC(O)N(R7)-, -CH(R7)N(R7)C(O)N(R7)- -CH(R7)NR7C(O)O-, -CH(R7)S(O)N(R7)-, -CH(R7)S(O)2N(R7)-, -CH(R7)N(C(O)R7)S(O)-, -CH(R7)N(C(O)R7)S(O)- -CH(R7)N(R7)S(O)N(R7)-, -CH(R7)N(R7)S(O)2N(R7)-, -CH(R7)C(O)N(R7)C(O)- -CH(R7)S(O)N(R7)C(O)-, -CH(R7)S(O)2N(R7)C(O)-, -CH(R7)OS(O)N(R7)-, -CH(R7)OS(O)2N(R7)-, -CH(R7)N(R7)S(O)O- -CH(R7)N(R7)S(O)2O-, -CH(R7)N(R7)S(O)C(O)-, -CH(R7)N(R7)S(O)2C(O)- -CH(R7)SON(C(O)R7)-, -CH(R7)SO2N(C(O)R7)-, -CH(R7)N(R7)SON(R7)-, -CH(R7)N(R7)SO2N(R7)-, or -CH(R7)C(O)O-; or
[222] wherein Q is substituted by said one to five independent G1 substituents wherein at least one of said G1 substituents is -(X1)n-(Y1)m-R4 J and wherein X1 and Y1 are each independently equal to -O-, -NR7-, -CR5R -, -S(O)j7-, or -C(O)-, and wherein n and m are both equal to 1 and j'7 is equal to 1 or 2; or
[223] wherein Q1 is substituted by said one to five independent G1 substituents wherein at least one of said G1 substituents is -(X1)n-(Y1)m-R4, and wherein X1 and Y1 are each independently -O- or -CR5R6-, and wherein n and m are equal to 1; or
[224] wherein R1 is cycloalkyl, bicycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, or heterobicycloalkyl, any of which is optionally substituted by one or more independent G11 substituents; or
[225] wherein R1 is cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, or heterocyclyl, any of which is optionally substituted by one or more independent G11 substituents; or
[226] wherein R1 is cycloalkyl or heterocyclyl, any of which is optionally substituted by one or more independent G11 substituents; or
[227] wherein R1 is cycloalkyl optionally substituted by one or more independent G11 substituents; or
[228] wherein R1 is heterocyclyl optionally substituted by one or more independent G11 substituents; or
[229] wherein R1 is aryl, heteroaryl, aralkyl, or heteroaralkyl, any of which is optionally substituted by one or more independent G11 substituents; or
[230] wherein R1 is aryl or heteroaryl, any of which is optionally substituted by one or more independent G11 substituents; or
[231] wherein G11 is -OR21, -NR21R31(R31a)j4, -C(O)R21, -CO2R21,
-CONR21R31, NR21(C=O)R31, NR 1(O=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31,
-O(C=O)OR21, -O(C=O)NR21R31, C0-10alkyl, cycloC3-8alkyl, cycloC3-8alkenyl, heterocyclyl-C0-10alkyl, or heterocyclyl-C2-10alkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221,
-NR2221R3331(R333a)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN,
-S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331,
NR2221(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221,
-NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al,
-NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, ~O(C=O)SR2221, -S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents; or aryl-C0-10alkyl, aryl-C2- 10alkenyl, or aryl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j5a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j5aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2 21(C=O)NR2221R3331, NR2221S(O)j5aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR 22alR333al, -NR2221(C=NR3331)OR222al, -NR2221(C=NR3331)SR333al, -O(C=O)OR222\ -O(CO)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents; or hetaryl-Co-ioalkyl, hetaryl-C2-10alkenyl, or hetaryl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j6a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j6aR2221, -SO2NR2221R3331, NR2221(CO)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j6aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR2 2alR333al, -NR2221(C-NR3331)OR22 al, -NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(CO)NR2221R3331 substituents; or
[232] wherein G11 is -OR21, -NR21R31, -CO2R21, -C(O)R21, -CONR21R31,
NR21(C=O)R31, NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31, -O(C=O)OR21, -O(CO)NR21R31, C0-10alkyl, cycloC3-8alkyl, cycloC3-8alkenyl, heterocyclyl-Co-ioalkyl, or heterocyclyl-C2-ι0alkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR22 1(C=NR3331)OR222al, -NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(D=O)OR2221, or -S(C=O)NR2221R3331 substituents; or [233] wherein R4 is H, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G41 substituents; or [234] wherein R4 is alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G41 substituents; or
[235] wherein R4 is alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G41 substituents; or wherein Q1 is phenyl substituted by said one to five independent G1 substituents wherein at least one of said G1 substituents is
-(X1)n-(Y1)m-R4, and wherein n = 1 and X1 is 3-(-O-), m = 1 and Y1 is -(-CH2-), and R4 is aryl optionally substituted by one or more independent G41 substituents; or
[236] wherein R1 is aryl, heteroaryl, cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents; or
[237] wherein R1 is cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents; or
[238] wherein R1 is cycloalkyl, optionally substituted by one or more independent G11 substituents; or
[239] wherein R1 is cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted by one or more independent G11 substituents; or
[240] wherein G11 is -OR21, -NR21R31, -CO2R21, -C(O)R21, -CONR21R31,
NR21(0=O)R31, NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31,
-O(C=O)OR21, -O(C=O)NR21R31, C0-1oalkyl, cycloC3-8alkyl, cycloC3-8alkenyl, heterocyclyl-Co-10alkyl, or heterocyclyl-C2-10alkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221,
-NR2221R3331(R333al)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN,
-S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331,
NR2221(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221,
-NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al,
-NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221,
-S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents; or
[241] wherein Q1 is phenyl substituted by said one to five independent G1 substituents wherein at least one of said G1 substituents is -(X1)n-(Y1)m-R4, and wherein n = 1 and X1 is 4-(-O-), m = 1 and Y1 is -(-CH2-), and R4 is aryl optionally substituted by one or more independent G41 substituents; or [242] wherein R1 is aryl, heteroaryl, cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents; or
[243] wherein R1 is cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents;
[244] wherein R1 is cycloalkyl, optionally substituted by one or more independent G11 substituents; or
[245] wherein R1 is cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted by one or more independent G11 substituents; or
[246] wherein G11 is -OR21, -NR21R31, -CO2R21, -C(O)R21, -CONR21R31,
NR21(C=O)R31, NR21(CO)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31,
-O(C=O)OR21, -O(C=O)NR21R31, C0.10alkyl, cycloC3-8alkyl, cycloC3-8alkenyl, heterocyclyl-C0-1oalkyl, or heterocyclyl-C -ι0alkenyl, any of which is optionally 9991 substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR ,
-NR2221R3331(R333al)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN,
-S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331,
NR2221(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221,
-NR2221(C=NR3331)NR2 2alR333al, -NR2221(C=NR3331)OR222al,
-NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221,
-S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents; or
[247] wherein Q1 is phenyl substituted by said one to five independent G1 substituents wherein at least one of said G1 substituents is -(X1)n-(Y1)m-R4, and wherein n = 1 and X1 is 3-(-O-), m = 0, and R4 is (Co-C8)alkyl or cycloalkyl optionally substituted by one or more independent G41 substituents; or
[248] wherein R1 is aryl, heteroaryl, cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents; or
[249] wherein R1 is cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents; or
[250] wherein R1 is cycloalkyl, optionally substituted by one or more independent G11 substituents; or
[251] wherein R1 is cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted by one or more independent G11 substituents; or [252] wherein G11 is -OR21, -NR21R31, -CO2R21, -C(O)R21, -CONR21R31,
NR21(C=O)R31, NR21(C=O)OR31, NR21(CO)NR21R31, NR21S(O)j4R31,
-O(C=O)OR21, -O(C=O)NR21R31, C0-ι0alkyl, cycloC3-8alkyl, cycloC3-8alkenyl, heterocyclyl-Co-ioalkyl, or heterocyclyl-C2-10alkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221,
-NR22 1R3331(R333al)i4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN,
-S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=0)R3331, NR2221(C=O)OR3331,
NR2221(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221,
-NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al,
-NR2 21(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221,
-S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents; or
[253] , wherein R4 is (C0-C6)alkyl; or
[254] wherein R4 is H or methyl; or
[255] wherein R4 is H or methyl; or
[256] wherein Q1 is phenyl substituted by said one to five independent G1 substituents wherein at least one of said G1 substituents is -(X1)n-(Y1)m-R4, and wherein n = 1 and X1 is 3-(-O-), m = 0, and R4 is aryl optionally substituted by one or more independent G41 substituents; or
[257] wherein R1 is aryl, heteroaryl, cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents; or
[258] wherein R1 is cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents; or
[259] wherein R1 is cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted by one or more independent G11 substituents; or
[260] wherein G11 is -OR21, -NR21R31, -CO2R21, -C(O)R21, -CONR21R31,
N 21(C=O)R31, NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31,
-O(C=O)OR21, -O(C=O)NR21R31, C0-ι0alkyl, cycloC3-8alkyl, cycloC3-8alkenyl, heterocyclyl-Co-10all<:yl, or heterocyclyl-C2-10alkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221,
-NR2221R3331(R333al)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN,
-S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2 21(CO)OR3331,
NR2221(C=O)NR2221R3331, NR 221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2 21(C=NR3331)OR222al,
-NR2221(C=NR3331)SR333al, -O(Q=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221,
-S(C=O)OR2221, or -S(CO)NR2221R3331 substituents; or
[261 ] wherein R4 is phenyl optionally substituted with G41 ; or
[262] wherein Q1 is phenyl substituted by said one to five independent G1 substituents wherein at least one of said G1 substituents is -(X1)n-(Y1)m-R , and wherein n = 1 and X1 is 3- or 4-(-NH-), m = 1 and Y1 is -(-SO2-), and R4 is aryl optionally substituted by one or more independent G4 substituents; or
[263] wherein R1 is aryl, heteroaryl, cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents; or
[264] wherein R1 is cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents; or
[265] wherein R1 is cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted by one or more independent G11 substituents; or
[266] wherein Gπ is -OR21, -NR21R31, -CO2R21, -C(O)R21, -CONR21R31,
NR21(C=O)R31, NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31,
-O(C=O)OR21, -O(C=O)NR21R31, C0-10alkyl, cycloC3-8alkyl, cycloC3-8alkenyl, heterocyclyl-Co-ioalkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221,
-NR2221R3331(R333al)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN,
-S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331,
NR2221(C=O)NR2221R3331, NR22 1S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221,
-NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al,
-NR2221(C=NR3331)SR333al, -O(CO)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221,
-S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents; or
[267] wherein R1 is cis- or trans- cyclobutyl substituted at the 3 -position by
G11 wherein G11 is -OH, -NH2, -N(CH3)2, -NHAc, -NH(CO)NHCH3,
-NH(CO)OCH3, -CH2OH, -CH2NH2, -CH2NHAc, CO2H, CONH2, -CH2N(CH3)2,
-CH2NH(CO)NHMe, -CH2NH(CO)OCH3, CO2CH3, CONHCH3,
Figure imgf000049_0001
[268] wherein R1 is cis- or trans- cyclohexyl substituted at the 4-position by
G11 wherein G11 is -OH, -NH2, -N(CH3)2, -NHAc, -NH(CO)NHCH3, -NH(CO)OCH3, -CH2OH, -CH2NH2, -CH2NHAc, CO2H, CONH2, -CH2N(CH3)2, -CH2NH(CO)NHMe, -CH2NH(CO)OCH3, CO2CH3, CONHCH3,
Figure imgf000050_0001
[269] wherein the compound of Formula I is selected from the group consisting of:
[ 1 -(3-Benzyloxy-phenyl)-3-cyclobutyl-imidazo[ 1 ,5-a]pyrazin-8-ylamine],
1 -(3-Benzyloxyphenyl)-3-phenyl-imidazo[ 1 ,5-α]pyrazin-8-ylamine,
3-Benzyl-l-(3-benzyloxyphenyl)-imidazo[l,5-α]pyrazin-8-ylamine,
1 -(3-Benzyloxyphenyl)-3-naphthalen-l -yl-imidazo[ 1 ,5-α]pyrazin-8-ylamine,
l-(3-Benzyloxyphenyl)-3-naphthalen-2-yl-imidazo[l,5-α]pyrazin-8-ylamine,
1 -(3-Benzyloxy-phenyl)-3-cyclopentyl-imidazo[ 1 ,5-a]pyrazin-8-ylamine,
l-(3-Benzyloxy-phenyl)-3-cyclohexyl-imidazo[l,5-a]pyrazin-8-ylamine,
1 -(3-Benzyloxy-phenyl)-3-cycloheptyl-imidazo[ 1 ,5-a]pyrazin-8-ylamine,
l-(3-Benzyloxy-phenyl)-3-(tehahydro-furan-3-yl)-imidazo[l,5-a]pyrazin-8-ylamine,
tra«i,-3-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]-cyclobutanol,
l-(3-Benzyloxy-phenyl)-3-(l-methyl-piperidin-4-yl)-imidazo[l,5-a]pyrazin-8- ylamine,
cώ-4-[8-Amino- 1 -(3-benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin-3-yl]- cyclohexanecarboxylic acid amide, trα7?-f-4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]- cyclohexanecarboxylic acid amide,
cω-{4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]-cyclohexyl}- methanol,
trans- {4-[8-Amino- l-(3-benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin-3-yl]-cyclohexyl} - methanol, cis-2- {A- [ 8- Amino- 1 -(3 -benzyloxy-phenyl)-imidazo [ 1 , 5-a]pyrazin-3 -yl] - cyclohexylmethyl}-isoindole-l,3-dione,
trans-2- {4-[8-Amino- 1 -(3-benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin-3-yl]- cyclohexyhnethyl} -isoindole- 1 ,3-dione,
cw-3-(4-Aminomethyl-cyclohexyl)-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-8- ylamine,
trα«,y-3-(4-Aminomethyl-cyclohexyl)-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin- 8-ylamine,
cti,-N-{4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]- cyclohexylmethyl} -acetamide, or
trα«,s'-N-{4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]- cyclohexylmethyl} -acetamide; or
[270] and the other variables are as defined above for Formula I.
[271 ] The present invention includes a method of inhibiting protein kinase activity comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof.
[272] The present invention includes a method of inhibiting IGF-IR activity comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof.
[273 ] The present invention includes a method of inhibiting protein kinase activity wherein the activity of said protein kinase affects hyperproliferative disorders comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof. [274] The present invention includes a method of inhibiting protein kinase activity wherein the activity of said protein kinase influences angiogenesis, vascular permeability, immune response, cellular apoptosis, tumor growth, or inflammation comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof.
[275] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity, said method comprising administering to the patient a therapeutically effective amount of a compound of
Formula I or a pharmaceutically acceptable salt thereof.
[276] The present invention includes a method of treating a patient having a condition which is mediated by IGF-IR activity, said method comprising administering to the patient a therapeutically effective amount of a compound of
Formula I or a pharmaceutically acceptable salt thereof.
[277] The present invention includes a method of treating a patient having a hyperproliferative disorder, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
[278] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the activity of said protein kinase influences angiogenesis, vascular permeability, immune response, cellular apoptosis, tumor growth, or inflammation, said method comprising administering to the patient a therapeutically effective amount of a compound of
Formula I or a pharmaceutically acceptable salt thereof.
[279] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the protein kinase is a protein serine/threonine kinase or a protein tyrosine kinase, said method comprising administering to the patient a therapeutically effective amount of a compound of
Formula I or a pharmaceutically acceptable salt thereof.
[280] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is one or more ulcers, said method comprising administering to the patient a therapeutically effective amount of a compound of
Formula I or a pharmaceutically acceptable salt thereof. [281] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is one or more ulcers wherein the ulcer or ulcers are caused by a bacterial or fungal infection; or the ulcer or ulcers are Mooren ulcers; or the ulcer or ulcers are a symptom of ulcerative colitis, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
[282] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is Lyme disease, sepsis or infection by Herpes simplex, Herpes Zoster, human immunodeficiency virus, parapoxvirus, protozoa, or toxoplasmosis, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
[283] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is Lyme disease, sepsis or infection by Herpes simplex, Herpes Zoster, human immunodeficiency virus, parapoxvirus, protozoa, or toxoplasmosis, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
[284] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is von Hippel Lindau disease, pemphigoid, psoriasis, Paget's disease, or polycystic kidney disease, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
[285] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is fibrosis, sarcoidosis, cirrhosis, thyroiditis, hyperviscosity syndrome, Osier- Weber-Rendu disease, chronic occlusive pulmonary disease, asthma, exudtaes, ascites, pleural effusions, pulmonary edema, cerebral edema or edema following burns, trauma, radiation, stroke, hypoxia, or ischemia, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. [286] The present invention includes a method of treating a patient having a condition wliich is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is ovarian hyperstimulation syndrome, preeclainpsia, menometrorrhagia, or endometriosis, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
[287] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase-activity is chronic inflammation, systemic lupus, glomerulonephritis, synovitis, inflammatory bowel disease, Crohn's disease, glomerulonephritis, rheumatoid arthritis and osteoarthritis, multiple sclerosis, or graft rejection, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
[288] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is sickle cell anaemia, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
[289] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is an ocular condition, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
[290] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is an ocular condition wherein the ocular condition is ocular or macular edema, ocular neovascular disease, seleritis, radial keratotomy, uveitis, vitritis, myopia, optic pits, chronic retinal detachment, post-laser treatment complications, conjunctivitis, Stargardt's disease, Eales disease, retinopathy, or macular degeneration, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. [291 ] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is a cardiovascular condition, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. [292] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is atherosclerosis, restenosis, ischemia/reperfusion injury, vascular occlusion, venous malformation, or carotid obstructive disease, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. [293] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is cancer, said method comprising admimstering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
[294] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is cancer wherein the cancer is a solid tumor, a sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, a rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, an hematopoietic malignancy, or malignant ascites, said method comprising administering to the patient a therapeutically effective amount of a compound of Fonnula I or a pharmaceutically acceptable salt thereof.
[295] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is cancer wherein the cancer is Kaposi's sarcoma, Hodgkin's disease, lymphoma, myeloma, or leukemia, said method comprising administering to the patient a therapeutically effective amount of a compound of Fonnula I or a pharmaceutically acceptable salt thereof. [296] The present invention includes a method of treating a patient having a condition wliich is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is Crow-Fukase (POEMS) syndrome or a diabetic condition, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
[297] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the condition mediated by protein kinase activity is Crow-Fukase (POEMS) syndrome or a diabetic condition wherein the diabetic condition is insulin-dependent diabetes mellitus glaucoma, diabetic retinopathy, or microangiopathy, said method comprising admimstering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
[298] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity wherein the protein kinase activity is involved in T cell activation, B cell activation, mast cell degranulation, monocyte activation, signal transduction, apoptosis, the potentiation of an inflammatory response or a combination thereof, said method comprising administering to the patient a therapeutically effective amount of a compound of
Formula I or a pharmaceutically acceptable salt thereof.
[299] The present invention includes a composition comprising a compound according to Formula I, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
[300] The present invention includes a composition comprising a compound according to Formula I, or a pharmaceutically acceptable salt thereof; and an anti- neoplastic, anti-tumor, anti-angiogenic, or chemotherapeutic agent.
[301] The present invention includes a composition comprising a compound according to Formula I, or a pharmaceutically acceptable salt thereof; and a cytotoxic cancer therapeutic agent.
[302] The present invention includes a composition comprising a compound according to Formula I, or a pharmaceutically acceptable salt thereof; and an angiogenesis inhibiting cancer therapeutic agent.
[303 ] The present invention includes a method of treating a patient having a condition which is mediated by protein kinase activity, said method comprising admimstering to the patient a therapeutically effective amount of a pharmaceutical composition comprising a compound according to Formula I, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
[304] Unless otherwise stated, the connections of compound name moieties are at the rightmost recited moiety. That is, the substituent name starts with a terminal moiety, continues with any bridging moieties, and ends with the connecting moiety. For example, hetarylthioC1- alkyl has a heteroaryl group connected through a thio sulfur to a C1-4 alkyl that connects to the chemical species bearing the substituent.
[305] As used herein, for example, "Co-4alkyl" is used to mean an alkyl having 0-4 carbons - that is, 0, 1, 2, 3, or 4 carbons in a straight or branched configuration. An alkyl having no carbon is hydrogen when the alkyl is a terminal group. An alkyl having no carbon is a direct bond when the alkyl is a bridging
(connecting) group.
[306] In all embodiments of this invention, the term "alkyl" includes both branched and straight chain alkyl groups. Typical alkyl groups are methyl, ethyl, n- propyl, isopropyl, ra-butyl, see-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, isooctyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, hexadecyl, octadecyl, eicosyl and the like.
[307] The term "halo" refers to fluoro, chloro, bromo or iodo.
[308] The term "haloalkyl" refers to an alkyl group substituted with one or more halo groups, for example chloromethyl, 2-bromoethyl, 3-iodopropyl, trifluoromethyl, perfluoropropyl, 8-chlorononyl and the like.
[309] The term "cycloalkyl" refers to a cyclic aliphatic ring structure, optionally substituted with alkyl, hydroxy and halo, such as cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl, 2-hydroxycyclopentyl, cyclohexyl, 4- chlorocyclohexyl, cycloheptyl, cyclooctyl and the like.
[310] The term "alkylcarbonyloxyalkyl" refers to an ester moiety, for example acetoxymethyl, «-butyryloxyethyl and the like.
[311] The term "alkynylcarbonyl" refers to an alkynylketo functionality, for example propynoyl and the like. [312] The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxy groups, for example hydroxymethyl, 2,3-dihydroxybutyl and the like.
[313] The term "alkylsulfonylalkyl" refers to an alkyl group substituted with an alkylsulfonyl moiety, for example mesylmethyl, isopropylsulfonylethyl and the like.
[314] The term "alkylsulfonyl" refers to a sulfonyl moiety substituted with an alkyl group, for example mesyl, H-propylsulfonyl and the like.
[315] The term "acetylaminoalkyl" refers to an alkyl group substituted with an amide moiety, for example acetylaminomethyl and the like.
[316] The temi "acetylaminoalkenyl" refers to an alkenyl group substituted with an amide moiety, for example 2-(acetylamino)vinyl and the like.
[317] The term "alkenyl" refers to an ethylenically unsaturated hydrocarbon group, straight or branched chain, having 1 or 2 ethylenic bonds, for example vinyl, allyl, 1-butenyl, 2-butenyl, isopropenyl, 2-ρentenyl and the like.
[318] The term "haloalkenyl" refers to an alkenyl group substituted with one or more halo groups.
[319] The term "cycloalkenyl" refers to a cyclic aliphatic ring structure, optionally substituted with alkyl, hydroxy and halo, having 1 or 2 ethylenic bonds such as methylcyclopropenyl, trifluoromethylcyclopropenyl, cyclopentenyl, cyclohexenyl, 1,4-cyclohexadienyl and the like.
[320] The term "alkynyl" refers to an unsaturated hydrocarbon group, straight or branched, having 1 or 2 acetylenic bonds, for example ethynyl, propargyl and the like.
[321] The term "haloalkynyl" refers to an alkynyl group substituted with one or more halo groups.
[322] The term "alkylcarbonyl" refers to an alkylketo functionality, for example acetyl, n-butyryl and the like.
[323] The term "alkenylcarbonyl" refers to an alkenylketo functionality, for example, propenoyl and the like.
[324] The term "aryl" refers to phenyl or naphthyl which may be optionally substituted. Typical aryl substituents include, but are not limited to, phenyl, 4- chlorophenyl, 4-fluorophenyl, 4-bromophenyl, 3-nitrophenyl, 2-methoxyphenyl, 2- methylphenyl, 3-methyphenyl, 4-methylphenyl, 4-ethylphenyl, 2-methyl-3- methoxyphenyl, 2,4-dibromophenyl, 3,5-difluorophenyl, 3,5-dimethylphenyl, 2,4,6- trichlorophenyl, 4-methoxyphenyl, naphthyl, 2-chloronaphthyl, 2,4-dimethoxyphenyl, 4-(trifluoromethyl)phenyl and 2-iodo-4-methylphenyl.
[325] The term "aryl^'refers to phenyl which may be optionally substituted.
Typical aryl1 substituents include, but are not limited to, phenyl, 4-chlorophenyl, 4- fluorophenyl, 4-bromophenyl, 3-nitrophenyl, 2-methoxyphenyl, 2-methylphenyl, 3- methyphenyl, 4-methylphenyl, 4-ethylphenyl, 2-methyl-3-methoxyphenyl, 2,4- dibromophenyl, 3,5-difluorophenyl, 3,5-dimethylphenyl, 2,4,6-trichlorophenyl, 4- methoxyphenyl, 2,4-dimethoxyphenyl, 4-(trifluoromethyl)phenyl and 2-iodo-4- methylphenyl.
[326] The terms "heteroaryl" or "hetaryl" refer to a substituted or unsubstituted 5- or 6-membered unsaturated ring containing one, two, three or four heteroatoms, preferably one or two heteroatoms independently selected from oxygen, nitrogen and sulfur or to a bicyclic unsaturated ring system containing up to 10 atoms including one heteroatom selected from oxygen, nitrogen and sulfur. Examples of hetaryls include, but are not limited to, 2-, 3- or 4-pyridinyl, pyrazinyl, 2-, 4-, or 5- pyrimidinyl, pyridazinyl, triazolyl, tetrazolyl, imidazolyl, 2- or 3-thienyl, 2- or 3- furyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzimidazolyl, benzotriazolyl, benzofuranyl, and benzothienyl. The heterocyclic ring may be optionally substituted with up to two substituents. [327] The terms "heteroaryl1" or "hetaryl1" refer to a substituted or unsubstituted 5- or 6-membered unsaturated ring containing one, two, three or four heteroatoms, preferably one or two heteroatoms independently selected from oxygen, nitrogen and sulfur. Examples of hetaryls include, but are not limited to, 2-, 3- or 4- pyridinyl, pyrazinyl, 2-, 4-, or 5-pyrimidinyl, pyridazinyl, triazolyl, tetrazolyl, imidazolyl, 2- or 3-thienyl, 2- or 3-furyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl. The heterocyclic ring may be optionally substituted with up to two substituents.
[328] The terms "aryl-alkyl" or "arylalkyl" are used to describe a group wherein the alkyl chain can be branched or straight chain with the aryl portion, as defined hereinbefore, forming a bridging portion of the aryl-alkyl moiety. Examples of aryl-alkyl groups include, but are not limited to, optionally substituted benzyl, phenethyl, phenpropyl and phenbutyl such as 4-chlorobenzyl, 2,4-dibromobenzyl, 2- methylbenzyl, 2-(3-fluorophenyl)ethyl, 2-(4-methylphenyl)ethyl, 2-(4-
(trifluoromethyl)phenyl)ethyl, 2-(2-methoxyphenyl)ethyl, 2-(3-nitrophenyl)ethyl, 2-
(2,4-dichlorophenyl)ethyl, 2-(3,5-dimethoxyphenyl)ethyl, 3-phenylpropyl, 3-(3- chlorophenyl)propyl, 3-(2-methylphenyl)proρyl, 3-(4-methoxyphenyl)propyl, 3-(4-
(trifluoromethyl)phenyl)propyl, 3-(2,4-dichlorophenyl)propyl, 4-phenylbutyl, 4-(4- chlorophenyl)butyl, 4-(2-methylphenyl)butyl, 4-(2,4-dichlorophenyl)butyl, 4-(2- methoxphenyl)butyl and 10-phenyldecyl.
[329] The terms "aryl-cycloalkyl" or "arylcycloalkyl" are used to describe a group wherein the aryl group is attached to a cycloalkyl group, for example phenylcyclopentyl and the like.
[330] The terms "aryl-alkenyl" or "arylalkenyl" are used to describe a group wherein the alkenyl chain can be branched or straight chain with the aryl portion, as defined hereinbefore, forming a bridging portion of the aralkenyl moiety, for example styryl (2-phenylvinyl), phenpropenyl and the like.
[331] The terms "aryl-alkynyl" or "arylalkynyl" are used to describe a group wherein the alkynyl chain can be branched or straight chain with the aryl portion, as defined hereinbefore, forming a bridging portion of the aryl-alkynyl moiety, for example 3 -phenyl- 1-propynyl and the like.
[332] The terms "aryl-oxy" or "aryloxy" are used to describe a terminal aryl group attached to a bridging oxygen atom. Typical aryl-oxy groups include phenoxy,
3,4-dichlorophenoxy and the like.
[333] The terms "aryl-oxyalkyl" or "aryloxyalkyl" are used to describe a group wherein an alkyl group is substituted with an aryl-oxy group, for example pentafluorophenoxymethyl and the like.
[334] The terms "hetaryl-oxy" or "heteroaryl-oxy" or "hetaryloxy" or
"heteroaryloxy" are used to describe a terminal hetaryl group attached to a bridging oxygen atom. Typical hetaryl-oxy groups include 4,6-dimethoxypyrimidin-2-yloxy and the like.
[335] The terms "hetarylalkyl" or "heteroarylalkyl" or "hetaryl-alkyl" or
"heteroaryl-alkyl" are used to describe a group wherein the alkyl chain can be branched or straight chain with the heteroaryl portion, as defined hereinbefore, forming a bridging portion of the heteroaralkyl moiety, for example 3-furylmethyl, thenyl, furfuryl and the like.
[336] The terms "hetarylalkenyl" or "heteroarylalkenyl" or "hetaryl-alkenyl" or "heteroaryl-alkenyl" are used to describe a group wherein the alkenyl chain can be branched or straight chain with the heteroaryl portion, as defined hereinbefore, forming a bridging portion of the heteroaralkenyl moiety, for example 3-(4-pyridyl)- 1-propenyl.
[337] The terms "hetarylalkynyl" or "heteroarylalkynyl" or
"hetaryl-alkynyl" or "heteroaryl-alkynyl" are used to describe a group wherein the alkynyl chain can be branched or straight chain with the heteroaryl portion, as defined hereinbefore, forming a bridging portion of the heteroaralkynyl moiety, for example 4-(2-thienyl)- 1 -butynyl.
[338] The term "heterocyclyl" refers to a substituted or unsubstituted 5 or 6 membered saturated ring containing one, two or three heteroatoms, preferably one or two heteroatoms independently selected from oxygen, nitrogen and sulfur or to a bicyclic ring system containing up to 10 atoms including one heteroatom selected from oxygen, nitrogen and sulfur wherein the ring containing the heteroatom is saturated. Examples of heterocyclyls include, but are not limited to, tetrahydrofuranyl, tetrahydrofuryl, pyrrolidinyl, piperidinyl, 4-pyranyl, tetrahydropyranyl, thiolanyl, morpholinyl, piperazinyl, dioxolanyl, dioxanyl, indolinyl, 5-methyl-6-chromanyl and
Figure imgf000061_0001
[339] The terms "heterocyclylalkyl" or "heterocyclyl-alkyl" are used to describe a group wherein the alkyl chain can be branched or straight chain with the heterocyclyl portion, as defined hereinabove, forming a bridging portion of the heterocyclylalkyl moiety, for example 3-piperidinyhnethyl and the like. [340] The terms "heterocyclylalkenyl" or "heterocyclyl-alkenyl" are used to describe a group wherein the alkenyl chain can be branched or straight chain with the heterocyclyl portion, as defined hereinbefore, forming a bridging portion of the heterocyclylalkenyl moiety, for example 2-morpholinyl-l-propenyl. [341] The terms "heterocyclylalkynyl" or "heterocyclyl-alkynyl" are used to describe a group wherein the alkynyl chain can be branched or straight chain with the heterocyclyl portion, as defined hereinbefore, forming a bridging portion of the heterocyclylalkynyl moiety, for example 2-pyrrolidinyl-l-butynyl.
[342] The term "carboxylalkyl" includes both branched and straight chain alkyl groups as defined hereinbefore attached to a carboxyl (-COOH) group.
[343] The term "carboxylalkenyl" includes both branched and straight chain alkenyl groups as defined hereinbefore attached to a carboxyl (-COOH) group.
[344] The term "carboxylalkynyl" includes both branched and straight chain alkynyl groups as defined hereinbefore attached to a carboxyl (-COOH) group.
[345] The term "carboxylcycloalkyl" refers to a carboxyl (-COOH) group attached to a cyclic aliphatic ring structure as defined hereinbefore.
[346] The term "carboxylcycloalkenyl" refers to a carboxyl (-COOH) group attached to a cyclic aliphatic ring structure having 1 or 2 ethylenic bonds as defined hereinbefore.
[347] The terms "cycloalkylalkyl" or "cycloalkyl-alkyl" refer to a cycloalkyl group as defined hereinbefore attached to an alkyl group, for example cyclopropylmethyl, cyclohexylethyl and the like.
[348] The terms "cycloalkylalkenyl" or "cycloalkyl-alkenyl" refer to a cycloalkyl group as defined hereinbefore attached to an alkenyl group, for example cyclohexylvinyl, cycloheptylallyl and the like.
[349] The terms "cycloalkylalkynyl" or "cycloalkyl-alkynyl" refer to a cycloalkyl group as defined hereinbefore attached to an alkynyl group, for example cyclopropylpropargyl, 4-cyclopentyl-2-butynyl and the like.
[350] The terms "cycloalkenylalkyl" or "cycloalkenyl-alkyl" refer to a cycloalkenyl group as defined hereinbefore attached to an alkyl group, for example 2-
(cyclopenten-l-yl)ethyl and the like.
[351] The terms "cycloalkenylalkenyl" or "cycloalkenyl-alkenyl" refer to a cycloalkenyl group as defined hereinbefore attached to an alkenyl group, for example l-(cyclohexen-3-yl)allyl and the like. [352] The terms "cycloalkenylalkynyl" or "cycloalkenyl-alkynyl" refer to a cycloalkenyl group as defined hereinbefore attached to an alkynyl group, for example l-(cyclohexen-3-yl)propargyl and the like.
[353] The term "carboxylcycloalkylalkyl" refers to a carboxyl (-COOH) group attached to the cycloalkyl ring portion of a cycloalkylalkyl group as defined hereinbefore.
[354] The tenn "carboxylcycloalkylalkenyl" refers to a carboxyl (-COOH) group attached to the cycloalkyl ring portion of a cycloalkylalkenyl group as defined hereinbefore.
[355] The term "carboxylcycloalkylalkynyl" refers to a carboxyl (-COOH) group attached to the cycloalkyl ring portion of a cycloalkylalkynyl group as defined hereinbefore.
[356] The term "carboxylcycloalkenylalkyl" refers to a carboxyl (-COOH) group attached to the cycloalkenyl ring portion of a cycloalkenylalkyl group as defined hereinbefore.
[357] The term "carboxylcycloalkenylalkenyl" refers to a carboxyl (-COOH) group attached to the cycloalkenyl ring portion of a cycloalkenylalkenyl group as defined hereinbefore.
[358] The term "carboxylcycloalkenylalkynyl" refers to a carboxyl (-COOH) group attached to the cycloalkenyl ring portion of a cycloalkenylalkynyl group as defined hereinbefore.
[359] The term "alkoxy" includes both branched and straight chain terminal alkyl groups attached to a bridging oxygen atom. Typical alkoxy groups include methoxy, ethoxy, κ-propoxy, isopropoxy, tert-butoxy and the like.
[360] The term "haloalkoxy" refers to an alkoxy group substituted with one or more halo groups, for example chloromethoxy, trifluoromethoxy, difluoromethoxy, perfluoroisobutoxy and the like.
[361] The term "alkoxyalkoxyalkyl" refers to an alkyl group substituted with an alkoxy moiety which is in turn substituted with a second alkoxy moiety, for example methoxymethoxymethyl, isopropoxymethoxyethyl and the like.
[362] The term "alkylthio" includes both branched and straight chain alkyl groups attached to a bridging sulfur atom, for example methylthio. [363] The term "haloalkylthio" refers to an alkylthio group substituted with one or more halo groups, for example trifluoromethylthio.
[364] The term "alkoxyalkyl" refers to an alkyl group substituted with an alkoxy group, for example isopropoxymethyl.
[365] The term "alkoxyalkenyl" refers to an alkenyl group substituted with an alkoxy group, for example 3-methoxyallyl.
[366] The term "alkoxyalkynyl" refers to an alkynyl group substituted with an alkoxy group, for example 3-methoxypropargyl.
[367] The term "alkoxycarbonylalkyl" refers to a straight chain or branched alkyl substituted with an alkoxycarbonyl, for example ethoxycarbonylmethyl, 2-
(methoxycarbonyI)propyl and the like.
[368] The term "alkoxycarbonylalkenyl" refers to a straight chain or branched alkenyl as defined hereinbefore substituted with an alkoxycarbonyl, for example 4-(ethoxycarbonyl)-2-butenyl and the like.
[369] The term "alkoxycarbonylalkynyl" refers to a straight chain or branched alkynyl as defined hereinbefore substituted with an alkoxycarbonyl, for example 4-(ethoxycarbonyl)-2-butynyl and the like.
[370] The term "haloalkoxyalkyl" refers to a straight chain or branched alkyl as defined hereinbefore substituted with a haloalkoxy, for example 2- chloroethoxyniethyl, trifluoromethoxymethyl and the like.
[371] The term "haloalkoxyalkenyl" refers to a straight chain or branched alkenyl as defined hereinbefore substituted with a haloalkoxy, for example 4-
(chloromethoxy)-2-butenyl and the like.
[372] The tenn "haloalkoxyalkynyl" refers to a straight chain or branched alkynyl as defined hereinbefore substituted with a haloalkoxy, for example 4-(2- fluoroethoxy)-2-butynyl and the like.
[373] The term "alkylthioalkyl" refers to a straight chain or branched alkyl as defined hereinbefore substituted with an alkylthio group, for example methylthiomethyl, 3-(isobutylthio)heptyl and the like.
[374] The term "alkylthioalkenyl" refers to a straight chain or branched allcenyl as defined hereinbefore substituted with an allcylthio group, for example 4-
(methylthio)-2-butenyl and the like. [375] The term "alkylthioalkynyl" refers to a straight chain or branched alkynyl as defined hereinbefore substituted with an alkylthio group, for example 4-
(ethylthio)-2-butynyl and the like.
[376] The term "haloalkylthioalkyl" refers to a straight chain or branched alkyl as defined hereinbefore substituted with an haloalkylthio group, for example 2- chloroethylthiomethyl, trifluoromethylthiomethyl and the like.
[377] The term "haloalkylthioalkenyl" refers to a straight chain or branched alkenyl as defined hereinbefore substituted with an haloalkylthio group, for example
4-(chloromethylthio)-2-butenyl and the like.
[378] The term "haloalkylthioalkynyl" refers to a straight chain or branched alkynyl as defined hereinbefore substituted with a haloalkylthio group, for example 4-
(2-fluoroethylthio)-2-butynyl and the like.
[379] The term "dialkoxyphosphorylalkyl" refers to two straight chain or branched alkoxy groups as defined hereinbefore attached to a pentavalent phosphorous atom, containing an oxo substituent, which is in turn attached to an alkyl, for example diethoxyphosphorylmethyl.
[380] The term "oligomer" refers to a low-molecular weight polymer, whose number average molecular weight is typically less than about 5000 g/mol, and whose degree of polymerization (average number of monomer units per chain) is greater than one and typically equal to or less than about 50.
[381] Compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof. The above Formula I is shown without a definitive stereochemistry at certain positions. The present invention includes all stereoisomers of Fonnula I and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included.
During the course of the synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers. [382] The invention also encompasses a pharmaceutical composition that is comprised of a compound of Formula I in combination with a pharmaceutically acceptable carrier.
[383] Preferably the composition is comprised of a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of a compound of Formula I as described above (or a pharmaceutically acceptable salt thereof). [384] Moreover, within this prefened embodiment, the invention encompasses a pharmaceutical composition for the treatment of disease by inhibiting kinases, comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula I as described above (or a pharmaceutically acceptable salt thereof).
[385] The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corcesponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Particularly prefened are the ammonium, calcium, magnesium, potassium and sodium slats. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines. Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N',N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmo holine, N- ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylameine, trimethylamine, tripropylamine, tromethamine and the like.
[386] When the compound of the present invention is basic, its conesponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, formic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methaiiesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like. Prefened are citric, hydrobromic, formic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids. Particularly prefened are formic and hydrochloric acid. [387] The pharmaceutical compositions of the present invention comprise a compound represented by Formula I (or a pharmaceutically acceptable salt thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
[388] In practice, the compounds represented by Formula I, or a prodrug, or a metabolite, or a pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in- water emulsion, or as a water-in-oil liquid emulsion, addition to the common dosage forms set out above, the compound represented by Formula I, or a pharmaceutically acceptable salt thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation. [389] Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound, or a pharmaceutically acceptable salt, of Formula I. The compounds of Formula I, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds. [390] The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, tena alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.
[391] In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the prefened oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques.
[392] A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient. [393] For example, a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Unit dosage fonns will generally contain between from about lmg to about 2g of the active ingredient, typically 25mg, 50mg, lOOmg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or lOOOmg. [394] Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms. [395] Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions, i all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof. [396] Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention, or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt% to about 10wt% of the compound, to produce a cream or ointment having a desired consistency.
[397] Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds. [398] In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound described by Formula I, or pharmaceutically acceptable salts thereof, may also be prepared in powder or liquid concentrate form.
[399] Generally, dosage levels on the order of from about O.Olmg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above- indicated conditions, or alternatively about 0.5mg to about 7g per patient per day. For example, inflammation, cancer, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS), cardiovascular disease, dermatology, and angiogenesis may be effectively treated by the administration of from about 0.01 to 50mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 3.5g per patient per day. [400] It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy. [4O1] Compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof. The above Formula I is shown without a definitive stereochemistry at certain positions. The present invention includes all stereoisomers of Formula I and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers. [402] The invention also encompasses a pharmaceutical composition that is comprised of a compound of Formula I in combination with a pharmaceutically acceptable carrier. [403] Preferably the composition is comprised of a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of a compound of Formula I as described above, or a pharmaceutically acceptable salt thereof. [404] Moreover, within this prefened embodiment, the invention encompasses a pharmaceutical composition for the treatment of disease by inhibiting tyrosine kinase enzymes, resulting in cell proliferation, growth, differentiation, metabolism, cell cycle events, apoptosis, motility, transcription, phosphorylation, translation and other signaling processes, comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of formula I as described above (or a pharmaceutically acceptable salt thereof). [405] The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its conesponding salt can be conveniently prepared from phannaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, fenous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Particularly prefened are the ammonium, calcium, magnesium, potassium and sodium slats. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines. Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N'.N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylameine, trimethylamine, tripropylamine, trometrxamine and the like.
[406] When the compound of the present invention is basic, its conesponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric-, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like. Particularly prefened are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids. [407] The pharmaceutical compositions of the present invention comprise a compound represented by formula I, or a pharmaceutically acceptable salt thereof, as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being admimstered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
[408] In practice, the compounds represented by Formula I, or phannaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration. E.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in- ater emulsion, or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compound represented by Formula I, or a pharmaceutically acceptable salt thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
[409] Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt of Formula I. The compounds of Formula I, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
[410] The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, tena alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.
[411] hi preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the prefened oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques.
[412] A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient.
[413] For example, a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Unit dosage forms will generally contain between from about lmg to about 2g of the active ingredient, typically 25mg, 50mg, lOOmg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or lOOOmg. [414] Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms. [415] Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthennore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions, hi all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof. [416] Pharmaceutical compositions of the present invention can be in a form suitable for topical sue such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention, or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt% to about 10wt% of the compound, to produce a cream or ointment having a desired consistency.
[417] Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. He suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds.
[418] In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound described by Formula I, or pharmaceutically acceptable salts thereof, may also be prepared in powder or liquid concentrate form.
[419] Generally, dosage levels on the order of from about O.Olmg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above- indicated conditions, or alternatively about 0.5mg to about 7g per patient per day. For example, inflammation, cancer, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS), cardiovascular disease, dermatology, and angiogenesis may be effectively treated by the administration of from about 0.01 to 50mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 3.5g per patient per day. [420] It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
BIOLOGICAL ASSAYS
[421] The efficacy of the Examples of the invention, compounds of Formula
I, as inhibitors of insulin-like growth factor- 1 receptor (IGF-IR) were demonstrated and confirmed by a number of pharmacological in vitro assays. The following assays and their respective methods have been carried out with the compounds according to the invention. Activity possessed by compounds of Formula I may be demonstrated in vivo.
In vitro tyrosine kinase assay
[422] The IGF-IR inhibitory of a compound of formula I can be shown in a tyrosine kinase assay using purified GST fusion protein containing the cytoplasmic kinase domain of human IGF-IR expressed in Sf9 cells. This assay is carried out in a final volume of 90 μL containing 1-lOOnM (depending on the specific activity) in an Immulon-4 96-well plate (Thermo Labsystems) pre-coated with lμg/well of substrate poly-glu-tyr (4: 1 ratio) in kinase buffer (50mM Hepes, pH 7.4, 125mM NaCl, 24mM
MgCl2, ImM MnCl2, 1% glycerol, 200μM Na3VO4, and 2mM DTT). The enzymatic reaction was initiated by addition of ATP at a final concentration of lOOμM. After incubation at room temperature for 30 minutes, the plates were washed with 2mM Imidazole buffered saline with 0.02% Tween-20. Then the plate was incubated with anti-phosphotyrosine mouse monoclonal antibody pY-20 conjugated with horse radish peroxidase (HRP) (Calbiochem) at 167ng/mL diluted in phosphate buffered saline (PBS) containing 3% bovine serum albumin (BSA), 0.5% Tween-20 and 200μM Na3VO4 for 2 hours at room temperature. Following 3X 250μL washes, the bound anti-phosphotyrosine antibody was detected by incubation with lOOμl/well ABTS (Kirkegaard & Peny Labs, Inc.) for 30 minutes at room temperature. The reaction was stopped by the addition of lOOμl /well 1% SDS, and the phosphotyrosine dependent signal was measured by a plate reader at 405/490 nm.
[423] Examples 1-21 showed inhibition of IGF-IR. Examples 1-21 showed efficacy and activity by inhibiting IGF-IR in the biochemical assay with IC50 values less than 15μM. Preferably the IC50 value is less than 5μM. More advantageously, the IC50 value is less than lμM. Even more advantageously, the IC50 value is less than 200nM. [424] The most prefened Examples are selective towards IGF-IR. Cell-based autophosphotyrosme Assay
[425] NH 3T3 cells stably expressing full-length human IGF-IR were seeded at lxlO4 cells/well in 0.1 ml Dulbecco's minimal essential medium (DMEM) supplemented with 10% fetal calf serum (FCS) per well in 96-well plates. On Day 2, the medium is replaced with starvation medium (DMEM containing 0.5% FCS) for 2 hours and a compound was diluted in 100% dimethyl sulfoxide (DMSO), added to the cells at six final concentrations in duplicates (20, 6.6, 2.2, 0.74, 0.25 and 0.082μM), and incubated at 37°C for additional 2 hours. Following addition of recombinant human IGF-1 (100 ng/mL) at 37°C for 15 minutes, the media was then removed and the cells were washed once with PBS (phosphate-buffered saline), then lysed with cold TGH buffer (1 % Triton-100, 10% glycerol, 50mM Hepes [pH 7.4]) supplemented with 150mM NaCl, 1.5mM MgCl, ImM EDTA and fresh protease and phosphatase inhibitors [lOμg/ml leupeptin, 25μg/ml aprotinin, ImM phenyl methyl sulphonyl fluoride (PMSF), and 200μM Na3VO4]. Cell lysates were transfened to a 96-well microlite2 plate (Corning CoStar #3922) coated with lOng/well of IGF-IR antibody (Calbiochem, Cat#GR31L) and incubated at 4°C overnight. Following washing with TGH buffer, the plate was incubated with anti-phosphotyrosine mouse monoclonal antibody pY-20 conjugated with horse radish peroxidase (HRP) for 2 hours at room temperature. The autophosphotyrosme was then detected by addition of Super Signal ELISA. Femto Maximum Sensitivity Substrate (Pierce) and chemiluminescence was read on a Wallac Victor2 1420 Multilabel Counter. The IC50 curves of the compounds were plotted using an ExcelFit program. [426] The following Examples showed efficacy and activity by inhibiting
IGF-IR in the above assay with IC50 values between lOOμM - about 8nM, with selectivity over insulin receptor expected to be in a range from 1-15 fold. The selectivity is preferably 5 fold, even more preferably the selectivity is 10 fold. Preferably the IC5o value is less than 5μM. More advantageously, the IC5o value is less than lμM. Even more advantageously, the IC50 value is less than 200nM. Insulin receptor autophosphotyrosme assays are performed essentially as described above for IGF-IR cell-based assays, but use insulin (10 nM) as activating ligand and an insulin receptor antibody as capture antibody with HepG2 cells expressing endogenous human insulin receptor. EXPERIMENTAL
[427] Schemes 1-13 below, as well as the Examples that follow, show how to synthesize compounds of this invention and utilize the following abbreviations: Me for methyl, Et for ethyl, :Pr or Pr for isopropyl, n-Bu for n-butyl, t-Bu for tert-butyl, Ac for acetyl, Ph for phenyl, 4C1-Ph or (4Cl)Ph for 4-chlorophenyl, 4Me-Ph or (4Me)Ph for 4-methylphenyl, (p-CH3O)Ph for - ethoxyphenyl, (p-NO2)Ph for p- nitrophenyl, 4Br-Ph or (4Br)Ph for 4-bromophenyl, 2-CF3-Ph or (2CF3)Ph for 2- trifluoromethylphenyl, DMAP for 4-(dimethylamino)pyridine, DCC for 1,3- dicyclohexylcarbodiimide, EDC for l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, HOBt for 1-hydroxybenzotriazole, HO At for l-hydroxy-7- azabenzotriazole, CDI for l,l'-carbonyldiimidazole, NMO for 4-methylmorpholine N-oxide, DEAD for diethlyl azodicarboxylate, DIAD for diisopropyl azodicarboxylate, DBAD for di-tert-butyl azodicarboxylate, HPFC for high performance flash chromatography, rt for room temperature, min for minute, h for hour, and Bn for benzyl.
[428] Accordingly, the following are compounds which are useful as intermediates in the formation of IGF-IR inhibiting Examples. [429] • The compounds of Formula I of this invention and the intermediates used in the synthesis of the compounds of this invention were prepared according to the following methods. Method A was used when preparing compounds of Formula I as shown below in Scheme 1 :
Method A: Scheme 1
Figure imgf000078_0001
I
[430] where Q1 and R1 are as defined previously for compound of Formula I.
[431 ] In a typical preparation of compounds of Formula I, compound of
Formula II was reacted with ammonia in a suitable solvent. Suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; dimethylformamide (DMF); dimethyl sulfoxide (DMSO); acetonitrile; alcoholics such as methanol, ethanol, isopropanol, trifluoroethanol, and the like; and chlorinated solvents such as methylene chloride (CH2C12) or chloroform (CHC13). If desired, mixtures of these solvents were used, however, the prefened solvent was isopropanol. The above process was carried out at temperatures between about -78 °C and about 120 °C. Preferably, the reaction was carried out between 80 °C and about 100 °C. The above process to produce compounds of the present invention was preferably carried out at about atmospheric pressure although higher or lower pressures were used if desired. Substantially, equimolar amounts of reactants were preferably used although higher or lower amounts were used if desired. [432] The compounds of Formula II of Scheme 1 were prepared as shown below in Scheme 2.
Scheme 2
Figure imgf000079_0001
III II
[433] where Q1 and R1 are as defined previously for compound of Formula I.
[434] In a typical preparation of a compound of Formula II, an intermediate of Formula III was treated Λvith POCl3 in a suitable solvent at a suitable reaction temperature. Suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; and chlorinated solvents such as methylene chloride (CH2C12) or chloroform (CHC13). If desired, mixtures of these solvents were used. The prefened solvent was methylene chloride. The above process was carried out at temperatures between about -78 °C and about 120 °C. Preferably, the reaction was carried out between 40 °C and about 70 °C. The above process to produce compounds of the present invention was preferably carried out at about atmospheric pressure although higher or lower pressures were used if desired. Substantially, equimolar amounts of reactants were preferably used although higher or lower amounts were used if desired.
Figure imgf000080_0001
[435] I III
[436] The compounds of Formula III of Scheme 2 were prepared as shown below in Scheme 3 : Scheme 3
[437] where Q1 and R1 are as defined previously for compound of Formula I and A1 = OH, alkoxy, or a leaving group such as chloro or imidazole. [438] In a typical preparation, of a compound of Formula III, a compound of
Formula IV and compound of Formula V were reacted under suitable amide coupling conditions. Suitable conditions include but are not limited to treating compounds of Formula IV and V (when A1 = OH) with coupling reagents such as DCC or EDC in conjunction with DMAP, HOBt, HOAt and the like. Suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; dimethylformamide (DMF); dimethyl sulfoxide (DMSO); acetonitrile; halogenated solvents such as chloroform or methylene chloride. If desired, mixtures of these solvents were used, however the prefened solvent was methylene chloride. The above process was carried out at temperatures between about 0 °C and about 80 °C. Preferably, the reaction was carried out between 22 °C. The above process to produce compounds of the present invention was preferably carried out at about atmospheric pressure although higher or lower pressures were used if desired. Substantially, equimolar amounts of reactants were preferably used although higher or lower amounts were used if desired. Additionally, other suitable reaction conditions for the conversion of RNH2 to CONHR can be found in Larock, R. C. Comprehensive Organic Transformations, 2nd ed.; Wiley and Sons: New York, 1999, pp 1941-1949. [439] The compounds of Formula IV of Scheme 3 were prepared as shown below in Scheme 4: Scheme 4
Figure imgf000081_0001
VI IV
1 7
[440] where Q is as defined previously for compound of Formula I and A = phthahmido or N3.
[441] In a typical preparation, of a compound of Formula IV, a compound of
Formula VI is reacted under suitable reaction conditions in a suitable solvent. When A2 = phthahmido, suitable conditions include treatment of compound of Fonnula VI with hydrazine in a suitable solvent. Suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; dimethylformamide (DMF); dimethyl sulfoxide (DMSO); acetonitrile; halogenated solvents such as chloroform or methylene chloride; alcoholic solvents such as methanol and ethanol. If desired, mixtures of these solvents may be used, however the prefened solvent was ethanol. The above process was carried out at temperatures between about 0 °C and about 80 °C. Preferably, the reaction was carried out between 22 °C. The above process to produce compounds of the present invention was preferably carried out at about atmospheric pressure although higher or lower pressures were used if desired. Substantially, equimolar amounts of reactants were preferably used although higher or lower amounts were used if desired. [442] The compounds of Formula IV of Scheme 3 can alternatively be prepared as shown below in Scheme 4a: Scheme 4a
Q1-CHO Qi_C=N-Si(CH3)3
Figure imgf000082_0001
IV
[443] where Q1 is as defined previously for compound of Formula I.
[444] in a typical preparation, of a compound of Formula TV, an aldehyde
Q^-CHO was reacted under suitable reaction conditions in a suitable solvent with lithium hexamethyldisilazide to give anN-TMS imine Q1-C=Ν-Si(CH3)3. Suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like. The prefened solvent was THF. The above process was carried out at temperatures between about -78 °C and about 20 °C. The prefened temperature was about 0 °C. The imine Q1-C=N-Si(CH3) thus obtained was then cooled to about —78 °C and treated with a lithiated 2-chloropyrazine under suitable reaction conditions in a suitable solvent to give a compound of Formula TV. Lithiated 2-chloropyrazine may be obtained by treating 2- chloropyrazine with a base such as lithium tetramethylpiperidide (Li-TMP). Lithium tetramethylpiperidide may be prepared by reacting tetramethylpiperidine with n- butyllithium at -78 °C and warming up to 0 °C. Suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like. Polar solvents such as hexamethylphosphoramide (HMPA), 1,3- dimethyl-3,4,5,6-tetrahydro-2(lH)-pyrimidinone (DMPU), and the like may be added if necessary. If desired, mixtures of these solvents were used, however, the prefened solvent was THF. The above process may be canied out at temperatures between about -80 °C and about 20 °C. Preferably, the reaction was carried out at -78 °C to 0 °C. The above process to produce compounds of the present invention was preferably carried out at about atmospheric pressure although higher or lower pressures were used if desired. Substantially, equimolar amounts of reactants were preferably used although higher or lower amounts were used if desired.
[445] The compounds of Formula VI of Scheme 4 were prepared as shown below in Scheme 5: Scheme 5
Figure imgf000083_0001
VII VI i 0
[446] where Q is as defined previously for compound of Formula I and A = phthahmido or N .
[447] In a typical preparation of a compound of Formula VI (when A2 = phthahmido), a compound of Formula VII was reacted with a phthalimide under typical Mitsunobu conditions in a suitable solvent in the presence of suitable reactants. Suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; dimethylformamide (DMF); dimethyl sulfoxide (DMSO); acetonitrile (CH3CN); chlorinated solvents such as methylene chloride (CH2C12) or chloroform (CHC13). If desired, mixtures of these solvents were used, however, the prefened solvent was THF. Suitable reactants for use in the above process included, but were not limited to, triphenylphosphine and the like and an azodicarboxylate (DIAD, DEAD, DBAD). The desired reactants were triphenylphosphine and DIAD. The above process may be carried out at temperatures between about -78 °C and about 100 °C. Preferably, the reaction was carried out at 22 °C. The above process to produce compounds of the present invention was preferably carried out at about atmospheric pressure although higher or lower pressures were used if desired. Substantially, equimolar amounts of reactants were preferably used although higher or lower amounts were used if desired. Generally, one equivalent of triphenylphospine, DIAD and phthalimide was used per equivalent of compound of Formula VII. The compounds of Formula VII were prepared according to known procedures (Pie, N.; et. al. Tetrahedron, 1998, 54, 9701- 9710) from aldehydes Q1— CHO. Additionally, compound of Formula VII can be reacted with Ts2O, Ms O, Tf2O, TsCl, MsCl, or SOCl2 in which the hydroxy group is converted to a leaving group such as its respective tosylate, mesylate triflate or halogen such as chloro and subsequently reacted with an amine equivalent such as NH(Boc)2, phthalimide, or azide. Conversion of the amine equivalents by known methods such as by treating under acidic conditions (NH(Boc)2), with hydrazine (phthalimide) as shown in Scheme 4, or with triphenylphosphine/water (azide) will afford the desired amine as shown in Scheme 4.
[448] The compounds of Formula I-A (compounds of Formula I where R1 =
Z — CONR2R3) were prepared as shown below in Scheme 6: Scheme 6
Figure imgf000084_0001
[449] where Q1, R2, and R3 are as defined previously for compound of
Formula I and A3 = hydrogen or alkyl such as methyl or ethyl.
[450] In a typical preparation of compound of Formula I-A (compounds of
Formula I where R1 = Z— CONR2R3), when A3 = alkyl and R2 and R3 were both equal to H, reaction of compound of Formula II- A with ammonia in a suitable solvent, afforded compound of Formula I-A. Suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; dimethylformamide (DMF); dimethyl sulfoxide (DMSO); acetonitrile; alcoholics such as methanol, ethanol, isopropanol, trifluoroethanol, and the like; and chlorinated solvents such as methylene chloride (CH C12) or chloroform (CHC13). If desired, mixtures of these solvents were used, however, the prefened solvent was isopropanol. The above process was carried out at temperatures between about -78 °C and about 120 °C. Preferably, the reaction was carried out between 80 °C and about
100 °C. The above process to produce compounds of the present invention was preferably carried out at about atmospheric pressure although higher or lower pressures were used if desired. Substantially, equimolar amounts of reactants were preferably used although higher or lower amounts were used if desired. Additionally, in a typical preparation of compound of Formula I-A (compounds of Formula I where
R1 = Z — CONR2R3), compound of Formula II- A (compounds of Formula II where R1 = Z— CO2A3) was reacted with HNR2R3 followed by ammonia in a suitable solvent. When A3 = H, typical coupling procedures as described in Scheme 3 (conversion of CO H to COCl via treatment with SOCl2 or oxalyl chloride followed by reaction with HNR2R3 or treatment of C02H and HNR2R3 with EDC or DCC in conjunction with DMAP, HOBT, or HOAt and the like) were employed to afford the transformation of a carboxylic acid to an amide. When A3 = alkyl such as methyl or ethyl, treatment of the ester with A1(NR2R3) afforded conversion of CO2A3 to CO(NR2R3). Subsequent treatment with ammonia afforded compounds of Formula I-A. [451] The compounds of Formula 1T-B (compounds of Formula II where R1
= Z — CH2OH) and I-B (compounds of Formula I where R1 = Z — CH2OH) were prepared as shown below in Scheme 7:
Scheme 7
Figure imgf000085_0001
[452] where Q1 is as defined previously for compound of Formula I and A3 = hydrogen or alkyl such as methyl or ethyl.
[453] In a typical preparation of compound of Formula I-B (compounds of
Formula I where R1 = Z — CH2OH), compound of Formula II-A (compounds of Formula II where R1 = Z — CO2A3) is treated with a suitable reducing agent such as lithium aluminum hydride in a suitable solvent, such as THF to afford compound of Formula II-B (compounds of Formula II where R1 = Z — CH2OH). Subsequent treatment of compound of Formula II-B (compounds of Formula II where R1 = Z — CH2OH) with ammonia in a suitable solvent, afforded compound of Formula I-B (compounds of Formula I where R1 = Z — CH2OH). Suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; dimethylformamide (DMF); dimethyl sulfoxide (DMSO); acetonitrile; alcoholics such as methanol, ethanol, isopropanol, trifluoroethanol, and the like; and chlorinated solvents such as methylene chloride (CH2C12) or chloroform (CHC13). If desired, mixtures of these solvents were used. The prefened solvent was isopropanol. The above process was carried out at temperatures between about -78 °C and about 120 °C. Preferably, the reaction was carried out between 80 °C and about 100 °C. The above process to produce compounds of the present invention was preferably carried out at about atmospheric pressure although higher or lower pressures were used if desired. Substantially, equimolar amounts of reactants were preferably used although higher or lower amounts were used if desired. [454] The compounds of Fonnula II-B (compounds of Formula II where R1
= Z— CH2OH), II-C (compounds of Formula II where R1 = Z— CH2A4), II-D (compounds of Formula II where R1 = Z — A5(R2)(R3)d), I-B (compounds of Formula I where R1 = Z — CH2OH) and I-C (compounds of Formula I where R1 = Z — S 7 ^
A (R )(R )d) were prepared as shown below in Scheme 8:
Scheme 8
Figure imgf000087_0001
[455] where Q1, R2, and R3 are as defined previously for compound of
Fonnula I; A4 = suitable leaving group such as OTs, OMs, OTf, or halo such as chloro, bromo, or iodo; d = 0 or 1; and A5 = N, O or S.
[456] In a typical preparation of compound of Fonnula l-C (compounds of
Formula I where R1 = Z — A5(R2)(R3)d), the hydroxy group of compound of Formula
II-B (compounds of Formula II where R1 = Z — CH2OH) was converted to a suitable leaving group, A4, such as CI or OTs, OMs, or OTf, by reaction with SOCl2 or Ts2O,
Ms2O, or Tf2O to afford compound of Formula II-C (compounds of Formula II where
R1 = Z — CH2A4). Reaction of compound of Formula II-C (compounds of Formula II where R1 = Z— CH2A4) with HA5(R2)(R3)d afforded compound of Formula II-D
(compounds of Formula 11 where R1 = Z — A5(R2)(R3)d). Subsequent reaction of compound of Formula II-D (compounds of Formula II where R1 = Z — A5(R2)(R3)d) with ammonia in a suitable solvent such as isopropanol or methanol, afforded compound of Formula l-C (compounds of Formula I where R1 = Z — A5(R2)(R3)d).
Additionally, compound of Formula II-B (compounds of Formula II where R1 = Z — CH OH) was converted to compound of Formula I-B (compounds of Formula I where R1 = Z — CH2OH) as described previously in Scheme 7. Further reaction of compound of Formula I-B (compounds of Formula I where R = Z — CH2OH) to compound of Formula I-C (compounds of Formula I where R1 = Z — A5(R2)(R3)d) was accomplished by following the previously described conditions for the conversion of compound of Formula II-B (compounds of Formula II where R1 = Z — CH2OH) to compound of Formula II-C (compounds of Formula II where R1 = Z — CH2A4) and the further conversion of compound of Formula II-C (compounds of Fonnula II where R = Z — CH A4) to compound of Formula II-D (compounds of Formula II where R1 = Z— A5(R2)(R3)d) (in the net conversion of OH to A5(R2)(R3)d). Furthermore, compound of Formula II-B (compounds of Formula II where R1 = Z — CH2OH) can be directly converted to compound of Formula II-D (compounds of Fonnula II where 1 *ϊ 7
R = Z — A (R )(R )d) by treating compound of Formula II-B with various alkylating agent or with phenols via the Mitsunobu reaction to afford compounds Formula II-D (compounds of Formula II where R1 = Z— A5(R2)(R3)d) in which A5 = O, d = 0, and R2 = alkyl or aryl.
[457] The compounds of Formula I-C (compounds of Formula I where R1 =
Z— CH2— A2), I-C" (compounds of Formula I where R1 = Z— CH2— NH2), and I- C" (compounds of Formula I where R1 = Z — CH2 — N(R2)(R3)) were prepared as shown below in Scheme 8a:
Scheme 8a
Figure imgf000088_0001
[458] where Q1, R2, and R3 are as defined previously for compound of
Formula I and A2 = phthahmido.
[459] In a typical preparation of compounds of Fonnula I-C (compounds of
Formula I where R1 = Z— CH2— A2), I-C" (compounds of Formula I where R1 = Z— CH2— NH2), and I-C" (compounds of Formula I where R1 = Z— CH2— (R2)(R3)), the hydroxy group of compound of Formula I-B (compounds of Formula I where R1 = Z — CH2OH) was converted to A2, a phthalimide group, following the procedures as described in Scheme 5 for the conversion of compound of Formula VII to compound of Formula VI. Reaction of compound of Formula I-C under conditions described in Scheme 4 afforded compound of Formula I-C". Reaction of compound of Formula I- C" with but not limited to various alkylating agents, various aldehydes/ketones under reductive animation conditions, various acylating agents such as acetic anhydride, benzoyl chlorides, or with carboxylic acids in the presence of EDC or DCC with HOBT or HOAT, or with sulphonylating agents such as Ts O or MeSO2Cl afforded compounds of Formula I-C". For example, in a typical preparation of compounds of Formula I-C" (compounds of Formula I where R1 = Z— CH2— (R2)(R3)), a compound of Formula I-C" is treated with a suitable acylating agent in the presence of a suitable base in a suitable solvent. Suitable solvents for use in the above process included, but were not limited to, ethers such as tetrahydrofuran (THF), glyme, and the like; and chlorinated solvents such as methylene chloride (CH2C12) or chloroform (CHC13). If desired, mixtures of these solvents were used, however, the prefened solvent was chloroform. Suitable bases for use in the above process included, but were not limited to, trialkylamines such as diisopropylethylamine, triethylamine, or resion bound trialkylamines such as PS-DEEA. The prefened base was PS-DIEA. In the case where the suitable acylating agent was acetic anhydride, the conversion of compound of Formula I-C" to compound of Formula I-C" where R2 = H and R3 = COCH3 was accomplished. The above process was carried out at temperatures between about -78 °C and about 120 °C. Preferably, the reaction was carried out between 0 °C and about 20 °C. The above process to produce compounds of the present invention was preferably carried out at about atmospheric pressure although higher or lower pressures were used if desired. Substantially, equimolar amounts of reactants were preferably used although higher or lower amounts were used if desired. [460] The compounds of Formula I-D (compounds of Formula I where R1 = 7 7
Z — H and Z is a heterocyclyl ring containing a nitrogen atom connected to H) and I- E (compounds of Formula I where R1 = Z2 — 2 and Z2 is a heterocyclyl ring ccoonnttaaiinniinngg a nitrogen atom connected to R2) were prepared as shown below in Scheme 9: Scheme 9
Figure imgf000090_0001
[461] where Q1 and R2 are as defined previously for compound of Formula I,
G1 is C(=O)A6 or CO2A6, and A6 = alkyl, aryl, or aralkyl.
[462] In a typical preparation of compound of Formula I-E (compounds of
Formula I where R1 = Z2 — R2 and Z2 is a heterocyclyl ring containing a nitrogen atom 7 1 connected to R ), compound of Formula II-E (compounds of Formula II where R = Z2 — G1 and Z2 is a heterocyclyl ring containing a nitrogen atom connected to G1) is treated with suitable reagents capable of deprotecting G1 to H and therefore afford compound of Formula I-D (compounds of Formula I where R1 = Z2 — H and Z2 is a heterocyclyl ring containing a nitrogen atom connected to H). For example, treatment 1 1 7 of compound of Formula II-E (compounds of Fonnula FI where R = Z — G and Z is a heterocyclyl ring containing a nitrogen atom connected to G1) when G1 is equal to C(=O)CF3 with ammonia in methanol affords compound of Formula I-D (compounds of Formula I where R1 = Z2 — H and Z2 is a heterocyclyl ring containing a nitrogen atom connected to H). Compound of Formula I-D (compounds of Formula I where 1 7
R = Z — H and Z is a heterocyclyl ring containing a nitrogen atom connected to H) can be subjected to various conditions including but not limited to reductive aminations, alkylations and ar(hetar)ylations, and acylations to afford amides, ureas, guanidines, carbamates, thiocarbamates, and variously substituted nitrogen adducts to afford the net conversion of NH to NR2.
[463] The compounds of Formula II-G (compounds of Formula II where R1
= Z3— OH), π-H (compounds of Formula II where R1 = Z3— A5(R2)(R3)d), I-F (compounds of Formula I where R1 = Z3 — OH), and I-G (compounds of Formula I where R1 = Z3 — A5(R2)(R3)d) were prepared as shown below in Scheme 10: Scheme 10
Figure imgf000091_0001
[464] where Q1, R2, and R3 are as defined previously for compound of
Formula I; d = 0 or 1; and A5 = N, O or S.
[465] In a typical preparation of compound of Formula I-F (compounds of
Formula I where R1 = Z3 — OH) and I-G (compounds of Fonnula I where R1 = Z3 — A5(R2)(R3)d), the following transformations occurred: Compound of Formula II-F (compounds of Formula I where R1 = Z3 — C=O) was reduced with a suitable reducing agent in a suitable solvent, such as sodium borohydride in methanol to afford compound of Fonnula II-G (compounds of Fonnula II where R1 = Z3 — OH). Compound of Formula II-G (compounds of Formula II where R1 = Z3 — OH) was subjected to ammonia in methanol to afford compound of Formula I-F (compounds of Formula I where R1 = Z3 — OH). Additionally, compounds of Formula II-F (compounds of Formula I where R = Z — C=O) can be reacted with various amines under reductive amination conditions (NaBHsCN with HA5(R2)(R3)d where d = 0, A5 9 ^
= N, and R and R are as previously descnbed for compound of Formula I) to afford compounds of Formula II-H (compounds of Formula II where R1 = Z3 — A5(R )(R3)d) where d = 0, A5 = N, and R2 and R3 are as previously described for compound of Formula I. Subsequent reaction of compounds of Formula II-H (compounds of Formula II where R1 = Z3— A5(R2)(R3)d where d = 0, A5 = N, and R2 and R3 are as previously described for compound of Formula I) with ammonia in methanol afforded compounds of Formula I-G (compounds of Formula I where R1 = Z3 — A5(R2)(R3)d). Furthermore, compounds of Formula II-H from II-G and I-G from I-F can be synthesized according to the conditions described in Scheme 8 for the transformations of II-B to II-D and I-B to I-C, respectively.
[466] The compounds of Formula II-F (compounds of Formula II where R1 =
Z3=O) and II-B (compounds of Formula II where R1 = Z — CH2OH) were prepared as shown below in Scheme 11 : Scheme 11
Figure imgf000092_0001
[467] where Q1 is as defined previously for compound of Formula I.
[468] In a typical preparation of compound of Formula II-F (compounds of 1
Formula II where R = Z =O), compounds of Formula II- J (compounds of Formula II where R1 = Z3=CH2) were treated under suitable oxidizing conditions to afford the conversion of the exocyclic methylene moiety to its respective ketone (see 3-[l-(3- Benzyloxy-phenyl)-8-chloro-imidazo[l,5-a]pyrazin-3-yl]-cyclobutanone (compound of Formula II-F where Z3 = 3-cyclobutyl and Q1 = Ph-(3-OBn)) in the Example section). Additionally, compound of Formula II-B (compounds of Formula II where R1 = Z — CH2OH) can be prepared by reacting compounds of Formula II- J (compounds of Formula II where R1 = Z3=CH2) under suitable hydroboration- oxidation conditions (see {3-[l-(3-Benzyloxyphenyl)-8-chloro-imidazo[l,5- β]pyrazin-3-yl] cyclobutyl} methanol in the Example section). It should be noted that compounds of Formula II-B (compounds of Formula II where R1 = Z — CH2OH) can be treated under suitable oxidative conditions such as those described within Example 65(a) to afford compoimds of Fonnula II-A (compounds of Fonnula II where R = Z— CO2A3).
[469] The compounds of Formula I-H (compounds of Formula I where R1 =
Z3— OH(CH2OH)), I-J (compounds of Formula I where R1 = Z3— OH(CH2A4)), and I-K (compounds of Formula I where R1 = Z3 — OH(CH2A5(R2)(R3)d), were prepared as shown below in Scheme 12: Scheme 12
Figure imgf000093_0001
1 9 "
[470] where Q , R , and R are as defined previously for compound of
Formula I; A4 = suitable leaving group such as OTs, OMs, or OTf; d = 0 or 1 ; and A5 = N, O or S.
[471 ] hi a typical preparation of compounds of Formula I-H (compounds of
Formula I where R = Z — OH(CH2OH)), I-J (compounds of Formula I where R = Z3— OH(CH2A4)) and I-K (compounds of Formula I where R1 = Z3— OH(CH2A5(R2)(R3)d)), the exocyclic olefinic moiety of compound of Formula II- J (compounds of Formula II where R1 = Z3=CH2) was reacted with a suitable dihydroxylating agent such as osmium tetraoxide in the presence of NMO in a suitable solvent such as THF to afford compound of Formula II-K (compounds of Formula II where R1 = Z3 — OH(CH2OH)) as a mixture of cis and trans isomers. Compound of Formula II-K (compounds of Formula II where R1 = Z3 — OH(CH2OH)) was reacted under ammonolysis conditions in a suitable solvent such as isopropanol in a sealed pressure vessel at 110°C to afford compound of Formula I-H (compounds of Formula I where R1 = Z3 — OH(CH2OH)). The primary hydroxy group of compound of Formula I-H (compounds of Formula I where R1 = Z3 — OH(CH2OH)) was converted to a suitable leaving group, A4, such as OTs, OMs, or OTf, by reaction with Ts2O, Ms2O, or Tf2O in the presence of a suitable base such as diisopropylamine or pyridine and solvent such as THF or methylene chloride to afford compound of Formula I-J (compounds of Fonnula I where R1 = Z3 — OH(CH2A4)). Reaction of compound of Formula I-J (compounds of Formula I where R1 = Z3 — OH(CH2A4)) with HA5(R2)(R3)d in a suitable solvent such as THF or methylene chloride afforded ' 1 " compound of Formula I-K (compounds of Formula I where R = Z — OH(CH2A5(R2)(R3)d).
[472] The compounds of Formula I-L (compounds of Formula I where R1 =
Z3 — OH(Gπ)) were prepared as shown below in Scheme 13:
Scheme 13
Figure imgf000094_0001
II-F ll-L l-L
[473] where Q1 and Gπ are as defined previously for compound of Formula
I.
[474] In a typical preparation of compounds of Formula I-L (compounds of
Formula I where R1 = Z3 — OH(Gπ)), the ketone moiety of compound of Formula II-F (compounds of Formula II where R1 = Z3=O) was reacted with a suitable nucleophilic reagent such as MeMgBr or MeLi in a suitable solvent such as THF to afford compound of Formula II-L (compounds of Formula II where R1 = Z3 — OH(Gu)) as a mixture of cis and trans isomers. Compound of Formula II-L (compounds of Formula II where R1 = Z3 — OH(Gn)) was reacted under previously described ammonolysis conditions in a sealed pressure vessel at 110°C to afford compound of Formula I-L (compounds of Fonnula I where R1 = Z3 — OH(Gn)).
[475] It would be appreciated by those skilled in the art that in some situations, a substituent that is identical or has the same reactivity to a functional group which has been modified in one of the above processes, will have to undergo protection followed by deprotection to afford the desired product and avoid undesired side reactions. Alternatively, another of the processes described within this invention may be employed in order to avoid competing functional groups. Examples of suitable protecting groups and methods for their addition and removal may be found in the following reference: "Protective Groups in Organic Syntheses", T. W. Green and P. G. M. Wutz, John Wiley and Sons, 1989.
[476] The following examples are intended to illustrate and not to limit the scope of the present invention.
Analytical HPLC Conditions:
[477] Unless otherwise stated, all HPLC analyses were run on a Micromass system with a XTERRA MS C18 5μ 4.6 x 50mm column and detection at 254 nm. Table A below lists the mobile phase, flow rate, and pressure.
Table A
Figure imgf000095_0001
Semipreparative HPLC Conditions:
[478] Where indicated as "purified by Gilson HPLC", the compounds of interest were purified by a preparative/semipreparative Gilson HPLC workstation with a Phenomenex Luna 5μ C18 (2) 60 x 21 20MM 5μ column and Gilson 215 liquid handler (806 manometric module, 81 IC dynamic mixer, detection at 254 nm). Table B lists the gradient, flow rate, time, and pressure.
Table B
Figure imgf000096_0002
[479] EXAMPLE 1: [l-(3-Benzyloxy-phenyl)-3-cyclobutyl-imidazo[l,5- a]pyrazin-8-ylamine] (compound of Formula I where R1 = cyclobutyl and Q1 = Ph-(3- OBn)): A methanolic solution (1.0 mL) of l-(3-benzyloxy-phenyl)-8-chloro-3- cyclobutyl-imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) (47.0 mg, 0.12 mmol) in a sealed tube was charged with 3.0 mL of 7N NH3 in MeOH and heated to 110°C for 48 h. The reaction was concentrated in vacuo, taken up into CH2C12 and purified using HPFC with a 2 g Jones silica gel column, (30% EtOAc: Hex) to yield the desired product as a off-white solid; 1H NMR (CDC13, 400 MHz) δ 1.99-2.18 (m, 2H), 2.47-2.52 (m, 2H), 2.61-2.66 (m, 2H), 3.81 (q, IH, J= 8.6 Hz), 5.15 (s, 4H), 7.02-7.05 (m, 2H), 7.10 (d, IH, J= 5.0 Hz), 7.24-7.52 (m, 8H); MS (ES) 371.30 (M+l), 372.31 (M+2), 373.31 (M+3).
Figure imgf000096_0001
[481] a) l-(3-Benzyloxy-phenyl)-8-chloro-3-cyclobutyl-imidazo[l,5- a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph-(3-OBn)): Cyclobutanecarboxyhc Acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] Amide (100.0 mg, 0.25 mmol) was dissolved in POCl3 (0.8 mL) and CH2C12 (0.2 mL) and allowed to stir at 45 °C for 24 h. The reaction mixture was concentrated in vacuo to a yellow oil, dissolved in EtOAc and neutralized with cold sat. NaHCO3. The aqueous layer was extracted with EtOAc (3x) and the combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo, to yield the desired product as a yellow gum; 1H NMR (CDC13, 400 MHz) δ 2.18-2.21 (m, IH), 2.49-2.53 (m, 2H), 2.63-2.69 (m, 2H), 3.82 (q, IH, J = 8.5 Hz), 5.14 (s, 2H), 7.03-7.05 (m, IH), 7.29-7.49 (m, 9H); MS (ES) 390.21 (M+l), 392.20 (M+3), 393.21 (M+4).
Figure imgf000097_0001
[483] b) Cyclobutanecarboxyhc Acid [(3-benzyloxy-phenyl)-(3-chloro- pyrazin-2-yl)-methyl] Amide (compound of Formula III where R1 = cyclobutyl and Q1 = Ph-(3-OBn)): Cyclobutanecarboxyhc acid (21.2 mg, 0.2 mmol), EDC (61.0 mg, 0.3) and HOBt (32.5 mg, 0.2 mmol) were dissolved in CH2C12 (1.0 mL) and allowed to stir at rt for 10 min. A CH2C12 solution (1.0 mL) of C-(3-benzyloxy-phenyl)-C-(3- chloro-pyrazin-2-yl)-methylamine (compound of Formula IV where Q1 = Ph-(3- OBn)) (69.0 mg, 0.2 mmol) was added to the reaction mixture and allowed to react at rt for 24 h. Purification via HPFC using a 5 g Jones silica gel column (30% EtOAc: Hex) yielded the desired product as a yellow solid; 1H NMR (CDC13, 400 MHz) δ 1.57 (s, IH), 1.87-2.13 (m, IH), 2.13-2.18 (m, 3H), 3.06 (q, IH, J= 8.5 Hz), 5.05 (s, 2H), 6.54 (d, IH, J= 7.9 Hz ), 6.86-6.94 (m, 3H), 7.20-7.58 (m, 5H), 8.31 (d, IH, J= 2.5 Hz), 8.53 (d, IH, J= 2.5 Hz); MS (ES) 408.26 (M+l), 410.26 (M+3), 411.27 (M+4).
Figure imgf000097_0002
[485] c) C-(3-Benzyloxy-phenyl)-C-(3 -chloro-ρyrazin-2-yl)-methylamine
(compound of Formula IV where Q1 = Ph-(3-OBn)): 2-[(3-Benzyloxy-ρhenyl)-(3- chloro-pyrazin-2-yl)-methyl]-isoindole-l,3-dione (compound of Formula VI where Q = Ph-(3-OBn) and A2 = phthahmido) (2.76 g, 6.05 mmol) was dissolved in EtOH (12 mL) and CH2C12 (4 mL) charged with N2H4 (0.57 mL, 18.16 mmol) and allowed to react for 16 h at rt. The white precipitate that was formed was filtered and washed with EtOAc. The filtrate and organic washings were concentrated in vacuo, and purified via HPFC using a 100 g Jones silica gel column (50% EtOAc: Hex to 5% MeOH: CH2C12) to yield the desired product as a reddish oil; 1H NMR (CDC13, 400 MHz) δ 5.04 (s, 2H), 5.52 (s, IH), 6.85-6.98 ( , 2H), 7.21-7.26 (m, 2H), 7.30-7.41 (m, 5H), 8.26 (d, IH, J= 2.5 Hz), 8.52 (d, IH, _/= 2.5 Hz); MS (ES) 326.25 (M+l), 328.23 (M+3), 329.24 (M+4). An alternative preparation of this compound is as follows: To a solution of 3-benzyloxybenzaldehyde (compound of Formula Q -CHO where Q1 = Ph-(3-OBn) (1.00 g, 4.71 mmol) in dry THF (5 mL), cooled by ice/water, was added LiHMDS (1 M solution in THF; 4.8 L, 4.8 mmol). After 30 min at 0 °C, this solution of (3-Benzyloxybenzylidene)-trimethylsilylamine (compound of Formula Q1-C=N-Si(CH3)3 where Q1 = Ph-(3-OBn) was cooled by CO2(s)/acetone. To a solution of 2,2,6,6-tetramethylpiperidine (0.90 mL, 0.75 g, 5.3 mmol) in dry THF (10 mL), cooled by CO2(s)/acetone, was added nBuLi (2.5 M in hexanes; 2.2 L, 5.5 mmol). The cooling bath was replaced with an ice/water bath for 15 min, and then the solution was re-cooled to -78 °C. After 15 min, 2-chloropyrazine (0.39 mL, 0.50 g,
4.4 mmol) was added. The cooled solution of (3-Benzyloxybenzylidene)- trimethylsilylamine (vide supra) was transfened into this solution of lithiochloropyrazine 2 by cannula 30 min later, and the mixture is stined at -78 °C for
2.5 h and at 0 °C for 0.5 h. The reaction was quenched by adding water and EtOAc. The mixture was filtered through Celite, the layers were separated, the aqueous layer was extracted with EtOAc (4x30 L), and the combined EtOAc extracts were washed with water and brine and dried over MgSO4. The crude material was adsorbed onto Hydromatrix and chromatographed on silica gel [Jones Flashmaster, 50 g / 150 mL cartridge, eluting with hexanes :EtO Ac 4:1 (1-44) → 1:1 (45-64) → EtOAc (65-97)], yielding the target compound as an orange foam.
Figure imgf000099_0001
[487] d) 2-[(3-Benzyloxy-phenyl)-(3-chloro-pyraz;in-2-yl)-methyl]- isoindole-l,3-dione (compound of Fonnula VI where Q1 = Ph-(3-OBn) and A2 = phthahmido): (3-Chloro-pyrazin-2-yl)-(3-benxyloxy-ρhenyl)-methanol (2.00 g, 6.12 mmol), triphenylphosphine (1.80 g, 6.70 mmol), and phthalimide (986 n g, 6.70 mmol) were dissolved in THF (20.0 mL) at rt. The reaction mixture was charged with
DIAD (1.30 mL, 6.70 mmol) dropwise and allowed to react for 24 h at rt (TLC analysis (20% EtOAc :Hex)). The crude product was purified by applying HPFC with a 100 g Jones silica gel column (20% EtOAc:Hex) to yield the desired product as a pale yellow solid; 1H NMR (CDC13, 400 MHz) δ 5.02 (s, 2H), 6.41 (brs, IH),
6.87-6.97 (m, 3H), 7.26-7.40 (m, 3H), 7.72-7.76 (m, 2H), 7.83-7.86 (m, 2H), 8.34
(d, IH, J= 2.4 Hz), 8.55 (d, IH, J= 2.4 Hz).
Figure imgf000099_0002
[489] e) (3-Chloro-pyrazin-2-yl)-(3-benzyloxy-phenyl)-methanol
[Compound of Formula VII where Q1 = Ph-(3-OBn)]: A THF (20 mL) solution of
2M H-BuLi in cyclohexanes was cooled to -78 °C and charged with 2,2,6,6- tetramethylpiperidine (1.8 mL, 10.48 mmol). The reaction vessel was removed from the cooling bath and allowed to warm to 0 °C for 15 min, then cooled back to -78 °C and charged with 2-chloropyrazine (1.0 g, 8.73 mmol) dropwise. The reaction was allowed to react for 15 min, and charged with a 10.0 mL THF solution of 3- benzyloxybenzaldehyde (2.0 g, 9.60 mmol) slowly at - 78 °C. The reaction was allowed to react for 2 h (TLC analysis (30% EtOAc:Hex)) and quenched with HClconc.
(2.0 mL), and H2O (30.0 mL). The crude product was extracted from the aqueous/THF layer 4x with CH2C12. The organic layers were combined and washed lx with H2O, lx brine, dried over Na2SO4 and concentrated in vacuo, to yield the cmde product as a brown oil. High performance flash chromatography (HPFC) with a 70 g Jones silica gel column (30% EtOAc:Hex) was applied to yield the desired product as a pale yellow solid; 1H NMR (CDC13, 400 MHz) δ 5.01 (s, 3H), 6.00 (s, 2H), 6.90-6.96 (m, 3H), 7.23-7.41 (m, 6H), 8.36 (d, IH, J= 2.4 Hz), 8.54 (d, IH, J= 2.5 Hz); MS (ES) 327.16 (M+l), 329.16 (M+3).
Figure imgf000100_0001
[491] EXAMPLE 2: l-(3-Benzyloxyphenyl)-3-ρhenyl-imidazo[l,5- α]pyrazin-8-ylamine (compound of Formula I where R1 = phenyl and Q1 = Ph-(3-
OBn)) was prepared according to the procedures described for Example 1 above except for the substitution of l-(3-benzyloxy-phenyl)-8-chloro-3-cyclobutyl- imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q = Ph-
(3-OBn)) with l-(3-benzyloxyphenyl)-8-chloro-3-phenylimidazo[l,5-α]pyrazine
(compound of Formula II where R1 = phenyl and Q1 = Ph-(3-OBn)); white solid, 1H
NMR (DMSO-d6, 400 MHz) δ 5.12 (s, 2H), 6.12 (bs, 2H), 7.04-7.06 (m, 2H), 7.20 (d,
IH, J= 7.6 Hz), 7.25-7.55 (m, 10H), 7.70 (d, IH, J = 4.8 Hz), 7.79 (d, 2H, J= 8.0
Hz).
Figure imgf000100_0002
[493] a) l-(3-Benzyloxyphenyl)-8-chloro-3-phenylimidazo[l,5- ]pyrazine
(compound of Formula II where R1 = phenyl and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for l-(3-benzyloxy-phenyl)-8-chloro-3- cyclobutyl-imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide with N-[(3- benzyloxyphenyl)-(3-chloropyrazin-2-yl)methyl]benzamide (compound of Formula III where R1 = phenyl and Q1 = Ph-(3-OBn)); yellow solid, 1H ΝMR (DMSO-d6, 400 MHz) δ 5.12 (s, 2H), 6.98 (ddd, IH, J= 1.2, 2.8, 8.2 Hz), 7.21-7.43 (m, 8H), 7.52- 7.59 (m, 4H), 7.84-7.87 (m, 2H), 8.37 (d, IH, J= 5.2 Hz).
Figure imgf000101_0001
[495] b) N-[(3-Benzyloxyphenyl)-(3-chloropyrazin-2-yl)methyl]benzamide
(compound of Formula III where R1 = phenyl and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for the synthesis of cyclobutanecarboxyhc Acid
[(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide (compound of Formula
III where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of benzoic acid for cyclobutanecarboxyhc acid; 1H ΝMR (DMSO-d6, 400 MHz) δ 5.02
(s, 2H), 6.58 (d, IH, J= 7.6 Hz), 6.91-6.93 (m, 2H), 6.99 (s, IH), 7.21-7.49 (m, 9H),
7.85 (d, 2H, J= 7.2 Hz), 8.43 (d, IH, J= 2.4 Hz), 8.63 (d, IH, J- 2.4 Hz), 9.23 (d,
IH, J= 7.6 Hz).
Figure imgf000101_0002
[497] EXAMPLE 3: 3-Benzyl-l-(3-benzyloxyphenyl)-imidazo[l,5- α]pyrazin-8-ylamine (compound of Formula I where R1 = benzyl and Q1 = Ph-(3- OBn)) was prepared according to the procedures described for Example 1 above except for the substitution of l-(3-benzyloxy-phenyI)-8-chloro-3-cyclobutyl- imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph- (3-OBn)) with 3-benzyl-l-(3-benzyloxyphenyl)-8-chloroimidazo[l,5-β]pyrazine (compound of Formula II where R1 = benzyl and Q1 = Ph-(3-OBn)); white solid; 1H ΝMR (DMSO-d6, 400 MHz) δ 4.40 (s, 2H), 5.12 (s, 2H), 6.08 (bs, 2H), 7.03 (d, IH, J= 4.8 Hz), 7.08 (ddd, 1H, J= 1.2, 2.8, 8.2 Hz), 7.19-7.49 (m, 13H), 7.57 (d, 1H, J= 5.2 Hz).
Figure imgf000102_0001
[499] a) 3-Benzyl-l-(3-benzyloxyphenyl)-8-chloroimidazo[l,5-α]pyrazine
(compound of Formula II where R1 = benzyl and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for l-(3-benzyloxy-phenyl)-8-chloro-3- cyclobutyl-imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of cyclobutanecarboxyhc acid
[(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide with N-[(3- benzyloxyphenyl)-(3-chloropyrazin-2-yl-methyl]-2-phenylacetamide (compound of
Formula III where R1 = benzyl and Q1 = Ph-(3-OBn)); yellow solid; 1H ΝMR
(DMSO-d6, 400 MHz) δ 5.12 (s, 2H), 6.98 (ddd, IH, J= 1.2 Hz, 2.8 Hz, 8.2 Hz),
7.21-7.43 (m, 8H), 7.52-7.59 (m, 4H), 7.84-7.87 (m, 2H), 8.37 (d, IH, J= 5.2 Hz).
Figure imgf000102_0002
[501] b) N-[(3-Benzyloxyphenyl)-(3-chloropyrazin-2-yl-methyl]-2- 1 1 phenylacetamide (compound of Formula III where R = benzyl and Q = Ph-(3-OBn)) was prepared according to the procedures described for the synthesis of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide (compound of Formula III where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of phenylacetic acid for cyclobutanecarboxyhc acid.
Figure imgf000102_0003
[503] EXAMPLE 4: l-(3-Benzyloxyphenyl)-3-naphthalen-l-yl-imidazo[l,5- ]pyrazin-8-ylamine (compound of Formula I where R1 = naphthalen-1-yl and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for Example 1 above except for the substitution of l-(3-benzyloxy-phenyl)-8-chloro-3-cyclobutyl- imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph- (3-OBn)) with l-(3-benzyloxy-phenyl)-8-chloro-3-naphthalen-l-yl-imidazo[l,5- a]pyrazine (compound of Formula II where R1 = naphthalen- 1-yl and Q = Ph-(3- OBn)); White solid; 1H NMR (DMSO-d6, 400 MHz) δ 5.20 (s, 2H), 6.27 (bs, 2H), 7.05 (d, IH, J= 4.8 Hz), 7.13 (m, IH), 7.21 (d, IH, J= 5.2 Hz), 7.33-7.51 (m, 8H), 7.55-7.65 (m, 3H), 7.70-7.72 (m, IH), 7.82-7.85 (m, 2H), 8.09 (d, IH, J= 1.6 Hz), 8.16 (d, lH, J= 8.4 Hz).
Figure imgf000103_0001
[505] a) 1 -(3 -benzyloxy-phenyl)-8-chloro-3 -naphthalen- 1 -yl-imidazo [1,5- a]pyrazine (compound of Formula II where R1 = naphthalen- 1-yl and Q1 = Ph-(3-
OBn)) was prepared according to the procedures described for l-(3-benzyloxy- phenyl)-8-chloro-3-cyclobutyl-imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide with naphthalene- 1 -carboxylic acid [(3-benzyloxyphenyl)-(3-chloropyrazin-2- yl)-methyl]-amide (compound of Formula II where R1 = naphthalen- 1-yl and Q1 = Ph-
(3-OBn)); MS (ES) 462.46 (M+l), 464.46 (M+3).
Figure imgf000103_0002
[507] b) Naphthalene- 1 -carboxylic acid [(3-benzyloxyphenyl)-(3- chloropyrazin-2-yl)-methyl]-amide (compound of Formula II where R1 = naphthalen-
1-yl and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for the synthesis of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-
2-yl)-methyl] amide (compound of Formula III where R1 = cyclobutyl and Q1 = Ph-
(3 -OBn)) above except for the substitution of 1-naphthanoic acid for cyclobutanecarboxyhc acid; White solid; XH NMR (DMSO-d6, 400 MHz) δ 5.12 (s, 2H), 6.72 (d, IH, J= 7.4 Hz), 6.98 (dd, IH, J= 2.4 Hz, 8.2 Hz), 7.06 (d, IH, J= 7.6 Hz), 7.12 (bs, IH), 7.29-7.44 (m, 5H), 7.53-7.57 (m, 4H), 7.65 (d, IH, J= 7.0 Hz), 7.97-8.03 (m, 2H), 8.13-8.15 (m, IH), 8.52 (d, IH, J=2.5 Hz), 8.73 (d, IH, J= 2.5 Hz).
Figure imgf000104_0001
[509] EXAMPLE 5: l-(3-Benzyloxyphenyl)-3-naphthalen-2-yl-imidazo[l,5- α]pyrazin-8-ylamine (compound of Formula I where R = naphthalen-2-yl and Q =
Ph-(3-OBn)) was prepared according to the procedures described for Example 1 above except for the substitution of l-(3-benzyloxy-phenyl)-8-chloro-3-cyclobutyl- imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph-
(3-OBn)) with l-(3-benzyloxy-phenyl)-8-chloro-3-naphthalen-2-yl-imidazo[l,5- a]pyrazine (compound of Formula II where R1 = naphthalen-2-yl and Q1 = Ph-(3-
OBn)); White solid; 1H NMR (DMSO-d6, 400 MHz) δ 5.18 (s, 2H), 6.18 (bs, 2H),
7.11-7.47 (m, 9H), 7.58-7.61 (m, 2H), 7.94-8.10 (m, 5H), 8.44 (s, 2H).
Figure imgf000104_0002
[511] a) l-(3-benzyloxy-phenyl)-8-chloro-3-naphthalen-2-yl-imidazo[l,5- a]pyrazine (compound of Formula II where R1 = naphthalen-2-yl and Q1 = Ph-(3- OBn)) was prepared according to the procedures described for l-(3-benzyloxy- phenyl)-8-chloro-3-cyclobutyl-imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide with naphthalene-2-carboxylic acid [(3-benzyloχyphenyl)-(3-chloropyrazin-2- yl)-methyl] -amide (compound of Formula II where R1 = naphthalen-2-yl and Q1 = Ph- (3-OBn)); MS (ES) 462.49 (M+l), 464.48 (M+3).
Figure imgf000105_0001
[513] b) Naphthalene-2-carboxylic acid [(3-benzyloxyphenyl)-(3- chloropyrazin-2-yl)-methyl]-amide (compound of Formula II where R1 = naphthalen-
2-yl and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for the synthesis of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-
2-yl)-methyl] amide (compound of Formula III where R1 = cyclobutyl and Q1 = Ph-
(3-OBn)) above except for the substitution of 2-naphthanoic acid for cyelobutanecarboxylic acid; Off white solid, 1H NMR (DMSO-d6, 400 MHz) δ 5.12
(s, 2H), 6.70 (d, IH, J= 7.5 Hz), 6.89-7.09 (m, 3H), 7.29-7.44 (m, 6H), 7.60-7.63
(m, 2H), 7.97-8.11 (m, 4H), 8.50 (d, IH, J= 2.5 Hz), 8.58 (s, IH), 8.72 (d, IH, J=
2.5 Hz).
Figure imgf000105_0002
[515] EXAMPLE 6: l-(3-Benzyloxy-phenyl)-3-cyclopentyl-imidazo[l,5- a]pyrazin-8-ylamine (compound of Formula I where R1 = cyclopentyl and Q1 = Ph-(3-
OBn)) was prepared according to the procedures described for Example 1 above except for the substitution of l-(3-benzyloxy-phenyl)-8-chloro-3-cyclobutyl- imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph- (3-OBn)) with l-(3-benzyloxy-phenyl)-8-chloro-3-cyclopentyl-imidazo[l,5- a]pyrazine (compound of Formula II where R1 = cyclopentyl and Q1 = Ph-(3-OBn)); MS (ES) 385.5 (M+l).
Figure imgf000105_0003
[517] a) l-(3-Benzyloxy-phenyl)-8-chloro-3-cyclopentyl-imidazo[l,5- a]pyrazine (compound of Formula II where R1 = cyclopentyl and Q = Ph-(3-OBn)) was prepared according to the procedures described for l-(3-benzyloxy-phenyι)-8- chloro-3-cyclobutyl-imidazo[l,5-a]pyrazine (compound of Formula II where R = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide with cyclopentanecarboxylic acid [(3-benzyloxy-phenyl)-(3~chloro-pyrazin-2- yl)-methyl] -amide (compound of Formula II where R1 = cyclopentyl and Q1 = Ph-(3- OBn)); MS (ES) 404.2 (M+l), 406.2 (M+3).
Figure imgf000106_0001
[519] b) Cyclopentanecarboxylic acid [(3-benzyloxy-phenyl)-(3-chloro- ρyrazin-2-yl)-methyl]-amide (compound of Formula II where R1 = cyclopentyl and Q
= Ph-(3-OBn)) was prepared according to the procedures described for the synthesis of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide (compound of Formula III where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of cyclopentane carboxylic acid for cyclobutanecarboxylic acid; MS (ES) 422.2 (M+l), 424.2 (M+3).
Figure imgf000106_0002
[521] EXAMPLE 7: l-(3-Benzyloxy-phenyl)-3-cyclohexyl-imidazo[l,5- a]pyrazin-8-ylamine (compound of Formula I where R1 = cyclohexyl and Q1 = Ph-(3-
OBn)) was prepared according to the procedures described for Example 1 above except for the substitution of l-(3-benzyloxy-phenyl)-8-chloro-3-cyclobutyl- imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph-
(3-OBn)) with l-(3-benzyloxy-phenyl)-8-chloro-3- cyclohexyl -imidazo[l,5- a]pyrazine (compound of Formula II where R1 = cyclohexyl and Q1 = Ph-(3-OBn));
MS (ES) 399.3 (M+l).
Figure imgf000107_0001
[523] a) l-(3-Benzyloxy-phenyl)-8-chloro-3-cyclohexyl-imidazo[l,5- a]pyrazine (compound of Formula II where R1 = cyclohexyl and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for l-(3-benzyloxy-phenyl)-8- chloro-3-cyclobutyl-imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide with cyclohexylcarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)- methyl] -amide (compound of Fonnula II where R1 = cyclohexyl and Q1 = Ph-(3-
OBn)); MS (ES) 418.2 (M+l), 420.2 (M+3).
Figure imgf000107_0002
[525] b) Cyclohexane carboxylic acid [(3-benzyloxy-phenyl)-(3-chloro- pyrazin-2-yl)-methyl] -amide (compound of Formula II where R1 = cyclohexyl and Q1
= Ph-(3-OBn)) was prepared according to the procedures described for the synthesis of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide (compound of Formula III where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of cyclohexane carboxylic acid for cyclobutanecarboxyhc acid; MS (ES) 436.2 (M+l), 438.2 (M+3).
Figure imgf000107_0003
[527] EXAMPLE 8: l-(3-Benzyloxy-phenyl)-3-cycloheptyl-imidazo[l,5- a]pyrazin-8-ylamine (compound of Formula I where R1 = cycloheptyl and Q1 = Ph-(3-
OBn)) was prepared according to the procedures described for Example 1 above except for the substitution of l-(3-benzyloxy-phenyl)-8-chloro-3-cyclobutyl- imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q = Ph- (3-OBn)) with l-(3-benzyloxy-phenyl)-8-chloro-3-cycloheptyl-imidazo[l,5- a]ρyrazine (compound of Formula II where R1 = cycloheptyl and Q1 = Ph-(3-OBn)); MS (ES) 413.3 (M+l).
Figure imgf000108_0001
[529] a) 1 -(3 -B enzyloxy-phenyl)-8 -chloro-3 -cycloheptyl-imidazo [1,5- a]pyrazine (compound of Formula II where R1 = cycloheptyl and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for l-(3-benzyloxy-phenyl)-8- chloro-3-cyclobutyl-imidazo[l,5-a]pyrazine (compound of Fonnula II where R = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide with cycloheptylcarboxylic acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2- yl)-methyl] -amide (compound of Formula II where R1 = cycloheptyl and Q1 = Ph-(3-
OBn)); MS (ES) 432.2 (M+l), 434.2 (M+3).
Figure imgf000108_0002
[531] b) Cycloheptane carboxylic acid [(3-benzyloxy-phenyι)-(3-chloro- pyrazin-2-yl)-methyl] -amide (compound of Formula II where R1 = cycloheptyl and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for the synthesis of cyclobutanecarboxyhc acid [(3-benzyloxy-ρhenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide (compound of Formula III where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of cycloheptane carboxylic acid for cyclobutanecarboxyhc acid; MS (ES) 450.2 (M+l), 452.2 (M+3).
Figure imgf000109_0001
[533] EXAMPLE 9: l-(3-Benzyloxy-phenyl)-3-(tetrahydro-furan-3-yl)- imidazo[l,5-a]pyrazin-8-ylamine (compound of Formula I where R1 = tefrahydrofuran-3-yl and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for Example 1 above except for the substitution of l-(3-benzyloxy-phenyl)-
8-chloro-3-cyclobutyl-imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) with l-(3-benzyloxy-phenyl)-8-chloro-3-
(tetrahydro-furan-3-yl)-imidazo[l,5-a]pyrazine (compound of Formula II where R1 = tetrahydrofuran-3-yl and Q1 = Ph-(3-OBn)); MS (ES) 387.5 (M+l).
Figure imgf000109_0002
[535] a) l-(3-Benzyloxy-phenyl)-8-chloro-3-(tefrahydro-furan-3-yl)- imidazo[l,5-a]pyrazine (compound of Formula II where R1 = tetrahydrofuran-3-yl and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for l-(3- benzyloxy-phenyl)-8-chloro-3-cyclobutyl-imidazo[l,5-a]pyrazine (compound of
Formula II where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-
2-yl)-methyl] amide with tetrahydro-furan-3-carboxylic acid [(3-benzyloxy-phenyl)-
(3-chloro-pyrazin-2-yl)-methyl]-amide (compound of Formula II where R1 = tetrahydrofuran-3-yl and Q1 = Ph-(3-OBn)); MS (ES) 406.2 (M+l), 408.2 (M+3).
Figure imgf000109_0003
[537] b) Tetrahydro-furan-3-carboxylic acid [(3-benzyloxy-phenyl)-(3- chloro-pyrazin-2-yl)-methyl]-amide (compound of Fonnula II where R1 = 3- tetrahydrofuranyl and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for the synthesis of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3- chloro-ρyrazin-2-yl)-methyl] amide (compound of Formula III where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of tetrahydro-furan-3- carboxylic acid for cyclobutanecarboxyhc acid; MS (ES) 424.2 (M+l), 426.2 (M+3).
Figure imgf000110_0001
[539] EXAMPLE 10: trøras-4-[8-Amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexanecarboxylic acid amide (compound of
Formula I-A where Z = cyclohexyl, C(=O)NR2R3 = 4-trans-C(=θyNH2, and Q1 = Ph-
(3-OBn)) was prepared as follows: A 0.2 M 2-propanol solution of tr< s-4-[l-(3- benzyloxyphenyl)-8-chloro-imidazo[l,5-a]pyrazin-3-yl] cyclohexane carboxylic acid methyl ester (compound of Formula II-A where Z = cyclohexyl, CO2A3 = 4-trans-
CO2Me, and Q1 = Ph-(3-OBn)) (150 mg, 0.32 mmol) in a 15 mL sealed tube was cooled to -78 °C and charged with ammonia for 30 sec. The reaction was heated to
110 °C for 4d, after which time the reaction mixture was charged with EtOAc and sat.
NaHCO3. The EtOAc layer washed with sat. NaHCO3 (3x) and brine (lx) and the organic layer was dried over Na2SO4, filtered, and concentrated in vacuo to afford the desired product as an off-white solid. The product was dry-loaded and purified by silica gel chromatography, eluting with 2% MeOH/CH2Cl2 to 5% MeOH/CH2Cl2.
The resulting white solid was recrystallized with CH C12, CH3CN, and hexanes to afford the title compound as a white powder; 1H NMR (DMSO-d6, 400 MHz) δ 1.57-
1.66 (m, 4H), 1.86-1.88 (m, 2H), 1.98-2.00 (m, 2H), 2.17-2.23 (m, IH), 3.07-3.13
(m, IH), 5.17 (s, IH), 6.02 (bs, 2H), 6.70 (bs, 2H), 7.03 (d, IH, J= 5.2 Hz), 7.07
(ddd, IH, J= 0.8, 2.4, 8.4 Hz), 7.18 (d, IH, J= 7.6 Hz), 7.21-7.22 (m, IH), 7.32-7.37
(m, IH), 7.40 (d, IH, J= 1.6 Hz), 7.41-7.44 (m, 2H), 7.46 (s, IH), 7.50 (d, IH, J=
1.6 Hz), 7.66 (d, IH, J = 4.8 Hz); MS (ES) 442.5 (M+l).
Figure imgf000111_0001
[541] a) t rans-4-[ 1 -(3-Benzyloxy-phenyl)-8-chloro-imidazo [ 1 ,5-a]pyrazin-
3-yl]-cyclohexanecarboxylic acid methyl (compound of Formula II-A where Z = cyclohexyl, CO2A3 = 4-tra/ω-CO2Me, and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for l-(3-benzyloxy-phenyl)-8-chloro-3-cyclobutyl- imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph-
(3-OBn)) above except for the substitution of cyclobutanecarboxyhc acid [(3- benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide (compound of Formula III where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) with tran,s-4-{[(3-benzyloxy-phenyl)-
(S-chloro-pyrazin-S-y^-methyy-carbamoyll-cyclohexanecarboxylic acid methyl ester
(compound of Formula III where R1 = tra«5-4-cyclohexane carboxylic acid methyl ester and Q1 = Ph-(3-OBn)); MS (ES) 476.2 (M+l), 478.2 (M+3).
[542]
Figure imgf000111_0002
[543] b) trans-4- {[(3-Benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl]- carbamoyl}-cyclohexanecarboxylic acid methyl ester (compound of Formula III where R1 = trαrø-4-cyclohexane carboxylic acid methyl ester and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for the synthesis of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide (compound of Formula III where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of trøTW-cyclohexane-l^-dicarboxylic acid monomethyl ester for cyclobutanecarboxyhc acid; MS (ES) 494.3 (M+l), 496.3 (M+3).
Figure imgf000112_0001
[545] EXAMPLE 11: trα«.s-{4-[8-Amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexyl} -methanol (compound of Formula I-B where
Z = cyclohexyl and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for the synthesis of 4-[8-amino-l-(3-benzyloxy-phenyl)-imidazo[l,5- a]pyrazin-3-yl]-cyclohexanecarboxylic acid amide except for the substitution of trans-
4- [ 1 -(3-benzyloxyphenyl)-8-chloro-imidazo[ 1 ,5-a]pyrazin-3-yl] cyclohexane carboxylic acid methyl ester (compound of Formula II-A where Z = cyclohexyl,
C02A3 = 4-trans-C0 e, and Q1 = Ph-(3-OBn)) with {4-[l-(3-benzyloxy-phenyl)-8- chloro-imidazo[l,5-a]pyrazin-3-yl]-cyclohexyl}-methanol (compound of Formula II-
B where Z = cyclohexyl and Q1 = Ph-(3-OBn)); 1H NMR (CDC13, 400 MHz) δ 1.21
(ddd, 2H, J= 25.2 Hz, 12.8 Hz, 3.6 Hz), 1.65-1.71 (m, IH), 1.91 (ddd, 2H, J= 29.6
Hz, 13.2 Hz, 3.6 Hz), 2.00-2.05 (m, 2H), 2.12-2.16 (m, 2H), 2.93 (tt, 1H, J= 11.6
Hz, 4.0 Hz), 3.56 (d, 2H, J= 6.0 Hz), 5.11 (bs, 2H), 5.16 (s, 2H), 7.05 (ddd, IH, J =
8.0 Hz, 2.8 Hz, 1.2 Hz), 7.07 (d, IH, J= 5.2 Hz), 7.20-7.22 (m, 2H), 7.23-7.24 (m,
2H), 7.31-7.35 (m, IH), 7.36-7.41 (m, 2H), 7.42-7.45 (m, 2H); MS (ES) 429.5
(M+l).
[546]
Figure imgf000112_0002
[547] a) traH5-{4-[l-(3-Benzyloxy-phenyl)-8-chloro-imidazo[l,5-a]pyrazin-
3 -yl] -cyclohexyl} -methanol (compound of Formula II-B where Z = cyclohexyl and
Q1 = Ph-(3-OBn)): A 0.2 M THF solution of trarø-4-[l-(3-benzyloxyphenyl)-8- chloro-imidazo[l,5-a]pyrazin-3-yl] cyclohexane carboxylic acid methyl ester (800 mg, 1.68 mmol) was cooled to -78 °C and charged with LiAlFL (63.8 mg, 1.68 mmol) portionwise; the reaction vessel was removed from the -78 °C cooling bath and allowed to warm to rt. After 2 h, the reaction mixture was charged with EtOAc, Na2SO4-10H2O, and silica gel and concentrated in vacuo to yellow solids. The material was purified by silica gel chromatography, eluting with EtOAc, to afford the desired product as a yellow solid; MS (ES) 448.2 (M+l), 450.2 (M+3).
[548]
Figure imgf000113_0001
[549] EXAMPLE 12: cw-3-[8-Amino-l-(3-benzyloxy-ρhenyl)-imidazo[l,5- a]pyrazin-3-yl]-cyclobutanol (compound of Formula I-F where Z = cis-3 -cyclobutyl and Q1 = Ph-(3-OBn)): 3-[l-(3-Benzyloxy-phenyl)-8-chloro-imidazo[l,5-a]pyrazin- 3-yl]-cyclobutanol (compound of Formula II-G where Z3 = cis-3 -cyclobutyl and Q1 = Ph-(3-OBn)) (84.0 mg, 0.2 mmol) was placed in a sealed tube and charged with 3.0 mL of 7N NH3 in MeOH and heated to 110 °C for 60 h. The reaction was concentrated in vacuo, taken up into CH2C12 and purified using HPFC with a 5 g Jones silica gel column (2% MeOH: CH2C12) to yield the desired product as a off- white solid; 1H NMR (CDCL, 400 MHz) δ 2.45-2.51 (m, 2H), 2.90-2.97 (m, 2H), 3.31 (q, IH, J= 8.0 Hz), 4.39 (q, IH, J= 7.0 Hz), 5.03 (brs, IH), 5.15 (s, 2H), 7.03- 7.13 (m, 2H), 7.23-7.52 (m, 9H); MS (ES) 387.3 (M+l), 389.3 (M+3).
Figure imgf000113_0002
[551] a) c/5-[l-(3-Benzyloxy-phenyl)-8-chloro-imidazo[l,5-a]pyrazin-3-yl]- cyclobutanol (compound of Formula II-G where Z3 = cis-3 -cyclobutyl and Q1 = Ph- (3-OBn)): A methanolic-CH2Cl2 solution (1.0 mL) of 3-[l-(3-benzyloxy-phenyl)-8- chloro-imidazo[l,5-a]pyrazin-3-yl]-cyclobutanone (compound of Formula II-F where Z3= cis-3 -cyclobutyl and Q1 = Ph-(3-OBn)) (80.0 mg, 0.2 mmol) was cooled to 0°C and charged with MP-borohydride (200.0 mg, 2.0 eq.). The reaction mixture was allowed to warm up to rt over a 24 h period. The resin-bound reducing agent was filtered and washed with EtOAc. The combined filtrate was concentrated in vacuo to yield the desired product as a light yellow solid; 1H NMR (CDC13, 400 MHz) δ 2.61- 2.68 (m, 2H), 2.94-3.01 (m, 2H), 3.36 (q, IH, J= 8.0 Hz), 4.42 (q, IH, J= 7.3 Hz), 5.15 (s, 2H), 7.00-7.09 (m, IH), 7.30-7.47 (m, 9H), 7.56 (d, IH, J= 5.0 Hz); MS (ES) 407.2 (M+l), 409.2 (M+3).
[552]
Figure imgf000114_0001
[553] b) 3-[l-(3-Benzyloxy-phenyl)-8-chloro-imidazo[l,5-a]pyrazin-3-yl]- cyclobutanone (compound of Formula II-F where Z = 3-cyclobutyl and Q = Ph-(3- OBn)): 3-Oxo-cyclobutanecarboxylic Acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin- 2-yl)-methyl] -amide (compound of Formula III where R1 = 3 -cyclobutanone and Q1 = Ph-(3-OBn)) (614.0 mg, 1.5 mmol) was dissolved in POCl3 (8.0 mL) and CH2C12 (2.0 mL) and allowed to stir at 55 °C for 24 h. The reaction mixture was concentrated in vacuo to a yellow solid, dissolved in cold EtOAc and neutralized with cold sat. NaHCO3. The aqueous layer was extracted with EtOAc (3x) and the combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. Purification via HPFC using a 20 g Jones silica gel column (50% EtOAc :Hex to 1% MeOH:CH2Cl2) followed by a recrystalization from hot EtOH yielded the desired product as a light yellow solid; 1H NMR (CDC13, 400 MHz) δ 3.61-3.68 (m, 2H), 3.86-3.95 (m, 3H), 5.15 (s, 2H), 7.00-7.09 (m, IH), 7.30-7.47 (m, 9H), 7.61 (d, IH, J = 5.0 Hz); MS (ES) 404.2 (M+l), 406.2 (M+3). Alternatively, 3-[l-(3-Benzyloxy- phenyl)-8-chloro-imidazo[l,5-a]pyrazin-3-yl]-cyclobutanone can be prepared from 1- (3-benzyloxyphenyl)-8-chloro-3-(3-methylenecyclobutyl)-imidazo[l,5-α]pyrazine (Example 44b) as follows: To a solution of l-(3-benzyloxyphenyl)-8-chloro-3-(3- methylenecyclobutyl)-imidazo[l,5- ]pyrazine (100 mg, 0.25 mmol) in THF (3 mL) and water (1 mL) were added NMO (0.1 mL, 0.5 mmol, 50% aq. solution) and K2OsO *H2O (5 mg, 0.013 mmol). The resulting mixture was stined at rt overnight. TLC showed the reaction was complete. The reaction was quenched with Na2SO3 (160 mg, 1.25 mmol), then diluted with EtOAc (40 mL) and water (5 mL), washed with brine (20 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to give 3-[l-(3-benzyloxy-phenyl)-8-chloro- imidazo[l,5-a]pyrazin-3-yl]-l-hydroxymethyl-cyclobutanol as a yellow solid (100 mg). LC-MS (ES, Pos.): m/z 436/438 (3/1) [MET"]. The solution of 3-[l-(3- benzyloxy-phenyl) -8 -chloro-imidazo [ 1 ,5 -a]pyrazin-3 -yl] - 1 -hydroxymethyl- cyclobutanol in THF (3 mL) and water (1 mL) was cooled to 0 °C and charged with sodium periodate (64 mg, 0.3 mmol). The resulting mixture was slowly warmed to rt in 2 h. TLC showed the reaction was complete. The mixture was diluted with EtOAc
(40 mL) and water (5 mL), washed with brine (20 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure and the crude product was purified by silica gel column chromatography (Hexanes:EtOAc = 50:50
—> 30:70) to give the title compound as a yellow solid (70 mg, 70% yield over two steps); LC-MS (ES, Pos.): m/z 404/406 (3/1) [MH+]; 1H NMR (CDC13, 400 MHz) δ
3.60-3.67 (m, 2H), 3.81-3.94 (m, 3H), 5.14 (s, 2H), 3.81-3.94 (m, 3H), 7.06 (m, IH),
7.27-7.47 (m, 9H), 7.59 (d, J= 4.9 Hz, IH).
Figure imgf000115_0001
[554]
[555] c) 3-Oxo-cyclobutanecarboxylic Acid [(3-benzyloxy-phenyl)-(3- chloro-pyrazin-2-yl)-methyl]-amide (compound of Formula III where R1 = 3- cyclobutanone and Q1 = Ph-(3-OBn)): 3-Oxo-cyclobutanecarboxylic acid (184.2 mg, 1.8 mmol), EDC (529.1 mg, 2.8 mmol) and HOBt (281.8 mg, 1.8 mmol) were dissolved in CH2C12 (18.0 mL) and allowed to stir at rt for 10 min. A CH2C12 solution (1.0 mL) of C-(3-Benzyloxy-phenyl)-C-(3-chloro-pyrazin-2-yl)-methylamine (600.0 mg, 1.8 mmol) was added to the reaction mixture, which was allowed to stir at rt for 24 h. Purification via HPFC using a 20 g Jones silica gel column (30% EtOAc :Hex to 50% EtOAc:Hex) yielded the desired product as a white solid; 1H NMR (CDC13, 400 MHz) δ 3.07-3.22 (m, 3H), 3.42-3.48 (m, 2H), 5.03 (s, 2H), 6.55 (d, IH, J= 7.8 Hz), 6.89-6.96 (m, 3H), 7.22-7.39 (m, 5H,), 8.35 (d, IH, J= 2.5 Hz), 8.50 (d, IH, J= 2.5 Hz); MS (ES) 422.2 (M+l), 424.2 (M+3).
Figure imgf000116_0001
[557] EXAMPLE 13: l-(3-Benzyloxy-phenyl)-3-(l-methyl-piperidin-4-yl)- imidazo[l,5-a]pyrazin-8-ylamine (compound of Formula I where R1 = 4-N- methylpiperidine and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for Example 1 above except for the substitution of l-(3-benzyloxy-phenyl)-
8-chloro-3-cyclobutyl-imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) with l-(3-benzyloxy-phenyl)-8-chloro-3-(l-methyl- piperidin-4-yl)-imidazo[l,5-a]pyrazine (compound of Formula II where R1 = 4-N- methylpiperidine and Q1 = Ph-(3-OBn)); white solid, purified by Gilson HPLC to yield the desired product as the formic acid salt as a colorless gum; 1H ΝMR
(CD3OD, 400 MHz) δ 2.24-2.27 (m, 4H), 2.94 (s, 3H), 3.24 (m, IH), 3.55-3.66 (m,
4H), 5.17 (s, 2H), 7.05-7.49 (m, 10H), 7.65 (d, IH, J= 5.1 Hz); MS (ES) 414.3
(M+l).
Figure imgf000116_0002
[559] a) 1 -(3 -Benzyloxy-phenyl)- 8 -chloro-3 -(1 -methyl-piperidin-4-yi)- imidazo[l,5-a]pyrazine (compound of Formula II where R1 = 4-N-methylpiperidine and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for l-(3- benzyloxy-phenyl)-8-chloro-3-cyclobutyl-imidazo[l,5-a]pyrazine (compound of Formula II where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin- 2-yl)-methyl] amide with l-methyl-piperidine-4-carboxylic acid [(3-benzyloxy- phenyl)-(3-chloro-pyrazin-2-yl)-methyl]-amide (compound of Formula III where R1 = 4-N-methylpiperidine and Q1 = Ph-(3-OBn)); Yellow oil; MS (ES) 433.2 (M+l), 435.2 (M+3).
Figure imgf000117_0001
[561] b) l-Methyl-piperidine-4-carboxylic acid [(3-benzyloxy-phenyl)-(3- chloro-pyrazin-2-yl)-methyl] -amide (compound of Formula III where R1 = 4-N- methylpiperidine and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for the synthesis of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3- chloro-pyrazin-2-yl)-methyl] amide (compound of Formula III where R = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of l-methyl-piperidine-4- carboxylic acid for cyclobutanecarboxyhc acid; 1H ΝMR (CDC13, 400 MHz) δ 1.25- 2.33 (brm, 10H), 2.95 (brs, 2H), 5.02 (s, IH), 6.50 (d, IH, J= 7.8 Hz), 6.87-6.94 (m, 3H), 7.19-7.38 (m, 5H), 8.33 (d, IH, J= 2.5 Hz), 8.50 (d, IH, J= 2.5 Hz); MS (ES) 451.2 (M+l), 453.2 (M+3).
Figure imgf000117_0002
[563] EXAMPLE 14: ets-4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5- a]pyrazin-3-yl]-cyclohexanecarboxylic acid amide (compound of Formula I-A where Z = cyclohexyl, C(=O)ΝR2R3 = 4-ct5-C(=O)NH2, and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for Example 10 except for the substitution of trα«5,-4-[l-(3-benzyloxyphenyl)-8-chloro-imidazo[l,5-a]pyrazin-3-yl] cyclohexane carboxylic acid methyl ester (compound of Formula II-A where Z = cyclohexyl, CO2A3 = 4-trα?w-CO2Me, and Q1 = Ph-(3-OBn)) with cw-4-[l-(3-benzyloxvphenyl)- 8-chloro-imidazo[l,5-a]pyrazin-3-yl] cyclohexane carboxylic acid methyl ester (compound of Formula II-A where Z = cyclohexyl, CO2A3 = 4-czs-CO2Me, and Q1 = Ph-(3-OBn)); MS (ES) 442.4 (M+l).
Figure imgf000117_0003
[565] a) cis-4-[ 1 -(3-Benzyloxy-phenyl)-8-chloro-imidazo[ 1 ,5-a]pyrazin-3- yl]-cyclohexanecarboxylic acid methyl ester (compound of Formula II-A where Z = cyclohexyl, CO2A3 = 4-cw-CO2Me, and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for l-(3-benzyloxy-phenyl)-8-chloro-3-cyclobutyl- imidazo[l,5-a]pyrazine (compound of Formula II where R = cyclobutyl and Q1 = Ph- (3-OBn)) above except for the substitution of cyclobutanecarboxyhc acid [(3- benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide (compound of Formula III where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) with cώ-4-{[(3-benzyloxy-phenyl)-(3- chloro-pyrazin-2-yl)-methyl]-carbamoyl}-cyclohexanecarboxylic acid methyl ester (compound of Formula III where R1 = trαR.s-4-cyclohexane carboxylic acid methyl ester and Q1 = Ph-(3-OBn)); MS (ES) 476.2 (M+l), 478.2 (M+3).
Figure imgf000118_0001
[567] b) cts-4-{[(3-Benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl]- carbamoyl}-cyclohexanecarboxylic acid methyl ester (compound of Formula III where R1 - cts-4-cyclohexane carboxylic acid methyl ester and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for the synthesis of cyclobutanecarboxyhc acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] amide (compound of Formula III where R1 = cyclobutyl and Q1 = Ph-(3-OBn)) above except for the substitution of cώ-cyclohexane-l,4-dicarboxylic acid monomethyl ester for cyclobutanecarboxyhc acid; MS (ES) 494.3 (M+l), 496.3 (M+3).
Figure imgf000118_0002
[569] EXAMPLE 15: cw-{4-[8-Amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexyl}-methanol (compound of Formula I-B where
Z = cyclohexyl and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for the synthesis of trans-4-[8-amino-l-(3-benzyloxy-phenyl)-imidazo[l,5- a]pyrazin-3-yl]-cyclohexanecarboxylic acid amide except for the substitution of cis-4- [l-(3-benzyloxyphenyl)-8-chloro-imidazo[l,5-a]pyrazin-3-yl] cyclohexane carboxylic acid methyl ester (compound of Formula II-A where Z = cyclohexyl, CO2A3 = 4-cis- CO2Me, and Q1 = Ph-(3-OBn)) with {4-[l-(3-benzyloxy-phenyl)-8-chloro- imidazo[l,5-a]pyrazin-3-yl]-cyclohexyl}-methanol (compound of Formula II-B where Z = cyclohexyl and Q1 = Ph-(3-OBn)); MS (ES) 429.2 (M+l).
Figure imgf000119_0001
[571] a) cw-{4-[l-(3-Benzyloxy-phenyl)-8-chloro-imidazo[l,5-a]pyrazin-3- yl] -cyclohexyl} -methanol (compound of Formula II-B where Z = cyclohexyl and Q1
= Ph-(3-OBn)) was prepared as described for the synthesis of trans- {4-[l-(3- benzyloxy-phenyl)-8-chloro-imidazo[ 1 ,5-a]pyrazin-3-yl]-cyclohexyl} -methanol
(compound of Formula II-B where Z = trans- 1,4-cyclohexyl and Q1' = Ph-(3-OBn)) except for the substitution of trans-4-[l-(3-benzyloxyphenyl)-8-chloro-imidazo[l,5- a]pyrazin-3-yl] cyclohexane carboxylic acid methyl ester with cw-4-[l-(3- benzyloxyphenyl)-8-chloro-imidazo[l,5-a]pyrazin-3-yl] cyclohexane carboxylic acid methyl ester; MS (ES) 448.2 (M+l), 450.2 (M+3).
Figure imgf000119_0002
[573] EXAMPLE 16: c/s-2-{4-[8-Amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexylmethyl}-isoindole-l,3-dione (compound of
Formula I-C where Z = cz's-l,4-cyclohexyl, A2 = phthahmido and Q1 = Ph-(3-OBn)) was prepared as follows: cz's-{4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5- a]pyrazin-3-yl]-cyclohexyl}-methanol (compound of Formula I-B where Z = cis-1,4- cyclohexyl and Q1 = Ph-(3-OBn)) (175 mg, 0.41 mmol), phthalimide (72 mg, 0.49 mmol), and resin-bound triphenylphosphine (PS-Ph3P [Argonaut, 2.33 mmol/g]) (263 mg) were dissolved in 2 mL of THF, evacuated, placed under nitrogen atmosphere and charged with DIAD (97 μL, 0.49 mmol). After stirring for 16 h, the reaction mixture was filtered through a cotton pipet plug, washed 6X with EtOAc, concentrated in vacuo, and purified by silica gel column chromatography (gradient of 30% EtOAc/hexanes to 70% EtOAc/hexanes) to afford the desired product as a foamy yellow solid; MS (ES+): m/z 558.5 (M+l).
Figure imgf000120_0001
[575] EXAMPLE 17: trarø-2-{4-[8-Amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexyhnethyl}-isoindole-l,3-dione (compound of Formula I-C where Z = 4-trΩ s-cyclohexyl, A2 = phthahmido and Q1 = Ph-(3-OBn)) was prepared according to the procedures described in Example 16 above except for the replacement of cis- {4-[8-amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyr azin-3- yl]-cyclohexyl} -methanol with tra«s-{4-[8-amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]ρyrazin-3-yl]-cyclohexyl}-methanol; MS (ES+): m/z 558.4 [MET4"].
Figure imgf000120_0002
[577] EXAMPLE 18: cts-3-(4-Aminomethyl-cyclohexyl)-l-(3-benzyloxy- phenyl)-imidazo[l,5-a]pyrazin-8-ylamine (compound of Formula I-C" where Z = cis-
1,4-cyclohexyl and Q1 = Ph-(3-OBn)) was prepared as follows: An ethanolic solution of cis-2- {4-[8-amino-l -(3-benzyloxy-phenyl)-imidazo[l ,5-a]pyrazin-3-yl]- cyclohexyhnethyl}-isoindole-l,3-dione (compound of Formula I-C where Z = cis-
1,4-cyclohexyl, A2 = phthahmido and Q1 = Ph-(3-OBn)) (490 mg, 0.92 mmol) was charged with an excess of hydrazine (10 μL) and allowed to stir at rt for 16 h. The solution was filtered through a fritted glass funnel and the solids washed with EtOH (4x). The filtrate was concentrated in vacuo and the crude product was purified by High Pressure Flash Chromatography (HPFC) (dry loaded, gradient of CH2C12 to 2% ~ 7NNH3 in MeOH/CH2Cl2) to afford the desired product as a white foamy solid; !H NMR (400 MHz, CDC13) δ 1.66-1.72 (m, 4H), 1.77-1.86 (m, 4H), 2.00-2.07 (m, 3H), 2.75 (d, 2H, J= 8.0 Hz), 3.10-3.13 (m, IH), 5.10 (bs, 2H), 5.14 (s, 2H), 7.00- 7.04 (m, 2H), 7.18-7.25 (m, 3H), 7.33-7.46 (m, 6H); MS (ES+): m/z 428.4 [MH+].
Figure imgf000121_0001
[579] EXAMPLE 19: tran -3-(4-Aminomethyl-cyclohexyl)-l-(3-benzyloxy- phenyl)-imidazo[l,5-a]pyrazin-8-ylamine (compound of Formula I-C" where Z = tra« -l,4-cyclohexyl and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for the synthesis of cts-3-(4-aminomethyl-cyclohexyl)-l-(3-benzyloxy- phenyl)-imidazo[l,5-a]pyrazin-8-ylamine (compound of Formula I-C" where Z = cis-
1,4-cyclohexyl and Q1 = Ph-(3-OBn)) above except for the replacement of cis-2-{4-
[8-amino- 1 -(3-benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin-3-yl]-cyclohexylmethyl} - isoindole-l,3-dione (compound of Formula I-C where Z = ct -l,4-cyclohexyl, A2 = phthahmido and Q1 = Ph-(3-OBn)) with trans-2-{4-[8-amino-l-(3-benzyloxy- phenyl)-imidazo [1,5 -a]pyrazin-3 -yl] -cyclohexylmethyl} -isoindole- 1 ,3 -dione
(compound of Formula I-C where Z = trans- 1,4-cyclohexyl, A2 = phthahmido and
Qi = Ph-(3-OBn)); 1H NMR (400 MHz, CDC13) δ 1.13 (ddd, 2H, J= 25.2 Hz, 12.8
Hz, 3.6 Hz), 1.31-1.52 (m, 3H), 1.88 (ddd, 2H, J= 29.6 Hz, 13.2 Hz, 3.6 Hz), 2.00-
2.05 (m, 2H), 2.12-2.16 (m, 2H), 2.62 (d, 2H, J = 6.4 Hz), 2.93 (rt, IH, J= 11.6 Hz,
4.0 Hz), 5.02 (bs, 2H), 5.14 (s, 2H), 7.01 (ddd, IH, J = 8.0 Hz, 2.8 Hz, 1.2 Hz), 7.04
(d, IH, J= 5.2 Hz), 7.21-7.22 (m, 2H), 7.23-7.24 (m, 2H), 7.34-7.36 (m, IH), 7.36-
7.41 (m, 2H), 7.42-7.45 (m, 2H); MS (ES) 428.5 (M+l). [580]
Figure imgf000122_0001
[581] EXAMPLE 20: cts-N-{4-[8-Amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexylmethyl} -acetamide (compound of Formula I-
C" where Z = cis- 1,4-cyclohexyl, R2 = H, R3 = C(=O)CH3, and Q1 = Ph-(3-OBn)) was prepared as follows: cts-3-(4-Aminomethyl-cyclohexyl)-l-(3-benzyloxy- phenyl)-imidazo[l,5-a]pyrazin-8-ylamine (compound of Formula I-C" where Z = cis-
1,4-cyclohexyl and Q1 = Ph-(3-OBn)) (10.8 mg, 0.03 mmol) was dissolved in 0.3 mL of chloroform and charged with PS-DIEA (10 mg, 0.04 mmol) followed by acetic anhydride (2.1 μL, 0.02 mmol) and allowed to stir for 0.5 h. The solution was filtered through a cotton pipet plug and the solids washed with chloroform (4x). The filtrate was concentrated in vacuo and the crude product was purified by silica gel chromatography (2% ~ 7NΝH3 in MeOH/CH2Cl2) to afford the desired product as a foamy white solid; MS (ES) 470.5 (M+l).
Figure imgf000122_0002
[583] EXAMPLE 21: trans-N-{4-[8-Amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexylmethyl} -acetamide (compound of Formula I-
C" where Z = trans- 1,4-cyclohexyl, R2 = H, R3 = C(=O)CH3, and Q1 = Ph-(3-OBn)) was prepared according to the procedures described for cts-N-{4-[8-amino-l-(3- benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]-cyclohexyhnethyl}-acetamide
(compound of Formula I-C" where Z = cis- 1,4-cyclohexyl, R2 = H, R3 = C(=O)CH3, and Q1 = Ph-(3-OBn)) above except for the replacement of cts-3-(4-ammomethyl- cyclohexyl)-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-8-ylamine (compound of
Formula I-C" where Z = cis- 1,4-cyclohexyl and Q1 = Ph-(3-OBn)) with trans-3-(4- aminomethyl-cyclohexyl)-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-8-ylamine (compound of Formula I-C" where Z = trans- 1,4-cyclohexyl and Q1 = Ph-(3-OBn)); 1H NMR (400 MHz, CDC13) δ 1.18 (ddd, 2H, J- 25.2 Hz, 12.8 Hz, 3.6 Hz), 1.60- 1.66 (m, IH), 1.85 (ddd, 2H, J= 29.6 Hz, 13.2 Hz, 3.6 Hz), 1.94-1.98 (m, 2H), 2.01 (s, 3H), 2.08-2.12 (m, 2H), 2.90 (tt, IH, J= 11.6 Hz, 4.0 Hz), 3.20 (dd, 2H, J= 6.4 Hz, 6.4 Hz), 5.07 (bs, 2H), 5.14 (s, 2H), 5.49 (m, IH), 7.02 (ddd, IH, J = 8.0 Hz, 2.8 Hz, 1.2 Hz), 7.04 (d, IH, J= 5.2 Hz), 7.19-7.22 (m, 2H), 7.23-7.24 (m, 2H), 7.31- 7.36 (m, IH), 7.36-7.41 (m, 2H), 7.43-7.46 (m, 2H); MS (ES) 470.5 (M+l).
[584]
Figure imgf000123_0001
Ac
[585] The following examples were synthesized according to the procedures described in Examples 1-22 unless stated otherwise.
[586] EXAMPLE 22: l-Biphenyl-3-yl-3-cyclobutylimidazo[l,5-α]pyrazin-
8-ylamine: Prepared according to the procedures for l-(3-Benzyloxy-phenyl)-3- cyclobutyl-imidazo[l,5-a]pyrazin-8-ylamine, white solid, MS (ES) 341.38 (M+l).
Figure imgf000123_0002
[588] a) 1 -Biphenyl-3 -yl-8 -chloro-3 -cyclobutylimidazo [1,5 -α]pyrazine :
Prepared according to the procedures for l-(3-Benzyloxy-phenyl)-8-chloro-3- cyclobutyl-imidazo[l,5-a]pyrazine, yellow solid, MS (ES) 360.36 (M+l).
Figure imgf000124_0001
[590] b) Cyclobutanecarboxyhc Acid [biphenyl-3-yl-(3-chloropyrazin-2- yl)methyl] amide: Prepared according to the procedures for Cyclobutanecarboxyhc Acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] Amide, off-white oil, MS (ES) 378.37 (M+l).
Figure imgf000124_0002
[592] c) C-Biphenyl-3-yl-C-(3-chloropyrazin-2-yl)-methylamine: Prepared according to the procedures for C-(3-Benzyloxy-phenyl)-C-(3-chloro-pyrazin-2-yl)- methylamine, orange oil, MS (ES) 296.18 (M+l), 279.18 (M-17).
Figure imgf000124_0003
[594] d) 2-[Biphenyl-3-yl-(3-chloropyrazin-2-yl)-methyl]-isoindole-l,3- dione: Prepared according to the procedures for 2-[(3-Benzyloxy-phenyI)-(3-chloro- pyrazin-2-yl)-methyl]-isoindole-l,3-dione, orange oil, MS (ES) 426.92 (M+l).
Figure imgf000124_0004
[596] e) Biphenyl-3-yl-(3-chloropyrazin-2-yl)-methanol: Prepared according to the procedures for (3-Chloro-pyrazin-2-yl)-(3-benzyloxy-phenyι)- methanol, orange oil, MS (ES) 297.11 (M+l), 278.13 (M-17).
Figure imgf000125_0001
[598] f) Biphenyl-3-carbaldehyde: Prepared from 3-bromo-benzaldehyde and phenylboronic acid utilizing Pd(PPh3)4, K2CO3, 4:1 DMF:H2O (see detailed description under the General synthesis to Suzuki analogues in Examples 24-26), following standard Suzuki Coupling procedures as described in the following reference: Strongin, R.M.; et. al. Org. Lett., 2000, 20, 3201-3204; Clear oil, 1H NMR
(CDC13, 400 MHz) δ 7.38-7.51 (m, 3H), 7.60-7.65 (m, 3H), 7.87 (dd, 2H, J= 2.8 Hz,
8.4 Hz), 8.11-8.12 (m, IH), 10.0 (s, IH); MS (ES) 183.28 (M+l).
Figure imgf000125_0002
[600] EXAMPLE 23: l-(3-Bromo-phenyl)-3-cyclobutylimidazo[l,5- α]pyrazin-8-ylamine: Prepared according to the procedures for l-(3-Benzyloxy- phenyl)-3-cyclobutyl-imidazo[l,5-a]pyrazin-8-ylamine, Light pink solid, 1H NMR
(CDC13, 400 MHz) δ 2.02-2.21 (m, 2H), 2.45-2.65 (m, 4H), 3.81 (p, IH, J= 8.8 Hz),
5.03 (bs, 2H), 7.07 (d, IH, J= 4.8 Hz), 7.13 (d, IH, J= 4.8 Hz), 7.33-7.37 (m, IH),
7.53 (d, IH, J= 7.2 Hz), 7.60 (d, IH, J= 7.2 Hz), 7.88 (d, IH, J= 1.6 Hz).
Figure imgf000125_0003
[602] a) l-(3-Bromophenyl)-8-chloro-3-cyclobutylimidazo[l,5-α]pyrazine:
Prepared according to the procedures for l-(3-Benzyloxy-phenyl)-8-chloro-3- cyclobutyl-imidazo[l,5-a]pyrazine, Yellow solid, 1H NMR (CDC13, 400 MHz) δ 2.04-2.22 (m, 2H), 2.50-2.67 (m, 4H), 3.84 (p, IH, J= 8.8 Hz), 7.29-7.33 (m, 2H),
7.51 (d, IH, J= 4.8 Hz), 7.52-7.55 (m, IH), 7.61-7.64 (m, IH), 7.86-7.87 (m, IH).
Figure imgf000126_0001
[604] b) Cyclobutanecarboxyhc Acid [(3-bromophenyl)-(3-chloropyrazin-2- yl)methyι] amide: Prepared according to the procedures for Cyclobutanecarboxyhc
Acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] Amide, White solid, 1H
NMR (CDC13, 400 MHz) δ 1.83-2.02 (m, 2H), 2.13-2.29 (m, 4H), 3.09 (p, IH, J=
8.8 Hz), 6.53 (d, IH, J= 8.0 Hz), 7.08 (d, IH, J= 8.0 Hz), 7.16^7.20 (m, IH), 7.34-
7.43 (m, 3H), 7.37 (d, IH, J= 2.8 Hz), 8.53 (d, IH, J= 2.8 Hz).
Figure imgf000126_0002
[606] c) C-(3-Bromophenyl)-C-(3-chloropyrazin-2-yl)-methylamine:
Prepared according to the procedures for C-(3-Benzyloxy-phenyl)-C-(3-chloro- pyrazin-2-yl)-methylamine, Orange oil, 1H NMR (CDC13, 400 MHz) δ 5.54 (s, IH), 7.17-7.21 (m, IH), 7.31 (d, IH, J= 8.0 Hz), 7.39 (d, IH, J= 8.4 Hz), 7.51-7.53 (d, IH, J= 8.4 Hz), 8.31 (d, IH, J= 2.8 Hz), 8.56 (d, IH, J= 2.4 Hz).
Figure imgf000126_0003
[608] d) 2-[(3-Bromophenyl)-(3-chloropyrazin-2-yl)-methyl]-isoindole-l,3- dione: Prepared according to the procedures for 2-[(3-Benzyloxy-phenyl)-(3-chloro- pyrazin-2-yl)-methyl]-isoindole-l,3-dione, Orange oil, 1H NMR (CDC13, 400 MHz) δ 6.84 (s, IH), 7.47-7.53 (m, 2H), 7.74-7.86 (m, 6H), 8.37 (dd, IH, J= 1.2 Hz, 2.6 Hz ), 8.48 (d, IH, J= 2.4 Hz).
Figure imgf000127_0001
[610] e) (3-Bromophenyl)-(3-chloropyrazin-2-yl)-methanol: Prepared according to the procedures for (3-Chloro-pyrazin-2-yl)-(3-benzyloxy-phenyl)- methanol, Light yellow solid, 1H NMR (CDC13, 400 MHz) δ 4.66 (d, IH, J= 8.0 Hz), 5.98 (d, IH, J= 8.0 Hz), 7.18-7.23 (m, IH), 7.29-7.49 (m, 3H), 8.40 (d, IH, J= 2.4 Hz), 8.57 (d, IH, J= 2.4 Hz).
[611]
Figure imgf000127_0002
General synthesis to Suzuki analogues Examples 24-26.
[612] A 4: 1 DMF:H2O solution was purged with N2 for 45 minutes prior to the reaction. 1 -(3-Bromo-phenyl)-3-cyclobutylimidazo[ 1 ,5-α]pyrazin-8-ylamine (1.0 equiv), the suitable boronic acid (1.1 equiv), K2CO3 (2.25 equiv), and PS-Pd(Ph3)4 (0.05 equiv) were slurried in enough 4:1 DMF:H2O to give a 0.25 M solution. The reaction mixture was heated to 90 °C overnight with stirring, cooled, diluted with CH2C12, filtered through Celite, and the resin washed with additional CH2C12. The filtrate was concentrated in vacuo, redissolved in DCM, and purified by chromatography (Jones Flashmaster Personal, 50:50 Hexane:EtOAc to 100 % EtOAc) to afford desired imidazopyrazines Examples 24-26.
[613] EXAMPLE 24: l-(4'-t-Butylbiphenyl-3-yl)-3-cyclobutylimidazo[l,5- α]pyrazin-8-ylamine: Light brown solid, 1H NMR (CDC13, 400 MHz) δ 1.34 (s, 9H), 2.02-2.21 ( , 2H), 2.45-2.68 (m, 4H), 3.83 (p, IH, J= 8.8 Hz), 5.18 (bs, 2H), 7.06 (d, IH, J= 5.2 Hz), 7.13 (d, IH, J= 5.2 Hz), 7.50-7.65 (m, 7H), 7.89 (d, IH, J= 1.6 Hz).
Figure imgf000128_0001
[615] EXAMPLE 25: 3-Cyclobutyl-l-(4'-methylbiphenyl-3-yl)-imidazo[l,5- α]pyrazin-8-ylamine: Off-white solid, MS (ES) 355.37 (M+l).
Figure imgf000128_0002
[617] EXAMPLE 26: 3-Cyclobutyl-l-(4'-methoxybiphenyl-3-yl)- imidazo[l,5-α]pyrazin-8-ylamine: White solid, MS (ES) 371.21 (M+l).
Figure imgf000128_0003
[619] EXAMPLE 27: l-(3-Benzyloxyphenyl)-3- cyclopentylmethylimidazo[l,5-a]pyrazin-8-ylamine: Prepared according to the procedures for 1 -(3-Benzyloxy-phenyl)-3-cyclobutyl-imidazo[l,5-a]pyrazin-8- ylamine, Clear oil, MS (ES) 399.20 (M+l).
Figure imgf000129_0001
[621] a) l-(3-Benzyloxphenyl)-8-chloro-3-cyclopentylmethylimidazo[l,5- α]pyrazine: Prepared according to the procedures for l-(3-Benzyloxy-phenyl)-8- chloro-3-cyclobutyl-imidazo[l,5-a]pyrazine, Yellow oil, MS (ES) 418.37 (M+l).
Figure imgf000129_0002
[623] b) N-[(3-Benzyloxyphenyl)-(3-chloropyrazin-2-yl)-methyl]-2- cyclopentyl-acetamide: Prepared according to the procedures for Cyclobutanecarboxyhc Acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] Amide, White solid, MS (ES) 436.32 (M+l).
Figure imgf000129_0003
[625] EXAMPLE 28: l-(3-Benzyloxyphenyl)-3- cyclohexylmethylimidazo[l,5-a]pyrazin-8-ylamine: Prepared according to the procedures for 1 -(3-Benzyloxy-phenyl)-3-cyclobutyl-imidazo[ 1 ,5-a]pyrazin-8- ylamine, White solid, 1H NMR (CDC13, 400 MHz) δ 1.07-1.27 (m, 5H), 1.64-1.73 (m, 5H), 1.83-1.93 (m, IH), 2.86 (d, IH, J = 6.8 Hz), 5.02 (bs, 2H), 5.15 (s, 2H), 7.01-7.06 (m, 2H), 7.19 (d, IH, J = 2.0 Hz, 4.8 Hz), 7.23-7.25 (m, 2H), 7.33-7.46 (m, 7H).
Figure imgf000130_0001
[627] a) l-(3-Benzyloxyphenyl)-8-chloro-3-cyclohexylmethylimidazo[l,5- a]pyrazine: Prepared according to the procedures for l-(3-Benzyloxy-phenyl)-8- chloro-3-cyclobutyl-imidazo[l,5-a]pyrazine, Yellow oil, 1H NMR (CDC13, 400 MHz) δ 1.08-1.26 (m, 5H), 1.66-1.73 (m, 5H), 1.85-1.93 (m, IH), 2.92 (d, IH, J = 7.2 Hz), 5.14 (s, 2H), 7.03 (dd, IH, J = 2.0 Hz, 7.8 Hz), 7.29-7.41 (m, 6H), 7.44-7.46 (m, 2H), 8.32 (d, IH, J = 2.0 Hz), 7.59 (d, IH, J = 4.8 Hz).
Figure imgf000130_0002
[629] b) N-[(3-Benzyloxyphenyl)-(3-chloropyrazin-2-yl)-methyl]-2- cyclohexyl-acetamide: Prepared according to the procedures for Cyclobutanecarboxylic Acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] Amide, White solid, XH NMR (CDC13, 400 MHz) δ 0.88-0.97 (m, 2H), 1.09-1.29 (m, 3H), 1.63-1.82 (m, 6H), 2.11 (d, IH, J = 7.2 Hz), 5.02 (s, 2H), 6.55 (d, IH, J = 7.6 Hz), 6.86-6.94 (m, 3H), 7.03 (d, IH, J = 7.6 Hz), 7.19-7.25 (m, IH), 7.30-7.40 (m, 6H), 8.32 (d, IH, J = 2.0 Hz), 8.49 (d, IH, J = 2.0 Hz).
Figure imgf000131_0001
[631] EXAMPLE 29: l-(3-Benzyloxyphenyl)-imidazo[l,5-a]pyrazin-8- ylamine: Prepared according to the procedures for l-(3-Benzyloxy-phenyl)-3- cyclobutyl-imidazo[l,5-a]pyrazin-8-ylamine, White solid, 1H NMR (CDC13, 400 MHz) δ 5.09 (bs, 2H), 5.15 (s, 2H), 7.05-7.10 (m, 3H), 7.34-7.45 (m, 8H), 8.11 (s, IH).
Figure imgf000131_0002
[633] a) l-(3-Benzyloxyphenyl)-8-chloroimidazo[l,5-a]pyrazine: Prepared according to the procedures for l-(3-Benzyloxy-phenyl)-8-chloro-3-cyclobutyl- imidazo[l,5-a]pyrazine, Yellow oil, MS (ES) 336.06 (M+l).
Figure imgf000131_0003
[634] b) N-[(3-Benzyloxyphenyl)-(3-chloropyrazin-2-yl)-methyl]- formamide: Prepared according to the procedures for Cyclobutanecarboxyhc Acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] Amide, White solid, 1H NMR (CDC13, 400 MHz) δ 5.03 (s, 2H), 6.62 (d, IH, J = 8.0 Hz), 6.88-6.97 (m, 3H), 7.22- 7.24 (m, IH), 7.32-7.41 (m, 5H), 8.29 (bs, IH), 8.35 (d, IH, J = 2.4 Hz), 8.51 (d, IH, J = 2.0 Hz).
Figure imgf000132_0001
[636] EXAMPLE 30: l-(3-Benzyloxyphenyl)-3-trifluoromethylimidazo[l,5- a]pyrazin-8-ylamine: Prepared according to the procedures for l-(3-Benzyloxy- phenyl)-3-cyclobutyl-imidazo[l,5-a]pyrazin-8-ylamine, Pink solid, 1H NMR (CDC13, 400 MHz) δ 5.15 (s, 2H), 5.25 (bs, 2H), 7.08-7.11 (m, IH), 7.23-7.29 (m, 3H), 7.34- 7.45 (m, 6H), 7.54 (d, IH, J = 4.8 Hz).
Figure imgf000132_0002
[638] a) l-(3-Benzyloxyphenyl)-8-chloro-3-trifluoromethylimidazo[l,5- a]pyrazine: Prepared according to the procedures for l-(3-Benzyloxy-phenyl)-8- chloro-3-cyclobutyl-imidazo[l,5-a]pyrazine, Yellow oil, 1H NMR (CDC13 400 MHz) δ 5.14 (s, 2H), 7.08-7.11 (m, IH), 7.28-7.46 (m, 8H), 7.59 (d, IH, J = 4.8 Hz), 7.99 (d, lH, J = 5.2 Hz).
Figure imgf000132_0003
[640] b) N-[(3-Benzyloxyphenyl)-(3-chloropyrazin-2-yl)-methyl]-2,2,2- trifluoroacetamide: Prepared according to the procedures for Cyclobutanecarboxyhc Acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] Amide, White solid, 1H NMR (CDC13, 400 MHz) δ 5.03 (s, 2H), 6.46 (d, IH, J = 7.6 Hz), 6.92-6.96 (m, 3H), 7.28-7.41 (m, 5H), 8.16 (d, IH, J = 6.4 Hz), 8.40 (d, IH, J = 2.4 Hz), 8.55 (d, IH, J = 2.4 Hz).
Figure imgf000133_0001
[642] EXAMPLE 31: 4-[8-Amino-l-(3-benzyloxyphenyl)-imidazo[l,5- a]pyrazin-3-yl] -benzamide: Prepared according to the procedures for l-(3- Benzyloxy-phenyl)-3-cyclobutyl-imidazo[l,5-a]pyrazin-8-ylamine, Yellow solid, 1H NMR (DMSO-d6, 400 MHz) δ 5.20 (s, 2H), 6.23 (bs, 2H), 7.12 (dd, IH, J = 2.4 Hz, 8.2 Hz), 7.16 (d, IH, J = 2.4 Hz), 7.27 (d, IH, J = 7.6 Hz), 7.32-7.50 (m, 8H), 7.85 (d, IH, J = 5.2 Hz), 7.96 (d, 2H, J = 8.8 Hz), 8.07 (d, 2H, J = 8.8 Hz), 8.14 (bs, IH).
Figure imgf000133_0002
[644] a) 4- [ 1 -(3 -Benzyloxyphenyl)-8 -chloroimidazo [1,5 -a]pyrazin-3 -yl] - benzoic Acid Methyl Ester: Prepared according to the procedures for l-(3- Benzyloxy-phenyl)-8-chloro-3-cyclobutyl-imidazo[l,5-a]pyrazine, Yellow solid, MS (ES) 469.90 (M+l).
Figure imgf000133_0003
[646] b) N-[(3-Benzyloxyphenyl)-(3-chloropyrazin-2-yl)-methyl]- terephthalamic Acid Methyl Ester: Prepared according to the procedures for Cyclobutanecarboxyhc Acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] Amide, Yellow solid, MS (ES) 490.01 (M+2).
[647]
Figure imgf000134_0001
[648] EXAMPLE 32: 3-Cyclobutyl-l-phenylimidazo[l,5-a]pvrazin-8- ylamine: Gaseous NH was condensed into a cooled (-78 °C) solution of 8-chloro-3- cyclobutyl-l-phenylimidazo[l,5-a]pyrazine (602.9 mg, 2.125 mmol) in NH /i-PrOH (2M, 15 mL) in a pressure tube until the volume had doubled. The tube was sealed and heated to 110 °C for 2 d. After excess NH3/i-PrOH was removed in vacuo, the residue was extracted with CH2C12 (3x30 mL), and the combined organic layers were washed with brine (3x30 mL), dried over anhydrous MgSO4, filtered, and concentrated. The material obtained (670 mg) was recrystallized from EtOAc, granting 393.3 mg (70%, 1.488 mmol) of the title compound, as pale pink crystals. The mother liquor was reduced ca. 50% in vacuo and again recrystallized from EtOAc, affording an additional 38.4 mg (7%, 0.145 mmol) of the title compound, as pink crystals, >99% pure by HPLC; mp. 164-166 °C; 1H NMR (CDC13, 400 MHz) δ 1.98-2.09 (m, IH), 2.11-2.23 (m, IH), 2.44-2.54 (m, 2H), 2.58-2.70 (m, 2H), 3.82 (quint, J = 8.4 Hz, IH), 5.02 (s, br, -NH2), 7.05 (d, J = 4.8 Hz, IH), 7.12 (d, J = 5.2 Hz, IH), 7.38-7.43 (m, IH), 7.46-7.53 (m, 2H), 7.65-7.70 (m, 2H). 13C NMR (CDC13, 100.6 MHz, DEPT135): δ 18.87 (-), 26.94 (2C, -), 31.48 (+), 106.61 (+), 113.93 (CqUart), 127.43 (+), 128.08 (+), 128.81 (2C, +), 129.67 (2C, +), 134.87 (Cquart), 135.32 (Cquart), 143.90 (Cquart), 151.75 (Cquart). MS (ES+): m/z 265.2 (100) [MH+].
Figure imgf000135_0001
[650] a) 8-Chloro-3-cyclohutyl-l-phenylimidazo[l,5-α]pyrazine: A mixture of cyclobutanecarboxyhc acid [(3-chloropyrazin-2-yl)-phenylmethyl]-amide (710 mg, 2.35 mmol) and POCl3 (15 mL, 25 g, 163 mmol) was heated to 55 °C, under N2 atmosphere, for 21 h. POCl3 was evaporated in vacuo, a cold solution of NH3 in i- PrOH (2M, 15 mL) was added until pH was basic, and rotary evaporation was used to remove excess solvent. The crude material was suspended between EtOAc and dH2O, the layers were separated, and the aqueous layer was extracted with EtOAc (4x50 mL). The combined organic layers were washed with NaHCO3 sat. aq. sol. (2x50 mL) and brine (1x50 mL), dried over anhydrous MgSO4, and filtered. Sample was purified by filtration through a silica gel plug with 10% EtOAc:CH2Cl2 (250 mL) and filtrate was concentrated in vacuo, affording 602.9 mg (90%, 2.125 mmol) of the title compound, containing « 0.5 equivalents of reduced DIAD and < 0.06 equivalents of cyclobutanecarboxyhc acid [(3-chloropyrazin-2-yl)-phenylmethyl]-amide (4), as a gold-colored solid; 1H NMR (CDC13, 400 MHz) δ 2.00-2.11 (m, IH), 2.13-2.26 (m,lH), 2.47-2.57 (m, 2H), 2.60-2.72 (m, 2H), 3.85 (quint, J= 8.4 Hz, IH), 7.30 (d, j = 5.2 Hz, IH), 7.38-7.47 (m, 3H), 7.50 (d, j = 5.2 Hz, IH), 7.67-7.71 (m, 2H). MS (ES+): m/z 284.1/286.1 (100/55) [MH+].
Figure imgf000135_0002
[651] b) Cyclobutanecarboxyhc acid [(3-chloropyrazin-2-yl)-phenylmethyι]- amide: To a solution of C-(3-chloropyrazin-2-yl)-C-phenylmethylamine (610.7 mg,
2.780 mmol), DMAP (17 mg, 0.139 mmol), and (zPr)2EtN (726 μ , 539 mg, 4.17 mmol) in dry CH2C12 (10 mL), cooled to 0 °C, cyclobutanecarbonyl chloride (350 L, 363 mg, 3.058 mmol) was added under N2 atmosphere, the cooling bath was removed, and the reaction mixture stined at ambient temperature for 2 h. The reaction mixture was quenched with dH2O, taken up by CH2C12 (3x 20 mL), washed (lx 30mL each) with 0.25M citric acid (pH 2-3), dH2O, NaHCO3 sat. aq. sol., and brine, dried over anhydrous MgSO4, and filtered. Sample was purified by filtration through a silica gel plug with 10% EtOAc:CH2Cl2 (250 mL) and filtrate was concentrated in vacuo, yielding the title compound as a gold-colored solid; 1H NMR (CDC13, 400 MHz) δ 1.80-2.02 (m, 2H), 2.10-2.22 (m, 2H), 2.22-2.34 (m, 2H), 3.09 (quint, J= 8.4 Hz, IH), 6.58 (d, J= 7.6 Hz, IH), 7.01 (d, J= 8.0 Hz, IH), 7.24-7.36 (m, 5H), 8.33 (d, J = 2.4 Hz, IH), 8.52 (d, J- 2.0 Hz, IH).
Figure imgf000136_0001
[653] c) C-(3-Chloropyrazin-2-yl)-C-phenylmethylamine: To a solution of
2-[(3-chloropyrazin-2-yl)-phenylmethyl]-isoindole-l,3-dione (7.70 g, 22 mmol), containing « 0.77 eq. of reduced DIAD, in EtOH (10 mL) and co-solvent CH2C12 (15 mL), N2H4 (10 mL, 7.91 g, 0.172 mol) was added and the reaction solution was stined at rt, under N2, for 1 d. The suspension was filtered, the orange solid was washed several times with CH2C12, and the filtrate was concentrated in vacuo. The residue was suspended between HCl (2M)/EtOAc and the EtOAc layer was discarded. The aqueous layer was brought to a basic pH using NaOH and extracted with CH2C12 (5x60 mL), washed with brine (2x50 mL), dried over MgSO4, filtered, and concentrated, giving 2.1923 g (45%; 9.9795 mmol) of the title compound, containing » 0.1 eq. of reduced DIAD, as a brown oil; 1H NMR (CDC13, 400 MHz) δ 2.24 (s, br, 2H), 5.56 (s, IH), 7.26-7.38 (m, 5H), 8.27 (s, IH), 8.55 (s, IH). MS (ES+): m/z 203.2/205.2 (100/73) [MH+-NH3].
[654] C-(3-Chloropyrazin-2-yl)-C-phenylmethylamine hydrochloride
(2ΗC1): To a solution of C-(3-chloropyrazin-2-yl)-C-phenylmethylamine (1.582 g, 7.20 mmol) in 1,4-dioxane (< 5 mL), HCl (2 mL, 7.55 mmol, 4M soln. in 1,4- dioxane) was added and left for approx. 5 min. The reaction mixture was filtered and the solid was washed several times with 1,4-dioxane, yielding the title compound as a tan solid. Sample contains « 0.1 eq. of 1,4-dioxane by 1H NMR; 1H NMR (d-MeOR, 400 MHz) δ 5.85 (s, IH), 7.35 (s, IH), 8.44 (d, J= 2.4 Hz, IH), 8.65 (d, J= 2.4 Hz, IH).
Figure imgf000137_0001
[656] d) 2-[(3-Chloropyrazin-2-yl)-phenylmethyl]isoindole-l ,3-dione:
Prepared according to the procedures for 2-[(3-Benzyloxy-phenyl)-(3-chloro-pyrazin- 2-yl)-methyl]-isoindole-l,3-dione, Yellow oil, MS (ES) 350.04 (M+l).
Figure imgf000137_0002
[658] e) (3-Chloropyrazin-2-yl)-phenylmethanol: Prepared according to the procedures for (3-Chloro-pyrazin-2-yl)-(3-benzyloxy-phenyl)-methanol, Yellow solid, 1H NMR (CDC13, 400 MHz) δ 4.62 (d, IH, j = 8.0 Hz), 6.04 (d, IH, j = 8.0 Hz), 7.29-7.36 (m, 5H), 8.37 (d, IH, j = 2.4 Hz), 8.56 (d, IH, j = 2.4 Hz).
Figure imgf000137_0003
[660] General procedure to Examples 33 and 34: A THF solution (3 mL) of trαw^-toluene-4-sulfonic acid 4-[8-amino-l-(3-benzyloxy-phenyl)imidazo[l,5- a]pyrazin-3-yl] -cyclohexylmethyl ester (200 mg, 0.34 mmol) in a sealed tube was charged with azetidine (8.92 mmol, 510 mg) and stined at 50 °C for 24 h. The reaction mixture concentrated in vacuo and partitioned b/w EtOAc and sat. NaHCO3.
The organic layer was washed with sat. NaHCO (2x), water (lx), brine (lx), dried over Na2SO4, filtered, and concentrated to a yellow oil. The cmde material was purified by silica gel column chromatography [Jones Flashmaster, 5 g / 25 mL cartridge, eluting with CH2C12 to 2% ~7 NNH3 in MeOH/CH2Cl2] to afford trans-3- (4-azetidin- 1 -yhnethyl-cyclohexyl)- 1 -(3-benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin-8- ylamine as a white solid (130 mg, 82%).
[661] EXAMPLE 33: (trans-3-(4-Azetidin-l-ylmethyl-cyclohexyl)-l-(3- benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-8-ylamine: MS (ES+): m/z 468.1.
Figure imgf000138_0001
[663] EXAMPLE 34: trαrø-l-(3-Benzyloxy-phenyl)-3-(4-pyrrolidin-l- ylmethyl-cyclohexyl)-imidazo[l,5-a]pyrazin-8-ylamine): MS (ES+): m/z 482.3.
Figure imgf000138_0002
[665] a) trα«5-Toluene-4-sulfonic acid 4-[8-amino-l-(3-benzyloxy- phenyl)imidazo[l,5-a]pyrazin-3-yl]-cyclohexyhnethyl ester: A pyridine solution (23 mL) of trans- {4- [ 8 -amino- 1 -(3 -benzyloxy-phenyl)-imidazo [1,5 -a]pyrazin-3 -yl] - cyclohexyl} -methanol (2.00 g, 4.67 mmol) was cooled to -20 °C and charged with Ts2O (1.52 g, 4.67 mmol). The reaction was allowed to warm to rt and stined for 16 h. The mixture was concentrated in vacuo to a tan foam and partitioned between CHC13 and water. The organic layer was washed with IM NaOH (2x), water (lx), brine (lx), dried over Na2SO4, filtered, and concentrated to tan foam. The crude material was purified by silica gel column chromatography [Jones Flashmaster, 50 g / 150 mL cartridge, eluting with 50% EtOAc/Hexanes to 5% MeOH/EtOAc] to afford trα«5-toluene-4-sulfonic acid 4-[8-amino-l-(3-benzyloxy-phenyl)imidazo[l,5- a]pyrazin-3-yl] -cyclohexylmethyl ester as a tan foam (1.90 g, 70%); MS (ES+): m/z 583.1 [666]
Figure imgf000139_0001
[667] EXAMPLE 35: trαns-4-[8-Amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexanecarboxylic acid methyl ester: An isopropanol solution (42 mL) of trαws-4-[l-(3-benzyloxy-phenyl)-8-chloro- imidazo[l,5-a]pyrazin-3-yl]-cyclohexanecarboxylic acid methyl ester (4.00 g, 8.4 mmol) in a sealed tube was cooled to -78 °C. Ammoma was bubbled into the solution for 2 min; the tube was capped and heated to 110 °C for 1 d. The reaction mixture was concentrated in vacuo and partitioned b/w EtOAc and water. The organic layer was washed with water (2x), brine (lx), dried over Na2SO4, filtered, and concentrated to a yellow oil. The cmde material was purified by silica gel column chromatography [Jones Flashmaster, 20 g / 70 mL cartridge, eluting with 50% EtOAc/Hexanes to 2% ~7 NNH3 in MeOH/EtOAc] to afford trα«-?-4-[8-amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexanecarboxylic acid methyl ester as a tan foam (1.50 g, 39%); recovered trα«5-4-[l-(3-benzyloxy-phenyl)-8-chloro-imidazo[l,5- a]pyrazin-3-yl]-cyclohexanecarboxylic acid methyl ester (1.20 g, 30%); MS (ES+): m/z 457.1.
[668]
Figure imgf000139_0002
[669] EXAMPLE 36: (trαrø-4-[8-Amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexanecarboxylic acid): A THF solution (11 mL) oftrα/75-4-[8-amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]- cyclohexanecarboxylic acid methyl ester (1.50 g, 3.28 mmol) was charged with 10 M NaOH (1.64 mL, 16.42 mmol); a minimal amount of methanol was added to make the reaction mixture homogeneous. The reaction stined at rt for 2 h. The reaction mixture was concentrated to solids and acidified to pH 5 with 2 M HCl. The resulting ppt was filtered, washed with water, and dried in a vacuum oven overnight at 50 °C to afford acid trα«i'-4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]- cyclohexanecarboxylic acid as an off-white solid (1.10 g, 76%); MS (ES+): m/z 443.1.
[670]
Figure imgf000140_0001
[671] • General procedure to EXAMPLES 37 and 38: A DMF solution (2 mL) of acid trαH1s,-4-[8-amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]- cyclohexanecarboxylic acid (100 mg, 0.23 mmol) and methylamine hydrochlori.de (153 mg, 2.26 mmol) in a sealed tube was charged with DIEA (394 μL, 2.26 mmol), 0.6 M HOAt in DMF (377 μL, 0.23 mmol), and then EDC (65 mg, 0.34 mmol). The reaction mixture stined at rt for 16 h. The reaction mixture was concentrated to solids, taken up in CH2C12, charged with silica, and concentrated to brown solids. The cmde material was purified by silica gel column chromatography [Jones Flashmaster, 20 g / 70 mL cartridge, eluting with 2% ~7 NNH3 in MeOH/CH2Cl2 to 5% ~7 NNH3 in MeOH/CH2Cl2] to afford trα/w-4-[8-amino-l-(3-benzyloxy-phenyl)-imidazo[l,5- a]pyrazin-3-yl]-cyclohexanecarboxylic acid methyl amide as an off-white solid (60 mg, 57%).
[672] EXAMPLE 37: (trα«s-4-[8-Amino- l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexanecarboxylic acid meihylamide: ; MS (ES+): m/z 456.3.
[674] EXAMPLE 38: 4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5- a]pyrazin-3-yl]-cyclohexanecarboxylic acid ethylamide: MS (ES+): m/z 470.4.
Figure imgf000141_0001
General reductive amination procedures:
[676] 3-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]- cyclobutanecarbaldehyde (225 mg, 565 mmol) was dissolved in dichloroethane (DCE) (4.0 mL) followed by the addition of resin bound-BH(OAc)3 (562 mg, 1.129 mmol), AcOH (70 μL, 1.186 mmol) and pynolidine (0.14 mL, 1.694 mmol). After stirring for 24h at rt the resin was filtered and washed with CH2C12 and the filtrate combined and concentrated in vacuo. The crude oil was purified by silica gel column chromatography (2-5% 7N NH3 in MeOH: CH2C12) to yield the desired compounds. The more polar spot is the cis isomer, which is the major isomer.
[677] EXAMPLE 39: trans-l-(3-Benzyloxy-phenyl)-3-(3-pynolidin-l- ylmethyl-cyclobutyl)-imidazo[l,5-a]pyrazin-8-ylamine: Followed general reductive amination conditions; JH NMR (400 MHz, CDC13) δ 1.75 (brs, 4H), 2.35 (brs, 2H), 2.66 (brm, 9H), 3.68-3.75 (m, IH), 4.94 (brs, 2H), 5.08 (s, 2H), 6.98-6.99 (m, 3H), 7.20-7.42 (m, 8H); MS (ES+): 454.15 (M+l), 455.15 (M+2), 456.17 (M+3);
Figure imgf000141_0002
[679] EXAMPLE 40: cis-l-(3-Benzyloxy-phenyl)-3-(3-pynolidin-l- ylmethyl-cyclobutyl)-imidazo[l,5-a]pyrazin-8-ylamine: Followed general reductive amination conditions; 1HNMR (400 MHz, CDCL) δ 1.88-1.91 (m, 4H), 2.39-2.43 (m, 2H), 2.64-2.82 (m, 9H), 3.73-3.90 (m, IH), 5.20 (brs, 2H), 5.26 (s, 2H), 7.13- 7.15 (m, IH), 7.22 (d, 1H, J= 5.0 Hz), 7.35-7.57 (m, 8H); MS (ES+): 454.11 (M+l), 455.06 (M+2), 456.20 (M+3);
Figure imgf000142_0001
[681] EXAMPLE 41: trans-3-(3-Azetidin-l-ylmethylcyclobutyl)-l-(3- benzyloxyphenyl)-imidazo[l,5-a]pyrazin-8-ylamine: Followed general reductive amination conditions; 1H NMR (400 MHz, CDC13) δ 2.07-2.11 (m, 2H), 2.20-44 (m, 2H), 2.51 (brm, IH), 2.63-2.71 (m, 4H), 3.25 (t, 4H, j = 7.04 Hz), 3.71-3.75 (m, IH), 5.00 (brs, 2H), 5.11 (s, 2H), 6.98-6.99 (m, 3H), 7.20-7.42 (m, 8H).
[682]
Figure imgf000142_0002
[683] EXAMPLE 42: cis-3-(3-Azetidin-l-yhnethylcyclobutyl)-l-(3- benzyloxyphenyl)-imidazo[l,5-a]pyrazin-8-ylamine: Followed general reductive amination conditions; 1H NMR (400 MHz, CDC13) δ 1.98-2.02 (m, 2H), 2.18-2.21
(m, 2H), 2.44-2.54 (m, 4H), 3.12 (t, 4H, J = 7.0 Hz), 3.52-3.57 (m, IH), 4.98 (brs,
4H), 6.95-6.97 (m, 2H), 7.03 (d, IH, J = 5.0 Hz), 7.16-7.45 (m, 8H); MS (ES+):
440.08 (M+l), 441.08 (M+2), 442.13 (M+3). Alternatively, cis-3-(3-Azetidin-l- ylmethylcyclobutyl)-l-(3-benzyloxyphenyl)-imidazo[l,5-a]pyrazin-8-ylamine could be prepared as follows: A sealed tube containing a solution of toluene-4-sulfonic acid
3-[8-amino-l-(3-benzyloxyphenyl)-imidazo[l,5-a]pyrazin-3-yl]cyclobutylmethyl ester (15 mg, 0.027 mmol) in THF (3 mL) was charged with azetidine (0.04 mL, 0.54 mmol), sealed, and heated at 50 °C overnight. The mixture was concentrated and the residue was diluted with ethyl acetate (20 mL), washed with sat. aq. NaHCO3 (2 x 10 mL) and brine (2 x 10 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to afford a white solid.
Figure imgf000143_0001
[685] EXAMPLE 43: Toluene-4-sulfonic acid 3-[8-amino-l-(3- benzyloxyphenyl)-imidazo[l,5-α]pyrazin-3-yl]cyclobutyhnethyl ester: A solution of {3-[8-amino- 1 -(3-benzyloxyphenyl)-imidazo[ 1 ,5-α]pyrazin-3-yl]cyclobutyl}methanol (23 mg, 0.057 mmol) in dry methylene chloride (3 mL) was charged with pyridine (0.1 mL) and Ts2O (21 mg, 0.063 mmol) at -20 °C under N2 atmosphere. The mixture was slowly warmed to rt overnight. The reaction was quenched with water (1 mL), diluted with ethyl acetate (20 mL), washed with sat. aq. NaHCO3 (10 mL) and brine (2 x 10 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure, and the cmde material was purified by silica gel column chromatography (eluting with EtOAc:MeOH = 98:2 — > 96:4), yielding the title compound as a white solid. Partial trans isomer was removed by chromatography and the ratio of cis and trans isomers raised to 8:1; MS (ES, Pos.): m/z 555 [MH+]. 1H NMR (CDC13, 400 MHz) δ 2.27-2.35 (m, 2H), 2.41 (s, 3H), 2.55- 2.62 (m, 2H), 2.80 (m, IH), 3.66 (m, IH), 4.07 (d, J= 6.1 Hz, 2H), 5.01 (br s, 2H, NH2), 5.15 (s, 2H), 7.02-7.85 (m, 15H). Anal. Calcd for C31H30N4O4S»1/3H2O: C, 66.41; H, 5.51; N, 9.99. Found: C, 66.43; H, 5.44; N, 10.07.
Figure imgf000143_0002
[687] EXAMPLE 44: {3-[8-Amino-l-(3-benzyloxyphenyl)-imidazo[l,5- α]pyrazin-3-yl]cyclobutyl}methanol: A solution of {3-[l-(3-benzyloxyphenyI)-8- chloro-imidazo[l,5-α]pyrazin-3-yl]cyclobutyl}methanol (40 mg, 0.095 mmol) in 5 mL of 2N NH3/'PrOH was cooled to -78°C and charged with NH gas for 1 min. This sealed tube was equipped with a teflon O-ring, sealed and heated at 110 °C overnight. The mixture was cooled to rt and the cap was removed. The solution was concentrated under reduced pressure and the crude material was purified by silica gel column chromatography (eluting with 100% ethyl acetate -» EtOAc^PrOH = 80:20), yielding the title compound as a white solid, a mixture of cis and trans isomers. MS (ES, Pos.): m/z 401 [MH+]. 1H NMR (CDC13, 400 MHz) δ 2.37-2.44 (m, 2H), 2.61- 2.74 (m, 3H), 3.65-3.82 (m, 3H), 5.03 (br s, 2H, NH2), 5.14 (s, 2H), 7.01-7.46 (m, 11H).
Figure imgf000144_0001
[689] a) {3-[l-(3-Benzyloxyphenyl)-8-chloro-imidazo[l,5-α]pyrazin-3- yl]cyclobutyl}methanol: To a solution of l-(3-benzyloxyphenyl)-8-chloro-3-(3- methylenecyclobutyl)-imidazo[l,5-α]pyrazine (345 mg, 0.86 mmol) in dry THF (5 mL) was added 9-BBN (2.6 mL, 1.3 mmol, 0.5 M in THF) dropwise at 0 °C under nitrogen atmosphere. The temperature was slowly warmed to rt overnight. Upon which time TLC showed the reaction was complete. The mixture was cooled to 0 °C, and 2 mL IN aq. NaOH and 0.4 mL 30% aq. H2O2 were added, the resulting mixture was stined at 0 °C for 10 min, then rt for 30 min. The resulting white solid was filtered off, the filtrate was diluted with ethyl acetate (60 mL), washed with brine (3 x
20 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure, and the cmde material was purified by silica gel column chromatography (eluting with 100% ethyl acetate), yielding the title compound as a yellow viscous oil, a mixture of cis and trans isomers. MS (ES, Pos.): MS (ES, Pos.): m/z 420/422 (3/1) [MH+]. H NMR (CDC13, 400 MHz) δ 2.32 (br s, IH), 2.60-2.85
(m, 5H), 3.88-4.11 (m, 3H), 5.36 (s, 2H), 7.27 (m, IH), 7.48-7.69 (m, 9H), 7.77 (d, J
= 5.0 Hz, IH).
Figure imgf000145_0001
[691 ] b) 1 -(3-Benzyloxvphenyl)-8-chloro-3-(3-methylenecyclobutyl)- imidazo[l,5-α]pyrazine: A mixture of 3-methylenecyclobutanecarboxylic acid [(3- benzyloxyphenyl)-(3-chloropyrazin-2-yl)methyl]amide (190 mg, 0.45 mmol) and
POCl3 (2 mL) was heated at 55 °C under N2 atmosphere overnight. The mixture was concentrated under reduced pressure, the residue was cooled to 0 °C, quenched with
2N ML PrOH to pH > 10, and the solid was filtered off and washed with methylene chloride. The filtrate was concentrated and the crude material was purified by silica gel column chromatography (eluting with hexanes:EtOAc = 80:20 — ■ 60:40), yielding the title product as a yellow solid; MS (ES, Pos.): m/z 402/404 (3/1) [MH+]; 1H NMR
(CDC13, 400 MHz) δ 3.26-3.44 (m, 4H), 3.86 (m, IH), 4.94 (m, 2H), 5.16 (s, 2H),
7.07 (ddd, J= 8.2, 2.6, 1.1 Hz, IH), 7.30-7.50 (m, 9H), 7.54 (d, J= 5.0 Hz, IH).
Figure imgf000145_0002
[693] c) 3-Methylenecyclobutanecarboxylic acid [(3-benzyloxyphenyl)-(3- chloropyrazin-2-yl)methyl]amide: To a suspension of C-(3-benzyloxyphenyl)-C-(3- chloropyrazin-2-yl)methylamine hydrochloride (724 mg, 2.0 mol) in methylene dichloride (10 mL) was added 'Pr^NEt (1.7 mL, 10.0 mmol), at which time the solid dissolved. The reaction was charged with 3-methylenecyclobutanecarboxylic acid (560 mg, 5.0 mmol), EDC (1.15 g, 6.0 mmol) and HOBt (270 mg, 2.0 mmol) and the resulting mixture was stined at rt overnight. The mixture was diluted with ethyl acetate (50 mL), washed with sat. aq. NaHCO3 (2 x 20 mL) and brine (2 x 20 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure, and the crude material was purified by silica gel column chromatography (eluting with hexanes:EtOAc = 80:20 -» 60:40), yielding the title product as a light-yellow viscous oil; MS (ES, Pos.): m/z 420/422 (3/1) [MF ]; 1H NMR (CDC13, 400 MHz) δ 2.85-3.09 (m, 5H), 4.78 (m, 2H), 5.03 (s, 2H), 6.55 (d, J= 7.9 Hz, IH), 6.87-6.95 (m, 3H), 7.08 (br d, IH, NH), 7.21-7.41 (m, 6H), 8.33 (d, J= 2.5 Hz, IH), 8.49 (d, J= 2.5 Hz, IH).
Figure imgf000146_0001
[695] d) 3-Methylenecyclobutanecarboxylic acid: To a solution of 3- methylenecyclobutanecarbonitrile (10.0 g, 107.4 mmol) in ethanol (100 mL) and water (100 mL) was added potassium hydroxide (28.0 g, 430 mmol, 85% pure); the resulting mixture was refluxed for 8 h. Ethanol was removed under reduced pressure, then the solution was cooled to 0 °C and acidified with cone. HCl to pH = 1. The mixture was extracted with diethyl ether (4 x 100 mL). The combined organic phases were dried over anhydrous sodium sulfate. Concentration in vacuo afforded the desired product as a colorless oil; 1H NMR (CDC13, 400 MHz) δ 2.91-3.18 (m, 4H), 3.14-3.22 (m, IH), 4.83 (m, 2H); 13C NMR (CDC13, 100 MHz) δ 32.95, 35.30, 107.14, 143.77, 181.02 ppm. COOH
[696]
Procedures for General Grisnard Reaction:
[697] 3-[l-(3-B enzyloxy-phenyl)-8-chloro-imidazo [1,5 -a]pyrazin-3 -yl] - cyclobutanone (100 mg, 248 mols) was dissolved in dry THF (1.0 mL) under inert atmosphere and cooled to - 78 °C. A solution of MeMgBr (40 μL, 322 mols) in toluene: THF (75:25) was added slowly to the cooled solution. After 24h of reaction at rt the reaction was cooled to 0 °C and quenched with NH4C1 sat. aq. solution and the aqueous layer was washed with EtOAc (2x). The organic layers where combined, dried over sodium sulfate, filtered and concentrated in vacuo. The crude oil was purified by silica gel column chromatography [Jones Flashmaster, 10 g / 70 mL cartridge, eluting with 2-5% ((7NNH3) in MeOH): CH2C12], yielding 3-[l-(3-
B enzyloxy-phenyl)-8 -chloro-imidazo [ 1 ,5 -a]pyrazin-3 -yl] - 1 -methyl-cyclobutanol as a brown solid.
[698] EXAMPLE 45: 3-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5- a]pyrazin-3-yl]-l-methyl-cyclobutanol: Prepared according to the procedures for 1- (3 -B enzyloxy-phenyl)-3 -cyclobutyl-imidazo [1,5 -a]pyrazin- 8-ylamine, Light brown crystals, 1H NMR (400 MHz, CDC13) δ 1.43 (s, 3H), 2.49-2.64 (m, 4H), 3.27-3.32 (m, IH), 5.07 (s, 2H), 6.96-7.38 (m, 11H); MS (ES+): 401.34 (M+l), 402.41 (M+2), 403.43 (M+3).
Figure imgf000147_0001
[700] a) 3-[ 1 -(3-Benzyloxy-phenyl)-8-chloro-imidazo[ 1 ,5-a]pyrazin-3-yl]-l - methyl-cyclobutanol was prepared according to the Procedures for General Grignard Reaction: MS (ES+): 420.35 (M+l), 422.35 (M+3), 423.47 (M+4).
Figure imgf000147_0002
[702] EXAMPLE 46: 3-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5- a]pyrazin-3-yl]-l-ethyl-cyclobutanol: Prepared according to the procedures for l-(3- Benzyloxy-phenyl)-3-cyclobutyl-imidazo[l,5-a]pyrazin-8-ylamine, Light yellow gum (7.9 mg, 22%) Light brown crystals, 1H NMR (400 MHz, CDC13) δ 0.94 (t, 3H, J= 7.2 Hz), 1.66 (q, 2H, J= 7.4 Hz), 2.41-2.46 (m, 2H), 2.60-2.65 (m, 2H), 3.26-3.32 (m, IH), 5.06 (s, 2H), 6.95-6.97 (m, 2H), 7.05 (d, IH, J= 5.1 Hz), 7.26-7.38 (m, 8H); MS (ES+): 415.27 (M+l), 416.34 (M+2), 417.40 (M+3).
Figure imgf000148_0001
[704] a) 3-[l -(3-Benzyloxy-phenyl)-8-chloro-imidazo[ 1 ,5-a]pyrazin-3-yl]- 1 - ethyl-cyclobutanol was prepared according to the Procedures for General Grignard Reaction: Light yellow gum (38 mg, 36%), 1H NMR (400 MHz, CDC13) δ 0.95 (t, 3H, J= 7.36 Hz), 1.68 (q, 2H, J= 7.36 Hz), 2.54-2.69 (m, 4H), 3.31-3.39 (m, IH), 5.08 (s, 2H), 6.99-7.00 (m, IH), 7.19-7.40 (m, 9H), 7.50 (d, IH, J= 5.0 Hz); MS (ES+): 434.08 (M+l), 436.09 (M+3), 437.05 (M+4).
Figure imgf000148_0002
[706] EXAMPLE 47: l-Allyl-3-[8-amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclobutanol: Prepared according to the procedures for l-(3-Benzyloxy-phenyl)-3-cyclobutyl-imidazo[l,5-a]pyrazin-8-ylamine, Light yellow foam (8.2 mg, 34%), 1H NMR (400 MHz, CDC13) δ 2.41 (d, 2H, J= 7.2 Hz), 2.47- 2.52 (m, 2H), 2.63-2.68 (m, 2H), 3.29-3.33 (m, IH), 5.07 (s, 2H), 5.13-5.18 (m, 2H), 5.86-5.92 (m, IH), 6.95-6.97 (m, 2H), 7.05 (d, IH, J= 5.0 Hz), 7.26-7.38 (m, 8H); MS (ES+): 427.28 (M+l), 428.34 (M+2), 429.38 (M+3).
Figure imgf000148_0003
[708] a) l-Allyl-3-[l-(3-benzyloxy-phenyl)-8-chloro-imidazo [l,5-a]pyrazin-
3-yl]-cyclobutanol was prepared according to the Procedures for General Grignard Reaction: Light yellow gum (25 mg, 23%), 1H NMR (400 MHz, CDC13) δ 2.40 (d, 2H, J= 7.2 Hz), 2.49-2.68 (m, 4H), 3.29-3.33 (m, IH), 5.06 (brs, 4H), 5.84 (m, IH), 6.99-7.00 (m, IH), 7.19-7.40 (m, 9H), 7.50 (d, IH, J= 5.0 Hz); MS (ES+): 446.08 (M+l), 448.07 (M+3), 449.05 (M+4).
Figure imgf000149_0001
[710] EXAMPLE 48: l-(3-Benzyloxyphenyl)-3-tert-butylimidazo[l,5- α]pyrazin-8-ylamine: Gaseous NH is condensed into a cooled (dry ice / acetone) solution of l-(3-benzyloxyphenyl)-3-tert-butyl-8-chloroimidazo[l,5-β]pyrazine (61.8 mg, 0.158 mmol) in z'PrOH (2mL) in a pressure tube until the volume is doubled, then the tube is sealed and heated to 110 °C (bath temp.) overnight. The seal has leaked during that time, LC indicates «50% conversion; therefore, ammonia is condensed in and the tube is heated as described before. The cmde material is purified by preparative TLC (1000 μm silica gel layer, 20x20 cm plate), eluting once with 1% MeOH in CH2C12 and then three times with hexanes :EtO Ac 3:1. One obtains the title compound as pale yellow solid, >95% pure by HPLC; 1H NMR (CDC13, 400 MHz) δ 1.57 (s, 9H), 5.06 (brs, 2H), 5.14 (s, 2H), 6.99-7.04 (m, 2H), 7.22-7.26 (m, 2H), 7.31-7.42 (m, 4H), 7.44 (d, J= 8.4 Hz, 2H), 7.46 (d, J= 5.3 Hz, IH). MS (ES+): m/z 373.1 (100) [MH+].
Figure imgf000149_0002
[712] a) l-(3-Benzyloxyphenyl)-3-tert-butyl-8-chloroimidazo[l,5- α]pyrazine: A mixture of POCl3 (3 mL, 5 g, 33 mmol) and N-[(3-benzyloxyphenyl)- (3-chloropyrazin-2-yl)-methyl]-2,2-dimethylpropionamide (109 mg, 0.266 mmol) is heated to 55 °C for 6 d. POCl3 is evaporated, a cold solution of ΝH3 in zPrOH (2 M, 5 mL) is added, the suspension is filtered, and the solid is washed with z'PrOH. The cmde material contained in the combined filtrate and washings is adsorbed onto Hydromatrix and chromatographed on silica gel [Jones Flashmaster, 10 g / 70 mL cartridge, eluting with hexanes: EtOAc 10:1 (1-22) → 5:1 (23-40)], yielding the title compound as yellow oil that slowly solidifies; 1H NMR (CDC13, 400 MHz) δ 1.59 (s, 9H), 5.13 (s, 2H), 7.03 (d, J= 8.0 Hz, IH), 7.27-7.42 (m, 7H), 7.46 (d, J= 7.2 Hz, 2H), 7.87 (d, J= 4.8 Hz, IH). MS (ES+): m/z 392.1/394.0 (12/4) [MH+].
Figure imgf000150_0001
[714] b) N-[(3-Benzyloxyphenyl)-(3-chloropyrazin-2-yl)-methyl]-2,2- dimethylpropionamide: To a solution of the crude C-(3-benzyloxyphenyl)-C-(3- chloropyrazin-2-yl)-methylamine (444 mg, max. 1.36 mmol) in CH2C12 (5 mL), cooled by ice/water, are added ΝEt3 (210 μL, 152 mg, 1.51 mmol), DMAP (8 mg, 0.07 mmol), and pivaloyl chloride (185 μL, 181 mg, 1.50 mmol), then the cooling bath is removed, and the reaction solution is stined at ambient temperature for 4.5 h. More pivaloyl chloride (90 μL, 88 mg, 0.73 mmol) and NEt3 (100 μL, 73 mg, 0.72 mmol) are added and also after further 2.5 h, and the solution is stined overnight at ambient temperature. The reaction mixture is taken up in EtOAc (35 mL), washed with diluted HCl, water, NaHCO3 sol., and brine, dried over MgSO4, filtered, and concentrated in vacuo. The cmde material is chromatographed on silica gel [Jones Flashmaster, 50 g / 150 mL cartridge, eluting with hexanes:EtOAc 10:1 (1-17) - • 3 : 1 (18-41) -> 2:1 (42-56)], yielding the title compound as orange oil; JH NMR (CDC13, 400 MHz) δ 1.21 (s, 9H), 5.03 (s, 2H), 6.50 (d, J= 8.0 Hz, IH), 6.86-6.90 (m, IH), 6.93-6.97 (m, 2H), 7.23 (t, J= 7.8 Hz, IH), 7.29-7.43 (m, 6H), 8.32 (d, J= 2.4 Hz, 2H), 8.50 (d, J= 2.4 Hz, IH). MS (ES+): m/z 410.1/412.1 (100/36) [MH+], 309.1/311.1 (32/12) [MH+ - tBuCONH2].
Figure imgf000150_0002
[716] EXAMPLE 49: cis-l-[3-(Benzyloxy)phenyl]-3-[3-(dimethylamino) cyclobutyl]imidazo[l,5-a]pyrazin-8-amine: A light yellow isopropanol solution (5.0 mL) ofcis-[3-(8-chloro-l-ρhenyl-imidazo[l,5-a]pyrazin-3-yl)-cyclobutyl]-dimethyl- amine (0.21 mmol, 90 mg) in a 15 mL sealed tube was cooled to -78 °C. Ammonia was bubbled into the solution for 90 sec; the tube was capped and heated to 114 °C for 10 h. The sealed tube was cooled to rt and then -78 °C before it was uncapped. The reaction mixture was filtered through a Buchner funnel to remove NH4C1 salt and the remaining solid was washed with EtOAc (15 mL x 2) and MeOH (15 mL x 2). The combined filtrates were concentrated to provide the light yellow greasy compound (90 mg), which was purified by mass directed HPLC (gradient: 5% to 60% CH3CN in water at pH 9 in 6 min). The title compound was obtained as off-white solid with >95% purity; 1H NMR (400 MHz, CDC13): δ 7.45 (d, J= 8.0 Hz, 2H), 7.41-7.31 (m, 4H), 7.26-7.22 (m, 2H), 7.13 (d, J= 5.2 Hz, IH), 7.04 (d, J= 4.0 Hz, IH), 7.01 (d, J= 2.4 Hz, IH), 5.11 (d, J= 24 Hz, 2H), 3.41 (p, J= 8.0 Hz, IH), 2.80 (p, J= 8.0 Hz, IH), 2.68-2.62 (m, 2H), 2.49-2.41 (m, 2H). MS (ES+): m/z 414 (100) [MH+].
Figure imgf000151_0001
[718] a) cis-[3-(8-Chloro-l-phenyl-imidazo[l,5-a]pyrazin-3-yl)-cyclobutyl]- dimethyl-amine: An DCE solution of 3- { 1 -[3-(benzyloxy)phenyl]-8- chloroimidazo[l,5-α]pyrazin-3-yl} cyclobutanone was charged with dimethylamine
(0.37 mmol, 0.19 mL) and then catalytic amount of AcOH (7 μL). The mixture was stined at rt for 30 min before resin-bound triacetoxyborohydride (0.5 mmol, 240 mg) was added. Reaction mixture was stined at rt for 16 h before the solution was filtered through a Buchner funnel to remove the resin. The filtrate was concentrated and the obtained oil was dissolved in DCM (15 mL), washed with saturated NaHCO3 solution
(2 X 15 mL) and brine (2 X 15 mL). The solvent was dried over sodium sulfate and concentrated under reduced pressure. The title compound was obtained as a yellow greasy oil; MS (ES+): m/z 433 (100) [MH+].
Figure imgf000152_0001
[720] EXAMPLE 50: 3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]ρyrazin-l- yl)-phenol: A solution of l-(3-Benzyloxy-phenyl)-3-cyclobutyl-imidazo[l,5- a]pyrazin-8-ylamine (1.82g, 4.92 mmol) in 4M HCl in dioxane (20 mL) was heated to 75 °C in a sealed tube for 1.5 h. The reaction was allowed to cool to rt, the dioxane was decanted off and the brown gum residue was cooled to 0 °C in an ice-bath and charged with 7N NH3 in MeOH until basic. The reaction mixture was concentrated in vacuo, triturated with EtOAc and CHC13, and the NH4C1 salts filtered off. The filtrate was concentrated in vacuo and purified by flash silica chromatography (8% MeOH in CHC13) resulting in an off-white solid; 1H NMR (DMSO-rt* 6, 400 MHz) δ 1.84-1.99 (m, IH), 2.00-2.16 (m, IH), 2.34-2.48 (m, 4H), 3.86^1.00 (m, IH), 6.08 (brs, 2H), 6.81 (dd, IH, J= 8.4 Hz, 8.0 Hz), 6.95-7.06 (m, 3H), 7.30 (t, IH, J= 8.4 Hz); 7.41 (d, IH, J= 5.2 Hz), 9.63 (brs, IH); MS (ES+): m/z 281.39 [MH+].
Figure imgf000152_0002
[722] EXAMPLE 51: 3-Cyclobutyl-l-[3-(4-fluoro-benzyloxy)-phenyl]- imidazo[l,5-a]pyrazin-8-ylamine: An anhydrous DMF (2 mL) solution of 3-(8- amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)-phenol ( 50 mg, 0.179 mmol) and K2CO3 (27 mg, 0.197 mmol) was charged with l-bromomethyl-4-fluoro-benzene (7) (24 μL, 0.197mmol) and stined 12 h at 40 °C. The reaction mixture was partitioned between CHC13 and H2O and separated. The aqueous layer was re-extracted with CHC13 (3X) and the combined organic fractions were washed with H2O (IX), brine (IX), dried over Na2SO4, filtered and concentrated in vacuo. The crude mixture was purified by MDP resulting in a light tan/waxy solid; JH NMR (CDC13, 400 MHz) δ 1.99-2.08 ( m, IH), 2.11-2.25 (m, IH), 2.44-2.55 (m, 2H), 2.58-2.70 (m, 2H), 3.75- 3.88 (m, IH), 5.06 (brs, 2H), 5.10 (s, 2H), 6.98-7.15 (m, 5H); 7.20-7.34 (m, 3H), 7.35-7.47 (m, 3H); MS (ES+): m/z 389.14.
Figure imgf000153_0001
[724] EXAMPLE 52: trans-4-[8-Amino-l-(3-hydroxy-phenyl)-imidazo[l,5- a]pyrazin-3-yl]cyclohexanecarboxylic acid methyl ester: A solution of trans-4-[8-
Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]-cyclohexanecarboxylic acid methyl ester (50 mg, 0.110 mmol) in 4M HCl in dioxane (2 mL) was heated to
75 °C in a oil-bath for ~ 2 h. The reaction mixture was allowed to cool to rt, the dioxane was decanted off and the reaction mixture was quenched with 7N NH3 in
MeOH solution (~2 mL). This crude mixture was concentrated in vacuo resulting in
79 mg of an off-white solid (containing NH4C1 salts). The cmde material was purified by flash silica chromatography (10% 7N NH3 in MeOH in CHC1 ) resulting in an off-white solid; 1H NMR (DMSO-tfV, 400 MHz) δ 1.51-1.78( m, 4H), 1.95-
2.08 (m, 4H), 2.38-2.48 (m, IH), 3.07-3.20 (m, IH), 3.63 (s, 3H), 6.06 (brs, 2H),
6.76-6.89 (m, IH), 6.95-7.05 (m, 3H), 7.29 (t, IH, J= 7.8 Hz), 7.65 (d, IH, J= 5.1
Hz), 9.62 (brs, IH); MS (ES+): m/z 361.26 [MH+].
Figure imgf000153_0002
[726] EXAMPLE 53: 3-[8-Amino-l-(3-benzyloxyphenyl)-imidazo[l,5- α]pyrazin-3-yl]-benzamide: Gaseous NH3 was condensed into a cooled (-78 °C) solution of 3-[l-(3-benzyloxyphenyl)-8-chloroimidazo[l,5-α]pyrazin-3-yl]-benzoic acid methyl ester (102 mg, 0.216 mmol) in NH3/z'-PrOH (2M, 3 mL) in a pressure tube until the volume had doubled. The tube was sealed and heated to 110 °C for 2 d. After excess NH /t-PrOH was removed in vacuo, the cmde material was taken up in CH2C12, adsorbed onto Hydromatrix, and purified by chromatography on silica gel [Jones Flashmaster, 5 g / 25 mL cartridge, eluting with MeOH:CH2Cl2 1% -> 5%], yielding the title compound, as an off-white solid; 1H NMR ( -DMSO, 400 MHz) δ 5.18 (s, 2H), 6.30 (s, br, -NH2), 7.10-7.18 (m, 2H), 7.25-7.58 (m, 9H), 7.67 (t, J= 1.6 Hz, IH), 7.81 (d, J= 4.4 Hz, IH), 8.00 (d, J= 7.6 Hz, 2H), 8.16 (s, IH), 8.31 (s, IH); MS (ES+): m/z 436.0 (100) [MH+].
Figure imgf000154_0001
[728] a) 3-[l-(3-Benzyloxyphenyl)-8-chloroimidazo[l,5-α]pyrazin-3-yl]- benzoic acid methyl ester: To a solution of N-[(3-benzyloxyphenyl)-(3- chloropyrazin-2-yl)-methyl]-isophthalamic acid methyl ester (610 mg, 1.25 mmol) in
THF (5 mL), cooled to 0 °C, KOtBu (1.6 mL, IM, 1.6 mmol) was added under Ν2 atmosphere, the cooling bath was removed, and the reaction mixture stined at rt for 5 min. Upon addition, the color of the solution changed from yellow to brown. THF was evaporated under reduced pressure, POCl3 (10 mL, 17 g, 109 mmol) was added, and the reaction mixture was vortexed at 55 °C for 2 d. POCl was removed in vacuo, a cold solution of NH3/t-PrOH (2M, 10 mL) was added, and excess solvent was evaporated. The residue was taken up in EtOAc (4x30 mL), washed with NaHCO3 sat. aq. sol. (2x20 mL) and brine (1x20 mL), dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The crude material was dissolved in CH2C12, adsorbed onto Hydromatrix, and purified by chromatography on silica gel [Jones Flashmaster,
50 g / 150 mL cartridge, eluting with EtOAc:CH2Cl2 1% → 5%], giving 264 mg
(45%, 0.562 mmol) of the title compound, as a yellow solid; 1H NMR (CDC13, 400
MHz) δ 3.97 (s, 3H), 5.15 (s, 2H), 7.08 (ddd, J= 8.0, 2.4, 1.2 Hz, IH), 7.30-7.43 (m,
7H), 7.44-7.48 (m, 2H), 7.67 (t, J= 7.2 Hz, IH), 8.04 (d, J= 4.8 Hz, IH), 8.05-8.09 (m, IH), 8.19-8.22 (m, IH), 8.50-8.52 (m, IH); MS (ES+): m/z 469.8/471.9 (100/39) [MH+].
Figure imgf000155_0001
[730] EXAMPLE 54: {3-[8-Amino-l-(3-benzyloxyphenyl)-imidazo[l,5- α]pyrazin-3-yl]-phenyl} -methanol: Gaseous NH3 was condensed into a cooled (-78 °C) solution of {3-[l-(3-benzyloxyphenyl)-8-chloroimidazo[l,5-α]pyrazin-3-yl]- phenyl} -methanol (366 mg, 0.829 mmol) in NH3/t-PrOH (2M, 5 mL) in a pressure tube until the volume had doubled. The tube was sealed and heated to 110 °C for 19 h. After excess NH3/t-PrOH was removed in vacuo, the residue was suspended between CH2C12 and water, the layers were separated, and the aqueous layer was extracted with CH2C12 (3x30 mL). The combined organic layers were washed with brine (3x30 mL), dried over anhydrous MgSO4, and filtered. The crude material was purified by filtration through a plug of silica gel, eluting with 5% MeOH:CH2Cl2 (400 mL), concentrated in vacuo, giving 311.5 mg (89%, 0.737 mmol) of the title compound, as a yellow solid; 1H NMR (CDC13, 400 MHz) δ 4.80 (s, 2H), 5.09 (s, - NH2), 5.16 (s, 2H), 7.05-7.09 (m, IH), 7.11 (d, J= 4.8 Hz, IH), 7.29-7.37 (m, 3H), 7.37-7.48 (m, 5H), 7.47-7.51 (m, IH), 7.54 (t, J= 7.8 Hz, IH), 7.63 (d, J= 4.8 Hz, IH), 7.73-7.78 (m, IH), 7.86 (s, IH); MS (ES+): m/z 423.0 (100) [MET"].
Figure imgf000155_0002
[732] a) {3-[l-(3-Benzyloxyphenyl)-8-chloroimidazo[l,5-α]pyrazin-3-yl]- phenyl} -methanol: To a solution of 3-[l-(3-benzyloxyphenyl)-8-chloroimidazo[l,5- α]pyrazin-3-yl]-benzoic acid methyl ester (552 mg, 1.17 mmol) in THF (25 mL), cooled to 0 °C, IM LiAlH4 (880 μL, 797 mg, 0.880 mmol) was added, under N2, and the reaction solution was vortexed for 2 h. Upon addition, the reaction mixture changed from yellow to dark green in color. The reaction was quenched with potassium sodium tartrate sat. aq. sol. (25 mL), extracted with EtOAc (3x20 mL), washed with brine (1x40 mL), dried over MgSO4, and filtered. The crude material was purified by filtration through a plug of silica gel plug [eluting with EtOAc:CH2Cl2 1:1 (400 mL)] and concentrated, affording 366.3 mg (71%, 0.829 mmol) of the title compound, as a yellow solid; 1H NMR (CDC13, 400 MHz) δ 4.82 (d, J= 6.0 Hz, 2H), 5.15 (s, 2H), 7.05-7.11 (m, IH), 7.32-7.43 (m, 7H), 7.44-7.49 (m, 2H), 7.52-7.61 (m, 2H), 7.73-7.78 (m, IH), 7.87 (s, IH), 8.05 (d, J= 4.8 Hz, IH); MS (ES+): m/z 441.9/443.9 (100/38) [MH+].
Figure imgf000156_0001
[734] EXAMPLE 55: 3-(3-Aminomethylphenyl)-l-(3-benzyloxyphenyl)- imidazo[l,5-α]pyrazin-8-ylamine: To a solution of 2-{3-[8-amino-l-(3- benzyloxyphenyl)-imidazo[l,5-α]pyrazin-3-yl]-benzyl}-isoindole-l,3-dione (328 mg, 0.594 mmol) in CH2C12 (4 mL), N2H4 (56 μL, 57 mg, 1.78 mmol) was added and the reaction was vortexed at rt for 17 h, under N2 atmosphere. Additional N2H (40 μL, 41 mg, 1.27 mmol) and CH2C12 (10 mL) were added and vortexing was continued for 3 d. The suspension was filtered, the solid was washed extensively with CH2C12, and the filtrate was concentrated in vacuo. The cmde material (273 mg) was purified by chromatography on silica gel [Jones Flashmaster, 5 g / 25 mL cartridge, eluting with MeOH (7N NH3):CH2C12 5% → 10%], affording 107.4 mg (43%, 0.255 mmol) of the title compound, as a yellow solid, containing 0.18 eq. of DMF. Mixed fractions were also collected, giving an additional 67.4 mg (max. 16%, 0.159 mmol) of the title compound, as a yellow solid, containing 0.8 eq. of DMF; 1H NMR (CDC13, 400 MHz) δ 1.88 (s, br, -NH2), 3.97 (s, 2H), 5.15 (s, 4H), 7.05-7.09 (m, IH), 7.10 (d, J= 4.8 Hz, IH), 7.29-7.47 (m, 9H), 7.51 (t, J= 7.8 Hz, IH), 7.63 (d, J= 5.2 Hz, IH), 7.69 (d, J= 7.6 Hz, IH), 7.81 (s, IH); MS (ES+): m/z 422.0 (14) [MH+].
Figure imgf000157_0001
[736] EXAMPLE 56: 2-{3-[8-Amino-l-(3-benzyloxyphenyl)-imidazo[l,5- α]pyrazin-3-yl]-benzyl}-isoindole-l,3-dione: To a solution/suspension of {3-[8- amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-α]pyrazin-3-yl]-phenyl}-methanol (312 mg, 0.737 mmol), isoindole-l,3-dione (130 mg, 0.885 mmol), and PS-PPh3 (loading 2.12 mmol/g; 696 mg, 1.47 mmol) in anhydrous THF (15 mL), cooled to 0 °C, DIAD (218 μL, 224 mg, 1.11 mmol) was added dropwise, under N2 atmosphere. After 10 min, the cooling bath was removed and the reaction mixture stined at ambient temperature for 3d. The resin was filtered off on a glass frit (porosity M) and washed with large volumes of THF and then CH2C12. The filtrate was concentrated, adsorbed onto Hydromatrix, and the cmde material (0.6843 g) was purified by chromatography on silica gel [Jones Flashmaster, 20 g / 70 mL cartridge, eluting with MeOH:CH2Cl2 0.5% - • 3%], yielding the title compound as a yellow solid. Sample contains * 0.3 eq. of reduced DIAD by 1H NMR; 1H NMR (CDC13, 400 MHz) δ 4.94 (s, 2H), 5.07 (s, 2H), 5.16 (s, 2H), 7.07 (ddd, J= 8.4, 2.8, 1.2 Hz, IH), 7.11 (d, J= 5.2 Hz, IH), 728-7.33 (m, 3H), 7.33-7.36 (m, IH), 7.37-7.43 (m, 2H), 7.43-7.47 (m, 2H), 7.50 (t, J= 7.6 Hz, IH), 7.53-7.56 (m, IH), 7.62 (d, J= 5.2 Hz, IH), 7.72 (dd, J= 5.6, 2.8 Hz, 2H), 7.74-7.77 (m, IH), 7.86 (dd, J= 5.2, 3.2 Hz, 2H), 7.92 (s, IH); MS (ES+): m/z 552.3 (100) [MH4].
Figure imgf000157_0002
[738] EXAMPLE 57: 4-{8-Amino-l-[3-(2,6-difluoro-benzyloxy)-phenyl]- imidazo[l,5-a]pyrazin-3-yl}-cyclohexanecarboxylic acid methyl ester: The procedures for 3-Cyclobutyl-l-[3-(4-fluoro-benzyloxy)-phenyl]-imidazo[l,5- a]pyrazin-8-ylamine were applied; MS (ES+): m/z 493.16 [MH ].
Figure imgf000158_0001
[740] EXAMPLE 58: 4-{8-Amino-l-[3-(2,6-difluoro-benzyloxy)-phenyl]- imidazo[l,5-a]pyrazin-3-yl}-cyclohexanecarboxylic acid: The saponification procedures applied to the synthesis of trαrø-4-[8-Amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclohexanecarboxylic acid was applied to 4-{8-Amino- l-[3-(2,6-difluoro-benzyloxy)-phenyl]-imidazo[l,5-a]pyrazin-3-yl}- cyclohexanecarboxylic acid methyl ester to afford the title compound; MS (ES+): m/z 479.10 [MH+].
Figure imgf000158_0002
[742] EXAMPLE 59: cis-3-(3-Dimethylaminomethyl-cyclobutyl)-l-(3- benzyloxyphenyl)-imidazo[l,5-α]pyrazin-8-ylamine: A sealed tube containing a solution of cis-toluene-4-sulfonic acid 3-[8-amino-l-(3-benzyloxyphenyl)- imidazo[l,5-α]pyrazin-3-yl]cyclobutylmethyl ester (100 mg, 0.18 mmol) in THF (3 mL) was charged with dimethylamine solution (1.8 mL, 3.6 mmol, 2.0 M in THF), sealed, and heated at 50 °C overnight. The mixture was concentrated and the residue was diluted with ethyl acetate (40 mL), washed with sat. aq. NaHCO3 (2 x 15 mL) and brine (2 x 15 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure, and the residue was recrystallized to afford a white solid; LC-MS (ES, Pos.): m/z 428 [MH "]; 1H NMR (CDC13, 400 MHz) δ 2.23 (s, 6H), 2.24-2.32 (m, 2H), 2.42 (d, J= 6.1 Hz, 2H), 2.61-2.69 (m, 3H), 3.64 (m, IH), 4.98 (br s, 2H, NH2), 5.15 (s, 2H), 7.00-7.04 (m, 2H), 7.12 (d, J= 5.0 Hz, IH), 7.23- 7.27 (m, 2H), 7.31-7.46 (m, 6H).
Figure imgf000159_0001
[744] EXAMPLE 60: cis-3-(3-Azetidin-l-ylmethylcyclobutyl)-l-(3- benzyloxyphenyl)-imidazo[l,5-α]pyrazin-8-ylamine: Procedures for 3-(3- Dimethylaminomethyl-cyclobutyl)-l-(3-benzyloxyphenyl)-imidazo[l,5-α]pyrazin-8- ylamine were followed, replacing dimethylamine with azetidine, LC-MS (ES, Pos.): m/z 440 [MH+].
Figure imgf000159_0002
[746] EXAMPLE 61: cis-3-(3-Pynolidin-l-ylmethylcyclobutyl)-l-(3- benzyloxyphenyl)-imidazo[l,5-α]pyrazin-8-ylamine: Procedures for 3-(3- Dimethylaminomethyl-cyclobutyl)-l-(3-benzyloxyphenyl)-imidazo[l,5-α]pyrazin-8- ylamine were followed, replacing dimethylamine with pyrrolidine, LC-MS (ES, Pos.): ra/z 454 [MH+].
Figure imgf000159_0003
[748] EXAMPLE 62: cis-3-(3-Azidomethyl-cyclobutyl)-l-(3- benzyloxyphenyl)-imidazo[l,5-α]pyrazin-8-ylamine: A solution of cis-toluene-4- sulfonic acid 3-[8-amino-l-(3-benzyloxyphenyl)-imidazo[l,5-α]pyrazin-3- yl]cyclobutylmethyl ester (100 mg, 0.18 mmol) in DMF (2 mL) was charged with sodium azide (35 mg, 0.54 mmol), the resulting mixture was stined at rt overnight. The mixture was diluted with water (5 mL), then extracted with ethyl acetate (3 x 10 mL), the combined organic phases were washed with water (2 x 10 mL) and brine (10 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluting with 100% ethyl acetate), yielding the title compound as a white solid; LC- MS (ES, Pos.): m/z 426 [MH4]; 1H NMR (CDC13, 400 MHz) δ 2.36-2.44 (m, 2H), 2.63-2.79 (m, 3H), 3.37 (d, J= 6.7 Hz, 2H), 3.69 (m, IH), 5.14 (s, 4H, -OCH2- and - NH2), 7.02-7.05 (m, 2H), 7.10 (d, J= 5.0 Hz, IH), 7.25-7.45 (m, 8H).
Figure imgf000160_0001
[750] EXAMPLE 63: cis-3-(3-aminomethyl-cyclobutyl)-l-(3- benzyloxyphenyl)-imidazo[ 1 ,5-α]pyrazin-8-ylamine: cis-3-(3-Azidomethyl- cyclobutyl)-l-(3-benzyloxyphenyl)-imidazo[l,5-α]pyrazin-8-ylamine (35 mg, 0.082 mmol) was dissolved in ethanol (5 mL) upon heating, the mixture was cooled to rt. and charged with Lindlar catalyst (30 mg). The mixture was hydrogenated at rt overnight. LC-MS showed the reaction was complete and clean. The catalyst was removed by filtration through a pad of celite, the filtrate was concentrated and the residue was purified by mass-directed purification to give a white solid; LC-MS (ES, Pos.): m/z 400 [MH+]; 1H NMR (CD3OD, 400 MHz) δ 2.17-2.24 (m, 2H), 2.56-2.67 (m, 3H), 2.79 (d, J= 6.5 Hz, 2H), 3.84 (m, IH), 5.17 (s, 2H), 6.98 (d, J= 5.1 Hz, IH), 7.15-7.47 (m, 10H).
Figure imgf000161_0001
[752] EXAMPLE 64: cis-3-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5- a]pyrazin-3-yl]-cyclobutane-carboxylic acid amide: A solution of cis-3-[l-(3- benzyloxy-phenyl)-8-chloro-imidazo[l,5-a]pyrazin-3-yl]-cyclobutane-carboxylic acid methyl ester (115 mg, 0.26 mmol) in 4 mL of 'PrOH was cooled to -78 °C and charged with NH3 gas for 2 min. This sealed tube was equipped with a teflon O-ring, sealed and heated at 110 °C overnight. The mixture was cooled to -78 °C and the cap was removed. The mixture was diluted with EtOAc (30 mL) and washed with brine (15 mL), dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure and the cmde product was purified by mass-directed purification to afford an off-white solid; LC-MS (ES, Pos.): m/z 414 [MH+]; 1H NMR (CD3OD, 400 MHz) δ 2.65-2.73 (m, 4H), 3.24 (m, IH), 3.87 (m, IH), 5.17 (s, 2H), 6.99 (d, J- 5.2 Hz, IH), 7.10-7.48 (m, 1 OH).
Figure imgf000161_0002
[754] EXAMPLE 65: trans-3-[8-Amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-cyclobutane-carboxylic acid amide: The title compound was prepared according to the procedure described for cis-3-[8-Amino-l-(3- benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]-cyclobutane-carboxylic acid amide above, LC-MS (ES, Pos.): m/z 414 [MH4]; 1H NMR (CD3OD, 400 MHz) δ 2.70-2.78 (m, 4H), 3.28 (m, IH), 4.03 (m, IH), 5.18 (s, 2H), 6.99 (d, J= 5.1 Hz, IH), 7.10-7.48 (m, 10H).
Figure imgf000162_0001
CONH2
[755]
[756] a) cis αnα' trα«1s'-3-[l-(3-Benzyloxy-phenyl)-8-chloro-imidazo[l,5- a]pyrazin-3-yl]-cyclobutane-carboxylic acid methyl ester: A solution of (COCl)2 (3.17 g, 2.2 mL, 25.0 mmol) in dry methylene chloride (20 mL) was charged with a solution of DMSO (3.90 g, 50.0 mmol) in methylene chloride (10 mL) dropwise at - 78 °C under nitrogen. The resulting mixture was stined at -78 °C for 30 min, followed by the addition of {3-[l-(3-benzyloxyphenyl)-8-chloro-imidazo[l,5- α]pyrazin-3-yl] cyclobutyl} methanol in methylene chloride (15 mL). The mixture was stined at -78 °C for 30 min, then quenched with Et N (17.5 mL, 125 mmol) and slowly warmed to rt. The mixture was diluted with methylene chloride (100 mL), then washed with water (30 mL), sat. aq. NaHCO3 (2 x 30 mL) and brine (30 mL), and dried over anhydrous sodium sulfate. TLC showed the reaction completed and produced the desired aldehydes (trails isomer is less polar than cis one). Evaporation afforded the cmde product as a yellow oil, which was directly used to the next step. The solution of the above aldehyde in anhydrous methanol (50 mL) was charged with NIS (6.75 g, 30 mmol) and potassium carbonate (4.14 g, 30 mmol), the resulting mixture was stined in the dark at rt overnight. TLC showed the reaction almost completed. The reaction was quenched with 20 mL of water and diluted with ethyl acetate (150 mL), then washed with sat. aq. Na2S2O (2 x 30 mL) and brine (50 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure, and the crude material was purified by silica gel column chromatography (eluting with Hexanes:EtOAc = 70:30 -» 60:40 -> 50:50) by which the two isomers were separated. cw-3-[l-(3-Benzyloxy-phenyl)-8-chloro- imidazo[l,5-a]pyrazin-3-yl]-cyclobutane-carboxylic acid methyl ester: yellow oil; LC-MS (ES, Pos.): m/z 448/450 (3/1) [MH4]; 1H NMR (CDC13, 400 MHz) δ 2.73- 2.80 (m, 2H), 2.89-2.97 (m, 2H), 3.30 (m, IH), 3.70 (s, 3H), 3.78 (m, IH), 5.14 (s, 2H), 7.04 (m, IH), 7.26-7.47 (m, 9H), 7.58 (d, J= 5.0 Hz, IH). trαrø-3-[l-(3- Benzyloxy-phenyl)-8-chloro-imidazo[l,5-a]pyrazin-3-yl]-cyclobutane-carboxylic acid methyl ester: yellow oil; LC-MS (ES, Pos.): m/z 448/450 (3/1) [MH4"]; 1H NMR (CDC13, 400 MHz) δ 2.76-2.83 (m, 2H), 2.88-2.95 (m, 2H), 3.33 (m, IH), 3.77 (s, 3H), 4.03 (m, IH), 5.14 (s, 2H), 7.05 (m,,lH), 7.26-7.47 (m, 9H), 7.50 (d, J= 4.9 Hz, IH).
[757]
Figure imgf000163_0001
[758] EXAMPLE 66: 3-[8-Amino-l-(3-benzyloxy-ρhenyl)-imidazo[l,5- a]pyrazin-3-yl]-l-hydroxymethyl-cyclobutanol: To a solution of l-(3- benzyloxyphenyl)-8-chloro-3-(3-methylenecyclobutyl)-imidazo[l,5-α]pyrazine (1.0 g, 2.5 mmol) in THF (21 mL) and water (7 mL) were added NMO (1.0 mL, 5.0 mmol, 50% aq. solution) and K2OsO4*H2O (46 mg, 0.125 mmol). The resulting mixture was stined at rt overnight. TLC showed the reaction was complete. The reaction was quenched with Na2SO3 (1.60 g, 12.5 mmol). Water (15 mL) was added to dissolve the salts and the organic phase was separated. The aqueous phase was extracted with EtOAc (3 x 25 mL), and the combined organic phases were washed with brine (20 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to give a yellow solid, a mixture of two isomers in ca. 3:2 ratio by 1H NMR (CDCl3, 400 MHz). LC-MS (ES, Pos.): m/z 436/438 (3/1) [MH4]. The solution of the above diol (260 mg, 0.6 mmol) in 5 mL of 'PrOH was cooled to -78 °C and charged with NH3 gas for 1 min. This sealed tube was equipped with a teflon O- ring, sealed and heated at 110 °C overnight. The mixture was cooled to -78 °C and the cap was removed. The mixture was diluted with methylene chloride (30 mL) and the salt was filtered off. The filtrate was concentrated under reduced pressure and the cmde product was purified by silica gel column chromatography (100% ethyl acetate - EtOAc MeOH = 95:5 to 90:10), the title compound as a pale solid, a mixture of two isomers in ca. 3:2 ratio; LC-MS (ES, Pos.): m/z 417 [MH4"]; 1H NMR (CDC13, 400 MHz) δ 2.54-2.80 (m, 4H), 2.80, 3.85 (2xm, IH, 2:3 ratio), 3.67, 3.71 (2xs, 2H, 3:2 ratio), 5.06 (br s, 2H), 5.14 (s, 2H), 7.03-7.45 (m, 11H).
Figure imgf000164_0001
[760] EXAMPLE 67 and 68: cis- and trαrø-Toluene-4-sulfonic acid 3-[8- amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]-l-hydroxy- cyclobutylmethyl ester: A solution of 3-[8-amino-l-(3-benzyloxy-phenyl)- imidazo[l,5-a]pyrazin-3-yl]-l-hydroxymethyl-cyclobutanol (500 mg, 1.2 mmol) in dry methylene chloride (10 mL) and pyridine (3 mL) was charged with a solution of Ts2O (470 mg, 1.44 mmol) in methylene chloride (3 mL) at -40 °C under N2 atmosphere. The mixture was slowly warmed to rt overnight. TLC showed the reaction was complete. The reaction was quenched with water (2 L), diluted with methylene chloride (40 mL), washed with sat. aq. NaHCO3 (2 x 15 mL) and brine (15 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure, and the cmde material was purified by silica gel column chromatography (eluting with Hexanes.ΕtOAc = 50:50 -» 30:70 -» 100% ethyl acetate, then 5% MeOH/EtOAc) afforded each pure isomer. cw-Toluene-4-sulfonic acid 3 - [8 -amino- 1 -(3 -benzyloxy-phenyl)-imidazo [ 1 ,5-a]pyrazin-3 -yl] - 1 -hydroxy- cyclobutylmethyl ester: less polar isomer, light yellow solid, LC-MS (ES, Pos.): m/z 571 [MH4"]; 1H NMR (CDC13, 400 MHz) δ 2.46 (s, 3H), 2.50-2.55 (m, 2H), 2.79-2.84 (m, 2H), 3.41 (m, IH), 4.10 (s, 2H), 5.06 (br s, 2H), 5.14 (s, 2H), 7.03-7.11 (m, 3H), 7.21-7.23 (m, 2H), 7.33-7.45 (m, 8H), 7.85 (d, J= 8.3 Hz, 2H). trαrø-Toluene-4- sulfonic acid 3-[8-amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]-l- hydroxy-cyclobutylmethyl ester: light yellow solid, LC-MS (ES, Pos.): m/z 571 [MH4"]; 1H NMR (CDCI3, 400 MHz) δ 2.37 (s, 3H), 2.60-2.70 (m, 4H), 3.85 (m, IH), 4.24 (s, 2H), 5.08 (br s, 2H), 5.17 (s, 2H), 6.99-7.08 (m, 3H), 7.20-7.27 (m, 3H), 7.33- 7.47 (m, 7H), 7.71 (d, J= 8.3 Hz, 2H).
Figure imgf000165_0001
[762] EXAMPLE 69: trαrø-3-[8-Amino-l-(3-benzyloxy-phenyι)- imidazo[l,5-a]pyrazin-3-yl]-l-azetidin-l-ylmethyl-cyclobutanol: A sealed tube containing a solution of trans-toluene-4-sulfonic acid 3-[8-amino-l-(3-benzyloxy- phenyl)-imidazo[l,5-a]pyrazin-3-yl]-l-hydroxy-cyclobutyhnethyl ester (100 mg, 0.18 mmol) in THF (5 mL) was charged with azetidine (0.24 mL, 3.6 mmol), sealed, and heated at 50 °C overnight. The mixture was concentrated and the residue was purified by mass-directed purification to afford the title compound as a white solid; LC-MS (ES, Pos.): m/z 456 [MH4"]; 1H NMR (CDC13, 400 MHz) δ 2.05-2.12 (m, 2H), 2.50- 2.63 (m, 6H), 3.30 (t, J= 7.0 Hz, 4H), 3.96 (m, IH), 4.15 (br s, IH, -OH), 5.15 (s, 4H, -OCH2- and -NH2), 7.03-7.09 (m, 3H), 7.25-7.46 (m, 8H).
Figure imgf000165_0002
[764] EXAMPLE 70: cw-3-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5- a]pyrazin-3 -yl] - 1 -azetidin- 1 -ylmethyl-cyclobutanol : The title compound was prepared according to the procedure described for trα«5,-3-[8-Amino-l-(3-benzyloxy- phenyl)-imidazo[l,5-a]pyrazin-3-yl]-l-azetidin-l-ylmethyl-cyclobutanol above, white solid; LC-MS (ES, Pos.): m/z 456 [MH4"]; 1H NMR (CDCL, 400 MHz) δ 2.05-2.17 (m, 2H), 2.56-2.68 (m, 4H), 2.70 (s, 2H), 3.30 (m, IH), 3.39 (t, J= 7.0 Hz, 4H), 4.29 (br s, IH, -OH), 5.10 (br s, 2H), 5.14 (s, 2H), 7.01-7.05 (m, 2H), 7.13 (d, J= 5.0 Hz, IH), 7.22-7.26 (m, 2H), 7.33-7.46 (m, 6H).
Figure imgf000166_0001
[766] EXAMPLE 71: l-[3-(4-tert-Butoxy-benzyloxy)-phenyl]-3-cyclobutyl- imidazo[l,5-a]pyrazin-8-ylamine: A solution of 3-(8-Amino-3-cyclobutyl- imidazo[l,5-a]pyrazin-l-yl)-phenol (200 mg, 0.71 mmol) in DMF (3.5 mL) was charged with Cs2CO3 (348 mg, 1.07 mmol) and stined at rt for 30 min. A solution of l-bromomethyl-4-tert-butoxy-benzene (162mg, 0.71mmole) in 0.5 mL of DMF, was added to the reaction mixture. After 15h, the reaction was complete by LC MS analysis. The product was an orange/brown solid. The cmde product was chromatographed on silica gel [Jones Flashmaster, 5 g cartridge, eluting with 10% ethyl acetate]. The product was then recrystalized with ethyl acetate and hexanes yielding the title compound as a white solid; 1H NMR (CDC13, 400 MHz) δ 1.36 (s, 9H), 2.11-2.23 (m, 2H), 2.45-2.52 (m, 2H), 2.59-2.69 (m, 2H), 3.77-3.85 (m, IH), 5.08 (s, 2H), 5.49 (brs, 2H), 7.01-7.04 (m, 3H), 7.05 (dd, J= 4.00 Hz, IH), 7.10 (d, J = 5.02 Hz, IH), 7.23-7.25 (m, IH), 7.29 (q, J= 40 Hz, IH), 7.34-7.36 (m, 2H), 7.41 (t, J= 16 Hz, IH); MS (ES+): m/z 443.04 (100) [MH4"].
Figure imgf000166_0002
[768] EXAMPLE 72: 2-[3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l- yl)-phenoxymethyl]-Benzonitrile: A solution of 3-(8-Amino-3-cyclobutyl- imidazo[l,5-a]pyrazin-l-yl)-phenol (500 mg, 1.78 mmol) in DMF (8.9 mL) was charged with Cs2CO3 (871 mg, 2.68 mmol) and stined for 30 min. at rt. A solution of 2-cyanobenzyl bromide (500 mg,1.78 mmol) in DMF was added to the reaction mixture. After 24h at rt the reaction mixture was concentrated in vacuo and chromatographed on silica gel [Jones Flashmaster, 10 g cartridge, eluting with 50% EtOAc: hexanes to 100%) EtOAc]. The product was then recrystalized with CH2C12 and hexanes yielding the title compound as a light red solid; 1H NMR (CDC13, 400 MHz) δ 2.02-2.06 (m, IH), 2.11-2.33 (m, IH), 2.45-2.53 (m, 2H), 2.59-2.69 (m, 2H), 3.77-3.86 (m, IH), 5.33 (s, 2H), 7.02-7.04 (m, IH), 7.05 (dd, J= 2.4 Hz, IH), 7.10 (d, J= 5.2 Hz, IH), 7.29-7.30 (m, IH), 7.33 (q, J- 3.6, IH), 7.40-7.64 (m, 2H), 7.61-7.66 (m, IH), 7.70-7.72 (m, 2H); MS (ES+): m/z 395.99 (100) [MH4"].
Figure imgf000167_0001
[770] EXAMPLE 73: 3-Cyclobutyl-l-[3-(2-nitro-benzyloxy)-ρhenyl]- imidazo[l,5-a]pyrazin-8-ylamine: A solution of 3-(8-Amino-3-cyclobutyl- imidazo[l,5-a]pyrazin-l-yl)-phenol (2.00 g, 7.13 mmol) in DMF (36.7 mL) was charged with Cs2CO3 (3.48 g, 10.7 mmol) and stined at rt for 30 min. A DMF solution of 2-nitrobenzyl bromide (1.54 g, 7.13 mmol), was then added to the reaction mixture. The reaction was allowed to progress at rt under nitrogen for 3.5h. TLC analysis showed that the reaction was complete. The product was purified using silica gel column chromatography (1-3% NH3 in MeOH:CH2Cl2). The final product was concentrated to a yellow solid; 1H NMR (CDC13, 400 MHz) δ 2.00-2.08 (m, IH), 2.11-2.23 (m, IH), 2.45-2.53 (m, 2H), 2.59-2.69 (m, 2H), 3.77-3.86 (m, IH), 5.57 (s, 2H), 7.01-7.05 (m, 2H), 7.11 (d, J= 5.6 HZ, IH), 7.27-7.30 (m, IH), 7.32-7.33 (m, IH), 7.42 (t, J= 16.4 Hz, IH), 7.48-7.52 (m, IH), 7.67-7.71 (m, IH), 7.92 (dd, J = 8.0 Hz, IH), 8.17 (d, J= 9.5 Hz, IH); MS (ES+): m/z 416.01 (100) [MH4"].
Figure imgf000167_0002
[772] EXAMPLE 74: l-[3-(2-Bromo-benzyloxy)-ρhenyl]-3-cyclobutyl- imidazo[l,5-a]pyrazin-8-ylamine: A solution of 3-(8-Amino-3-cyclobutyl- imidazo[l,5-a]pyrazin-l-yl)-phenol (100 mg, 0.36 mmol) in DMF (1.8 mL) was charged with Cs2CO3 (174 mg, 0.54 mmol) and stined at rt for 30 min. A solution of 2-bromobenzyl bromide (89.2 mg, 0.36 mmol) in DMF was added to the reaction mixture. Reaction mixture was stined overnight at rt under nitrogen. The cmde product was left under high vacuum to remove the DMF for 2h. The product was then purified by silica gel column chromatography (3% NH3 in MeOH):CH2Cl2 to yield the title compound as a brown/red solid; 1H NMR (CDC13, 400 MHz) δ 2.02-2.08 (m, IH), 2.14-2.21 (m, IH), 2.45-2.53 (m, 2H), 2.59-2.69 (m, 2H), 3.77-3.85 (m, IH), 5.21 (s, 2H), 7.00 (d, J = 5.6 Hz, IH), 7.04-7.07 (m, IH), 7.11 (d, J = 5.2 Hz, IH), 7.18-7.23 (m, IH), 7.25-7.30 (m, 2H), 7.33-7.37 (m, IH), 7.42 (t, J = 16 Hz, IH), 7.55-7.61 (m, 2H); MS (ES+): m/z 450.81 (100) [MH4"].
Figure imgf000168_0001
[774] EXAMPLE 75: l-[3-(3-Aminomethyl-benzyloxy)-ρhenyl]-3- cyclobutyl-imidazo [1,5 -a]pyrazin-8-ylamine : 2- {3 - [3 -(8- Amino-3 -cyclobutyl- imidazo[ 1 ,5-a]pyrazin- 1 -yl)-phenoxymethyl] -benzyl} -isoindole-1 ,3 -dione (100 mg, 0.19 mmol) was dissolved in EtOH (0.76 mL) and charged with hydrazine (60 mg, 1.89 mmol) and stined overnight at rt. The white ppt filtered and washed with EtOH. The filtrate was concentrated in vacuo, silica gel was added in CH2C12, and concentrated to solid. The product was chromatographed on silica gel [Jones Flashmaster, 2 g cartridge, eluting with -2% 7N NH3 MeOH:CH2Cl2] and isolated the title compound as a yellow solid; 1H NMR (CDC13, 400 MHz) δ 1.84-1.92 (m, IH), 1.97-2.09 (m, IH), 2.34-2.40 (m, 2H), 2.44-2.46 (m, 2H), 3.69 (s, 2H), 3.84-3.92 ( , IH), 5.10 (s, 2H), 6.96 (d, J= 5.2 Hz, IH), 7.01-7.03 (m, IH), 7.13-7.16 (m, IH), 7.18-7.19 (m, IH), 7.23-7.32 (m, 3H), 7.35-7.40 (m, 3H); MS (ES+): m/z 400.17 (100) [MH4"].
Figure imgf000169_0001
[776] EXAMPLE 76: 3-[3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l- yl)-ρhenoxymethyl] -benzoic acid methyl ester. A solution of 3-(8-Amino-3- cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)-phenol (2.87 g, 10.2 mmol) in DMF was charged with Cs2CO3 (4.98 g, 15.3 mmol) and stined at rt for 30 min. A DMF solution of methyl (3-bromomethyl)benzoate (2.33 g, 10.2 mmol) was added to the reaction mixture. The reaction mixture was stined overnight at rt under nitrogen. The cmde product was placed under high vacuum to remove the residual DMF. The product was then purified using silica gel column chromatography (1% NH3 in MeOH:CH2Cl2). The product was recrystalized with CH2C12 and hexanes to yield the title compounds as a white solid; 1H NMR (CDC13, 400 MHz) δ 2.00-2.07 (m, IH), 2.11-2.22 (m, IH), 2.45-2.52 (m, 2H), 2.58-2.68 (m, 2H), 3.76-3.85 (m, IH), 3.93 (s, 3H), 5.18 (s, 2H), 7.01-7.04 (m, 2H), 7.10-7.11 (m, IH), 7.24-7.29 (m, 2H), 7.38-7.49 (m, 2H), 7.65 (d, J= 1.6 Hz, IH), 8.01 (d, J= 8.0 Hz, IH), 8.13 (s, IH); MS (ES+): m/z 429.18 (100) [MH4"].
Figure imgf000169_0002
[778] EXAMPLE 77: 3-[3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l- yl)-phenoxymethyl]-Benzamide: 3-[3-(8-Amino-3-cyclobutyl-imidazo[ 1 ,5-a]pyrazin- l-yl)-ρhenoxymethyl]-benzoic acid methyl ester (150 mg, 0.35 mmol) was dissolved in a sealed tube with 2.0 ml of 7N NH3 in MeOH and heated to 60 °C overnight. LC/MS analysis indicated that the reaction was incomplete, therefore NH3 gas was bubbled into the solution and the reaction was ran at 100 °C in a 100 mL Pan pressure vessel. The product was chromatographed on silica gel [Jones Flashmaster, 5 g cartridge, eluting with 2% NH3 in MeOH:CH2Cl2] to yield the title compound as a white solid; 1H NMR (CDC13, 400 MHz) δ 1.99-2.08 (m, IH), 2.13-2.25 (m, IH), 2.46-2.55 (m, 2H), 2.55-2.65 (m, 2H), 3.78-3.87 (m, IH), 5.21 (s, 2H), 6.95 (d, J = 5.2 Hz, IH), 7.08-7.11 (m, IH), 7.13 (d, J = 5.6 Hz, IH), 7.22-7.24 (m, 2H), 7.42-7.51 (m, 2H), 7.61 (d, J - 8.4 Hz, IH), 7.80-7.83 (m, IH), 7.94 s, IH); MS (ES+): m/z 414.21 (100) [MH4"].
Figure imgf000170_0001
[780] EXAMPLE 78: {3-[3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin- l-yl)-phenoxymethyl] -phenyl} -methanol: A solution of 3-[3-(8-Amino-3-cyclobutyl- imidazo[l,5-a]pyrazin-l-yl)-phenoxymethyl]-benzoic acid methyl ester (600 mg, 1.40 mmol) in THF was cooled to -78 °C in an acetone/ dry ice bath for 5.0 min. The reaction was purged with nitrogen and charged dropwise with IM lithium aluminum hydride (LAH) (1.40 mL). After all the LAH was added, the solution was removed from the bath and allowed to warm to room temperature (rt). As the solution warmed, a white solid formed on the sides of the flask. The reaction mixture was then charged with ethyl acetate, Na2SO4'10H2O and silica. This solution was then concentrated in vacuo to a solid, and was chromatographed on silica gel [Jones Flashmaster, 50 g cartridge, eluting with 2% NH in MeOH:CH2Cl2] to yield the title compound as a white solid; 1H NMR (CDC13, 400 MHz) δ 1.99-2.07 (m, IH), 2.11-2.22 (m, IH), 2.44-2.52 (m, 2H), 2.58-2.68 (m, 2H), 3.76-3.84 (m, IH), 4.69 (s, 2H), 5.16 (s, 2H), 6.98 (d, J = 13.2 Hz, IH), 7.02-7.05 (m, IH), 7.08 (d, J = 4.8 Hz, IH), 7.16-7.17 (m, IH), 7.25-7.28 (m, IH), 7.35-7.43 (m, 5H); MS (ES+): m/z 401.19 (100) [MH4"].
Figure imgf000171_0001
[782] EXAMPLE 79: 2-{3-[3-(8-Amino-3-cyclobutyl-imidazo[l,5- a]pyrazin-l-yl)-phenoxymethyl]-benzyl}-isoindole-l,3-dione: Phthalimide (44 mg, 0.25 mmol), PS-triphenylphosphine (169 mg, 0.37 mmol) and {3-[3-(8-Amino-3- cyclobutyl-imidazo[ 1 ,5-a]pyrazin- l-yl)-phenoxymethyl]-phenyl} -methanol (100 mg, 0.25 mmol) were added to a dry rbf and dissolved with THF (1.25 mL), which was then evacuated and purged three times with nitrogen. DIAD (61 mg, 0.30 mmol) was added slowly to the reaction mixture and allowed to slowly stir for 24h at rt. LC/MS analysis indicated that the reaction was nearly finished with some starting material left, but mostly product. Therefore, 0.2 eq. of DIAD and phthalimide were added and the reaction was left to proceed. The reaction mixture was filtered through a glass frit and washed with CH2C12 multiple times. The filtrate was concentrated to a red/brown oil and purified using silica gel column chromatography (1% NH3 in MeOH:CH Cl2) to afford the title compound; 1H NMR (CDC13, 400 MHz) δ 2.00-2.09 (m, IH), 2.11-2.23 (m, IH), 2.45-2.53 (m, 2H), 2.59-2.69 (m, 2H), 3.77-3.85 (m, IH), 4.87 (s, 2H), 5.11 (s, 2H), 6.99-7.02 (m, 2H), 7.10 (d, J= 5.2Hz, IH), 7.23-7.26 (m, 2H), 7.35-7.42 (m, 4H), 7.49 (s, IH), 7.69-7.73 (m, 2H), 7.82-7.87 (m, 2H); MS (ES+): m/z 530.14 (100) [MH4"].
Figure imgf000171_0002
[784] EXAMPLE 80: 3-[3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l- yl)-phenoxymethyl] -benzoic acid: A 5 mL methanolic solution of 3-[3-(8-Amino-3- cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)-phenoxymethyl]-benzoic acid methyl ester (600 mg, 1.40 mmol) with 5 mL THF was charged with 5 mL of 10 N NaOH and the reaction mixture was heated to 60 °C. After lh, the reaction was allowed to cool to rt and the pH of the reaction mixture was lowered to 3-4. A white precipitate formed, which was filtered and washed with hexanes to afford the title compound as a white powder; 1H NMR (CDC13, 400 MHz) δ 1.90-1.97 (m, IH), 2.04-2.15 (m, IH), 2.36-2.56 (m, 4H), 3.60-3.79 (m, IH), 5.10 (s, 2H), 6.84 (d, J- 5.2 Hz, IH), 6.97-7.01 (m, IH), 7.07 (d, J= 5.6 Hz, IH), 7.12-7.15 (m, 2H), 7.32-7.40 (m, 2H), 7.54 (d, J= 7.2 Hz, IH), 7.91 (d, J= 7.6 Hz, IH), 8.02 (s, IH); MS (ES+): m/z 415.15 (100) [MH4"].
Figure imgf000172_0001
[786] EXAMPLE 81: 3-[3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l- yl)-phenoxymethyl]-N-methyl-Benzamide: A solution of 3-[3-(8-Amino-3- cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)-phenoxymethyl]-benzoic acid (100 mg, 0.24 mmol) and methylamine HCl (163 mg, 2.41 mmol) in DMF (1.2 mL) was charged with DIEA (0.42 mL, 2.41 mmol), HOBt (37.0 mg, 0.24 mmol), and EDC (69.0 mg, 0.36 mmol). The brown colored reaction mixture was allowed to stir for 18 h. LC/MS analysis indicated that the reaction was nearly complete. The reaction was heated to 50 °C and allowed to react for an additional 18 h. The DMF was removed in vacuo and the product was chromatographed on silica gel [Jones Flashmaster, 5 g cartridge, eluting with 2% 7N NH3 MeOH:CH2Cl2] to yield the title compound as a pink solid; 1H NMR (CDC13, 400 MHz) δ 1.99-2.07 (m, IH), 2.11-2.20 (m, IH), 2.44-2.50 (m, 2H), 2.57-2.67 (m, 2H), 3.01 (d, J= 5.2 Hz, 3H), 3.76-3.85 (m, IH), 5.17 (s, 2H), 6.99-7.02 (m, 2H), 7.10 (d, J= 5.2 Hz, IH), 7.24-7.27 (m, 2H), 7.37-7.46 (m, 2H), 7.55 (d, J= 7.6 Hz, IH), 7.71 (d, J= 7.6 Hz, IH), 7.85 (s, IH); MS (ES+): m/z 428.17 (100) [MH4"].
Figure imgf000173_0001
[788] EXAMPLE 82: l-(3-Benzyloxy-phenyl)-3-(3-methoxymethylene- cyclobutyl)-imidazo[l,5-a]pyrazin-8-ylamine: Prepared according to the procedures for l-(3-Benzyloxy-phenyl)-3-cyclobutyl-imidazo[l,5-a]pyrazin-8-ylamine; Light brown foam; 1H NMR (CD3OD, 400 MHz) δ 3.27-3.29 (m, 4H), 3.58 (s, 3H), 3.85 (q, IH, J= 7.7 Hz), 5.13 (s, 2H), 5.93 (s, IH), 7.26-7.66 (m, 11H); MS (ES) 413.15 (M+l), 414.11 (M+2), 415.12 (M+3).
Figure imgf000173_0002
[790] a) l-(3-Benzyloxy-phenyl)-8-chloro-3-(3-methoxymethylene- cyclobutyl)-imidazo[l,5-a]pyrazine: To a solution of Ph3PCH2OMeCl (2.6 g, 7.44 mmol) in benzene (37 mL) a solution of sodium tert-amylate (819.0 mg, 7.44 mmol) in benzene (9.0 mL) was added at rt. The dark red solution was allowed to stir at rt for 10 min. at which point a solution of 3-[l-(3-Benzyloxy-phenyl)-8-chloro- imidazo[l,5-a]pyrazin-3-yl]-cyclobutanone in benzene (30.0 mL) was added dropwise at rt. The reaction mixture was then heated to 70 °C for 4h. The reaction was then quenched with NH C1 sat. Aq. and extracted with diethyl ether (3x). The organic layers were washed with H2O (lx), brine (lx), dried over Na2SO4, filtered and concentrated in vacuo. Purification via HPFC using a 50 g Jones silica gel column (30% EtOAc: Hex) to yield the desired product as a light yellow solid; 1H NMR (CDC13, 400 MHz) δ 3.29-3.33 (m, 4H), 3.59 (s, 3H), 3.90 (q, IH, J= 8.2 Hz), 5.14 (s, 2H), 5.93 (s, IH), 7.26-7.66 (m, 11H); MS (ES) 432.05 (M+l), 434.01 (M+3), 435.02 (M+4).
Figure imgf000174_0001
[792] EXAMPLE 83: 3-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5- a]pyrazin-3-yl] cyclobutanecarbaldehyde: To a methylene chloride solution (6.0 mL) of l-(3-Benzyloxy-phenyl)-3-(3-methoxymethylene-cyclobutyl)-imidazo[l,5- a]pyrazin-8-ylamine (287.0 mg, 0.696 mmol), CF3CO2H (0.11 mL, 1.392 mmol) was added, followed by H2O (0.5 mL). The reaction mixture was allowed to react for lh at rt. After which an ethanolic solution (5.0 mL) of K2CO3 (192.3 mg, 1.392 mmol) was added to the reaction and allowed to stir at rt for an additional 2h. The reaction mixture extracted between water and EtOAc. The organic layers were washed with brine (lx), dried over Na2SO , filtered and concentrated in vacuo to yield the desired product as a brown solid; 1H NMR (CDC13, 400 MHz) (mixture of cis and trans isomers) δ 2.45-2.84 (m, 4H), 3.25-3.32 (m, IH), 3.74-3.79 (m, IH), 5.22 (s, 2H), 6.84-6.85 ( , IH), 7.00-7.17 (m, 5H), 7.27-7.39 (m, 6H), 9.69 (s, IH), 9.88 (s,lH); MS (ES) 399.07 (M+l), 400.0 (M+2), 401.0 (M+3).
Figure imgf000174_0002
[794] EXAMPLE 84-A and 84-B: s/trαns-l-(3-Benzyloxy-phenyl)-3-(4- methoxy-cyclohexyl)-imidazo[l,5-a]ρyrazin-8-ylamine: Prepared according to the procedures for l-(3-Benzyloxy-phenyl)-3-cyclobutyl-imidazo[l,5-a]pyrazin-8- ylamine;. 84-A (Cw-isomer): Off-white solid, 1H NMR (CDC13, 400 MHz) δ 1.59- 2.11 (m, 5H), 2.12-2.21 (brm, 3H), 3.01 (m, IH), 3.35 (s, 3H), 3.56 (brs, IH), 5.15 (s, 2H), 6.92 (d, IH, J= 5.4 Hz), 7.09 (dd, IH, J= 0.9 Hz), 7.20-7.52 (m, 9H); MS (ES) 430.16 (M+l), 431.11 (M+2), 432.12 (M+3). 84-B (2rατω-isomer): Off-white solid, 1H NMR (CDCI3, 400 MHz) δ 1.30-1.34 (m, 4H), 1.80-2.22 (brm, 6H), 2.85 (tt, IH, J= 3.6 Hz), 3.18-3.31 (m, IH), 3.33 (s, 3H), 5.03 (s, 2H), 6.93 (d, 2H, J= 5.4 Hz), 7.19-7.38 (m, 9H);
Figure imgf000175_0001
[796] a) l-(3-Benzyloxy-phenyl)-8-chloro-3-(4-methoxy-cyclohexyl)- imidazo[l,5-a]pyrazine: Prepared according to the procedures for l-(3-Benzyloxy- phenyl)-8-chloro-3-cyclobutyl-imidazo[l,5-a]pyrazine utilizing 4-Methoxy- cyclohexanecarboxylic Acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl]- amide (331.0 mg, 0.71 mmol), POCl3 (3.0 mL); Yellow oil; MS (ES) 448.11 (M+l), 450.13 (M+3), 451.08 (M+4).
Figure imgf000175_0002
[798] b) 4-Methoxy-cyclohexanecarboxylic Acid [(3-benzyloxy-phenyI)-(3- chloro-pyrazin-2-yl)-methyl]-amide: Prepared according to the procedures for Cyclobutanecarboxyhc Acid [(3-benzyloxy-phenyl)-(3-chloro-pyrazin-2-yl)-methyl] Amide utilizing 4-methoxy-cyclohexanecarboxylic acid (145.7 mg, 0.92 mmol), EDC (264.8 mg, 1.38 mmol), HOBt (141.1 mg, 0.92 mmol) and C-(3-Benzyloxy-phenyl)- C-(3-chloro-pyrazin-2-yl)-methylamine (300.0 mg, 0.92 mmol); Purified using a 5g Jones silica column, (30% EtOAc: Hex) to yield afford the title compound as a light yellow solid; 1H NMR (CDC13, 400 MHz) δ 1.44-2.23 (m, 10H), 3.29 (s, 3H), 5.02 (s, 2H), 6.53 (t, IH, J= 8.0 Hz), 6.91-6.94 (m, 3H), 6.86-7.41 (m, 7H), 8.31 (t, IH, J = 3.0 Hz), 8.53 (d, IH, J= 2.6 Hz); MS (ES) 466.41 (M+l), 468.38 (M+3), 469.45 (M+4).
Figure imgf000176_0001
[800] EXAMPLE 85: cts-tert-Butyl ({3-[8-amino-l-(3-benzyloxyphenyl)- imidazo [l,5-α]pyrazin-3-yl]-cyclobutyl}oxy)acetate: Prepared according to the procedures for 1 -(3-Benzyloxy-phenyl)-3-cyclobutyl-imidazo[ 1 ,5-a]pyrazin-8- ylamine; 1H NMR (400 MHz, CD3OD) δ 7.48-7.31 (m, 7H), 7.26 (t, J= 1.6 Hz, IH), 7.20 (td, J= 1.2, 6.4 Hz, IH), 7.13 (dd, J= 4, 8 Hz, IH), 6.99 (d, J= 5.2 Hz, IH), 5.18 (s, 2H), 4.21 (p, J= 6.8 Hz, IH), 3.99 (s, 2H), 3.43-3.35 (m, IH), 2.87-2.81 (m, 2H) 2.49-2.41 (m, 2H), 1.49 (s, 9H). MS (ES+): m/z 501 (100) [MH4"].
Figure imgf000176_0002
[801]
[802] a) cw-tert-Butyl ({3-[8-chloro-l-(3- benzyloxyphenyl)imidazo[l,5- α]pyrazin-3-yl]cyclobutyl} oxy) acetate: cis-3-[ 1 -(3-Benzyloxyphenyl)-8- chloroimidazo[l,5-α]pyrazin-3-yl]cyclobutanol (1.58 mmol, 640 mg) was dissolved in THF (8 mL) and cooled to -78 °C when it was charged with sodium bis(trimethylsilyl)amide (2.37 mmol, 2.37 mL), followed by adding tert-butyl bromoacetate (3.15 mmol, 0.47 mL) portion by portion. The reaction mixture was stined under -20 °C for 30 min and 0 °C for 1 h before it was allowed to warm to rt slowly and stined for 16 h. The reaction mixture was concentrated under reduced pressure, dissolved in DCM,' washed with water (3 X 15 mL) and dried over Na2SO4. The cmde oil was purified by silica gel column chromatography (Jones Flashmaster, 50 g / 150 mL cartridge, eluting with EtOAc: Hexane (2 : 3)), yielding the title compound as a colorless oil; 1H NMR (400 MHz, CDC13) δ 7.53 (d, J= 4.8 Hz, IH), 7.46 (d, IH, J= 8.0 Hz, IH), 7.40-7.27 (m, 7H), 7.04 (dd, J= 2.0, 8.0 Hz, IH), 5.14 (s, 2H), 4.25 (p, J= 8.0 Hz, IH), 3.36-3.27 (m, IH), 2.90-2.84 (m, 2H), 2.70-2.62 (m, 2H), 1.48 (s, 9H).
Figure imgf000177_0001
[803] EXAMPLE 86: cts-2-{3-[8-Amino-l-(3- benzyloxyphenyl)imidazo[ 1 ,5-α]pyrazin-3-yl]cyclobutoxy} ethanol: cw-tert-Butyl ({3-[8-amino-l-(3-benzyloxyphenyl)-imidazo [l,5-α]ρyrazin-3- yl]cyclobutyl}oxy)acetate (0.4 mmol, 200 mg) was dissolved in THF (2 mL) and charged with LiAlH (4 mmol, 4 mL, 1 M in THF) at -78 °C, and stined under rt for 1 h before the reaction mixture was heated to 50 °C for 16 h. Mixture was charged with EtOAc and allowed to stir at rt for 10 min, followed by an addition of Na2SO -10H2O. The reaction mixture was passed through a pad of Celite and concentrated under reduced pressure. The crude oil was purified by silica gel column chromatography (Jones Flashmaster, 20 g / 70 mL cartridge, eluting with 1-3% MeOH in DCM), yielding the title compound as a colorless oil; NMR 1H NMR (400 MHz, CD3OD) δ 7.47(td, 2H), 7.43-7.42 ( , IH), 7.39-7.36 (m, 2H), 7.33-7.29 (m, IH), 7.25 (t, J= 2.0 Hz, IH), 7.19 (td, J= 1.2 Hz, 8 Hz, IH), 7.13 (dd, J= 2.4 Hz, 8.0 Hz, IH), 6.98 (d, J = 4.8 Hz, IH), 5.17 (s, 2H), 4.16 (p, J= 7.2 Hz, IH), 3.66-3.65 (m, 2H), 3.51 (t, J= 2.4 Hz, 2H), 3.50-3.43 (m, IH), 2.88-2.81 (m, 2H), 2.46-2.38 (m, 2H). MS (ES+): m/z 431 (100) [MH4"].
Figure imgf000177_0002
[804] [805] EXAMPLE 87: αs-Toluene-4-sulfonic acid 2-{3-[8-amino-l-(3- benzyloxyphenyl)imidazo [ 1 ,5-α]pyrazin-3-yl]cyclobutoxy} ethyl ester: Followed tosylation procedures described for previously described Toluene-4-sulfonic acid 3- [8-amino-l-(3-benzyloxyphenyl)-imidazo[l,5-α]pyrazin-3-yl]cyclobutylmethyl ester; 1H NMR (400 MHz, CDC13) δ 7.85-7.76 (m, 2H), 7.47-7.29 (m, 9H), 7.21-7.06 (m, 4H), 6.81 (d, J= 8.0 Hz, IH), 5.19 (s, 2H), 4.20-4.10 (m, 3H), 3.65-3.60 (m, 2H), 3.34-3.27 (m, IH), 2.84-2.80 (m, 2H), 2.57-2.44 (m, 2H), 2.44-2.41 (m, 4H). MS (ES+): m/z 585 (100) [MH4"].
Figure imgf000178_0001
[806]
[807] EXAMPLE 88: cw-l-(3-Benzyloxyphenyl)-3-[3-(2- dimethylaminoethoxy)-cyclobutyl]imidazo[l,5-α]pyrazin-8-yl amine: Followed general procedures described in Examples 33 and 34; 1H NMR (400 MHz, CD3OD) δ 7.47.7.44 (m, 3H), 7.42-7.35 (m, 3H), 7.33-7.28 (m, IH), 7.25-7.24 (m, IH), 7.19 (td, J- 0.8 Hz, 8.0 Hz, IH), 7.12 (ddd, J= 0.8 Hz, 2.8 Hz, 8.0 Hz, IH), 6.98 (d, J= 5.2 Hz, IH), 5.17 (s, 2H), 4.12 (q, J= 8.0 Hz, IH), 3.55 (t, J= 5.2 Hz, 2H), 3.49-3.40 (m, IH), 2.85-2.82 (m, 2H), 2.61 (t, J= 5.6 Hz, 2H), 2.42-2.39 (m, 2H), 2.32 (s, 6H). MS (ES+): m/z 458 (100) [MH4"].
Figure imgf000178_0002
[808]
[809] EXAMPLE 89: cw-{3-[8-Amino-l-(3-benzyloxyphenyl)imidazo[l,5- α]pyrazin-3-yl]-cyclobutoxy} acetic acid: cw-tert-Butyl ({3-[8-chloro-l-(3- benzyloxyphenyl)imidazo[l,5-α]pyrazin-3-yl]cyclobutyl}oxy) acetate (0.1 mmol, 50 mg) was dissolved in 1 mL DCM and cooled in ice bath when it was charged with Et3SiH (0.1 mmol, 15 μL) and 1 mL TFA. The reaction mixture was warmed to rt during 1 h and stined for another hour at rt. Reaction mixture was diluted with 10 mL DCM and quenched with K2CO3 (20 mL) aqueous solution. The desired product was extracted in aqueous layer and reaction impurities were left in organic phase. The aqueous phase was acidified to pH 3 before it was washed with DCM (3 X 15 mL). DCM solution was dried over Na2SO and concentrated under reduced pressure. The cmde oil was brought to next step without purification; 1H NMR (400 MHz, CD3OD) δ 7.65 (d, J= 8.0 Hz, 2H), 7.52-7.45 (m, 4H), 7.40-7.36 (m, 2H), 7.34-7.32 (m, 2H), 7.26 (d, J= 8.0 Hz, IH), 7.25-7.19 (m, 2H), 6.96 (d, J= 6.4 Hz, IH), 5.18 (s, 2H), 4.25 (p, J= 6.8 Hz, IH), 3.50 (p, J= 6.8 Hz, IH), 2.90-2.83 (m, 2H), 2.55-2.46 (m, 2H). MS (ES+): m/z 445 (100) [MH4"].
[810]
Figure imgf000179_0001
[811] EXAMPLE 90: cw-2-{3-[8-Amino-l-(3- benzyloxyphenyl)imidazo[ 1 ,5-α]pyrazin-3-yl]cyclobutoxy} -N-methylacetamide: Followed general procedures described in Example 37; lB NMR (400 MHz, CD3OD) δ 7. 47-7.41 (m, 4H), 7.37 (t, J= 7.6 Hz, 2H), 7.32-7.28 (m, IH), 7.25 (t, J= 1.6 Hz, IH), 7.20 (d, J= 8 Hz, IH), 7.13 (td, J= 1.2 Hz, 8 Hz, IH), 6.99 (d, J= 5.2 Hz, IH), 5.17 (s, 2H), 4.18 (p, J= 8 Hz, IH), 3.91 (s, 2H), 3.46 (p, J= 8 Hz, IH), 2.88-2.79 (m, 2H), 2.76 (s, 3H), 2.50-2.43 (m, 2H). MS (ES+): m/z 458 (100) [MH4"].
Figure imgf000179_0002
[812] [813] EXAMPLE 91: cώ-2-{3-[8-Amino-l-(3-benzyloxy- phenyl)imidazo[i,5-α]pyrazin-3-yl]cyclobutoxy} acetamide was prepared from cis- tert-Butyl ( {3-[8-chloro- 1 -(3- benzyloxyphenyl)imidazo[ 1 ,5-α]pyrazin-3- yl] cyclobutyl} oxy) acetate following the procedures for l-(3-Benzyloxy-phenyl)-3- cyclobutyl-imidazo[l,5-a]pyrazin-8-ylamine; 1H NMR (400 MHz, CDC13) δ 7.34- 7.21 (m, 6H), 7.15-7.10 (m, 3H), 6.96-6.93 (m, IH), 6.91 (d, J= 4.8 Hz, IH), 6.50 (b, IH), 5.74 (b, IH), 5.19 (b, 2H), 5.04 (s, 2H), 4.02 (p, J= 0.8 Hz, IH), 3.71 (s, 2H), 3.25 (p, J= 2 Hz, IH), 2.72-2.65 (m, 2H), 2.31-2.26 (m, 2H). MS (ES+): m/z 444 (100) [MH4"].
Figure imgf000180_0001
[814]
[815] EXAMPLE 92: l-(3-benzyloxy-4-methoxyphenyl)-3-cyclobutyl- imidazo[l,5-α]pyrazin-8-ylamine: An 'PrOH (5 ml)/DCM (4 ml) solution of l-(3- benzyloxy-4-methoxyphenyl)-8-chloro-3-cyclobutylimidazo[l,5-α]pyrazine (290 mg, 87%, 0.601 mmol), cooled to -78 °C in a dry ice/acetone bath, was charged with liquid NH3 for 15 min. The sealed tube was equipped with a Teflon washer, sealed and heated 110 °C for 14 h. After that time, the excess NH3 and the solvent were evaporated. The remaining material was purified by chromatography on silica gel to obtain the title compound as a brown oil. The impurities that could not be removed by conventional methods (eg. TLC, HPLC etc.), were removed by SCX column (washed with 7 ml of DCM, 7 ml of MeOH and 7 ml of 2 N NH3 in MeOH); [816] 1H NMR (CDC13, 400 MHz) δ 2.00 - 2.24 (m, 2 H), 2.42 - 2.66 (m, 4
H), 3.78 (quintet, 1 H, J= 8.4 Hz), 3.95 (s, 3 H), 4.95 (brs, 2 H), 5.23 (s, 2 H), 6.98 - 7.02 (m, 2 H), 7.07 (d, 1 H, J= 5.2 Hz), 7.17 (d, 1 H, J= 2.0 Hz), 7.23 (dd, 1 H, J= 2.0 and 8.0 Hz), 7.29 - 7.45 (m, 5 H); MS(ES): 401.1 (M+l).
Figure imgf000181_0001
[818] (a) l-(3-Benzyloxy-4-methoxyphenyl)-8-chloro-3- cyclobutylimidazo[l,5-α]pyrazine: Cyclobutanecarboxyhc acid [(3-benzyloxy-4- methoxyphenyl)-(3-chloropyrazin-2-yl)-methyl]-amide (308 mg, 0.703 mmol) was dissolved in POCl3 (5 ml) and heated at 55 °C for 17 h. After that time, the excess POCl3 was removed in vacuo and the remaining mixture was basified with NH3 (2 N in 'PrOH). The precipitate formed was filtered off and washed with CH2C12, and the filtrate was purified by chromatography on silica gel to obtain a yellow-brown solid of the title compound (87% purity by LC-MS); 1H NMR (DMSO-d6, 400 MHz) δ 2.03 - 2.20 (m, 2 H), 2.47 - 2.67 (m, 4 H), 3.95 (s, 3 H), 5.22 (s, 2 H), 7.00 (d, 1 H, J = 8.0 Hz), 7.25 - 7.47 (m, 8 H); MS(ES): 420.0/422.1 (M/M+2).
Figure imgf000181_0002
[820] (b) Cyclobutanecarboxyhc acid [(3-benzyloxy-4-methoxyphenyI)-(3- chloropyrazin-2-yl)-methyl]-amide: Into the DMF (6 ml) solution of C-(3-benzyloxy- 4-methoxyphenyl)-C-(3-chloropyrazin-2-yl)-methylamine (290 mg, 0.815 mmol), cyclobutanecarboxyhc acid (156 μl, 2 eq.) and Et3N (342 μl, 3 eq.), was added EDC hydrochloride (469 mg, 3 eq.) and HOBt monohydrate (250 mg, 2 eq.) at rt under N2, After stirring for 24 h at rt, the mixture was poured into saturated Na2CO3 (10 ml) and H2O (10 ml), extracted with EtOAc (3 x 20 ml). The extracts were washed with H2O (20 ml) and brine (20 ml), and dried over MgSO4. After concentration in vacuo, a brown syrup (363 mg) was obtained that was then purified by chromatography on silica gel and a brown syrup of cyclobutanecarboxyhc acid [(3-benzyloxy-4- methoxyphenyl)-(3-chloropyrazin-2-yl)-methyl]-amide was obtained; H NMR (CDCI3, 400 MHz) δ 1.86 - 1.98 (m, 2 H), 2.11 - 2.27 (m, 4 H), 3.04 (quintet, 1 H, J = 8.4 Hz), 3.85 (s, 3 H), 5.12 (s, 2 H), 6.43 (d, 1 H, J= 8.0 Hz), 6.79 - 6.90 (m, 4 H), 7.28 - 7.38 (m, 5 H), 8.29 (d, 1 H, J= 2.8 Hz), 8.45 (d, 1 H, J= 2.4 Hz); MS(ES): 438.1/440.1 (M/M+2).
Figure imgf000182_0001
[822] (c) C-(3-Benzyloxy-4-methoxyphenyl)-C-(3-chloropyrazin-2-yl)- methylamine: The mixture of 2-[(3-benzyloxy-4-methoxyphenyl)-(3-chloropyrazin- 2-yl)-methyl]-isoindole-l,3-dione (400 mg, 0.823 mmol) and H2NNH2 (64.0 μl, 3 eq.) in EtOH (6 ml)/CH2Cl2 (2 ml) was stined at rt under N2 for 65 h. After that time, the grey solid was filtered off, and the solvent and the excess hydrazine were removed in vacuo to obtain a brown-red oil of C-(3-benzyloxy-4-methoxyphenyl)-C-(3- chloropyrazin-2-yl)-methylamine; 1H NMR (CD3OD, 400 MHz) δ 3.84 (s, 3 H), 4.96 & 5.00 (AB, 2 H, J= 12.0 Hz), 5.41 (s, 1 H), 6.94 - 6.97 (m, 3 H), 7.29 - 7.40 (m, 5 H), 8.34 (d, 1 H, J= 2.8 Hz), 8.63 (d, 1 H, J= 2.4 Hz); MS(ES): 356.1/358.1 (M/M+2).
Figure imgf000182_0002
[824] (d) 2-[(3-Benzyloxy-4-methoxyphenyl)-(3-chloropyrazin-2- yl)-methyl]-isoindole-l,3-dione: DIAD (515 μl, 1.1 eq.) was added dropwise into the THF solution (14 ml) of MS-PPh3 (2.12 mmol/g, 1.24 g, 1.1 eq.), (3-benzyloxy-4- methoxyphenyl)-(3-chloropyrazin-2-yl)-methanol (849 mg, 2.38 mmol) and phthalimide (385 mg, 1.1 eq.) at 0 °C under N2 over 5 min. After stirring for 20 h at rt, the mixture was separated by chromatography on silica gel and eluted incrementally with 400 ml, 10%, 20%, 30%, 40%, and 50% EtOac/Hexane, to obtain a light-yellow oil of 2-[(3-benzyloxy-4-methoxyphenyl)-(3-chloropyrazin-2-yl)- methyl]-isoindole-l,3-dione; 1H NMR (CDC13, 400 MHz) δ 3.87 (s, 3 H), 5.08 & 5.14 (AB, 2 H, J= 12.0 Hz), 6.75 (s, 1 H), 6.85 (d, 1 H, J= 8.0 Hz), 6.88 - 6.92 (m, 2 H), 7.17 - 7.35 (m, 5 H), 7.72 - 7.75 (m, 2 H), 7.82 - 7.84 ( , 2 H), 8.31 (d, 1 H, J= 2.4 Hz), 8.43 (d, 1 H, J= 2.4 Hz); MS(ES): 486.0/487.9 (M/M+2).
Figure imgf000183_0001
[826] (e) (3-Benzyloxy-4-methoxyphenyl)-(3-chloroρyrazin-2-yl)-methanol
2,2,6,6-Tetramethylpiρeridine (1775 μl, 1.2 eq.) was added dropwise over 5 min into the THF (20 ml) solution of n-BuLi (2.5 M in cyclohexane, 4.2 ml, 1.2 eq.), which was cooled in a dry ice/acetone bath. The reaction vessel was removed from the cooling bath and allowed to warm to 0 °C for 15 min, then cooled back to -78 °C and charged with chloropyrazine (780 μl, 8.733 mmol) dropwise over 5 min. The reaction was allowed to react for 15 min, and charged with a THF (10 ml) solution of 3- benzyloxy-4-methoxybenzaldehyde (2328 mg, 1.1 eq.) over 10 min. After 2 h, the reaction mixture was warmed to rt and aqueous HCl (1 N, 15 ml) was added. The mixture was extracted with CH2C12 (3 x 50 ml). The combined extracts were washed with water (50 ml) and brine (50 ml), and dried over MgSO4. After concentration in vacuo, a cmde black oil (3.163 g) was obtained that was then purified by chromatography on silica gel (500 ml 10%, 30%, 40%, 50%, and 60% EtOAc/Hexane) and a brown oil of (3-benzyloxy-4-methoxyphenyl)-(3- chloropyrazin-2-yl)-methanol was obtained; lK NMR (DMSO-d6, 400 MHz) δ 3.74 (s, 3 H), 5.04 (s, 2 H), 6.00 (d, 1 H, J= 6.0 Hz), 6.09 (d, 1 H, J= 6.0 Hz), 7.10 (s, 1 H), 7.31 - 7.42 (m, 7 H), 8.43 (d, 1 H, J= 2.4 Hz), 8.67 (d, 1 H, J= 2.4 Hz); MS(ES): 357.4/359.4 (M/M+2).
Figure imgf000183_0002
[828] EXAMPLE 93: l-(3-Benzyloxy-4-fluorophenyl)-3-cyclobutyl- imidazo[l,5-α]pyrazin-8-ylamine: Followed General Ammonolysis described in Example 92; 1H NMR (CDC13, 400 MHz) δ 1.98 - 2.24 (m, 2 H), 2.44 - 2.66 (m, 4 H), 3.78 (quintet, 1 H, J= 8.4 Hz), 5.22 (s, 2 H), 7.01 (d, 1 H, J- 4.8 Hz), 7.10 (d, 1 H, J= 5.2 Hz), 7.20 - 7.46 (m, 8 H); MS(ES): 389.1 (M+l).
Figure imgf000184_0001
[830] (a) l-(3-Benzyloxy-4-fluorophenyl)-8-chloro-3- cyclobutylimidazo[l,5-α]pyrazine; Followed General Cyclization described in Example 92-(a); 1H NMR (CDC13, 400 MHz) δ 2.05 - 2.24 (m, 2 H), 2.50 - 2.69 (m, 4 H), 3.84 (quintet, 1 H, J= 8.4 Hz), 5.21 (s, 2 H), 7.15 - 7.49 (m, 9 H); MS(ES): 408.0/410.0 (M/M+2).
Figure imgf000184_0002
[832] (b) Cyclobutanecarboxyhc acid [(3-benzyloxy-4-fluorophenyl)-(3- chloropyrazin-2-yl)-methyl]-amide: Followed General Amide Formation described in Example 92-(b); 1H NMR (CDC13, 400 MHz) δ 1.82 - 1.97 (m, 2 H), 2.11 - 2.34 (m, 4 H), 3.04 (quintet, 1 H, J= 8.0 Hz), 5.10 (s, 2 H), 6.44 (d, 1 H, J= 7.6 Hz), 6.75 - 6.79 (m, 1 H), 6.95 - 7.02 (m, 3 H), 7.27 - 7.38 (in, 5 H), 8.31 (d, 1 H, J= 2.4 Hz), 8.46 (d, 1 H, J= 2.4 Hz); MS(ES): 426.0/428.0 (M/M+2
Figure imgf000185_0001
[834] (c) C-(3-Benzyloxy-4-fluorophenyl)-C-(3-chloropyrazin-2-yl)- methylamine: Followed General Primary Amine Formation described in Example 92-(c); 1H NMR (CD3OD, 400 MHz) δ 5.15 & 5.19 (AB, 2 H, J= 12.0 Hz), 5.44 (s, 1 H), 6.90 - 6.95 (m, 1 H), 7.02 - 7.12 (m, 2 H), 7.28 - 7.38 (m, 5 H), 8.33 (d, 1 H, J= 2.4 Hz), 8.61 (d, 1 H, J= 2.4 Hz); MS(ES): 327.3/329.3 (M-16/M-16+2).
Figure imgf000185_0002
[836] (d) 2-[(3-Benzyloxy-4-fluorophenyl)-(3-chloropyrazin-2-yl)-methyl]- isoindole-l,3-dione: Followed General Mitsunobu Reaction described in Example 92-(d); 1H NMR (CDC13, 400 MHz) δ 5.07 & 5.12 (AB, 2 H, J= 11.6 Hz), 6.78 (s, 1 H), 6.89 - 6.92 (m, 1 H), 7.03 - 7.09 (m, 2 H), 7.28 - 7.37 (m, 2 H), 7.74 - 7.77 (m, 2 H), 7.84 - 7.86 (m, 2 H), 8.35 (d, 1 H, J= 2.4 Hz), 8.45 (d, 1 H, J= 2.8 Hz). MS(ES): 474.0/476.0 (M/M+2).
Figure imgf000185_0003
[838] (e) (3-Benzyloxy-4-fluorophenyl)-(3-chloropyrazin-2-yl)-methanol:
Followed General Lithiation described in Example 92-(e); lB NMR (CDC13, 400 MHz) δ 4.58 (d, 1 H, J= 8.0 Hz), 5.00 & 5.04 (AB, 2 H, J= 12.0 Hz), 5.94 (d, 1 H, J = 8.0 Hz), 6.85 - 6.89 (m, 1 H), 6.98 - 7.06 (m, 2 H), 7.26 - 7.40 (m, 5 H), 8.36 (d, 1 H, J= 2.8 Hz), 8.53 (d, 1 H, J= 2.4 Hz); MS(ES): 327.1/329.1 (M-18/M-18+2).
Figure imgf000186_0001
[840] (f) 3-Benzyloxy-4-fluorobenzaldehyde: The mixture of benzyl bromide (1062 μL, 1.050 eq.), potassium carbonate (1500 mg, 1.274 eq.), 4-fluoro-3- hydroxybenzaldehyde (1193 mg, 8.515 mmol) and acetone (50 ml) was stined at rt for 24 h. After that time, water (40 ml) was added to dissolve inorganic solid and the acetone was removed in vacuo. The mixture was extracted with ethyl acetate (3 x 50 ml), the combined organic extracts were washed with aqueous acetic acid (5%, 40 ml), water (2 x 40 ml) and brine (40 ml), and dried over MgSO4. After concentration in vacuo, a brown oil of 3-benzyloxy-4-fluorobenzaldehyde was obtained; 1H MR (CDC13, 400 MHz) δ 5.20 (s, 2 H), 7.23 - 7.59 (m, 8 H), 9.89 (s, 1 H).
Figure imgf000186_0002
[842] (g) 4-Fluoro-3-hydroxybenzaldehyde: BBr3 (125 ml, 3.383 eq., 1 M in CH2C12) was added into the solution of 4-fluoro-3-methoxybenzaldehyde (5.695 g, 36.95 mmol) in CH2C12 (50 ml) under N2 at 0 °C over 30 min. After stirring at rt for 19 Lα, the reaction mixture was poured into ice/water (250 ml) slowly. After separation, the oil phase was extracted with aqueous NaOH (2 N, 2 x 150 ml). The basic extracts were acidified by aqueous HCl (37%) until pH<2, which was then extracted with CH2C12 (3 x 200 ml). The organic extracts was washed with brine (100 ml) and dried over MgSO . After concentration in vacuo, a yellow-brown solid of 4- fluoro-3-hydroxybenzaldehyde was obtained; 1H NMR (DMSO-^, 400 MHz) δ 7.43 - 7.52 (m, 3 H), 9.93 (s, 1 H), 10.55 (brs, 1 H).
Figure imgf000186_0003
[844] EXAMPLE 94: l-(3-Benzyloxy-4-isopropoxyphenyl)-3- cyclobutylimidazo[l,5-α]pyrazin-8-ylamine: Followed General Ammonolysis described in Example 92; 1H NMR (CDC13, 400 MHz) δ 1.40 (d, 6 H, J= 6.0 Hz), 1.98 - 2.21 (m, 2 H), 2.43 - 2.67 (m, 4 H), 3.77 (quintet, 1 H, J= 8.0 Hz), 4.60 (septet, 1 H, J= 6.1 Hz), 4.88 (brs, 2 H), 5.21 (s, 2 H), 7.00 (d, 1 H, J= 5.2 Hz), 7.04 - 7.08 (m, 2 H), 7.17 - 7.22 ( , 2 H), 7.29 - 7.45 (m, 5 H); MS(ES): 429.1 (M+l).
Figure imgf000187_0001
[846] (a) l-(3-Benzyloxy-4-isopropoxyphenyl)-8-chloro-3- cyclobutylimidazo[l,5-α]pyrazine: quantitative yield: Followed General Cyclization described in Example 92-(a); 1H NMR (CDC13, 400 MHz) δ 1.40 (d, 6 H, J= 6.0 Hz), 1.87 - 2.09 (m, 2 H), 2.43 - 2.72 (m, 4 H), 3.82 (quintet, 1 H, J= 8.4 Hz), 4.61 (septet, 1 H, J= 6.1 Hz), 5.19 (s, 2 H), 7.03 (d, 1 H, J= 8.4 Hz), 7.24 - 7.47 (m, 9 H); MS(ES): 447.9/449.9 (M/M+2).
Figure imgf000187_0002
[848] (b) Cyclobutanecarboxyhc acid [(3-benzyloxy-4-isopropoxyphenyl)-
(3-chloropyrazin-2-yl)-methyl]-amide: Followed General Amide Formation described in Example 92-(b); quantitative yield; 1H NMR (CDC13, 400 MHz) δ 1.34 (d, 6 H, J= 6.0 Hz), 1.84 - 1.98 (m, 2 H), 2.11 - 2.30 (m, 4 H), 3.05 (quintet, 1 H, J= 8.4 Hz), 4.48 (septet, 1 H, J= 5.9 Hz), 5.11 (s, 2 H), 6.45 (d, 1 H, J= 1.6 Hz), 6.82 - 6.90 (m, 4 H), 7.28 - 7.38 ( , 5 H), 8.31 (d, 1 H, J= 2.8 Hz), 8.45 (d, 1 H, J= 2.8 Hz). MS(ES): 465.9/467.9 (M/M+2).
Figure imgf000188_0001
[850] (c) C-(3-Benzyloxy-4-isopropoxyphenyl)-C-(3-chloropyrazin-2-yl)- methylamine: Followed General Primary Amine Formation described in Example 92-(c); 1H NMR (CDC13, 400 MHz) δ 1.34 (s, 6 H, J= 6.0 Hz), 4.48 (septet, 1 H, J= 6.2 Hz), 5.10 (s, 2 H), 5.43 (s, 1 H), 6.33 (brs, 2 H), 6.84 - 6.91 (m, 3 H), 7.28 - 7.40 (m, 5 H), 8.24 (d, 1 H, J= 2.4 Hz), 8.49 (d, 1 H, J= 2.8 Hz); MS(ES): 384.0/386.0 (M/M+2).
Figure imgf000188_0002
[852] (d) 2-[(3-Benzyloxy-4-isopropoxyphenyl)-(3-chloropyrazin-2-yl)- methyl]-isoindole-l,3-dione: Followed General Mitsunobu Reaction described in Example 92-(d); 1H NMR (CDC13, 400 MHz) δ 1.35 (d, 6 H, J= 6.0 Hz), 4.53 (septet, 1 H, J= 6 H), 5.05 & 5.10 (AB, 2 H, J= 12.0 Hz), 6.75 (s, 1 H), 6.82 - 6.90 (m, 2 H), 6.94 (s, 1 H), 7.19 - 7.52 (m, 5 H), 7.72 - 7.74 (m, 2 H), 7.82 - 7.84 (m, 2 H), 8.31 (d, 1 H, J= 2.4 Hz), 8.43 (d, 1 H, J= 2.4 Hz); MS(ES): 513.9/515.9 (M/M+2).
Figure imgf000188_0003
[854] (e) (3-Benzyloxy-4-isopropoxyphenyl)-(3-chloropyrazin-2-yl)- methanol: Followed General Lithiation described in Example 92-(e); 1H NMR (CDC13, 400 MHz) δ 1.34 (d, 6 H, J= 6.4 Hz), 4.50 (septet, 1 H, J= 6.0 Hz), 5.10 (AB, 2 H, J= 12.4 Hz), 5.91 (d, 1 H, J= 8.0 Hz), 6.84 - 6.86 (m, 4 H), 7.26 - 7.39 (m, 5 H), 8.34 (d, 1 H, J= 2.4 Hz), 8.50 (d, 1 H, J= 2.4 Hz); MS(ES): 367.0/369.0 (M/M+2).
Figure imgf000189_0001
[856] (f) 3-Benzyloxy-4-isopropoxybenzaldehyde: A mixture of 3- benzyloxy-4-hydroxybenzaldehyde (1297 mg, 5.683 mmol) and Cs2CO3 (2777 mg, 1.5 eq.) in DMF (5 ml) was stined at rt for 30 min under N2, and then 2- bromopropane (800 μl, 1.5 eq.) was added and heated with stirring at 75 °C overnight. The reaction mixture was cooled, and to it was added H2O (20 ml), and then was extracted with EtOAc (4 x 20 ml). The organic extracts were washed with H2O (3 x 20 ml) and brine (20 ml), and dried over MgSO4. After concentration in vacuo, a brown oil of 3-benzyloxy-4-isopropoxybenzaldehyde was obtained, which was used without further purification. 1H NMR (CDCL, 400 MHz) δ 1.43 (d, 6 H, J- 6.4 Hz), 4.69 (septet, 1 H, J= 6.0Hz), 5.18 (s, 2 H), 7.01 (d, 1 H, J= 8.0 Hz), 7.26 - 7.46 (m, 7 H), 9.81 (s, 1 H); MS(ES): 271.1 (M+l).
Figure imgf000189_0002
[858] (g) 3-Benzyloxy-4-hydroxybenzaldehyde: A solution of 3-benzyloxy-
4-(4-methoxybenzyloxy)-benzaldehyde (2593 mg, 7.443 mmol) in AcOH (20 ml) was heated to reflux (150 °C) for 27 h. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOAc (20 ml). The organic solution was washed with H2O (20 ml) and aqueous NaOH (0.5 N, 5 x 20 ml). The basic extracts were combined, acidified to pH = 2 - 3 with aqueous HCl (2 N) and back-extracted with EtOAc (2 x 30 ml). The organic solution was dried over MgSO4, filtered and concentrated to give 3-benzyloxy-4-hydroxybenzaldehyde as a brown solid. 1H NMR (CDC13, 400 MHz) δ 5.18 (s, 2 H), 6.22 (brs, 1 H), 7.08 (d, 1 H, J= 8.0 Hz), 7.39 - 7.52 (m, 7 H), 9.82 (s, 1 H); MS(ES): 229.1 (M+l).
Figure imgf000190_0001
[860] (h) 3-Benzyloxy-4-(4-methoxybenzyloxy)-benzaldehyde: Benzyl bromide (5.84 ml, 1.1 eq.) was added dropwise into the mixture of 3-hydroxy-4-(4- methoxybenzyloxy)-benzaldehyde (11.5 g, 44.6 mmol) and cesium carbonate (8.73g, 0.6 eq.) in DMF (75 ml) at rt under N2 over 15 min. After stirring at rt for 70 h, the reaction mixture was poured into water (150 ml) and was then extracted with ethyl acetate (200 ml). The organic extracts were washed with water (100 ml), aqueous NaOH (0.5 M, 100 ml), and brine (100 ml) and dried over MgSO4. After concentration in vacuo, a cmde brown solid of 3-benzyloxy-4-(4-methoxybenzyloxy)~ benzaldehyde was obtained; 1H NMR (CDC13, 400 MHz) δ 3.83 (s, 3 H), 5.18 (s, 2 H), 5.20 (s, 2 H), 6.92 (dd, 2 H, J= 2 and 6.8 Hz), 7.04 (d, 2 H, J= 8.0 Hz), 7.33 - 7.47 (m, 9 H), 9.80 (s, 1 H).
[861]
Figure imgf000190_0002
[862] (i) 3-Hydroxy-4-(4-methoxybenzyloxy)-benzaldehyde: 4-
Methoxybenzyl chloride (11.9 g, 1.05 eq.) was added dropwise into the mixture of 3,4-dihydrobenzaldehyde (10.0 g, 72.4 mmol), (n-C4H9)4NI (21.4 g, 0.8 eq.) and cesium carbonate (17.7 g, 0.75 eq.) in DMF (100 ml) at rt under N2 over 15 min. After stirring at rt for 67 h, the reaction mixture was poured into water (200 ml) and, was then extracted with ethyl acetate (3 x 100 ml). The organic extracts was washed with aqueous HCl (0.5 M, 200 ml), water (4 x 100 ml), and brine (100 ml) and dried over MgSO4. After concentration in vacuo, a crude yellow-brown solid (18.0 g) was obtained, which was then triturated with ethyl acetate/hexane (75 ml/150 ml) to give a yellow-brown solid of 3-hydroxy-4-(4-methoxybenzyloxy)-benzaldehyde; 1H NMR (CDC13, 400 MHz) δ 3.84 (s, 3 H), 5.13 (s, 2 H), 5.78 (brs, 1 H), 6.96 (d, 2 H, J= 8.0 Hz), 7.06 (d, 2 H, J= 8.0 Hz), 7.37 (d, 2 H, J= 8.4 Hz), 7.40 - 7.45 (m, 2 H), 9.84 (s, 1 H); MS(ES): 259.2 (M+l).
Figure imgf000191_0001
[864] EXAMPLE 95: l-(3-Benzyloxy-4-ethoxyphenyl)-3- cyclobutylirnidazo[l,5-α]pyrazin-8-ylamine: Followed General Ammonolysis described in Example 92; 1H NMR (CDC13, 400 MHz) δ 1.50 (t, 3 H, J= 7.0 Hz), 1.99 - 2.19 (m, 2 H), 2.42 - 2.67 (m, 4 H), 3.78 (quintet, 1 H, J= 8.4 Hz), 4.19 (q, 2 H, J= 6.9 Hz), 4.83 (brs, 2 H), 5.23 (s, 2 H), 6.98 - 7.47 (m, 10 H).; MS(ES): 415.1
(M+l).
Figure imgf000191_0002
[866] (a) l-(3-Benzyloxy-4-ethoxyphenyl)-8-chloro-3- cyclobutylimidazo[l,5-α]pyrazine: quantitative yield: Followed General Cyclization described in Example 92-(a); 1H NMR (CDC13, 400 MHz): 1.49 (t, 3 H, J= 7.0 Hz), 2.01 - 2.22 ( , 2 H), 2.48 - 2.70 (m, 4 H), 3.82 (quintet, 1 H, J= 8.4 Hz), 4.17 (q, 2 H, J= 7.0 Hz), 5.21 (s, 2 H), 7.00 (d, 1 H, J= 8.8 Hz), 7.25 - 7.47 (m, 9 H); MS(ES): 433.9/435.9 (M/M+2).
Figure imgf000191_0003
[868] (b) Cyclobutanecarboxylic acid [(3-benzyloxy-4-ethoxyphenyl)-(3- chloropyrazin-2-yl)-methyl]-amide: A mixture of cyclobutanecarboxylic acid [(3- benzyloxy-4-hydroxyphenyl)-(3-chloropyrazin-2-yl)-methyl]-amide (162 mg, 0.382 mmol) and Cs2CO3 (187 mg, 0.573 mmol) in DMF (2 ml) was stined at rt for 30 min under N2, and then Etl (45.9 μL, 0.573 mmol) was added and heated with stirring at 50 °C for 5 h. The reaction mixture was cooled, and to it was added H2O (15 ml), and then was extracted with EtOAc (3 x 15 ml). The organic extracts were washed with H2O (3 x 15 ml) and brine (15 ml), and dried over MgSO4. After concentration in vacuo, a brown oil of 3 cyclobutanecarboxylic acid [(3-benzyloxy-4-ethoxyphenyl)- (3-chloropyrazin-2-yl)-methyl]-amide was obtained, wliich was used without further purification. A more pure sample was obtained by Gilson HPLC purification for LC- MS and HPLC; 1H NMR (CDC13, 400 MHz) δ 1.42 (t, 3 H, J= 7.0 Hz), 1.84 - 2.11 (m, 2 H), 2.12 - 2.18 (m, 4 H), 3.04 (quintet, 1 H, J- 8.4 Hz), 4.04 (q, 2 H, J= 6.9 Hz), 5.11 (s, 2 H), 6.43 (d, 1 H, J= 1.6 Hz), 6.78 - 6.88 (m, 4 H), 7.25 - 7.38 (m, 5 H), 8.29 (d, 1 H, J= 2.4 Hz), 8.44 (d, 1 H, J= 2.4 Hz); MS(ES): 451.9/453.9 (M/M+2).
Figure imgf000192_0001
[870] (c) Cyclobutanecarboxylic acid [(3-benzyloxy-4-hydroxyphenyl)-(3- chloropyrazin-2-yl)-methyl] -amide: A solution of cyclobutanecarboxylic acid [[3- benzyloxy-4-(4-methoxybenzyloxy)-phenyl]-(3-chloropyrazin-2-yl)-methyl]-amide (300 mg, 0.551 mmol) in AcOH (10 ml) was heated to reflux (150 °C) for 7 h. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOAc (15 ml). The organic solution was washed with saturated NaHCO3 (10 ml), H2O (2 x 10 ml) and brine (10 ml), and dried over MgSO4, filtered and concentrated to give a brown oil. The cmde oil was purified by silica gel (eluting with 200 ml of 2%, 4%, 6% MeOH/CH2Cl2) to obtain a light-yellow oil of cyclobutanecarboxylic acid [(3- benzyloxy-4-hydroxyphenyl)-(3-chloropyrazin-2-yl)-methyl]-amide; 1H NMR (CDCI3, 400 MHz) δ 1.82 - 1.99 (m, 2 H), 2.13 - 2.31 (m, 4 H), 3.07 (quintet, 1 H, J = 8.4 Hz), 5.10 (s, 2 H), 5.64 (brs, 1 H), 6.47 (d, 1 H, J= 8.0 Hz), 6.72 (dd, 1 H, J= 1.6 & 8.0 Hz), 6.84 (d, 1 H, J= 8.0 Hz), 6.98 (d, 1 H, J= 7.2 Hz), 7.03 (d, 1 H, J= 1.6 Hz), 7.30 - 7.38 (m, 5 H), 8.32 (d, 1 H, J= 2.4 Hz), 8.49 (d, 1 H, J= 2.8 Hz); MS(ES): 423.9/425.9 (M/M+2).
Figure imgf000193_0001
[872] (d) Cyclobutanecarboxylic acid [[3-benzyloxy-4-(4- methoxybenzyloxy)-phenyl]-(3-chloropyrazin-2-yl)-methyl]-amide: Followed General Amide Formation described in Example 92-(b); H NMR (CDC13, 400 MHz) δ 1.84 - 1.98 (m, 2 H), 2.11 - 2.26 (m, 4 H), 3.04 (quintet, 1 H, J= 8.4 Hz), 3.80 (d, 3 H, J= 1.2 Hz), 5.04 (s, 2 H), 5.12 (s, 2 H), 6.44 (d, 1 H, J= 8.0 Hz), 6.78 - 6.89 (m, 6 H), 7.26 - 7.38 (m, 7 H), 8.29 (d, 1 H, J= 2.0 Hz), 8.50 (d, 1 H, J= 2.4 Hz); MS(ES): 544.0/546.0 (M/M+2).
Figure imgf000193_0002
[874] (e) C-[3-Benzyloxy-4-(4-methoxybenzyloxy)-ρhenyl]-C-(3- chloropyrazin-2-yl)-methylamine: Followed General Primary Amine Formation described in Example 92-(c); quantitative yield; lB NMR (CD3OD, 400 MHz) δ 3.80 (s, 3 H), 5.04 (s, 2 H), 5.12 (m, 2 H), 6.89 - 6.92 (m, 3 H), 6.98 - 7.00 (m, 2 H), 7.30 - 7.39 (m, 7 EC), 8.34 (d, 1 H, J= 2.4 Hz), 8.63 (d, 1 H, J= 2.4 Hz); MS(ES): 461.9/463.9 (M/M+2).
Figure imgf000193_0003
[876] (f) 2-[[3-Benzyloxy-4-(4-methoxy-benzyloxy)-phenyl]-(3-chloro- pyrazin-2-yl)-methyl]-isoindole-l,3-dione: Followed General Mitsunobu Reaction described in Example 92-(d); lB NMR (CDC13, 400 MHz) δ 3.80 (s, 3 H), 4.97 - 5.14 (m, 4 H), 6.75 (s, 1 H), 6.87 - 6.91 (m, 4 H), 6.96 (d, 1 H, J= 2.0 Hz), 7.19 - 7.24 (m, 2 H), 7.33 - 7.36 (m, 5 H), 7.72 - 7.74 (m, 2 H), 7.82 - 7.84 (m, 2 H), 8.31 (dd, 1 H, J = 0.8 and 2.4 Hz), 8.43 (d, 1 H, J= 2.0 Hz); MS(ES): 592.0/594.0 (M/M+2).
Figure imgf000194_0001
[878] (g) [3-Benzyloxy-4-(4-methoxybenzyloxy)phenyl]-(3-chloropyrazin-
2-yl)-methanol: Followed General Lithiation described in Example 92-(e); H NMR (CDC13, 400 MHz) δ 3.80 (s, 4 H), 4.49 (d, 1 H, J= 8.0 Hz), 5.06 (s, 2 H), 5.10 & 5.14 (AB, 2 H, J= 12.4 Hz), 5.91 (d, 1 H, J= 8.0 Hz), 6.82 - 6.88 (m, 5 H), 7.27 - 7.38 (m, 7 H), 8.33 (d, 1 H, J= 2.4 Hz), 8.49 (d, 1 H, J= 2.8 Hz); MS(ES): 444.9/446.9 (M-18/M-18+2).
Figure imgf000194_0002
[880] EXAMPLE 96: 4-(8-Amino-3-cyclobutylimidazo[l,5-α]ρyrazin-l-yl)-
2-benzyloxyphenol: Phosphoramidic acid 2-benzyloxy-4-(8-chloro-3- cyclobutylimidazo[l,5-α]pyrazin-l-yl)-phenyl ester isopropyl ester (300mg, 0.569 mmol) was dissolved in 2 N NH3 in 'PrOH (3 ml) and charged with liquid NH3 (1 ml) in a dry ice/acetone bath. The above mixture was then sealed in a sealed tube and heated at 110 °C. After stirring for 14 h, the excess NH3 and the solvent were evaporated. THF (3 ml) was added followed by the addition of LiAlH4 (88.0 mg, 2.28 mmol) at O °C under N2. The mixture was then stined at rt for 26 h. After that time, the reaction mixture was poured into aqueous AcOH (5%, 15 ml) and extracted with EtOAc (3 x 20 ml). The extracts were washed with H2O (3 x 15 ml), brine (15 ml) and dried over MgSO4. After concentrating in vacuo, a brown oil (50 mg) was obtained, which was purified by TLC eluting with 3% MeOH/CH2Cl2 to afford 4-(8- amino-3-cyclobutylimidazo[l,5-α]pyrazin-l-yl)-2-benzyloxyphenol as an off-white solid; 1H NMR (CDCI3, 400 MHz) δ 1.96 - 2.22 (m, 2 H), 2.44 - 2.68 (m, 4 H), 3.80 (quintet, 1 H, J= 8.6 Hz), 5.06 (brs, 2 H), 5.19 (s, 2 H), 7.01 (d, 1 H, J= 5.2 Hz), 7.05 (d, 1 H, J= 8.0 Hz), 7.09 (d, 1 H, J= 5.2 Hz), 7.17 (dd, 1 H, J= 1.6 & 8.4 Hz), 7.25 (d, 1 H, J= 2.0 Hz), 7.35 - 7.44 (m, 5 H); MS(ES): 387.0 (M+l). [881]
Figure imgf000195_0001
|[883| » * \(a) Phosphoramidic acid 2-benzyloxy-4-(8-chloro-3- cyclobutyhmidazo[l,5-α]pyrazm-l-yl)-phenyl ester isopropyl ester: Followed General Cyclization described in Example 92-(a) whereby Cyclobutanecarboxylic acid [[3-benzyloxy-4-(4-methoxybenzyloxy)-phenyl]-(3-chloropyrazin-2-yl)-methyl]- amide was treated with POCl3 and then quenched with 2N NH3 m zPrOH to afford the title compound; 1H NMR (CDC13, 400 MHz) δ 1.31 (d, 3 H, J- 6.0 Hz), 1.35 (d, 3 H, J= 6.4 Hz), 2.01 - 2.26 (m, 2 H), 2.47 - 2.69 (m, 4 H), 3.02 (d, 2 H, J= 4.0 Hz), 3.84 (quintet, 1 H, J= 8.4 Hz), 4.78 (septet, 1 H, J= 6.1 Hz), 5.17 (s, 2 H), 7.27 - 7.53 (m, 10 H); MS(ES): 526.9/528.9 (M/M+2).
Figure imgf000195_0002
[885] EXAMPLE 97: 4-{8-Amino-l-[3-(2,6-difluoro-benzyloxy)-phenyl]- imidazo[l,5-a]pyrazin-3-yl}-cyclohexanecarboxylic acid amide: The procedures for trα«5-4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]- cyclohexanecarboxylic acid amide were applied to 4-{8-Ammo-l-[3-(2,6-difluoro- benzyloxy)-phenyl]-imidazo[l,5-a]pyrazin-3-yl}-cyclohexanecarboxylic acid methyl ester to afford the title compound; MS (ES+): m/z 478.02 [MH+].
Figure imgf000196_0001
[887] EXAMPLE 98: 4-{8-Amino-l-[3-(2,6-difluoro-benzyloxy)-phenyl]- imidazo[l,5-a]pyrazin-3-yl}-cyclohexanecarboxylic acid methylamide: The amide coupling procedures applied to the synthesis of (trα«s-4-[8-Amino-l-(3-benzyloxy- phenyl)-imidazo[l,5-a]pyrazin-3-yl]-cyclohexanecarboxylic acid methylamide was applied to 4-{8-Amino-l-[3-(2,6-difluoro-benzyloxy)-phenyl]-imidazo[l,5-a]pyrazin-
3-yl}-cyclohexanecarhoxylic acid to afford the title compound; MS (ES+): m/z
492.12 [MH+].
Figure imgf000196_0002
[888]
[889] The following analytical conditions and equipment were utilized in
Examples 99-293:
[890] NMR spectra were acquired at 27 °C on a Varian Mercury 400 spectrometer operating at 400 MHz or on a Bruker AMX2 500 spectrometer operating at 500 MHz. Flow-injection samples were ran on a Bruker BEST system comprising the Bruker AMX2 50O spectrometer, a Gilson 215 autosampler, a heated transfer line and a Bruker 4mm FI-SEI NMR probe. The BEST system was controlled by XWP NMR software V2.6.
[891] Analytical LC/MS: Samples were analyzed on a multiplexed LC/MS system consisting of a Micromass LCT mass spectrometer with a 5 channel MUX interface, a Waters 1525 binary HPLC pump, 4 Jasco PU-1585 pumps, a CTC HTS PAL autosampler with 4 injection valves, a Waters 2488 UV detector and 4 Waters Atlantis C18 columns (3.1x30mm, 3μm). A water/acetonitrile + 0.1% formic acid gradient with a cycle time of 6 minutes and a flow rate of 0.85ml/min was used to elute the compounds. The UV detector was set to 220nm. The system was controlled by MassLynx 4.0 software.
[892] Mass-directed Purification: The Mass-directed Purification system consisted of a Micromass Platform LC mass spectrometer, a Waters 600 HPLC pump, a Waters Reagent Manager, a Waters 2700 autosampler, a Waters 996 PDA detector, a Waters Fraction Collector II and Waters Xtena Prep MS C18 columns (19x50mm). Compounds were eluted with variable water/acetonitrile + 0.1% formic acid gradients running over a period of 8 minutes. The flow rate was 20ml/min. The system was controlled by MassLynx and FractionLynx software V3.5.
[893] UV-directed Purification: UV-directed Purification was carried out on a 4 channel Biotage Parallex Flex system equipped with 4 Waters Xtena Prep MS C18 columns (19x50mm). Compounds were eluted using a water/acetonitrile + 0.1% formic acid gradient with a cycle time of 10 minutes and a flow rate of 20ml/min. UV detection was at 220nm and 254nm. The system was controlled by Biotage Parallex Flex software V2.9.
[894] Analytical LC/MS: Compounds are analyzed using an LC/MS method using the following parameters:
[895] FTPLC Gradient:
Solvent A - HPLC grade water + 0.1% Formic Acid
Solvent B - HPLC grade Acetonitrile +0.1% Formic Acid [896] Flow rate 0.85ml/min
0 - 0.3 mins 100% A
0.3 - 4.25 mins 100% A to 10% A
4.25 - 4.40 mins 10% A to 0% A
4.40 - 4.90 mins hold at 100% B
4.90 - 5.00 mins 0% A to 100% A
5.00 - 6.00 mins Hold at 100% A for re-equilibration
[897] Column: Waters Atlantis C18 3u 2.1x30mm with Phenomenex Polar
RP 4.0x2.0mm Guard column; UV Detection: 220nm; MS conditions: 80-700 amu scan; Sample cone 30V; Capillary 3.2k V;
[898] Methods run using the following equipment:
Waters 1525 Binary HPLC pump
4 x Jasco PU-1585 pumps
CTC HTS Pal Autosampler with 4 injection valves
Waters 2488 UV detector
Micromass LCT with 5 channel MUX interface
Data acquired using Masslynx V4.0
Mass-directed Purification
Micromass Platform LC Masslynx V3.5
Waters 600 HPLC pump Waters Reagent manager Waters 2700 Autosampler Waters Fraction Collector II Waters 996 PDA detector
Flow rate 20ml/min
Acetonitrile/Water + 0.1% Formic Acid with Gradient running over a period of 8 minutes.
Waters Xterra Prep MS C18 columns 19x50mm
UV-directed Purification
Biotage Parallex Flex 4 Channel UV prep system.
UV detection at 220 and 254nm
Waters Xtena Prep MS C18 columns 19x50mm
Acetonitrile/Water + 0.1% Formic Acid with Gradient ranning from 95% Aqueous to
100% Organic over a period of 10 minutes.
Flex software V2.9
[899] EXAMPLE 99: N-{3-[3-(8-Amino-3-cyclobutyl-imidazo[l,5- a]pyrazin-l-yl)-phenoxymethyl]-phenyl}-acetamide
Figure imgf000199_0001
[900] Argon was bubbled through a suspension of l-[3-(3-bromobenzyloxy)- phenyl]-3-cyclobutyl-imidazo[l,5-a]pyrazin-8-ylamine (1, 25 mg, 0.056 mmol), potassium carbonate (15 mg, 0.109 mmol), copper(I) iodide (10 mg, 0.052 mmol), acetamide (40 mg, 0.68 mmol) and N,N'-dimethylethylenediamine (5 mg, 0.057 mmol), in dioxane (0.5ml) in a thick walled 5 ml microwave tube. The tube was sealed and heated to 170 °C for 2 hours using the CEM Discover microwave oven at a maximum power of 250W. The reaction mixture was then partitioned between water (3 ml) and ethyl acetate (3 ml) and the aqueous layer was extracted with further ethyl acetate (2 x 3ml). The combined organic extracts were washed with water (2 x 3ml) and brine (3ml) then evaporated in vacuo. The residues after evaporation were dissolved in methanol and loaded on to lg SCX cartridges, then eluted with methanol and methanol/ammonia (concentrated aqueous ammonia in methanol, 3% v/v). Fractions containing product were combined and evaporated to furnish N-{3-[3-(8- Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)-phenoxymethyl]-ρhenyl}-acetamide as an off white solid (10 mg, 0.023 mmol, 42%, 85% pure). This was purified further using preparative mass directed HPLC purification (conditions) to afford 2 as an off white solid (6.3 mg, O.015 mmol, 27%; (M+H)+ m/z 428.2; Retention Time; 2.87 min; 1H-NMR (D4-MeOH) δ 7.72 (IH, br t), 7.53 (IH, br d, J = 8Hz), 7.49 (IH, t, J = 8Hz), 7.43 (IH, d, J = 5.1Hz), 7.35 (IH, t, 7.8Hz), 7.29 (IH, br t), 7.25 - 7.22 (2H, m), 7.17 (IH, dd, J = 2.8, 8.2Hz), 7.01 (IH, d, J = 5.1Hz), 5.21 (2H, s), 4.00 (IH, p, J = 8.4Hz), 2.55 (4H, m), 2.22 (IH, m), 2.15 (3H, s), 2.10 - 2.02 (IH, m). [901] The following Examples were synthesized following the method described for - {3-[3-(8-Amino-3-cyclobutyl-imidazo[ 1 ,5-a]pyrazin- 1 -yl)- phenoxymethyl]-phenyl} -acetamide.
Figure imgf000200_0001
Figure imgf000201_0001
Figure imgf000202_0001
[902] The following compounds were synthesized in the same manner using the isomeric l-[3-(2-bromobenzyloxy)-phenyl]-3-cyclobutyl-imidazo[l,5-a]pyrazin- 8-ylamine as starting material.
Figure imgf000203_0002
Figure imgf000204_0001
[903] General procedure for alkylation reactions of toluene-4-sulfonic acid 4-
[8 -amino- 1 -(3 -benzyloxy-phenyl)-imidazo [1,5 -a]pyrazin-3 -yl] -cyclohexylmethyl ester and toluene-4-sulfonic acid 4-[8-amino-l-(3-benzyloxy-phenyl)-imidazo[l,5- a]pyrazin-3-yl]-2-ethyl-butyl ester with amines
Figure imgf000205_0001
[905] EXAMPL 124: l-(3-Benzyloxy-phenyl)-3-(4-phenylaminomethyl- cyclohexyl)-imidazo[ 1 ,5-a]pyrazin-8-ylamine
[906] To a solution of toluene-4-sulfonic acid 4-[8-amino-l-(3-benzyloxy- phenyl)-imidazo[l,5-a]pyrazin-3-yl]-cyclohexylmethyl ester (29mg, 0.05mmol) in DMF (0.5ml) was added aniline (23 μl, 0.25mmol). The reaction was inadiated in the microwave (200W, 150°C, 10m), then evaporated to dryness. The cmde reaction product was dissolved in MeOH (2ml) and added to a pre- wetted MCX cartridge (6ml/500mg). The cartridge was washed with MeOH (10ml) and the product was then eluted using 1% NH3 in MeOH (15ml). The product was further purified using mass- directed HPLC, to give l-(3-benzyloxy-phenyl)-3-(4-phenylaminomethyl- cyclohexyl)-imidazo[l,5-a]pyrazin-8-ylamine formic acid salt (7.8mg, 31%) as an off-white solid: IH NMR (400MHz, CD3OD) δ 8.25 (s, IH), 7.60 (d, IH, J = 5.5 Hz), 7.48 - 7.41 (m, 3H), 7.36 (t, 2H, J = 7.3 Hz), 7.33 - 7.27 (m, IH), 7.25 - 7.22 (m, IH), 7.18 (d, IH, J = 7.4 Hz), 7.13 (dd, IH, J = 5.5 Hz, 2.3 Hz), 7.08 (t, 2H, J = 7.8 Hz), 6.97 (d, IH, J = 5.5 Hz), 6.63 (d, 2H, J = 7.4 Hz), 6.58 (t, IH, J = 7.4 Hz), 5.16 (s, 2H), 3.12 (m, IH), 3.00 (d, 2H, J = 6.7 Hz), 2.06 (br. d, 4H, J = 11.7 Hz), 1.88 - 1.70 (m, 3H), 1.30 - 1.22 (m, 2H), 3H not observed (NH2 an H); MS (ES+) m/z 504.24 [MH+] at Rt 3.47 min.
Figure imgf000206_0001
Figure imgf000206_0002
Figure imgf000207_0001
Figure imgf000208_0001
2005/037836
Figure imgf000209_0001
Figure imgf000210_0001
Figure imgf000210_0002
Figure imgf000211_0001
[907] General procedure for amide couplings of 4-[8-amino-l -(3-benzyloxy- phenyl)-imidazo[l,5-a]pyrazin-3-yl]-cyclohexanecarboxylic acid with amines
Figure imgf000212_0001
[909] EXAMPLE 175: 4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5- a]pyrazin-3-yl]-cyclohexanecarboxylic acid (2-diethylamino-ethyl)-amide
[910] To a stined solution of 2-(dimethylamino)ethylamine (11.6mg,
O.lmmol) in MeCN (0.4ml) was added 4M HCl in 1,4-dioxane (0.1ml, 0.4mmol). After stirring for 1 hour at room temperature, a solution of 4-[8-amino-l-(3- benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin-3-yl]-cyclohexanecarboxylic acid (22mg, 0.05mmol) in DMF (1ml) was added, followed by a solution of EDCI.HCI (14.3mg, 0.075mmol), HOAt (10.2mg, 0.075mmol) and a catalytic amount of DMAP in DMF (0.5ml). DIPEA (0.087ml, 0.5mmol) was added, and the reaction was stined at room temperature overnight. The reaction mixture was poured onto saturated aqueous NaHCO solution (10ml) and extracted with EtOAc (2 x 10ml). The combined organics were washed with brine (3 x 10ml), dried (MgSO ), filtered and concentrated in vacuo. The crude product was purified using mass-directed HPLC to give 4-[8- Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]-cyclohexanecarboxylic acid (2-diethylamino-ethyl)-amide fe-formic acid salt (10.8mg, 40%) as an off-white solid: IH NMR (400MHz, CD3OD) δ 8.38 (s, 2H), 7.60 (d, IH, J = 5.4 Hz), 7.47 - 7.43 (m, 3H), 7.37 (t, 2H, J = 7.4 Hz), 7.33 - 7.28 (m, IH), 7.24 (s, IH), 7.19 (d, IH, J = 7.4 Hz), 7.15 - 7.13 (dd, IH, J = 5.3 Hz, 2.4 Hz), 6.99 (d, IH, 5.5 Hz), 5.17 (s, 2H), 3.56 (t, 2H, J = 6.1 Hz), 3.32 - 3.24 (m, 6H), 3.18 (t, IH, J = 10.0 Hz), 2.38 (t, IH, J = 8.4 Hz), 2.10 (dd, 2H, J = 7.9 Hz, 2.4 Hz), 2.01 (dd, 2H, J = 6.7 Hz, 2.7 Hz), 1.89 - 1.66 (m, 4H), 1.34 (t, 6H, J = 7.4 Hz), 3H not observed (NH2 & NH); LCMS (ES+) m/z 541.01 [MH+] at Rt 2.99 min.
Figure imgf000213_0001
Figure imgf000213_0002
2005/037836
Figure imgf000214_0001
Figure imgf000215_0001
Figure imgf000216_0001
Figure imgf000217_0002
[911] General procedure for phenolic alkylations of 3-(8-Amino-3- cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)-phenol with alkyl halides
[912]
Figure imgf000217_0001
[913] EXAMPLE 211: 2-[3-(8-Amino-3-cyclobutyl-imidazo[ 1 ,5- a]pyrazin-l-yl)-phenoxy]-ethanol
[914] To a solution of 3-(8-amino-3-cyclohutyl-imidazo[l,5-a]pyrazin-l-yl)- phenol (28mg, O.lmmol) in anhydrous DMF (1ml) was added cesium carbonate (49mg, 0.15mmol) followed by a solution of 2-bromoethanol (12.5mg, O.lmmol) in DMF (0.5ml). The reaction was stined at 60 °C overnight. The reaction was poured onto saturated NaHCO3 (10ml) and extracted with EtOAc (2 x 10ml). The combined organics were washed with water (10ml) and aqueous brine solution (3 x 10ml), dried (MgSO4), filtered and concentrated in vacuo. Purification by mass-directed HPLC gave 2-[3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)-phenoxy]-ethanol formic acid salt (4.0mg, 12%) as an off-white solid: IH NMR (400MHz, CD3OD) δ 8.54 (s, IH), 7.48 - 7.41 (m, 2H), 7.13 - 7.09 (m, 2H), 7.01 (d, IH, J = 10.3 Hz), 6.93 (d, IH, J = 5.8 Hz), 4.14 (t, 2H, J = 4.9 Hz), 4.03 - 3.97 m, IH), 3.92 (t, 2H, J = 4.9 Hz), 2.61 - 2.51 (m, 4H), 2.15 - 2.10 (m, IH), 2.06 - 2.01 (m, IH), 3H not observed (NH2 & OH); LCMS (ES+) m/z 325.08 [MH+] at Rt 2.39 min.
Figure imgf000218_0001
Figure imgf000218_0002
Figure imgf000219_0001
05/037836
Figure imgf000220_0001
Figure imgf000221_0002
[915] General procedure for phenolic alkylations of 3-(8-Amino-3- cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)-phenol with benzyl halides [916]
Figure imgf000221_0001
[917] EXAMPLE 236: 3-Cyclob tyl-l-[3-(3-methoxy-benzyloxy)~phenyl]- imidazo[ 1 ,5-a]pyrazin-8-ylamine
[918] To a solution of 3-(8-amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)- phenol (28mg, O.lmmol) in anhydrous DMF (1ml) was added cesium carbonate (49mg, 0.15mmol) followed by a solution of 3-methoxybenzyl bromide (20mg, O.lmmol) in DMF (0.5ml). The reaction was stirred at room temperature overnight. The reaction was poured onto saturated NaHCO3 (10ml) and extracted with EtOAc (2 x 10ml). The combined organics were washed with water (10ml) and aqueous brine solution (3 x 10ml), dried (MgSO ), filtered and concentrated in vacuo, to give 3- cyclobutyl-l-[3-(3-methoxy-benzyloχy)-phenyl]-imidazo[l,5-a]pyrazin-8-ylamine as a brown solid (24.1mg, 60%): IH NMR (400MHz, CDC13) δ 7.42 (t, IH, J = 7.8 Hz), 7.35 - 7.27 (m, 3H), 7.13 (d, IH, J = 5.1 Hz), 7.08 - 7.03 (m, 4H), 6.90 (d, IH, J = 8.6 Hz), 5.17 (s, 2H), 3.84 (s, 3H), 3.86 - 3.79 (m, IH, obscured), 2.72 - 2.62 (m, 2H), 2.56 - 2.47 (m, 2H), 2.25 - 2.14 (m, IH), 2.11 - 2.02 (m, IH), 2H not observed (NH2); LCMS (ES+) m/z 401.34 [MH+] at Rt 3.20 min.
Figure imgf000222_0001
[919]
Figure imgf000222_0002
2005/037836
Figure imgf000223_0001
2005/037836
Figure imgf000224_0001
2005/037836
Figure imgf000225_0001
Figure imgf000226_0001
Figure imgf000227_0002
[920] General procedure for SNAT reactions of l-(3-Benzyloxy-phenyl)-8- chloro-3-cyclobutyl-imidazo[l,5-a]pyrazine with amines
[921]
Figure imgf000227_0001
[922] EXAMPLE 281: [l-(3-Benzyloxy-phenyl)-3-cyclobutyl-imidazo[l,5- a]pyrazin-8 -yl] -isopropyl-amine
[923] To a solution of l-(3-benzyloxy-phenyl)-8-chloro-3-cyclobutyl- imidazo[l,5-a]pyrazine (30mg, 0.075mmol) in NMP (0.4ml) was added isopropylamine (44mg, 0.75mmol). The reaction was irradiated in the microwave (200W, 150°C, 5min.) and then poured onto water (10ml) and extracted with EtOAc (2 x 10ml). The combined organics were washed with brine (3 x 10ml), dried (MgSO4), filtered and evaporated to dryness. Purification by mass-directed HPLC gave [l-(3-Benzyloxy-phenyl)-3-cyclobutyl-imidazo[l,5-a]pyrazin-8-yl]-isopropyl- amine formic acid salt (1 l.Omg, 36%) as a colorless solid: IH NMR (400MHz, CD3OD) δ 8.21 (s, IH), 7.49 (d, 3H, J = 8.2 Hz), 7.44 - 7.31 (m, 4H), 7.29 (s, IH), 7.24-7.17 (m, 2H), 7.04 (d, IH, J = 5.1 Hz), 5.21 (s, 2H), 4.24-4.11 (m, IH), 4.04- 3.94 (m, IH), 2.64-2.47 (m, 4H), 2.28-2.17 (m, IH), 2.10-2.01 (m, IH), 1.14 (d, 6H, J = 6.7 Hz), IH not observed (NH); LCMS (ES+) m/z 413.21 [MH+] at Rt 3.40 mm.
Figure imgf000228_0001
[924]
Figure imgf000228_0002
Figure imgf000229_0001
[925] EXAMPLE 294: 8-Amino-l-(3-Benzyloxy-2-fluorophenyl)-3- cyclobutylimidazo[l,5-a]pyrazine: l-(3-Benzyloxy-2-fluoro-phenyl)-8-chloro-3- cyclobutyl-imidazo[l,5-a]pyrazine (500 mg, 1.2 mmole) in methylene chloride was placed in a Parr pressure reactor, cooled in ice salt bath and charged with a saturated solution of NH3 in 2-propanol (10 mL). The pressure reactor was heated at 125°C overnight. The reaction was cooled to room temperature and the crude reaction mixture was evaporated and triturated with methylene chloride and filtered. The filtrate was evaporated to dryness and purified by silica-gel column chromatography [eluant CH2Cl2:hexane (70:30)] to afford the title compound (350 mg, 75%); FAB- MS: m/z 388.9 (M + H)*. [926]
Figure imgf000230_0001
[927] a) l-(3-Benzyloxy-2-fluorophenyl)-8-chloro-3-cyclobutylimidazo[l,5- a]pyrazine: Cyclobutanecarboxylic acid [(3-benzyloxy-2-fluoro-phenyl)-(3-chloro- pyrazin-2-yl)-methyl] -amide (0.850 g, 2 mmole) was dissolved in POCl (6 mL) and heated at 55°C overnight. The excess POCl3 was removed in vacuo. The residue was cooled to 0°C and charged with a saturated solution of NH3 in 2-propanol (6 mL). The mixture was left overnight at room temperature. The separated solid was then filtered and washed with methylene chloride. The filtrate was evaporated to dryness and purified by silica-gel column chromatography using hexane:ethyl acetate (60:40) as the eluant to afford the title compound (615 mg, 75%). FAB-MS: m/z 408.3 (M + H)*. [928]
Figure imgf000230_0002
[929] b) N-[(3-benzyloxy-2-fluorophenyl) (3-chloropyrazin-2-yl)methyl] cyclobutylcarboxamide: To a solution of C-(3-benzyloxy-2-fluoro-phenyl)-C-(3- chloro-pyrazin-2-yl)-methylamine (1.1 g, 3.2 mmole) in methylene chloride (10 mL) was added diisopropylethylamine (1.1 mL, 6.4 mmole) under a nitrogen atmosphere. The reaction mixture was cooled in an ice bath and cyclobutanecarboxylic acid chloride (0.55 mL, 4.8 mmole) was added in one portion. The reaction mixture was stirred overnight at room temperature then quenched with water (10 mL). The organic layer separated and washed with 10% aqueous ΝaHCO3, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column chromatography using hexane:ethyl acetate (60:40) as an eluant to give the title compound (911 mg, 67%). FAB-MS: m/z 426.3 (M + H)+. [930]
Figure imgf000231_0001
[931] c) (3-Benzyloxy-2-fluorophenyl) (3-chloropyrazin-2-yl) aminomethane: A mixture of 2-[(3-benzyloxy-2-fluoro-phenyl)-(3-chloro-pyrazin-2- yl)-methyl]-isoindole-l,3-dione (1.63 g, 3.45 mmole) and hydrazine (0.270 mL, 8.6 mmole) in ethanol (30 mL) and methylene chloride (10 mL) was stirred at room temperature under nitrogen. After 65 h, separated phthalazine-l,4-dione solid was filtered, and the solid cake was washed with methylene chloride. The filtrate was concentrated in vacuo to obtain red oil comprising the desired title compound, which solidified on standing (1.0 g, 85%).
Figure imgf000232_0001
[932] d) 2-[(3-Benzyloxy-2-fluoro-phenyl)-(3-chloro-pyrazin-2-yl)-methyl]- isoindole-l,3-dione: In a 250 mL three-necked flask, equipped with a N -inlet and a thermometer was placed triphenylphosphine (3.28 g, 12.5 mmole) in THF (30 mL). The mixture was cooled to 0 to 5°C and DEAD (1.97 mL, 12.5 mmole) was added slowly in 15 minutes while maintaining the temperature at 0-3 °C. Stirring was continued for a further 30 minutes at the same temperature. To the cold solution was then added a solution of (3-benzyloxy-2-fluorophenyl) (3-chloropyrazin-2-yl) carbinol (1.96 g, 5.685 mmole) and phthalimide (8, 1.0 g, 6.8 mmole) in THF (30 mL) at 0-5°C over 10 min. The temperature was slowly allowed to rise to room temperature and then left stirring overnight. The reaction mixture was concentrated in vacuo and purified by column chromatography using hexane: ethyl acetate (70:30) as the eluant. The pure desired product was obtained. [933]
Figure imgf000232_0002
[934] e) (3-Benzyloxy-2-fluoroρhenyl) (3-chloropyrazin-2-yl) carbinol: In a
100 mL three-necked round-bottom flask equipped with a N2-inlet and a thermometer was placed THF (28 mL). This was cooled to -40°C and there was added 2.5 M solution of n-BuLi in hexane (11.52 mL, 28.8 mmole) followed by 2,2,6,6- tetramethylpiperidine (4.84 mL, 28.8 mmole). The temperature of the mixture was allowed to rise to 0°C and stirring was continued at -5 to 0°C for 30 minutes. The mixture was then cooled to -70°C, and the chloropyrazine (1.28 mL, 14.4 mmole) was added slowly over 15 minutes and the stirring was continued for 30 minutes. A solution of 3-benzyloxy-2-fluorobenzaldehyde (3.04 g. 13.2 mmole) in THF (7 mL) was then added at -70°C and stirring was continued at -70 to -60°C for 2 h. There after the temperature was allowed to rise to room temperature over 1 h. The reaction mixture was quenched with 2 N HCl (6 mL) and stirred overnight at room temperature. The mixture was then evaporated on a rotary evaporator to remove most of the THF. Ethyl acetate (20 mL) was added to the residue. The organic layer was separated, washed with water (10 mL), finally with brine (10 mL), dried over Na2SO , filtered and concentrated. The crude residue obtained was 4.4 g. The above reaction was repeated four times and the products were combined. This was purified by silica- gel column chromatography using as the eluent ethyl acetate: hexane (30:70) and the title compound (3.8 g, 21%) was obtained. [935] [936] f) 3-Benzyloxy-2-fluorobenzaldehyde: 3- Hydroxy-2-
Figure imgf000233_0001
fluorobenzaldehyde {reported by Kirk et. al., J Med. Chem. 1986, 29, 1982} (15 g,
107 mmole) was added to an aqueous NaOH solution {(5.14 g, 128 mmole in water
(50 mL)} and the mixture was stirred for 5 min to effect complete dissolution. To this was added a solution of benzyl bromide (16.46 g, 96.3 mmole) in methylene chloride
(75 mL) followed by tetrabutylarnmonium iodide (0.5 g, 1.35 mmole) and vigorous stirring was continued overnight. The organic layer was separated and the aqueous layer was extracted with methylene chloride (100 mL). The combined organic layers were washed with 5% aqueous NaOH solution (2 x 25 mL) followed by water (50 mL) and finally with brine (20 mL). This solution was dried over anhydrous Na2SO , filtered and evaporated to dryness. The resulting crude light yellow solid was crystallized from cyclohexane (150 mL) to afford the title compound (16.5 g, 75%); mp 88-89 °C.

Claims

WHAT IS CLAIMED IS: 1. A compound represented by Formula I:
Figure imgf000234_0001
or a pharmaceutically acceptable salt thereof, wherein: Q1 is aryl1, heteroaryl1, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one to five independent
G1 substituents; R1 is alkyl, cycloalkyl, bicycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, or heterobicycloalkyl, any of which is optionally substituted by one or more independent G11 substituents; G1 and G41 are each independently halo, oxo, -CF3, -OCF3, -OR2,
-NR2R3(R3a)ii, -C(O)R2, -CO2R2, -CONR2R3, -NO2, -CN, -S(O)j!R2, -SO2NR2R3,
NR2(C=O)R3, NR2(C=O)OR3, NR2(C=O)NR2R3, NR2S(O)jlR3, -(C=S)OR2,
-(C=O)SR2, -NR2(C=NR3)NR2aR3a, -NR2(C=NR3)OR2a, -NR2(C=NR3)SR3a,
-O(C=O)OR2, -O(C=O)NR2R3, -O(C=O)SR2, -S(C=O)OR2, -S(C=O)NR2R3, C0- loalkyl, C -10alkenyl, C2-1oalkynyl,
Figure imgf000234_0002
C1-10alkoxyC2-1oalkenyl, Q.
1oalkoxyC2-1oalkynyl, CMoalkylthioCi-ioalkyl, C1-10alkylthioC2-10alkenyl, Ci-
1oalkylthioC2-1oalkynyl, cycloC -8alkyl, cycloC3-8alkenyl, cycloC3-8alkylC1-10alkyl,
Figure imgf000234_0003
cycloC3-8alkylC2-10alkenyl, cycloC3-8alkenylC2-ι0alkenyl, cycloC3-8alkylC2-1oalkynyl, cycloC3-8alkenylC2-1oalkynyl, heterocyclyl-C0-ioalkyl, heterocyclyl-C2-1oalkenyl, or heterocyclyl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, oxo, -CF , -OCF , -OR222,
-NR222R333(R333a)jla, -C(O)R222, -CO2R222, -CONR222R333, -NO2, -CN,
-S(O)jlaR222, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333,
NR222(C=O)NR222R333, NR222S(O)jlaR333, -(C=S)OR222, -(C=O)SR222, -NR222(C=NR333)NR222aR333a, -NR222(C=NR333)OR222a, -NR222(C=NR333)SR333a,
-O(C=O)OR222, -O(C=O)NR222R333, -O(C=O)SR222, -S(C=O)OR222, or
-S(C=O)NR222R333 substituents; or -(X1)n-(Y1)m-R4; or aryl-C0-10alkyl, aryl-C2-10alkenyl, or aryl-C2-10alkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333(R333a)j2a,
-C(O)R222, -CO2R222, -CONR222R333, -NO2, -CN, -S(O)j2aR222, -SO2NR222R333,
NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j2aR333,
-(C=S)OR222, -(C=O)SR222, -NR222(C=NR333)NR222aR333a, -NR222(C=NR333)OR222a,
-NR222(C=NR333)SR333a, -O(C=O)OR222, -O(C=O)NR222R333, -O(C=O)SR222,
-S(C=O)OR222, or -S(C-O)NR222R333 substituents; or hetaryl-C0-10alkyl, hetaryl-C2-10alkenyl, or hetaryl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333(R333a)j3a,
-C(O)R222, -CO2R222, -CONR222R333, -NO2, -CN, -S(O)j3aR222, -SO2NR222R333,
NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j3aR333,
-(C=S)OR222, -(C=O)SR222, -NR222(C=NR333)NR222aR333a, -NR222(C=NR333)OR222a,
-NR222(C=NR333)SR333a, -O(C=O)OR222, -O(C=O)NR222R333, -O(C=O)SR222,
-S(C=O)OR222, or -S(C=O)NR222R333 substituents; G11 is halo, oxo, -CF3, -OCF3, -OR21, -NR21R31(R3al)j4, -C(O)R21, -CO2R21,
-CONR21R31, -NO2, -CN, -S(O)j4R21, -SO2NR21R31, NR21(C=O)R31,
NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31, -(Q=S)OR21, -(C=O)SR21,
-NR21(G=NR31)NR2alR3al, -NR21(C=NR31)OR2al, -NR21(C=NR31)SR3al,
-O(C=O)OR21, -O(C=O)NR21R31, -O(C ))SR21, -S(CO)OR21, -S(C ))NR21R31,
-P(O)OR21OR31, Co.ιoalkyl, C2_10alkenyl, C2-10alkynyl, C1-10alkoxyC1-10alkyl,
C1-10alkoxyC2-10alkenyl, C1-10alkoxyC2-10alkynyl, -ioalkylthioCi-ioalkyl,
C1-1oalkylthioC2-10alkenyl, C1-1oalkylthioC2-10alkynyl, cycloC3-8alkyl, cycloC3-8alkenyl, cycloC3-8alkylC1-10alkyl, cycloC3-8alkenylC1-10alkyl, cycloC3-8alkylC2-1oalkenyl, cycloC3-8alkenylC2-ιoalkenyl, cycloC3-8alkylC2-1oalkynyl, cycloC3-8alkenylC2-10alkynyl, heterocyclyl-C0-1oalkyl, heterocyclyl-C2-10alkenyl, or heterocyclyl-C2-10alkynyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j4a, -C(O)R2221,
-CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j4aR2221, -SO2NR2221R3331,
NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C-S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al, -NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(CO)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, -P(O)OR2221OR3331, or -S(C=O)NR2221R3331 substituents; or aryl-C0-ιoalkyl, aryl-C2-10alkenyl, or aryl-C2- 10alkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j5a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j5aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j5aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR2 2al, -NR2221(C-NR3331)SR333al, -O(C=O)OR2221, -O(CO)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, -P(O)OR2221OR3331, or -S(C=O)NR2221R3331 substituents; or hetaryl-Co-ioalkyl, hetaryl-C2-10alkenyl, or hetaryl-C2-10alkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR , -NR2221R3331(R333al)j6a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j6aR2221, -SO2NR2 21R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j6aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al, -NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, -P(O)OR2221OR3331, or -S(C=O)NR2221R3331 substituents; or G11 is taken together with the carbon to which it is attached to form a double bond which is substituted with R5 and G111; τ>2 D2a -,-, 3 τ>3a >222 τ>222a τ>333 τ 333a r>21 τ)2al r,31 τ 3al τ>2221 r)222al τ 3331 JK. , JS. , . , is. , . , , K , K. , K , is. , is. , is. , is. , . , is. , and R333al are each independently equal to Co.10alkyl, C2-10alkenyl, C2-10alkynyl, d.^alkoxyCMoalkyl, C1-10alkoxyC2-1oalkenyl, C1-1oalkoxyC2-1oalkynyl, C1- 0alkylthioC1-10alkyl, C1-10alkylthioC2-10alkenyl, C1-10alkylthioC2-1oalkynyl, cycloC3-8alkyl, cycloC3-8alkenyl, cycloC3-8alkylC1-10allcyl, cycloCs-salkenylCi-ioalkyl, cycloC3-8alkylC2-1oalkenyl, cycloC3-8alkenylC2-10alkenyl, cycloC3_8alkylC2-10alkynyl, cycloC3.8alkenylC2-1oalkynyl, heterocyclyl-Co-ioalkyl, heterocyclyl-C2-10alkenyl, or heterocyclyl-C2-1oalkynyl, any of which is optionally substituted by one or more G 111 substituents; or aryl-Co-ι0alkyl, aryl-C2-10alkenyl, or aryl-C2-1oalkynyl, hetaryl-C0-1oalkyl, hetaryl-C2-10alkenyl, or hetaryl-C2-10alkynyl, any of which is optionally substituted by one or more G111 substituents; or in the case of -NR2R3(R3a)jl or -NR222R333(R333a)jla or -NR222R333(R333a)j2a or
_NR2221R3331(R333al).3a Qτ _NR2221R3 31(R333a1)j4a of _NR2221R3331(R333al)j5a Qr
-NR2221R3331(R333al)j6a, R2 and R3 or R222 and R333 or R2221 and R3331 taken together with the nitrogen atom to which they are attached form a 3-10 membered saturated ring, unsaturated ring, heterocyclic saturated ring, or heterocyclic unsaturated ring, wherein said ring is optionally substituted by one or more G substituents; X1 and Y1 are each independently -O-, -NR7-, -S(O)j7- -CR5R6-, -N(C(O)OR7)-, -N(C(O)R7)-, -N(SO2R7)-, -CH2O- -CH2S- -CH2N(R7)-, -CH(NR7)-, -CH2N(C(O)R7)-, -CH2N(C(O)OR7)-, -CH2N(SO2R7)- -CH(NHR7)- -CH(NHC(O)R7)-, -CH(NHSO2R7)-, -CH(NHC(O)OR7)-, -CH(OC(O)R7)-, -CH(OC(O)NHR7)-, -CH=CH-, -C - -, -C(=NOR7)-, -C(O)-, -CH(OR7)-, -C(O)N(R7)-, -N(R7)C(O)-, -N(R7)S(O)-, -N(R7)S(O)2- -OC(O)N(R7)-, -N(R7)C(O)N(R7)-, -NR7C(O)O- -S(O)N(R7)-, -S(O)2N(R7)-, -N(C(O)R7)S(O)-, -N(C(O)R7)S(O)2- -N(R7)S(O)N(R7)-, -N(R7)S(O)2N(R7)-, -C(O)N(R7)C(O)-, -S(O)N(R7)C(O)-, -S(O)2N(R7)C(O)-, -OS(O)N(R7)-, -OS(O)2N(R7)-, -N(R7)S(O)O- -N(R7)S(O)2O- -N(R7)S(O)C(O)-, -N(R7)S(O)2C(O)-, -SON(C(O)R7)-, -SO2N(C(O)R7)-, -N(R7)SON(R7)-, -N(R7)SO2N(R7)-, -C(O)O-, -N(R7)P(OR8)O-, -N(R7)P(OR8)-, -N(R7)P(O)(OR8)O-, -N(R7)P(O)(OR8)-, -N(C(O)R7)P(OR8)O-, -N(C(O)R7)P(OR8)-, -N(C(O)R7)P(O)(OR8)O- -N(C(O)R7)P(OR8)-, -CH(R7)S(O)-, -CH(R7)S(O)2-, -CH(R7)N(C(O)OR7)-, -CH(R7)N(C(O)R7)-, -CH(R7)N(SO2R7)-, -CH(R7)O-, -CH(R7)S- -CH(R7)N(R7)-, -CH(R7)N(C(O)R7)-, -CH(R7)N(C(O)OR7)-, -CH(R7)N(SO2R7)-, -CH(R7)C(=NOR7)-, -CH(R7)C(O)-, -CH(R7)CH(OR7)-, -CH(R7)C(O)N(R7)-, -CH(R7)N(R7)C(O)-, -CH(R7)N(R7)S(O)-, -CH(R7)N(R7)S(O)2-, -CH(R7)OC(O)N(R7)-, -CH(R7)N(R7)C(O)N(R7)-, -CH(R7)NR7C(O)O-, -CH(R7)S(O)N(R7)-, -CH(R7)S(O)2N(R7)-, -CH(R7)N(C(O)R7)S(O)-, -CH(R7)N(C(O)R7)S(O)-, -CH(R7)N(R7)S(O)N(R7)-, -CH(R7)N(R7)S(O)2N(R7)-, -CH(R7)C(O)N(R7)C(O)-, -CH(R7)S(O)N(R7)C(O)-, -CH(R7)S(O)2N(R7)C(O)-, -CH(R7)OS(O)N(R7)-, -CH(R7)OS(O)2N(R7)-, -CH(R7)N(R7)S(O)O-, -CH(R7)N(R7)S(O)2O-, -CH(R7)N(R7)S(O)C(O)-, -CH(R7)N(R7)S(O)2C(O)-, -CH(R7)SON(C(O)R7)-, -CH(R7)SO2N(C(O)R7)-, -CH(R7)N(R7)SON(R7)-, -CH(R7)N(R7)SO2N(R7)-, -CH(R7)C(O)O-, -CH(R7)N(R7)P(OR8)O-, -CH(R7)N(R7)P(OR8)-, -CH(R7)N(R7)P(O)(OR8)O-, -CH(R7)N(R7)P(O)(OR8)-, -CH(R7)N(C(O)R7)P(OR8)O-, -CH(R7)N(C(O)R7)P(OR8)-, -CH(R7)N(C(O)R7)P(O)(OR8)O-, or -CH(R7)N(C(O)R7)P(OR8)-; or X1 and Y1 are each independently represented by one of the following structural formulas:
Figure imgf000238_0001
R10, taken together with the phosphinamide or phosphonamide, is a 5-, 6-, or 7-membered aryl, heteroaryl or heterocyclyl ring system; R5, R6, and G111 are each independently a C0-10alkyl, C2-ιoalkenyl, C2- ioalkynyl,
Figure imgf000238_0002
C1-10alkoxyC2-1oalkenyl, C1-ιoalkoxyC2-1oalkynyl, Ci.walkylthioC io lkyl, C1-1oalkylthioC2-1oalkenyl, C1-10alkylthioC2-1oalkynyl, cycloC3-8alkyl, cycloC3-8alkenyl, cycloCs-salkylC oalkyl, cycloCs-salkenylCi-ioalkyl, cycloC3-8alkylC2-1oalkenyl, cycloC3-8alkenylC2-10alkenyl, cycloC -8alkylC2-ι0alkynyl, cycloC3-8alkenylC2-1oalkynyl, heterocyclyl-C0-1oalkyl, heterocyclyl-C2-1oalkenyl, or heterocyclyl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR77, -NR77R87, -C(O)R77, -CO2R77, -CONR77R87, -NO2, -CN, -S(O)j5aR77, -SO2NR77R87, NR77(C=O)R87, NR77(C=O)OR87, NR77(C=O)NR78R87, NR77S(O)j5aR87, -(C=S)OR77, -(C=O)SR77, -NR77(C=NR87)NR78R88, -NR77(C=NR87)OR78, ~NR77(C=NR87)SR78, -O(C=O)OR77, -O(C=O)NR77R87, -O(C=O)SR77, -S(C=O)OR77, -P(O)OR77OR87, or -S(C=O)NR77R87 substituents; or aryl-C0-ι0alkyl, aryl-C2-1oalkenyl, or aryl-C2-ι0alkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR77, -NR77R87, -C(O)R77, -CO2R77, -CONR77R87, -NO2, -CN, -S(O)j5aR77, -SO2NR77R87, NR77(C=O)R87, NR77(C=O)OR87, NR77(C=O)NR78R87, NR77S(O)j5aR87, -(C=S)OR77, -(C=O)SR77, -NR77(C=NR87)NR78R88, -NR77(C=NR87)OR78, -NR77(C=NR87)SR78, -O(C=O)OR77, -O(C=O)NR77R87, -O(C=O)SR77, -S(C=O)OR77, -P(O)OR77OR87, or -S(C=O)NR77R87 substituents; or hetaryl-Co-ioalkyl, hetaryl-C2-1oalkenyl, or hetaryl-C2-10alkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR77, -NR77R87, -C(O)R77, -CO2R77, -CONR77R87, -NO2, -CN, -S(O)j5aR77, -SO2NR77R87, NR77(C=O)R87, NR77(C=O)OR87, NR77(C=O)NR78R87, NR77S(O)j5aR87, -(C=S)OR77, -(C=O)SR77, -NR77(C=NR87)NR78R88, -NR77(C=NR87)OR78, -NR77(C=NR87)SR78, -O(d=O)OR77, -O(C=O)NR77R87, -O(C=O)SR77, -S(C=O)OR77, -P(O)OR77OR87, or -S(C=O)NR77R87 substituents; or R5 with R6 taken together with the respective carbon atom to which they are attached, form a 3-10 membered saturated or unsaturated ring, wherein said ring is optionally substituted with R69; or R5 with R6 taken together with the respective carbon atom to which they are attached, form a 3-10 membered saturated or unsaturated heterocyclic ring, wherein said ring is optionally substituted with R ; R and R are each independently H, acyl, alkyl, alkenyl, aryl, heteroaryl, heterocyclyl or cycloalkyl, any of which is optionally substituted by one or more G111 substituents; R4 is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more G41 substituents; R69 is equal to halo, -OR78, -SH, -NR78R88, -CO2R78, -CONR78R88, -NO2, -CN, -S(O)j8R78, -SO2NR78R88, C0-10alkyl, C2-10alkenyl, C2-10alkynyl, C_. 10alkoxyC1-10alkyl, C1-1oalkoxyC2-1oalkenyl, d-ioaUcoxyd-ioalkynyl, d_ ioalkylthioCi-ioalkyl, C1-1oalkylthioC2-ιoalkenyl, C1-10alkylthioC2-1oalkynyl, cycloC3-8alkyl, cycloC3-8alkenyl, cycloCs-salkyld-ioalkyl, cycloCs-salkenylC ioalkyl, cycloC3-8alkylC2-10alkenyl, cycloC3-8alkenylC2-10alkenyl, cycloC3-8alkylC2-1oallcynyl, cycloC3-8alkenylC2-10alkynyl, heterocyclyl-C0-10alkyl, heterocyclyl-C2-ι0alkenyl, or heterocyclyl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, cyano, nitro, -OR778, -SO2NR778R888, or -NR778R888 substituents; or aryl-Co-ioalkyl, aryl-C2-10alkenyl, or aryl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, cyano, nitro, -OR , C1-10alkyl, d-ioalkenyl, C2-1oalkynyl, haloCi-ioalkyl, haloC2-1oalkenyl, haloC2.1oalkynyl, -COOH, C1-4alkoxycarbonyl, -CONR778R888, -SO2NR778R888, or -NR778R888 substituents; or hetaryl-C0-1oalkyl, hetaryl-C2-10alkenyl, or hetaryl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, cyano, nitro, -OR778, C1-10alkyl, C2-ιoalkenyl, C2-1oalkynyl, haloCι-10alkyl, haloC2-ιoalkenyl, haloC2_ι0alkynyl, -COOH, C1-4alkoxycarbonyl, -CONR778R888, -SO2NR778R888, or -NR778R888 substituents; or mono(C1-6alkyl)aminoCι-6alkyl, di(C1- 6alkyl)aminoC1-6alkyl, mono(aryl)aminoC1-6alkyl, di(aryl)aminoC1-6alkyl, or -N(C1-6alkyl)-C1-6alkyl-aryl, any of which is optionally substituted with one or more independent halo, cyano, nitro, -OR778, C1-10alkyl, C2-1oalkenyl, C2-1oalkynyl, halod-ioalkyl, haloC2-10alkenyl, haloC2-10alkynyl, -COOH, C1- alkoxycarbonyl, -CONR778R888, -SO2NR778R888, or -NR778R888 substituents; or in the case of -NR78R88, R78 and R88 taken together with the nitrogen atom to which they are attached form a 3-10 membered saturated ring, unsaturated ring, heterocyclic saturated ring, or heterocyclic unsaturated ring, wherein said ring is optionally substituted with one or more independent halo, cyano, hydroxy, nitro, Ci-ioalkoxy, -SO2NR778R888, or -NR778R888 substituents; R77, R78, R87, R88, R778, and R888 are each independently C0-ιoalkyl, C2-10alkenyl, C2-ι0alkynyl, C1-10alkoxyC1-10alkyl, C1-1oalkoxyC2-10alkenyl, Cι-10alkoxyC2-1oalkynyl, C1-10alkylthioC1-10alkyl,
Figure imgf000240_0001
C1-1oalkylthioC2-10alkynyl, cycloC3-8alkyl, cycloC3-8alkenyl, cycloC3-8alkylC1-10alkyl, cycloCs-salkenyld.ioalkyl, cycloC3-8alkylC2-ι0alkenyl, cycloC3-8alkenylC2-10alkenyl, cycloC3-8alkylC2-ιoalkynyl, cycloC3-8alkenylC2-10alkynyl, heterocyclyl-Co-ioalkyl, heterocyclyl-C2-10alkenyl, heterocyclyl-C2-1oalkynyl, d-^alkylcarbonyl, C2-1oalkenylcarbonyl, C2-1oalkynylcarbonyl, C1-10alkoxycarbonyl, Ci.ϊoalkoxycarbonylCj.ioalkyl, monoC1-6alkylaminocarbonyl, diC1-6alkylaminocarbonyl, mono(aryl)aminocarbonyl, di(aryl)aminocarbonyl, or
Figure imgf000240_0002
any of which is optionally substituted with one or more independent halo, cyano, hydroxy, nitro, d..10alkoxy, -SO2N(C0- 4alkyl)(C0-4alkyl), or -N(Co-4alkyl)(Co-4alkyl) substituents; or aryl-Co-ioalkyl, aryl-C2-1oalkenyl, or aryl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, cyano, nitro, -O(Co-4alkyl), Cι-ιoalkyl, C2-1oalkenyl, C2-ιoalkynyl, haloC1-10alkyl, haloC2-1oalkenyl, haloC2-1oalkynyl, -COOH, C1-4alkoxycarbonyl, -CON(C0-4alkyl)(C0-10alkyl), -SO2N(C0-4alkyl)(Co- allyl), or -N(C0-4alkyl)(Co-4alkyl) substituents; or hetaryl-Co-ioalkyl, hetaryl-C2-1oalkenyl, or hetaryl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, cyano, nitro, -O(Co-4alkyl), Ci-ioalkyl, C2-10alkenyl, C2-1oalkynyl, haloCι-10alkyl, haloC2-10alkenyl, haloC2-1Qalkynyl, -COOH, C1- alkoxycarbonyl, -CON(Co-4alkyl)(Co- alkyl), -SO2N(Co- alkyl)(C0-4alkyl), or -N(C0-4alkyl)(C0-4alkyl) substituents; or mono(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)aminoCι-6alkyl, mono(aryl)aminoC1-6alkyl, di(aryl)aminoC1-6alkyl, or -N(C1-6alkyl)-C1-6alkyl-aryl, any of which is optionally substituted with one or more independent halo, cyano, nitro, -O(Co-4alkyl), d^oalkyl, C2-10alkenyl, C2-1oalkynyl, haloCnoalkyl, haloC2-1oalkenyl, haloC2-1oalkynyl, -COOH, C1- alkoxycarbonyl, -CON(C0-4alkyl)(C0- alkyl), -SO2N(C0-4alkyl)(C0-4alkyl), or -N(C0-4alkyl)(C0-4alkyl) substituents; and n, m, jl, jla, j2a, j3a, j4, j4a, j5a, j6a, j7, and j8 are each independently equal to O, l, or 2.
2. The compound of claim 1, wherein Q1 is aryl1 or heteroaryl1, any of which is optionally substituted by one or more independent G1 substituents.
3. The compound of claim 2, wherein Q1 is heteroaryl1, any of which is optionally substituted by one or more independent G1 substituents.
4. The compound of claim 3, wherein Q1 is aryl1, any of which is optionally substituted by one or more independent G1 substituents.
5. The compound of claim 1 , wherein G1 is halo, -CF3, -OCF3, -OR2, -NR2R3, -C(O)R2, -CO2R2, -CONR2R3, -S(O)jiR2, -SO2NR2R3, NR2(C=O)R3, NR2(C=O)OR3, NR2(C=O)NR2R3, NR2S(O)jlR3, -O(C=O)OR2, -O(C=O)NR2R3,
Co-ioalkyl, C2-10alkenyl, C2-1oalkynyl, C1-10alkoxyC1-10alkyl, C1-10allcoxyC2-10alkenyl, C1-10alkoxyC2-1oalkynyl, Cwoalkylthiod-^alkyl, C1.1oalkylthioC2-iQalkenyl, Ci. 10alkylthioC2-1oalkynyl, cycloC3-8alkyl, cycloC3-8alkenyl, cycloC3.8alkylC1-10alkyl, cycloC3-8alkenylC1-10alkyl, cycloC3-8alkylC2-1oalkenyl, cycloC3-8alkenylC2-10alkenyl, cycloC3-8alkylC2-ιoalkynyl, cycloC3-8alkenylC2-10alkynyl, heterocyclyl-Co-ioalkyl, heterocyclyl-C2-1oalkenyl, or heterocyclyl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR , -NR222R333(R333a)jia, -C(O)R222, -CO2R222, -CONR222R333, -NO2, -CN, -S(O)jlaR222, -SO2NR222R333, NR2 2(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR22 R333, NR222S(O)jiaR333, -(C=S)OR222, -(C=O)SR222, -NR222(C=NR333)NR222aR333a, -NR222(C=NR333)OR222a, -NR222(C=NR333)SR333a, -O(C=O)OR222, -O(C=O)NR222R333, -O(C=O)SR222, -S(C=O)OR222, or -S(C=O)NR222R333 substituents; or -(X1)n-(Y1)m-R4; or aryl-C0-10alkyl, aryl-C2- ioalkenyl, or aryl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333(R333a)j2a, -C(O)R222, -CO2R222, -CONR222R333, -NO2, -CN, -S(O)j2aR222, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR2 2R333, NR222S(O)j2aR333, -(C=S)OR222, -(C=O)SR222, -NR222(C=NR333)NR222aR333a, -NR222(C=NR333)OR222a, -NR222(C=NR333)SR333a, -O(C=O)OR222, -O(C=O)NR222R333, -O(C=O)SR222, -S(C=O)OR222, or -S(C=O)NR222R333 substituents; or hetaryl-C0-10alkyl, hetaryl-C2-1oalkenyl, or hetaryl-C2-10alkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333(R333a)j3a, -C(O)R222, -CO2R222, -CONR222R333, -NO2, -CN, -S(O)j3aR222, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j3aR333, -(C=S)OR222, -(C=O)SR222, -NR222(C=NR333)NR222aR333a, -NR222(C=NR333)OR222a, -NR222(C=NR333)SR333a, -O(C=O)OR222, -O(C=O)NR222R333, -O(C=O)SR222, -S(C=O)OR222, or -S(C=O)NR222R333 substituents.
6. The compound of claim 1, wherein G1 is halo, -OR2, -NR2R3,
-C(O)R2, -CO2R2, -CONR2R3, -SO2NR2R3, NR2(C=O)R3, NR2(C=O)OR3,
NR2(C=O)NR2R3, NR2S(O)jlR3, -O(C=O)OR2, -O(C=O)NR2R3, Co-10alkyl, C2-10alkenyl, d.ϊoalkoxyd-ioalkyl, CMoalkoxyd-ioalkenyl, Ci-ioalkylttood-ioalkyl, C1_10alkylthioC2-10alkenyl, cycloC3-8alkyl, cycloC3-8alkenyl, cycloC3-8alkylC1-10alkyl, cycloC3-8alkenylC1-10alkyl, cycloC3-8allcylC -1oalkenyl, cycloC3-8alkenylC2.10alkenyl, or heterocyclyl-Co-ioalkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, -OCF3, -OR222, -NR 22R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333,
Figure imgf000243_0001
-NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or -(X1)n-(Y1)m-R4; or aryl-Co-ioalkyl optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR2 2S(O)j2aR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or hetaryl-Co-ioalkyl, optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C-O)OR333, NR222(C=O)NR222R333, NR222S(O)j3aR333, -NR222(C=NR333)NR222aR333a, or -O(CO)NR222R333 substituents.
7. The compound of claim 1, wherein G1 is halo, -OR2, -NR2R3,
-C(O)R2, -CO2R2, -CONR2R3, -SO2NR2R3, NR2(0=O)R3, NR2(C=O)OR3,
NR2(C=O)NR2R3, NR2S(O)jlR3, -O(C=O)OR2, -O(C=O)NR2R3, C0-ι0alkyl,
C2-10alkenyl,
Figure imgf000243_0002
CuioalkylthioC ioalkyl, cycloC3-8alkyl, cycloC -8alkenyl, or heterocyclyl-C0-ioalkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, -OCF3,
-OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333,
NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)jlaR333,
-NR222(C=NR333)NR2 2aR333a, or -O(C=O)NR222R333 substituents; or
-(X1)n-(Y1)m-R4; or aryl-Co-ioalkyl, optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222,
-CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333,
NR222(C=O)NR222R333, NR222S(O)j2aR333, -NR222(C=NR333)NR222aR333a, or
-O(C=O)NR R substituents; or hetaryl-Co-ioalkyl, optionally substituted with one or more independent halo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR 222 (C=0)NR 222 R 333 j ^^(O^R333, -NR222(C=NR333)NR222aR333a, or
-O(C=O)NR222R333 substituents.
8. The compound of claim 1 , wherein G1 is halo, -OR2, -NR2R3, -C(O)R2, -CO2R2, -CONR2R3, -SO2NR2R3, NR2(C=O)R3, NR2(C=O)OR3, NR2(C-O)NR2R3, NR2S(O)jlR3, -O(C=O)OR2, -O(C=O)NR2R3, Co-ioalkyl, C2-10alkenyl,
Figure imgf000244_0001
Ci.ioalkylthioC oalkyl, cycloC3-8alkyl, cycloC3-8alkenyl, or heterocyclyl-Co-10alkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent oxo, -CF3, -OCF3, -OR222, -NR222R333, -C(O)R222, -CO2R222, -CONR222R333, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR 22R333, NR222S(O)jlaR333, -NR222(C=NR333)NR222aR333a, or -O(C=O)NR222R333 substituents; or -(X1)n-(Y1)m-R4.
9. The compound of claim 1, wherein X1 and Y1 are each independently -O-, -NR7-, -S(O)j7- -CR5R6-, -N(C(O)OR7)-, -N(C(O)R7)-, -N(SO2R7)-, -CH2O-, -CH2S-, -CH2N(R7)-, -CH(NR7)-, -CH2N(C(O)R7)-, -CH2N(C(O)OR7)-, -CH2N(SO2R7)-, -CH(NHR7)-, -CH(NHC(O)R7)-, -CH(NHSO2R7)-, -CH(NHC(O)OR7)-, -CH(OC(O)R7)-, -CH(OC(O)NHR7)-, -C(O)-, -CH(OR7)-, -C(O)N(R7)-, -N(R7)C(O)-, -N(R7)S(O)-, -N(R7)S(O)2- -OC(O)N(R7)-, -N(R7)C(O)N(R7)-, -NR7C(O)O-, -S(O)N(R7)-, -S(O)2N(R7)-, -N(C(O)R7)S(O)-, -N(C(O)R7)S(O)2- -N(R7)S(O)N(R7)-, -N(R7)S(O)2N(R7)-, -C(O)N(R7)C(O)-, -S(O)N(R7)C(O)-, -S(O)2N(R7)C(O)-, -OS(O)N(R7)-, -OS(O)2N(R7)-, -N(R7)S(O)O-, -N(R7)S(O)2O-, -N(R7)S(O)C(O)-, -N(R7)S(O)2C(O)-, -SON(C(O)R7)-, -SO2N(C(O)R7)-, -N(R7)SON(R7)-, -N(R7)SO2N(R7)-, -C(O)O-, -CH(R7)S(O)-, -CH(R7)S(O)2-, -CH(R7)N(C(O)OR7)-, -CH(R7)N(C(O)R7)-, -CH(R7)N(SO2R7)-, -CH(R7)O-, -CH(R7)S- -CH(R7)N(R7)-, -CH(R7)N(C(O)R7)-, -CH(R7)N(C(O)OR7)-, -CH(R7)N(SO2R7)-, -CH(R7)C(=NOR7)-, -CH(R7)C(O)-, -CH(R7)CH(OR7)-,
-CH(R7)C(O)N(R7)-, -CH(R7)N(R7)C(O)-, -CH(R7)N(R7)S(O)-, -CH(R7)N(R7)S(O)2-, -CH(R7)OC(O)N(R7)-, -CH(R7)N(R7)C(O)N(R7)-, -CH(R7)NR7C(O)O-, -CH(R7)S(O)N(R7)-, -CH(R7)S(O)2N(R7)-, -CH(R7)N(C(O)R7)S(O)-, -CH(R7)N(C(O)R7)S(O)-, -CH(R7)N(R7)S(O)N(R7)-, -CH(R7)N(R7)S(O)2N(R7)-, -CH(R7)C(O)N(R7)C(O)-, -CH(R7)S(O)N(R7)C(O)-, -CH(R7)S(O)2N(R7)C(O)-, -CH(R7)OS(O)N(R7)-, -CH(R7)OS(O)2N(R7)-, -CH(R7)N(R7)S(O)O-, -CH(R7)N(R7)S(O)2O- -CH(R7)N(R7)S(O)C(O)-, -CH(R7)N(R7)S(O)2C(O)-, -CH(R7)SON(C(O)R7)-, -CH(R7)SO2N(C(O)R7)-, -CH(R7)N(R7)SON(R7)-, -CH(R7)N(R7)SO2N(R7)-, or -CH(R7)C(O)O-.
10. The compound of claim 1 wherein Q1 is substituted by said one to five independent G1 substituents wherein at least one of said G1 substituents is -(X1)n-(Y1)m-R4, and wherein X1 and Y1 are each independently equal to -O-, -NR7-, -CR5R6-, -S(O)j7-, or -C(O)-, and wherein n and m are both equal to 1 and j7 is equal to 1 or 2.
11. The compound of claim 1 wherein Q1 is substituted by said one to five independent G1 substituents wherein at least one of said G1 substituents is
Figure imgf000245_0001
and wherein X1 and Y1 are each independently -O- or -CR5R6-, and wherein n and m are equal to 1.
12. The compound of claim 1 wherein R1 is cycloalkyl, bicycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, or heterobicycloalkyl, any of which is optionally substituted by one or more independent G11 substituents.
13. The compound of claim 1 wherein R1 is cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, or heterocyclyl, any of which is optionally substituted by one or more independent G11 substituents.
14. The compound of claim 1 wherein R1 is cycloalkyl or heterocyclyl, any of which is optionally substituted by one or more independent G11 substituents.
15. The compound of claim 1 wherein R1 is cycloalkyl optionally substituted by one or more independent G11 substituents.
16. The compound of claim 1 wherein R1 is heterocyclyl optionally substituted by one or more independent G11 substituents.
17. The compound of claim 1 wherein R1 is aryl, heteroaryl, aralkyl, or heteroaralkyl, any of which is optionally substituted by one or more independent G1 substituents.
18. The compound of claim 1 wherein R1 is aryl or heteroaryl, any of which is optionally substituted by one or more independent G11 substituents.
19. The compound of claim 1 wherein G11 is -OR21, -NR21R31(R31a)j4, -C(O)R21, -CO2R21, -CONR21R31, NR21(C=O)R31, NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31, -O(C=O)OR21, -O(C=O)NR21R31, C0-10alkyl, cycloC3-8alkyl, cycloC3-8alkenyl, heterocyclyl-Co-ioalkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333a)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al, -NR2221(O=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents; or aryl-Co-i0alkyl, aryl-C2-ιoalkenyl, or aryl-C2.1oalkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j5a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j5aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2 21S(O)j5aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al, -NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents; or hetaryl-C0-i0alkyl, hetaryl-C2-1oalkenyl, or hetaryl-C2-1oalkynyl, any of which is optionally substituted with one or more independent halo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j6a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j6aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j6aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al, -NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(DO)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents.
20. The compound of claim 1 wherein G11 is -OR21, -NR21R31, -CO2R21, -C(O)R21, -CONR21R31, NR21(C=O)R31, NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31, -O(C=O)OR21, -O(C=O)NR21R31, C0-ι0alkyl, cycloC3-8alkyl, cycloC3-8alkenyl, heterocyclyl-C0-1oalkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al, -NR2221(C=NR3331)SR333al, -0(C=O)0R2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents.
21. The compound of claim 1 wherein R4 is H, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G41 substituents.
22. The compound of claim 10 wherein R4 is alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G41 substituents.
23. The compound of claim 11 wherein R4 is alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G41 substituents.
24. The compound of claim 1 wherein Q1 is phenyl substituted by said one to five independent G1 substituents wherein at least one of said G substituents is -(X1)„-(Y1)m-R4, and wherein n = 1 and X1 is 3-(-O-), m = 1 and Y1 is -(-CH2-), and R4 is aryl optionally substituted by one or more independent G l substituents.
25. The compound of claim 24 wherein R1 is aryl, heteroaryl, cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents.
26. The compound of claim 25 wherein R1 is cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents.
27. The compound of claim 26 wherein R1 is cycloalkyl, optionally substituted by one or more independent G11 substituents.
28. The compound of claim 27 wherein R1 is cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted by one or more independent G11 substituents.
29. The compound of claim 27 wherein G11 is -OR21, -NR21R31, -CO2R21, -C(O)R21, -CONR21R31, NR21(C=0)R31, NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31, -O(C=O)OR21, -O(C=O)NR21R31, C0-ι0alkyl, cycloC3-8alkyl, cycloC3- 8alkenyl, heterocyclyl-Co-ioalkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al, -NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(Q=O)NR2221R3331 substituents.
30. The compound of claim 1 wherein Q1 is phenyl substituted by said one to five independent G1 substituents wherein at least one of said G1 substituents is -(X^n-tY^m-R4, and wherein n = 1 and X1 is 4-(-O-), m = 1 and Y1 is -(-CH2-), and R is aryl optionally substituted by one or more independent G 41 substituents.
31. The compound of claim 30 wherein R1 is aryl, heteroaryl, cycloalkyl or heterocyclyl, optionally substituted by one or more independent G 11 substituents.
32. The compound of claim 31 wherein R1 is cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents.
33. The compound of claim 32 wherein R1 is cycloalkyl, optionally substituted by one or more independent G1 substituents.
34. The compound of claim 33 wherein R1 is cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted by one or more independent G11 substituents.
35. The compound of claim 33 wherein G11 is -OR21, -NR21R31, -CO2R21, -C(O)R21, -CONR21R31, NR21(C=O)R31, NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31, -O(C=O)OR21, -O(C=O)NR21R31, C0-ι0alkyl, cycloC3-8alkyl, cycloC3- 8alkenyl, heterocyclyl-Co-ioalkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j4a, -C(O)R2221, -CO2R2221, -CONR 221R3331, -NO2, -CN, -S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR222l(C=NR3331)NR222alR333al, -NR22 1(C=NR3331)OR222al, -NR2221(C=NR3331)SR333al, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents.
36. The compound of claim 1 wherein Q1 is phenyl substituted by said one to five independent G1 substituents wherein at least one of said G1 substituents is
Figure imgf000249_0001
and wherein n = 1 and X1 is 3-(-O-), m = 0, and R4 is (C0-C8)alkyl or cycloalkyl optionally substituted by one or more independent G41 substituents.
37. The compound of claim 36 wherein R1 is aryl, heteroaryl, cycloalkyl or heterocyclyl, optionally substituted by one or more independent G substituents.
38. The compound of claim 37 wherein R1 is cycloalkyl or heterocyclyl, optionally substituted by one or more independent G1 substituents.
39. The compound of claim 38 wherein R1 is cycloalkyl, optionally substituted by one or more independent G11 substituents.
40. The compound of claim 39 wherein R1 is cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted by one or more independent G11 substituents.
41. The compound of claim 39 wherein G11 is -OR21, -NR21R31, -CO2R 21 -C(O)R21, -CONR21R31, NR21(C=O)R31, NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31, -O(C=O)OR21, -O(C=O)NR21R31, C0-ιoalkyl, cycloC3-8alkyl, cycloC3- salkenyl, heterocyclyl-Co-ioalkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C-O)OR3331, NR22 1(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al, -NR2221(C=NR3331)SR333aI, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents.
42. The compounds of claim 36 wherein R4 is (Co-C6)alkyl.
43. The compound of claim 41 wherein R4 is (Co-C6)alkyl.
44. The compounds of claim 36 wherein R4 is H or methyl.
45. The compound of claim 43 wherein R4 is H or methyl.
46. The compound of claim 1 wherein Q1 is phenyl substituted by said one to five independent G1 substituents wherein at least one of said G1 substituents is -(Xl)n-(Y -R and wherein n = 1 and X1 is 3-(-O-), m = 0, and R4 is aryl optionally substituted by one or more independent G41 substituents.
47. The compound of claim 46 wherein R1 is aryl, heteroaryl, cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents.
48. The compound of claim 46 wherein R1 is cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents.
49. The compound of claim 48 wherein R1 is cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted by one or more independent G11 substituents.
50. The compound of claim 48 wherein G11 is -OR21, -NR21R31, -CO2R21, -C(O)R21, -CONR21R31, NR21(C=O)R31, NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31, -O(C=O)OR21, -O(C=O)NR21R31, C0-10alkyl, cycloC3-8alkyl, cycloC3- 8alkenyl, heterocyclyl-Co-ioalkyl, or heterocyclyl-C2-1oall enyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333al)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al, -NR2221(C=NR3331)SR333al, -O(CO)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents.
51. The compounds of claim 46 wherein R4 is phenyl optionally substituted with G41.
52. The compound of claim 1 wherein Q1 is phenyl substituted by said one to five independent G1 substituents wherein at least one of said G1 substituents is -(X1)n-(Y1)m-R4, and wherein n = 1 and X1 is 3- or 4-(-NH-), m = 1 and Y1 is - (-SO2-), and R4 is aryl optionally substituted by one or more independent G41 substituents.
53. The compound of claim 52 wherein R1 is aryl, heteroaryl, cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents.
54. The compound of claim 53 wherein R1 is cycloalkyl or heterocyclyl, optionally substituted by one or more independent G11 substituents.
55. The compound of claim 54 wherein R1 is cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted by one or more independent G11 substituents.
56. The compound of claim 54 wherein G11 is -OR21, -NR21R31, -CO2R21, -C(O)R21, -CONR21R31, NR21(C=O)R31, NR21(CO)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31, -O(C=O)OR21, -O(C=O)NR21R31, C0-10alkyl, cycloC3-8alkyl, cycloC3- 8alkenyl, heterocyclyl-Co-ioalkyl, or heterocyclyl-C2-1oalkenyl, any of which is optionally substituted with one or more independent halo, oxo, -CF3, -OCF , -OR2221, -NR2221R3331(R333al)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222alR333al, -NR2221(C=NR3331)OR222al, -NR2221(C=NR3331)SR333al, -O(Q=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, or -S(C=O)NR2221R3331 substituents.
57. The compound of claim 56 wherein R1 is cis- or trans- cyclobutyl substituted at the 3-position by G11 wherein G11 is -OH, -NH2, -N(CH3)2, -NHAc, -NH(CO)NHCH3, -NH(CO)OCH3, -CH2OH, -CH2NH2, -CH2NHAc, CO2H, CONH2, -CH2N(CH3)2, -CH2NH(CO)NHMe, -CH2NH(CO)OCH3, CO2CH3, CONHCH3,
Figure imgf000252_0001
58. The compound of claim 56 wherein R1 is cis- or trans- cyclohexyl substituted at the 4-position by G11 wherein G11 is -OH, -NH2, -N(CH3)2, -NHAc, -NH(CO)NHCH3, -NH(CO)OCH3, -CH2OH, -CH2NH2, -CH2NHAc, CO2H, CONH2, -CH2N(CH3)2, -CH2NH(CO)NHMe, -CH2NH(CO)OCH3, CO2CH3, CONHCH3,
Figure imgf000253_0001
59. A compound selected from the group consisting of: [ 1 -(3 -Benzyloxy-phenyl)-3 -cyclobutyl-imidazo[ 1 ,5-a]pyrazin-8-ylamine] ,
1 -(3-Benzyloxyphenyl)-3-phenyl-imidazo[ 1 ,5-α]pyrazin-8-ylamine,
3-Benzyl-l-(3-benzyloxyphenyl)-imidazo[l,5-β]pyrazin-8-ylamine,
1 -(3-Benzyloxyphenyl)-3-naphthalen- 1 -yl-imidazo[ 1 ,5-α]pyrazin-8-ylamine, l-(3-Benzyloxyphenyl)-3-naphthalen-2-yl-imidazo[l,5-α]pyrazin-8-ylamine, l-(3-Benzyloxy-phenyl)-3-cyclopentyl-imidazo[l,5-a]pyrazin-8-ylamine, l-(3-Benzyloxy-phenyl)-3-cyclohexyl-imidazo[l,5-a]pyrazin-8-ylamine, l-(3-Benzyloxy-phenyl)-3-cycloheptyl-imidazo[l,5-a]pyrazin-8-ylamine, l-(3-Berizyloxy-phenyl)-3-(tetrahydro-furan-3-yl)-imidazo[l,5-a]pyrazin-8-ylamine, trans-3-[8-Ammo- 1 -(3-benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin-3-yl]-cyclobutanol, l-(3-Benzyloxy-phenyl)-3-(l-methyl-piperidin-4-yl)-imidazo[l,5-a]pyrazin-8- ylamine, eώ-4-[8-Amino- 1 -(3-benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin-3-yl]- cyclohexanecarboxylic acid amide, traR.s'-4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]- cyclohexanecarboxylic acid amide, cis- {4-[8-Amino- 1 -(3-benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin-3-yl]-cyclohexyl} - methanol,
trαrø-{4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]-cyclohexyl}- methanol, cis-2- {4-[8-Amino- 1 -(3-benzyloxy-phenyl)-imidazo[l ,5-a]pyrazin-3-yl]- cyclohexylmethyl} -isoindole- 1 ,3-dione, tra725'-2-{4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]- cyclohexylmethyl} -isoindole- 1 ,3-dione, ct5-3-(4-Aminomethyl-cyclohexyl)-l-(3-benzyloxy-ρhenyl)-imidazo[l,5-a]pyrazin-8- ylamine, trα«5-3-(4-Aminomethyl-cyclohexyl)-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin- 8-ylamine, cw-N-{4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]ρyrazin-3-yl]- cyclohexylmethyl} -acetamide, or trans-N- {4- [ 8- Amino- 1 -(3 -benzyloxy-phenyl)-imidazo[ 1 , 5 -a]pyrazin-3 -yl] - cyclohexylmethyl} -acetamide. or pharmaceutically acceptable salts thereof.
60. A method of inhibiting protein kinase activity comprising administering a compound of claim 1 or a pharmaceutically acceptable salt thereof.
61. The method of claim 60 wherein said protein kinase is IGF-IR.
62. The method of claim 60 wherein the activity of said protein kinase affects hyperproliferative disorders.
63. The method of claim 60 wherein the activity of said protein kinase influences angiogenesis, vascular permeability, immune response, cellular apoptosis, tumor growth, or inflammation.
64. A method of treating a patient having a condition which is mediated by protein kinase activity, said method comprising administering to the patient a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
65. The method of claim 64 wherein said protein kinase is IGF-IR.
66. The method of claim 64 wherein the condition mediated by protein kinase activity is a hyperproliferative disorder.
67. The method of claim 64 wherein the activity of said protein kinase influences angiogenesis, vascular permeability, immune response, cellular apoptosis, tumor growth, or inflammation.
68. The method of claim 64 wherein the protein kinase is a protein serine/threonine kinase or a protein tyrosine kinase.
69. The method of claim 64 wherein the condition mediated by protein kinase activity is one or more ulcers.
70. The method of claim 69 wherein the ulcer or ulcers are caused by a bacterial or fungal infection; or the ulcer or ulcers are Mooren ulcers; or the ulcer or ulcers are a symptom of ulcerative colitis.
71. The method of claim 64 wherein the condition mediated by protein kinase activity is Lyme disease, sepsis or infection by Herpes simplex, Herpes Zoster, human immunodeficiency virus, parapoxvirus, protozoa, or toxoplasmosis.
72. The method of claim 64 wherein the condition mediated by protein kinase activity is von Hippel Lindau disease, pemphigoid, psoriasis, Paget's disease, or polycystic kidney disease.
73. The method of claim 64 wherein the condition mediated by protein kinase activity is fibrosis, sarcoidosis, cirrhosis, thyroiditis, hyperviscosity syndrome, Osier- Weber-Rendu disease, chronic occlusive pulmonary disease, asthma, exudtaes, ascites, pleural effusions, pulmonary edema, cerebral edema or edema following burns, trauma, radiation, stroke, hypoxia, or ischemia.
74. The method of claim 64 wherein the condition mediated by protein kinase activity is ovarian hyperstimulation syndrome, preeclainpsia, menometrorrhagia, or endometriosis.
75. The method of claim 64 wherein the condition mediated by protein kinase-activity is chronic inflammation, systemic lupus, glomerulonephritis, synovitis, inflammatory bowel disease, Crohn's disease, glomerulonephritis, rheumatoid arthritis and osteoarthritis, multiple sclerosis, or graft rejection.
76. The method of claim 64 wherein the condition mediated by protein kinase activity is sickle cell anaemia.
77. The method of claim 64 wherein the condition mediated by protein kinase activity is an ocular condition.
78. The method of claim 77 wherein the ocular condition is ocular or macular edema, ocular neovascular disease, seleritis, radial keratotomy, uveitis, vitritis, myopia, optic pits, chronic retinal detachment, post-laser treatment complications, conjunctivitis, Stargardt's disease, Eales disease, retinopathy, or macular degeneration.
79. The method of claim 64 wherein the condition mediated by protein kinase activity is a cardiovascular condition.
80. The method of claim 79 wherein the condition mediated by protein kinase activity is atherosclerosis, restenosis, ischemia/reperfusion injury, vascular occlusion, venous malformation, or carotid obstructive disease.
81. The method of claim 64 wherein the condition mediated by protein kinase activity is cancer.
82. The method of claim 81 wherein the cancer is a solid tumor, a sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, a rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, an hematopoietic malignancy, or malignant ascites.
83. The method of claim 82 wherein the cancer is Kaposi's sarcoma, Hodgkin's disease, lymphoma, myeloma, or leukemia.
84. The method of claim 64 wherein the condition mediated by protein kinase activity is Crow-Fukase (POEMS) syndrome or a diabetic condition.
85. The method of claim 84 wherein the diabetic condition is insulin- dependent diabetes mellitus glaucoma, diabetic retinopathy, or microangiopathy.
86. The method of claim 64 wherein the protein kinase activity is involved in T cell activation, B cell activation, mast cell degranulation, monocyte activation, signal transduction, apoptosis, the potentiation of an inflammatory response or a combination thereof.
87. A composition comprising a compound according to claim 1, or a phannaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
88. A composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof; and an anti-neoplastic, anti-tumor, anti- angiogenic, or chemotherapeutic agent.
89. A composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof; and a cytotoxic cancer therapeutic agent.
90. A composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof; and an angiogenesis inhibiting cancer therapeutic agent.
91. A method of treating a patient having a condition which is mediated by protein kinase activity, said method comprising admimstering to the patient a therapeutically effective amount of a pharmaceutical composition according to claim 87.
92. A compound selected from the group consisting of: trans-N- {4-[8-Amino- 1 -(3-benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin-3-yl]- cyclohexylmethyl} -acetamide, l-Biphenyl-3-yl-3-cyclobutylimidazo[l,5-α]pyrazin-8-ylamine,
1 -(3-Bromo-phenyl)-3-cyclobutylimidazo[ 1 ,5-α]pyrazin-8-ylamine, l-(4'-t-Butylbiphenyl-3-yl)-3-cyclobutylimidazo[l,5-α]pyrazin-8-ylamine,
3-Cyclobutyl- 1 -(4'-methylbiphenyl-3-yl)-imidazo[ 1 ,5-α]pyrazin-8-ylamine,
3-Cyclobutyl- 1 -(4'-methoxybiphenyl-3-yl)-imidazo[ 1 ,5-α]pyrazin-8-ylamine,
1 -(3-Benzyloxyphenyl)-3-cyclopentyhnethylimidazo[ 1 ,5-a]pyrazin-8-ylamine, l-(3-Benzyloxyphenyl)-3-cyclohexylmethylimidazo[l,5-a]pyrazin-8-ylamine,
1 -(3-Benzyloxyphenyl)-imidazo[ 1 ,5-a]pyrazin-8-ylamine, l-(3-Benzyloxyphenyl)-3-trifluoromethylimidazo[l,5-a]pyrazin-8-ylamme,
4-[8-Amino- 1 -(3-benzyloxyphenyl)-imidazo[ 1 ,5-a]pyrazin-3-yl]-benzamide,
3-Cyclobutyl- 1 -phenylimidazo[ 1 ,5-a]pyrazin-8-ylamine, (trans-3 -(4- Azetidin- 1 -ylmethyl-cyclohexyl)- 1 -(3 -benzyloxy-phenyl)-imidazo [1,5- a]pyrazin-8-ylamine, trans- 1 -(3-Benzyloxy-phenyl)-3-(4-pyrrolidin- l-ylmethyl-cyclohexyl)-imidazo[ 1 ,5- a]pyrazin-8-ylamine), tra«5-4-[8-Amino-l-(3-benzyloxy-ρhenyl)-imidazo[l,5-a]pyrazin-3-yl]- cyclohexanecarboxylic acid methyl ester,
(tr rø-4-[8-Amino- 1 -(3-benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin-3-yl]- cyclohexanecarboxylic acid,
(trα«5-4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]- cyclohexanecarboxylic acid methylamide,
4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]- cyclohexanecarboxylic acid ethylamide, trα«i'-l-(3-Benzyloxy-phenyl)-3-(3-pvrrolidin-l-ylmethyl-cyclobutyl)-imidazo[l,5- a]pyrazin-8-ylamine, cis- 1 -(3-Benzyloxy-phenyl)-3 -(3 -pyrrolidin- 1 -ylmethyl-cyclobutyl)-imidazo [ 1 ,5- a]pyrazin-8-ylamine, tra«5-3-(3-Azetidin-l-ylmethylcyclobutyl)-l-(3-benzyloxyphenyl)-imidazo[l,5- a]pyrazin-8-ylamine, c/.s-3-(3-Azetidin-l-ylmethylcyclobutyl)-l-(3-benzyloxyphenyl)-imidazo[l,5- a]pyrazin-8-ylamine, toluene-4-sulfonic acid 3-[8-amino- 1 -(3-benzyloxyphenyl)-imidazo[ 1 ,5-α]pyrazin-3- yl] cyclobutylmethyl ester, {3-[8-Amino-l -(3-benzyloxyphenyl)-imidazo[ 1 ,5-α]pyrazin-3- yl]cyclobutyl}methanol,
3-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]-l-methyl- cyclobutanol,
3-[8-Amino-l -(3-benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin-3-yl]- 1 -ethyl- cyclobutanol, l-Allyl-3-[8-amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]- cyclobutanol, l-(3-Benzyloxyphenyl)-3-tert-butylimidazo[l,5-α]pyrazin-8-ylamine, ct-5-l-[3-(Benzyloxy)phenyl]-3-[3-(dimethylamino) cyclobutyl]imidazo[l,5-a]pyrazin- 8-amine,
3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)-phenol,
3-Cyclobutyl-l-[3-(4-fluoro-benzyloxy)-phenyl]-imidazo[l,5-a]pyrazin-8-ylamine, trα«-f-4-[8-Amino- 1 -(3-hydroxy-phenyl)-imidazo[l ,5-a]pyrazin-3- yljcyclohexanecarboxylic acid methyl ester,
3-[8-Amino-l-(3-benzyloxyphenyl)-imidazo[l,5- ]pyrazin-3-yl]-benzamide,
{3-[8-Amino-l-(3-benzyloxyphenyl)-imidazo[l,5-α]pyrazin-3-yl]-phenyl}-methanol,
3-(3-Aminomethylphenyl)-l-(3-benzyloxyphenyl)-imidazo[l,5-α]pyrazin-8-ylamine,
2-{3-[8-Amino-l-(3-benzyloxyphenyl)-imidazo[l,5-α]pyrazin-3-yl]-benzyl}- isoindole-l,3-dione,
4- {8-Amino- 1 -[3-(2,6-difluoro-benzyloxy)-phenyl]-imidazo[ 1 ,5-a]ρyrazin-3-yl} - cyclohexanecarboxylic acid methyl ester, 4- {8-Amino- 1 -[3-(2,6-difluoro-benzyloxy)-phenyl]-imidazo[l ,5-a]pyrazin-3-yl} - cyclohexanecarboxylic acid, c^-3-(3-Dimethylaminomethyl-cyclobutyl)-l-(3-benzyloxyphenyl)-imidazo[l,5- α]pyrazin-8-ylamine, cw-3-(3-Azetidin-l-ylmethylcyclobutyl)-l-(3-benzyloxyphenyl)-imidazo[l,5- α]pyrazin-8-ylamine, c^-3-(3-Pyrrolidin-l-ylmethylcyclobutyl)-l-(3-benzyloxyphenyl)-imidazo[l,5- α]pyrazin-8-ylamine, cw-3-(3-Azidomethyl-cyclobutyl)- 1 -(3-benzyloxyphenyl)-imidazo[ 1 ,5-α]pyrazin-8- ylamine, c/5-3-(3-aminomethyl-cyclobutyl)-l-(3-benzyloxyphenyl)-imidazo[l,5-α]pyrazin-8- ylamine, cis-3-[ 8- Amino- 1 -(3 -benzyloxy-phenyl)-imidazo [ 1 ,5 -a]pyrazin-3 -yl] -cyclobutanecarboxylic acid amide, tr M5-3-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]-cyclobutane- carboxylic acid amide,
3 - [8 -Amino- 1 -(3 -benzyloxy-phenyl)-imidazo [ 1 , 5-a]pyrazin-3 -yl] - 1 -hydroxymethyl- cyclobutanol, cti'-Toluene-4-sulfonic acid 3-[8-amino-l-(3-benzyloxy-phenyl)-imidazo[l,5- a]pyrazin-3 -yl] - 1 -hydroxy-cyclobutylmethyl ester, trα«i'-Toluene-4-sulfonic acid 3-[8-amino-l-(3-benzyloxy-phenyl)-imidazo[l,5- a]pyrazin-3 -yl] - 1 -hydroxy-cyclobutylmethyl ester, trans-3-[8-Ammo- 1 -(3-benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin-3-yl]-l -azetidin-1 - ylmethyl-cyclobutanol, cw-3-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-3-yl]-l-azetidin-l- ylmethyl-cyclobutanol, l-[3-(4-tert-Butoxy-benzyloxy)-phenyl]-3-cyclobutyl-imidazo[l,5-a]pyrazin-8- ylamine,
2-[3-(8-Amino-3-cyclobutyl-imidazo[ 1 ,5-a]pyrazin- 1 -yl)-phenoxymethyl]- Benzonitrile,
3-Cyclobutyl- 1 -[3-(2-nitro-benzyloxy)-phenyl]-imidazo[ 1 ,5-a]pyrazin-8-ylamine, l-[3-(2-Bromo-benzyloxy)-phenyl]-3-cyclobutyl-imidazo[l,5-a]pyrazin-8-ylamine, l-[3-(3-Aminomethyl-benzyloxy)-phenyl]-3-cyclobutyl-imidazo[l,5-a]pyrazin-8- ylamine,
3-[3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)-phenoxymethyl]-benzoic acid methyl ester,
3-[3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)-phenoxymethyl]- benzamide, {3-[3-(8-Amino-3-cyclobutyl-imidazo[ 1 ,5-a]pyrazin-l -yl)-phenoxymethyl]-phenyl} - methanol,
2-{3-[3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)-phenoxymethyl]- benzyl} -isoindole- 1 ,3-dione,
3-[3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)-phenoxymethyl]-benzoic acid,
3-[3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)-phenoxymethyl]-N-methyl- Benzamide, l-(3-Benzyloxy-phenyl)-3-(3-methoxymethylene-cyclobutyl)-imidazo[l,5-a]pyrazin- 8-ylamine,
3-[8-Amino-l -(3-benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin-3-yl] cyclobutanecarbaldehyde, cis - 1 -(3-Benzyloxy-phenyl)-3-(4-methoxy-cyclohexyl)-imidazo[ 1 ,5-a]pyrazin-8- ylamine, trβ«5,-l-(3-Benzyloxy-phenyl)-3-(4-methoxy-cyclohexyl)-imidazo[l,5-a]pyrazin-8- ylamine, c/5'-tert-Butyl ({3-[8-amino-l-(3-benzyloxyphenyl)-imidazo [l,5-α]pyrazin-3-yl]- cyclobutyl} oxy)acetate, cis-2- {3-[8-Amino- 1 -(3-benzyloxyphenyl)imidazo[ 1 ,5-α]pyrazin-3- yl]cyclobutoxy} ethanol, c^-Toluene-4-sulfonic acid 2-{3-[8-amino-l-(3-benzyloxyphenyl)imidazo[l,5- α]pyrazin-3-yl]cyclobutoxy} ethyl ester, cis- 1 -(3 -Benzyloxyphenyl)-3 - [3 -(2-dimethylaminoethoxy)-cyclobutyl] imidazo [1,5- α]pyrazin-8-yl amine, cis- {3 - [ 8 -Amino- 1 -(3 -benzyloxyphenyl)imidazo [ 1 , 5- ]pyrazin-3 -yl] - cyclobutoxy} acetic acid, c/>s'-2-{3-[8-Amino-l-(3-benzyloxyphenyl)imidazo[l,5- ]pyrazin-3-yl]cyclobutoxy}- N-methylacetamide, ct5-2-{3-[8-Amino-l-(3-benzyloxy-phenyl)imidazo[7,5-α]pyrazin-3- yl]cyclobutoxy} acetamide, l-(3-benzyloxy-4-methoxyphenyl)-3-cyclobutyl-imidazo[l,5-α]pyrazin-8-ylamine, 1 -(3-Benzyloxy-4-fluorophenyl)-3-cyclobutyl-imidazo[ 1 ,5-α]pyrazin-8-ylamine, l-(3-Benzyloxy-4-isopropoxyphenyl)-3-cyclobutylimidazo[l,5-α]pyrazin-8-ylamine, l-(3-Benzyloxy-4-ethoxyphenyl)-3-cyclobutylimidazo[l,5-α]pyrazin-8-ylamine,
4-(8-Amino-3 -cyclobutylimidazo[ 1 ,5-α]pyrazin- 1 -yl)-2-benzyloxyphenol,
4- {8-Amino-l -[3-(2,6-difluoro-benzyloxy)-phenyl]-imidazo[ 1 ,5-a]pyrazin-3-yl} - cyclohexanecarboxylic acid amide,
4-{8-Amino-l-[3-(2,6-difluoro-benzyloxy)-phenyl]-imidazo[l,5-a]pyrazin-3-yl}- cyclohexanecarboxylic acid methylamide,
N-{3-[3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)-phenoxymethyl]- phenyl} -acetamide, or pharmaceutically acceptable salts thereof.
93. A compound selected from the group consisting of:
Figure imgf000262_0001
Figure imgf000263_0001
Figure imgf000264_0001
or a p armaceutca y accepta e salt thereof.
94. A compound selected from the group consisting of:
Figure imgf000264_0002
5/037836
Figure imgf000265_0001
annaceutca y accepta e salt t ereof. A compound selected from the group consisting of:
Figure imgf000266_0001
Figure imgf000266_0002
Rl Name
N' l-(3-Benzyloxy-phenyl)-3-{4-[(ethyl-methyl-amino)-methyl]- cyclohexyl}-imidazo[l,5-a]pyrazin-8-ylamine
1 - {4-[8 -Amino- 1 -(3 -benzyloxy-phenyl)-imidazo [ 1 ,5 -a]pyrazin- 3 -yl] -cyclohexylmethyl } -piperidin-3 -ol
Figure imgf000267_0001
N-{4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin- 3 -yl] -cyclohexylmethyl } -N,N',N'-trimethyl-ethane- 1 ,2-diamine
HO N' 2-( {4-[8-Amino-l -(3 -benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin- 3-yl]-cyclohexylmethyl}-methyl-amino)-ethanol
4- {4-[8 -Amino- 1 -(3 -benzyloxy-phenyl)-imidazo [ 1 ,5 -ajpyrazin- 3-yl]-cyclohexylmethyl}-piperazin-2-one
l-(3-Benzyloxy-phenyl)-3-[4-(2,5-dihydro-pyrrol-l-ylmethyl)-
Figure imgf000267_0002
cyclohexyl] -imidazo [1,5 -a]pyrazin-8-ylamine
l-(3-Benzyloxy-phenyl)-3-(4-propylaminomethyl-cyclohexyl)- H imidazo[l,5-a]pyrazin-8-ylamine
3 -[4-(Benzylamino-methyl)-cyclohexyl] - 1 -(3 -benzyloxy-
Figure imgf000267_0003
phenyl)-imidazo[l,5-a]pyrazin-8-ylamine
1 -(3 -Benzyloxy-phenyl)-3 -[4-(isopropylamino-methyl)- N' cyclohexyl]-imidazo[l,5-a]pyrazin-8-ylamine H Rl Name y l-(3-Benzyloxy-phenyl)-3-(4-butylaminomethyl-cyclohexyl)- imidazo[ 1 ,5-a]pyrazin-8-ylamine
-N. N- {4-[8 -Amino- 1 -(3 -benzyloxy-phenyl)-imidazo[ 1 , 5 -a]pyrazin- H 3 -yl]-cyclohexylmethyl} -N',N'-dimethyl-ethane- 1 ,2-diamine
HO 2-( {4-[8-Amino- 1 -(3 -benzyloxy-phenyl)-imidazo [1,5 -a]pyrazin- H 3-yl]-cyclohexylmethyl}-amino)-ethanol
( 1 - {4-[8-Amino- 1 -(3-benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin- 3 -yl] -cyclohexylmethyl } -piperidin-3 -yl)-methanol
(1 - {4~[8-Amino- 1 -(3-benzyloxy-phenyl)-imidazo[ 1 ,5-a]pyrazin-
Figure imgf000268_0001
3-yl]-cyclohexylmethyl}-piperidin-4-yl)-methanol
l-{4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-
Figure imgf000268_0002
3-yl]-cyclohexylmethyl}-pynolidin-3-ol
l-{4-[8-Amino-l-(3-benzyloxy-phenyl)-imidazo[l,5-a]pyrazin-
Figure imgf000268_0003
3-yl]-cyclohexylmethyl}-pyrrolidin-3-ol
l-(3-Benzyloxy-phenyl)-3-(4-{[(tetrahydro-furan-2-ylmethyl)-
Figure imgf000268_0004
amino]-methyl}-cyclohexyl)-imidazo[l,5-a]pyrazin-8-ylamine
H N- {4- [ 8 -Amino- 1 -(3 -benzyloxy-phenyl)-imidazo [1,5 -a]pyr azin- 3-yl]-cyclohexylmethyl}-N',N'-dimethyl-propane-l,3-diamine
Figure imgf000269_0001
pharmaceutically acceptable salt thereof, wherein * is the point of attachment.
96. A compound selected from the group consisting of:
Figure imgf000270_0001
Figure imgf000270_0002
Figure imgf000271_0001
pharmaceutically acceptable salt thereof, wherein * is the point of attachment.
97. A compound selected from the group consisting of:
Figure imgf000272_0001
Figure imgf000272_0002
Figure imgf000273_0001
Figure imgf000274_0001
Figure imgf000275_0001
Figure imgf000276_0002
or a pharmaceutically acceptable salt thereof, wherein * is the point of attachment.
98. A compound selected from the group consisting of:
Figure imgf000276_0001
Figure imgf000276_0003
Figure imgf000277_0001
Figure imgf000278_0001
Figure imgf000279_0002
or a pharmaceutically acceptable salt thereof, wherein * is the point of attachment.
99. A compound selected from the group consisting of:
Figure imgf000279_0001
Figure imgf000279_0003
Rl Name l-[3-(2-Chloro-benzyloxy)-phenyl]-3-cyclobutyl- imidazo[l ,5-a]pyrazin-8-ylamine
1 -[3 -(3 -Chloro-benzyloxy)-phenyl] -3 -cyclobutyl-
Figure imgf000280_0001
imidazo [ 1 , 5 -a]pyrazin- 8 -ylamine
1 -[3 -(4-Chloro-benzyloxy)-phenyl] -3 -cyclobutyl-
Figure imgf000280_0002
imidazo [1,5 -a]pyrazin-8 -ylamine
3 -Cyclobutyl- 1 - [3 -(pyridin-3 -ylmethoxy) -phenyl] -
Figure imgf000280_0003
imidazo[l ,5-a]pyrazin-8-ylamine
3-Cyclobutyl-l-[3-(5-methyl-isoxazol-3-ylmethoxy)- -O phenyl]-imidazo[l,5-a]pyrazin-8-ylamine
3-Cyclobutyl-l-[3-(2,6-dichloro-pyridin-4-ylmethoxy)- phenyl]-imidazo[l,5-a]pyrazin-8-ylamine
1 -[3 -(Biphenyl-4-ylmethoxy)-phenyl]-3 -cyclobutyl- imidazo[l,5-a]pyrazin-8-ylamine
1 -[3-(2-Benzenesulfonyl-benzyloxy)-phenyl] -3 -cyclobutyl- imidazo[l ,5-a]pyrazin-8-ylamine
3 -Cyclobutyl- 1 -[3 -(naphthalen-2-ylmethoxy)-phenyl] -
Figure imgf000280_0004
imidazo[l,5-a]pyrazin-8-ylamine Name
3-Cyclobutyl-l-[3-(4-[l,2,4]triazol-l-yl-benzyloxy)-phenyl]- imidazo[l,5-a]pyrazin-8-ylamine
Figure imgf000281_0001
3 -Cyclobutyl- 1 - [3 -(4-methyl-benzyloxy) -phenyl] - imidazo[l,5-a]pyrazin-8-ylamine
3 -Cyclobutyl- 1 -[3 -(2,6-dichloro-benzyloxy)-phenyl] - imidazo[l,5-a]pyrazin-8-ylamine
Figure imgf000281_0002
3-Cyclobutyl-l-[3-(3-trifluoromethyl-benzyloxy)-phenyl]- imidazo[l,5-a]pyrazin-8-ylamine
l-[3-(4-tert-Butyl-benzyloxy)-phenyl]-3-cyclobutyl- imidazo [1,5 -a]pyrazin-8-ylamine
1 - [3 -(Biphenyl-2-ylmethoxy)-phenyl] -3 -cyclobutyl- imidazo[l,5-a]pyrazin-8-ylamine
4-[3-(8-Amino-3-cyclobutyl-imidazo[l,5-a]pyrazin-l-yl)- phenoxymethyl]-benzonitrile
3-Cyclobutyl-l-[3-(2,3-difluoro-benzyloxy)-phenyl]- imidazo[l,5-a]pyrazin-8-ylamine
3-Cyclobutyl-l-[3-(3,5-dimethyl-benzyloxy)-phenyl]- imidazo[l,5-a]pyrazin-8-ylamine
Figure imgf000281_0003
Figure imgf000282_0001
Figure imgf000283_0001
Rl Name
3 -Cyclobutyl- 1 -[3 -(2-difluoromethoxy-benzyloxy)-phenyl] -
Figure imgf000284_0001
imidazo[l,5-a]pyrazin-8-ylamine
3 -Cyclobutyl- 1 -[3 -(3 -difluoromethoxy-benzyloxy)-phenyl] -
Figure imgf000284_0002
imidazo[ 1 ,5-a]pyrazin-8-ylamine
3-Cyclobutyl-l-[3-(quinolin-8-ylmethoxy)-phenyl]- imidazo[l,5-a]pyrazin-8-ylamine
3 -Cyclobutyl- 1 - [3 -( 1 -phenyl-ethoxy)-phenyl] -imidazo [1,5-
Figure imgf000284_0003
a]pyrazin-8-ylamine
3 -[3 -(8-Amino-3 -cyclobutyl-imidazo [ 1 ,5 -a]pyrazin- 1 -yl)-
Figure imgf000284_0004
phenoxymethyl] -benzoic acid
3-Cyclobutyl-l-[3-(pyridin-2-ylmethoxy)-phenyl]-
Figure imgf000284_0005
imidazo[l,5-a]pyrazin-8-ylamine
3-Cyclobutyl-l-[3-(3,5-dimethyl-isoxazol-4-ylmethoxy)- phenyl]-imidazo[l,5-a]pyrazin-8-ylamine
3 -Cyclobutyl- 1 -[3 -(5 -methyl-3 -phenyl-isoxazol-4-
Figure imgf000284_0006
ylmethoxy)-phenyl]-imidazo[l,5-a]pyrazin-8-ylamine armaceutically acceptable salt thereof, wherein * is the point of attachment.
100. A compound selected from the group consisting of:
Figure imgf000285_0001
Figure imgf000285_0002
Figure imgf000286_0001
or a pharmaceutically acceptable salt thereof, wherein * is the point of attachment.
PCT/US2004/034219 2003-10-15 2004-10-14 Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors WO2005037836A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AP2006003620A AP2006003620A0 (en) 2003-10-15 2004-10-14 Imidazopyrazine tyroshine kinase inhibitors
AT04795392T ATE525377T1 (en) 2003-10-15 2004-10-14 IMIDAZOÄ1,5-AÜPYRAZINE AS TYROSINKINASE INHIBITORS
BRPI0415395-2A BRPI0415395A (en) 2003-10-15 2004-10-14 compound, methods for inhibiting protein kinase activity and treating a patient who has a condition that is mediated by protein kinase activity, and,
CN2004800372564A CN1898240B (en) 2003-10-15 2004-10-14 Imidazopyrazine tyrosine kinase inhibitors
AU2004282219A AU2004282219C1 (en) 2003-10-15 2004-10-14 Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
UAA200605222A UA83509C2 (en) 2003-10-15 2004-10-14 Imidazopyrazines as tyrosine kinase inhibitors
CA002542481A CA2542481A1 (en) 2003-10-15 2004-10-14 Imidazopyrazine tyrosine kinase inhibitors
JP2006535379A JP4916883B2 (en) 2003-10-15 2004-10-14 Imidazopyrazine tyrosine kinase inhibitor
EP04795392A EP1675860B1 (en) 2003-10-15 2004-10-14 Imidazo[1,5-a]pyrazines as tyrosine kinase inhibitors
IL174948A IL174948A0 (en) 2003-10-15 2006-04-11 Imidazopyrazine tyrosine kinase inhibitors
NO20062136A NO20062136L (en) 2003-10-15 2006-05-12 Imidazopyrazintyrosin kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51171203P 2003-10-15 2003-10-15
US60/511,712 2003-10-15

Publications (2)

Publication Number Publication Date
WO2005037836A2 true WO2005037836A2 (en) 2005-04-28
WO2005037836A3 WO2005037836A3 (en) 2005-06-09

Family

ID=34465267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/034219 WO2005037836A2 (en) 2003-10-15 2004-10-14 Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors

Country Status (19)

Country Link
US (2) US7459554B2 (en)
EP (1) EP1675860B1 (en)
JP (1) JP4916883B2 (en)
KR (1) KR100872204B1 (en)
CN (1) CN1898240B (en)
AP (1) AP2006003620A0 (en)
AR (1) AR046337A1 (en)
AT (1) ATE525377T1 (en)
AU (1) AU2004282219C1 (en)
BR (1) BRPI0415395A (en)
CA (1) CA2542481A1 (en)
ES (1) ES2372694T3 (en)
IL (1) IL174948A0 (en)
NO (1) NO20062136L (en)
RU (1) RU2405784C2 (en)
SG (1) SG132683A1 (en)
TW (1) TW200530238A (en)
UA (1) UA83509C2 (en)
WO (1) WO2005037836A2 (en)

Cited By (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097800A1 (en) * 2004-04-02 2005-10-20 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2007064993A2 (en) 2005-12-02 2007-06-07 Osi Pharmaceuticals, Inc. Bicyclic protein kinase inhibitors
WO2007067709A1 (en) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Process to prepare substituted imidazopyrazine compounds
WO2007087395A2 (en) * 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
WO2007079164A3 (en) * 2005-12-29 2007-09-27 Abbott Lab Protein kinase inhibitors
WO2007061737A3 (en) * 2005-11-17 2007-12-06 Osi Pharm Inc FUSED BICYCLIC mTOR INHIBITORS
WO2007138072A3 (en) * 2006-05-31 2008-02-14 Galapagos Nv Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
WO2008022060A2 (en) * 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
WO2008141145A1 (en) * 2007-05-09 2008-11-20 Abbott Laboratories Condensed heterocyclic compounds as inhibitors of protein kinases
WO2008141140A1 (en) * 2007-05-09 2008-11-20 Abbott Laboratories Condensed heterocyclic compounds as inhibitors of protein kinases
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010126960A1 (en) * 2009-04-29 2010-11-04 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
WO2011029915A1 (en) 2009-09-10 2011-03-17 Novartis Ag Ether derivatives of bicyclic heteroaryls
US7939272B2 (en) 2007-10-03 2011-05-10 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011095556A1 (en) * 2010-02-08 2011-08-11 N.V. Organon 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109572A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011112666A1 (en) 2010-03-09 2011-09-15 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8048621B2 (en) 2007-10-03 2011-11-01 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011157793A1 (en) 2010-06-17 2011-12-22 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
WO2011157787A1 (en) 2010-06-17 2011-12-22 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
US8119607B2 (en) 2008-07-03 2012-02-21 Biota Scientific Management Pty Ltd Bicyclic nucleosides and nucleotides as therapeutic agents
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
US8148369B2 (en) 2007-05-10 2012-04-03 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012120469A1 (en) 2011-03-08 2012-09-13 Novartis Ag Fluorophenyl bicyclic heteroaryl compounds
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
WO2013010868A1 (en) 2011-07-19 2013-01-24 Msd Oss B.V. 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
WO2013071056A2 (en) 2011-11-11 2013-05-16 Duke University Combination drug therapy for the treatment of solid tumors
WO2013087647A1 (en) * 2011-12-15 2013-06-20 Bayer Intellectual Property Gmbh Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2014015280A1 (en) 2012-07-20 2014-01-23 Novartis Pharma Ag Combination therapy of inhibitors for igf1 r and pi3k
US8710104B2 (en) 2008-11-07 2014-04-29 Triact Therapeutics, Inc. Catecholic butanes and use thereof for cancer therapy
WO2014116504A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
WO2014114185A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
CN104136439A (en) * 2012-02-23 2014-11-05 拜耳知识产权有限责任公司 Substituted benzothienyl-pyrrolotriazines and uses thereof
WO2015058084A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
WO2015027067A3 (en) * 2013-08-23 2015-05-07 Virginia Commonwealth University Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease
WO2015095102A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
WO2015095099A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
US9079908B2 (en) 2007-03-28 2015-07-14 Pharmacyclics, Inc. Inhibitors of Bruton'S tyrosine kinase
US9096604B2 (en) 2012-11-15 2015-08-04 Pharmacyclics, Inc. Pyrrolopyrimidine compounds as kinase inhibitors
JP2015193639A (en) * 2005-03-25 2015-11-05 サーフェイス ロジックス，インコーポレイティド Pharmacokinetically improved compounds
WO2015132799A3 (en) * 2014-02-03 2015-11-12 Cadila Healthcare Limited Heterocyclic compounds
US9273051B2 (en) 2011-12-30 2016-03-01 Pharmacyclics Llc Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9296753B2 (en) 2012-06-04 2016-03-29 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
WO2016106652A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
WO2016109222A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016109223A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016109216A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016109215A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016109220A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
EP2900673A4 (en) * 2012-09-26 2016-10-19 Univ California Modulation of ire1
US9533991B2 (en) 2014-08-01 2017-01-03 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US9624224B2 (en) 2013-09-30 2017-04-18 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US9655857B2 (en) 2015-03-03 2017-05-23 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
US9796721B2 (en) 2015-07-02 2017-10-24 Acerta Pharma B.V. Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
US9801881B2 (en) 2010-06-03 2017-10-31 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (BTK)
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
US9862722B2 (en) 2011-07-13 2018-01-09 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US20180028537A1 (en) 2014-08-07 2018-02-01 Pharmacyclics Llc Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
US9949971B2 (en) 2014-06-17 2018-04-24 Acerta Pharma B.V. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
WO2018102785A2 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
WO2018103688A1 (en) * 2016-12-07 2018-06-14 Beigene, Ltd. IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
US10328080B2 (en) 2013-12-05 2019-06-25 Acerta Pharma, B.V. Therapeutic combination of PI3K inhibitor and a BTK inhibitor
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020186291A1 (en) * 2019-03-15 2020-09-24 Alterity Therapeutics Limited Compounds for and methods of treating diseases
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
US10954567B2 (en) 2012-07-24 2021-03-23 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
US10988477B2 (en) 2018-01-29 2021-04-27 Merck Patent Gmbh GCN2 inhibitors and uses thereof
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11155547B1 (en) 2020-06-18 2021-10-26 Alterity Therapeutics Limited Compounds for and methods of treating diseases
US11166951B2 (en) 2014-08-11 2021-11-09 Acerta Pharma B.V. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor
US11220506B2 (en) 2017-09-08 2022-01-11 Beigene, Ltd. Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors
US12084438B2 (en) 2018-01-29 2024-09-10 Merck Patent Gmbh GCN2 inhibitors and uses thereof

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004268918A1 (en) * 2003-09-03 2005-03-10 Galapagos Nv Imidazo(1,5-a)pyridine or imidazo(1,5-a)piperidine derivatives and their use for the preparation of medicament against 5-HT2A receptor-related disorders
AU2004282219C1 (en) * 2003-10-15 2009-12-17 Osi Pharmaceuticals, Inc. Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
CA2681756C (en) * 2007-03-28 2015-02-24 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2009038012A1 (en) * 2007-09-18 2009-03-26 Taisho Pharmaceutical Co., Ltd. Heterocyclic compound
EP2250173A1 (en) * 2008-01-18 2010-11-17 OSI Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
EA018144B1 (en) * 2008-03-19 2013-05-30 Оси Фармасьютикалз, Инк. mTOR INHIBITOR SALT FORMS
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
JP2012524119A (en) * 2009-04-20 2012-10-11 オーエスアイ・ファーマシューティカルズ，エルエルシー Preparation of C-pyrazine-methylamine
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
WO2011060112A1 (en) 2009-11-12 2011-05-19 Osi Pharmaceuticals, Inc. Deuterated tyrosine kinase inhibitors
US9765037B2 (en) 2010-01-28 2017-09-19 University Of Washington Through Its Center For Commercialization Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
EP2528919B1 (en) * 2010-01-28 2016-11-02 University of Washington Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
AR080754A1 (en) * 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS
WO2014189947A1 (en) 2013-05-20 2014-11-27 University Of Washington Through Its Center For Commercialization 5-aminopyrazole-4-carboxamide inhibitors of cdpk1 from t. gondii and c. parvum
WO2015057992A1 (en) 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
US10325032B2 (en) 2014-02-19 2019-06-18 Snowflake Inc. Resource provisioning systems and methods
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
TW201618774A (en) 2014-08-11 2016-06-01 艾森塔製藥公司 Methods of using BTK inhibitors to treat solid tumors and other diseases through modulation of the tumor microenvironment
WO2016024231A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
TW201618773A (en) 2014-08-11 2016-06-01 艾森塔製藥公司 Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a CDK4/6 inhibitor
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
MA44909A (en) 2015-09-15 2018-07-25 Acerta Pharma Bv THERAPEUTIC ASSOCIATION OF A CD19 INHIBITOR AND A BTK INHIBITOR
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
WO2017122175A1 (en) 2016-01-13 2017-07-20 Acerta Pharma B.V. Therapeutic combinations of an antifolate and a btk inhibitor
CN106831789A (en) * 2016-12-21 2017-06-13 南京亘泰医药技术有限公司 Bruton's tyrosine kinase inhibitor
PT3697789T (en) * 2017-10-18 2021-12-31 Incyte Corp Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
IL312413A (en) 2018-08-29 2024-06-01 Acerta Pharma Bv Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
CN110964016B (en) * 2018-09-29 2021-05-28 南京药捷安康生物科技有限公司 Amino-norbornane derivative and preparation method and application thereof
CA3112073A1 (en) * 2018-10-11 2020-04-16 Basf As Aromatic compounds and pharmaceutical uses thereof
CN113620957B (en) * 2020-05-08 2022-04-19 盛世泰科生物医药技术(苏州)有限公司 Preparation method of aminomethyl pyrazine compound
WO2023014817A1 (en) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
CN114920745B (en) * 2022-03-28 2024-05-24 深圳海博为药业有限公司 Imidazo pyrazine compound and application thereof as IGF1R inhibitor

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US6194439B1 (en) 1991-05-29 2001-02-27 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
MX9304801A (en) 1992-08-06 1997-06-28 Warner Lambert Co 2-thioindoles and related disulfides which inhibit protein tyrosine kinases and which have antitumor properties.
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CH690773A5 (en) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo (2,3-d) pyrimides and their use.
US6514971B1 (en) 1996-03-15 2003-02-04 Zeneca Limited Cinnoline derivatives and use as medicine
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6713474B2 (en) * 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
WO2000035455A1 (en) 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
EP2042194A3 (en) * 1999-05-14 2009-04-22 Imclone Systems, Inc. Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US7087613B2 (en) * 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
WO2001072751A1 (en) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
GB0017635D0 (en) * 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
WO2002045653A2 (en) * 2000-12-08 2002-06-13 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
WO2002055106A2 (en) * 2001-01-09 2002-07-18 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
CA2436487A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
MXPA03008560A (en) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Single-stage pfc + ballast control circuit/general purpose power converter.
CN1507355A (en) * 2001-05-08 2004-06-23 Ĭ��ר�����޹�˾ Combination therapy using anti-EGFR antibodies and anti-hormonal agents
AR035885A1 (en) * 2001-05-14 2004-07-21 Novartis Ag DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
SE0102168D0 (en) 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
WO2003000187A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
GB0122560D0 (en) 2001-09-19 2001-11-07 Aventis Pharma Ltd Chemical compounds
SE0104140D0 (en) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
US20050215564A1 (en) 2002-02-14 2005-09-29 Stiles Charles D Methods and compositions for treating hyperproliferative conditions
KR20040103964A (en) * 2002-04-16 2004-12-09 아스트라제네카 아베 Combination therapy for the treatment of cancer
DE10230604A1 (en) 2002-07-08 2004-01-29 Bayer Ag Heterocyclically substituted imidazotriazines
DE10230605A1 (en) 2002-07-08 2004-01-29 Bayer Ag Substituted imidazotriazines
TW200501960A (en) * 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
MXPA05009660A (en) 2003-03-12 2005-10-20 Pfizer Prod Inc Pyridyloxymethyl and benzisoxazole azabicyclic derivatives.
AU2004282219C1 (en) * 2003-10-15 2009-12-17 Osi Pharmaceuticals, Inc. Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
PT1740591E (en) * 2004-04-02 2009-09-24 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
WO2005117916A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
EP1979002A2 (en) * 2005-12-19 2008-10-15 OSI Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735405B2 (en) 2004-04-02 2014-05-27 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
EP2168968A1 (en) * 2004-04-02 2010-03-31 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US7534797B2 (en) 2004-04-02 2009-05-19 Osi Pharmaceuticals, Inc. 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors
WO2005097800A1 (en) * 2004-04-02 2005-10-20 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US7820662B2 (en) 2004-04-02 2010-10-26 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
JP4832426B2 (en) * 2004-04-02 2011-12-07 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 6,6-bicyclic substituted heterobicyclic protein kinase inhibitors
EA012873B1 (en) * 2004-04-02 2009-12-30 Оси Фармасьютикалз, Инк. 6,6-bicyclic ring substituted heterocyclic protein kinase inhibitors
US8101613B2 (en) 2004-04-02 2012-01-24 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US8367826B2 (en) 2004-04-02 2013-02-05 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
AP2139A (en) * 2004-04-02 2010-08-21 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors.
JP2015193639A (en) * 2005-03-25 2015-11-05 サーフェイス ロジックス，インコーポレイティド Pharmacokinetically improved compounds
EP2372363A1 (en) 2005-09-20 2011-10-05 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2007061737A3 (en) * 2005-11-17 2007-12-06 Osi Pharm Inc FUSED BICYCLIC mTOR INHIBITORS
US8796455B2 (en) 2005-11-17 2014-08-05 OSI Pharmaceuticals, LLC Fused bicyclic mTOR inhibitors
US8314111B2 (en) 2005-11-17 2012-11-20 OSI Pharmaceuticals, LLC Fused bicyclic motor inhibitors
CN102936250B (en) * 2005-11-17 2014-07-09 Osi医药有限责任公司 Fused bicyclic mtor inhibitors
JP2010065049A (en) * 2005-11-17 2010-03-25 Osi Pharmaceuticals Inc FUSED BICYCLIC mTOR INHIBITOR
AU2006316605B2 (en) * 2005-11-17 2012-04-26 Osi Pharmaceuticals, Inc. Fused bicyclic mTOR inhibitors
EP2325186A3 (en) * 2005-11-17 2011-10-26 OSI Pharmaceuticals, Inc. Fused Bicyclic mTor Inhibitors
CN102936250A (en) * 2005-11-17 2013-02-20 Osi医药有限责任公司 Fused bicyclic mtor inhibitors
JP2009519222A (en) * 2005-11-17 2009-05-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Fused bicyclic mTOR inhibitor
EA015463B1 (en) * 2005-11-17 2011-08-30 Оси Фармасьютикалз, Инк. FUSED BICYCLIC COMPOUND - mTOR INHIBITOR, PHARMACEUTICAL COMPOSITION, CONTAINING THE SAME, AND METHOD FOR TREATING CANCER
WO2007064993A2 (en) 2005-12-02 2007-06-07 Osi Pharmaceuticals, Inc. Bicyclic protein kinase inhibitors
WO2007067709A1 (en) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Process to prepare substituted imidazopyrazine compounds
JP2014088397A (en) * 2005-12-29 2014-05-15 Abbvie Inc Protein kinase inhibitor
WO2007079164A3 (en) * 2005-12-29 2007-09-27 Abbott Lab Protein kinase inhibitors
US7772231B2 (en) 2005-12-29 2010-08-10 Abbott Laboratories Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors
WO2007087395A2 (en) * 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
JP2009524671A (en) * 2006-01-25 2009-07-02 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Unsaturated mTOR inhibitor
WO2007087395A3 (en) * 2006-01-25 2007-11-08 Osi Pharm Inc UNSATURATED mTOR INHIBITORS
WO2007138072A3 (en) * 2006-05-31 2008-02-14 Galapagos Nv Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
WO2008022060A3 (en) * 2006-08-14 2008-12-31 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
WO2008022060A2 (en) * 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
US9181263B2 (en) 2007-03-28 2015-11-10 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US9556182B2 (en) 2007-03-28 2017-01-31 Pharmacylics LLC Inhibitors of Bruton's tyrosine kinase
US9079908B2 (en) 2007-03-28 2015-07-14 Pharmacyclics, Inc. Inhibitors of Bruton'S tyrosine kinase
US9139591B2 (en) 2007-03-28 2015-09-22 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2008141145A1 (en) * 2007-05-09 2008-11-20 Abbott Laboratories Condensed heterocyclic compounds as inhibitors of protein kinases
WO2008141140A1 (en) * 2007-05-09 2008-11-20 Abbott Laboratories Condensed heterocyclic compounds as inhibitors of protein kinases
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
US8148369B2 (en) 2007-05-10 2012-04-03 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
US9006237B2 (en) 2007-05-10 2015-04-14 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
US8048621B2 (en) 2007-10-03 2011-11-01 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US7939272B2 (en) 2007-10-03 2011-05-10 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US8119607B2 (en) 2008-07-03 2012-02-21 Biota Scientific Management Pty Ltd Bicyclic nucleosides and nucleotides as therapeutic agents
US8501699B2 (en) 2008-07-03 2013-08-06 Biota Scientific Management Pty Ltd Bicyclic nucleosides and nucleotides as therapeutic agents
US8415309B2 (en) 2008-07-03 2013-04-09 Biota Scientific Managment Pty Ltd Bicyclic nucleosides and nucleotides as therapeutic agents
US8710104B2 (en) 2008-11-07 2014-04-29 Triact Therapeutics, Inc. Catecholic butanes and use thereof for cancer therapy
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2424368A1 (en) * 2009-04-29 2012-03-07 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
WO2010126960A1 (en) * 2009-04-29 2010-11-04 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
EP2424368A4 (en) * 2009-04-29 2012-10-17 Locus Pharmaceuticals Inc Pyrrolotriazine compounds
WO2011029915A1 (en) 2009-09-10 2011-03-17 Novartis Ag Ether derivatives of bicyclic heteroaryls
KR101661383B1 (en) 2010-02-08 2016-09-29 머크 샤프 앤 도메 비.브이. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
WO2011095556A1 (en) * 2010-02-08 2011-08-11 N.V. Organon 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
KR20130002991A (en) * 2010-02-08 2013-01-08 엠에스데 오쓰 베.베. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
US8658794B2 (en) 2010-02-08 2014-02-25 Merck Sharp & Dohme B.V. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109572A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011112666A1 (en) 2010-03-09 2011-09-15 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US10478439B2 (en) 2010-06-03 2019-11-19 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (Btk)
US10004745B2 (en) 2010-06-03 2018-06-26 Pharmacyclics Llc Use of inhibitors of Bruton'S tyrosine kinase (Btk)
US10653696B2 (en) 2010-06-03 2020-05-19 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (BTK)
US10751342B2 (en) 2010-06-03 2020-08-25 Pharmacyclics Llc Use of inhibitors of Bruton's tyrosine kinase (Btk)
US11672803B2 (en) 2010-06-03 2023-06-13 Pharmacyclics Llc Use of inhibitors of Brutons tyrosine kinase (Btk)
US9814721B2 (en) 2010-06-03 2017-11-14 Pharmacyclics Llc Use of inhibitors of bruton'S tyrosine kinase (BTK)
US9801883B2 (en) 2010-06-03 2017-10-31 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (Btk)
US10016435B2 (en) 2010-06-03 2018-07-10 Pharmacyclics Llc Use of inhibitors of Bruton's tyrosine kinase (Btk)
US9801881B2 (en) 2010-06-03 2017-10-31 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (BTK)
US10004746B2 (en) 2010-06-03 2018-06-26 Pharmacyclics Llc Use of inhibitors of Bruton's tyrosine kinase (Btk)
WO2011157787A1 (en) 2010-06-17 2011-12-22 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
WO2011157793A1 (en) 2010-06-17 2011-12-22 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012120469A1 (en) 2011-03-08 2012-09-13 Novartis Ag Fluorophenyl bicyclic heteroaryl compounds
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
US9862722B2 (en) 2011-07-13 2018-01-09 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US9758524B2 (en) 2011-07-19 2017-09-12 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
WO2013010380A1 (en) 2011-07-19 2013-01-24 Merck Sharp & Dohme Corp. Btk inhibitors
US9718828B2 (en) 2011-07-19 2017-08-01 Merck Sharp & Dohme Corp. BTK Inhibitors
US9290504B2 (en) 2011-07-19 2016-03-22 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
EP3495368A1 (en) 2011-07-19 2019-06-12 Merck Sharp & Dohme B.V. (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor
US10239883B2 (en) 2011-07-19 2019-03-26 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
EP4249076A2 (en) 2011-07-19 2023-09-27 Merck Sharp & Dohme B.V. (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor
EP3689878A1 (en) 2011-07-19 2020-08-05 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
EA037644B1 (en) * 2011-07-19 2021-04-26 Мерк Шарп и Доум Б.В. METHOD OF PREPARING Btk INHIBITOR
WO2013010868A1 (en) 2011-07-19 2013-01-24 Msd Oss B.V. 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
US9790226B2 (en) 2011-07-19 2017-10-17 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as BtK inhibitors
US10934296B2 (en) 2011-07-19 2021-03-02 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
US9931402B2 (en) 2011-11-11 2018-04-03 Duke University Compositions for the treatment of solid tumors
WO2013071056A2 (en) 2011-11-11 2013-05-16 Duke University Combination drug therapy for the treatment of solid tumors
US9700619B2 (en) 2011-11-11 2017-07-11 Duke University Combination drug therapy for the treatment of solid tumors
WO2013087647A1 (en) * 2011-12-15 2013-06-20 Bayer Intellectual Property Gmbh Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer
US9598416B2 (en) 2011-12-15 2017-03-21 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer
US9273051B2 (en) 2011-12-30 2016-03-01 Pharmacyclics Llc Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN104136439A (en) * 2012-02-23 2014-11-05 拜耳知识产权有限责任公司 Substituted benzothienyl-pyrrolotriazines and uses thereof
US9475815B2 (en) 2012-02-23 2016-10-25 Bayer Intelletual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
CN104136439B (en) * 2012-02-23 2017-01-18 拜耳知识产权有限责任公司 Substituted benzothienyl-pyrrolotriazines and uses thereof
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9540382B2 (en) 2012-06-04 2017-01-10 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US9725455B1 (en) 2012-06-04 2017-08-08 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
US10266540B2 (en) 2012-06-04 2019-04-23 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10752634B2 (en) 2012-06-04 2020-08-25 Pharmacyclics Llc Crystalline forms of a brutons tyrosine kinase inhibitor
US9713617B2 (en) 2012-06-04 2017-07-25 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US9828383B1 (en) 2012-06-04 2017-11-28 Pharmacyclic s LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
US10294231B2 (en) 2012-06-04 2019-05-21 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10294232B2 (en) 2012-06-04 2019-05-21 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10125140B1 (en) 2012-06-04 2018-11-13 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
US10106548B2 (en) 2012-06-04 2018-10-23 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10961251B1 (en) 2012-06-04 2021-03-30 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10065968B2 (en) 2012-06-04 2018-09-04 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
US9296753B2 (en) 2012-06-04 2016-03-29 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
WO2014015280A1 (en) 2012-07-20 2014-01-23 Novartis Pharma Ag Combination therapy of inhibitors for igf1 r and pi3k
US10954567B2 (en) 2012-07-24 2021-03-23 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1
US10822340B2 (en) 2012-09-26 2020-11-03 The Regents Of The University Of California Substituted imidazolopyrazine compounds and methods of using same
EP2900673A4 (en) * 2012-09-26 2016-10-19 Univ California Modulation of ire1
US11613544B2 (en) 2012-09-26 2023-03-28 The Regents Of The University Of California Substituted imidazo[1,5-a]pyrazines for modulation of IRE1
US9540385B2 (en) 2012-11-15 2017-01-10 Pharmacyclics Llc Pyrrolopyrimidine compounds as kinase inhibitors
US9096604B2 (en) 2012-11-15 2015-08-04 Pharmacyclics, Inc. Pyrrolopyrimidine compounds as kinase inhibitors
US9481682B2 (en) 2013-01-23 2016-11-01 Merck Sharp & Dohme Corp. Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors
WO2014116504A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
WO2014114185A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
EP2948458A4 (en) * 2013-01-23 2016-07-27 Merck Sharp & Dohme Btk inhibitors
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
WO2015027067A3 (en) * 2013-08-23 2015-05-07 Virginia Commonwealth University Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
US9624224B2 (en) 2013-09-30 2017-04-18 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
WO2015058084A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
US10328080B2 (en) 2013-12-05 2019-06-25 Acerta Pharma, B.V. Therapeutic combination of PI3K inhibitor and a BTK inhibitor
WO2015095099A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
WO2015095102A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
US11090302B2 (en) 2014-01-21 2021-08-17 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
US11771696B2 (en) 2014-01-21 2023-10-03 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
WO2015132799A3 (en) * 2014-02-03 2015-11-12 Cadila Healthcare Limited Heterocyclic compounds
US9840509B2 (en) 2014-02-03 2017-12-12 Cadila Healthcare Limited Heterocyclic compounds
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
US9949971B2 (en) 2014-06-17 2018-04-24 Acerta Pharma B.V. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
US9533991B2 (en) 2014-08-01 2017-01-03 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US20180028537A1 (en) 2014-08-07 2018-02-01 Pharmacyclics Llc Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor
US11654143B2 (en) 2014-08-11 2023-05-23 Acerta Pharma B.V. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor
US11166951B2 (en) 2014-08-11 2021-11-09 Acerta Pharma B.V. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor
WO2016109216A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016109220A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2016106652A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
WO2016109222A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016109223A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
US10208047B2 (en) 2014-12-31 2019-02-19 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine BTK inhibitors
WO2016106624A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016109215A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
US10828259B2 (en) 2015-03-03 2020-11-10 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US10213386B2 (en) 2015-03-03 2019-02-26 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US9655857B2 (en) 2015-03-03 2017-05-23 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US10010507B1 (en) 2015-03-03 2018-07-03 Pharmacyclics Llc Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
US11059829B2 (en) 2015-07-02 2021-07-13 Acerta Pharma B.V. Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate
US10640509B2 (en) 2015-07-02 2020-05-05 Acerta Pharma B.V. Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma
US11820777B2 (en) 2015-07-02 2023-11-21 Acerta Pharma B.V. Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
US10167291B2 (en) 2015-07-02 2019-01-01 Acerta Pharma B.V. Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
US9796721B2 (en) 2015-07-02 2017-10-24 Acerta Pharma B.V. Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
WO2018102785A2 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
AU2017372377B2 (en) * 2016-12-07 2022-03-03 Beigene, Ltd. Imidazo [1,5-a] pyrazine derivatives as PI3Kdelta inhibitors
US11136323B2 (en) 2016-12-07 2021-10-05 Beigene, Ltd. Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors
TWI762534B (en) * 2016-12-07 2022-05-01 英屬開曼群島商百濟神州有限公司 IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS
WO2018103688A1 (en) * 2016-12-07 2018-06-14 Beigene, Ltd. IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS
IL266986A (en) * 2016-12-07 2019-07-31 Beigene Ltd Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
EP3551630A4 (en) * 2016-12-07 2020-07-15 Beigene, Ltd. IMIDAZO [1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS
US11725012B2 (en) 2016-12-07 2023-08-15 Beigene, Ltd. Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors
US11905294B2 (en) 2017-09-08 2024-02-20 Beigene, Ltd. Imidazo[1,5-a]pyrazine derivatives as PI3Kδ inhibitors
US11220506B2 (en) 2017-09-08 2022-01-11 Beigene, Ltd. Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors
US10988477B2 (en) 2018-01-29 2021-04-27 Merck Patent Gmbh GCN2 inhibitors and uses thereof
US12084438B2 (en) 2018-01-29 2024-09-10 Merck Patent Gmbh GCN2 inhibitors and uses thereof
WO2020186291A1 (en) * 2019-03-15 2020-09-24 Alterity Therapeutics Limited Compounds for and methods of treating diseases
US10941143B2 (en) 2019-03-15 2021-03-09 Alterity Therapeutics Limited Imidazo [1,5-a]pyridine compounds and their use
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11155547B1 (en) 2020-06-18 2021-10-26 Alterity Therapeutics Limited Compounds for and methods of treating diseases

Also Published As

Publication number Publication date
ATE525377T1 (en) 2011-10-15
KR100872204B1 (en) 2008-12-09
EP1675860A2 (en) 2006-07-05
ES2372694T3 (en) 2012-01-25
WO2005037836A3 (en) 2005-06-09
CA2542481A1 (en) 2005-04-28
AU2004282219B2 (en) 2009-07-30
RU2405784C2 (en) 2010-12-10
TW200530238A (en) 2005-09-16
AU2004282219A1 (en) 2005-04-28
AR046337A1 (en) 2005-12-07
CN1898240A (en) 2007-01-17
CN1898240B (en) 2011-08-03
RU2006116503A (en) 2007-11-20
US7459554B2 (en) 2008-12-02
KR20060086987A (en) 2006-08-01
JP4916883B2 (en) 2012-04-18
SG132683A1 (en) 2007-06-28
EP1675860B1 (en) 2011-09-21
BRPI0415395A (en) 2006-12-12
US20080227788A9 (en) 2008-09-18
AU2004282219C1 (en) 2009-12-17
UA83509C2 (en) 2008-07-25
JP2007509060A (en) 2007-04-12
IL174948A0 (en) 2006-08-20
NO20062136L (en) 2006-06-26
AP2006003620A0 (en) 2006-06-30
US20060084654A1 (en) 2006-04-20
US20090181940A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
EP1675860B1 (en) Imidazo[1,5-a]pyrazines as tyrosine kinase inhibitors
EP1957496B1 (en) Bicyclic protein kinase inhibitors
US6660744B1 (en) Pyrazolopyrimidines as therapeutic agents
JP4918038B2 (en) Imidazopyrazine as a tyrosine kinase inhibitor
RU2379308C2 (en) 6,6-bicyclic ring substituted heterobicyclic proteinkinase inhibitors
US20020156081A1 (en) Pyrazolopyrimidines as therapeutic agents
NZ510587A (en) 4-aminopyrrolopyrimidines as kinase inhibitors
WO2007084667A2 (en) Fused heterobicyclic kinase inhibitors
WO2009091939A1 (en) Imidazopyrazinol derivatives for the treatment of cancers
MXPA06004245A (en) Imidazopyrazine tyrosine kinase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480037256.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2542481

Country of ref document: CA

Ref document number: 12006500742

Country of ref document: PH

Ref document number: 174948

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1290/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006535379

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/004245

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004795392

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004282219

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006116503

Country of ref document: RU

Ref document number: 1020067009419

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2004282219

Country of ref document: AU

Date of ref document: 20041014

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004282219

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004795392

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067009419

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0415395

Country of ref document: BR